10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________________________________

FORM 10-Q

__________________________________________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to

__________________________________________

Cano Health, Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

Commission File Number: 001-39289

Delaware

(State or other jurisdiction of incorporation or organization)

9725 NW 117th Avenue, Suite #200, Miami, FL

(Address of principal executive offices)

98-1524224

(IRS Employer Identification No.)

33178

(Zip Code)

(855) 226-6633

(Registrant's telephone number, including area code)

_____________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, $0.0001 par value per share	CANO	The New York Stock Exchange
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share	CANO/WS	The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer     ☐

Non-accelerated filer     ☒

Accelerated filer         ☐

Smaller reporting company    ☐

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 8, 2021 the registrant had 180,410,977 shares of Class A common stock outstanding and 299,575,289 shares of Class B common stock outstanding.

Table of Contents

	Page
PART I FINANCIAL INFORMATION
Cautionary Note Regarding Forward-Looking Statements and Summary Risk Factors	2
Item 1. Financial Statements (Unaudited)	6
Condensed Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020	6
Condensed Consolidated Statements of Operations for the Three and Nine Months ended September 30, 2021 and September 30, 2020	8
Condensed Consolidated Statements of Stockholders' Equity / Members' Capital for the Three and Nine Months ended September 30, 2021 and September 30, 2020	10
Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2021 and September 30, 2020	13
Notes to Interim Condensed Consolidated Financial Statements	15
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	59
Item 3. Quantitative and Qualitative Disclosures About Market Risk	81
Item 4. Controls and Procedures	82
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	84
Item 1A. Risk Factors	84
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	132
Item 3. Default Upon Senior Securities	132
Item 4. Mine Safety Disclosures	132
Item 5. Other Information	132
Item 6. Exhibits	132
SIGNATURES	134

i

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q may constitute “forward-looking statements” for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements about:

•the benefits of the Business Combination (as defined herein) and the acquisitions described in this Quarterly Report on Form 10-Q;

•our financial and business performance;

•changes in our strategy, future operations, financial position, estimated revenues, forecasts, projected costs, prospects and plans;

•changes in applicable laws or regulations, including with respect to health plans and payors and our relationships with such plans and payors, and provisions that impact Medicare and Medicaid programs;

•our ability to realize expected results with respect to patient membership, revenue and earnings;

•our ability to grow market share in existing markets or enter into new markets and success of acquisitions;

•the risk that we may not be able to procure sufficient space as we continue to grow and open additional medical centers;

•our predictions about need for our wellness centers after the coronavirus disease 2019, or COVID-19 pandemic, including the attractiveness of our offerings and member retention rates;

•competition in our industry, the advantages of our products and technology over competing products and technology existing in the market, and competitive factors including with respect to technological capabilities, cost and scalability;

•the impact of the COVID-19 pandemic or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on our business, financial condition and results of operations and the actions we may take in response thereto;

•our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act of 2012;

•our future capital requirements and sources and uses of cash;

•our business, expansion plans and opportunities;

•anticipated financial performance, including gross margin, and the expectation that our future results of operations will fluctuate on a quarterly basis for the foreseeable future;

•our expected capital expenditures, cost of revenue and other future expenses, and the sources of funds to satisfy liquidity needs;

•our ability to maintain proper and effective internal controls; and

•the outcome of any known and unknown litigation and regulatory proceedings.

These forward-looking statements are based on information available to us at the time of this Quarterly Report on Form 10-Q and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

ii

The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include:

•the ability to maintain the listing of our Class A common stock and warrants on the New York Stock Exchange ("NYSE");

•the price of our securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which we operate, variations in performance across competitors, changes in laws and regulations affecting our business and changes in our capital structure;

•the risk of downturns and the possibility of rapid change in the highly competitive industry in which we operate;

•the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all;

•the risk that we experience difficulties in managing our growth and expanding operations; and

•other risks and uncertainties described in this Quarterly Report on Form 10-Q, including those under the section entitled “Risk Factors.”

iii

SUMMARY RISK FACTORS

Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. This summary should be read in conjunction with the risk factors detailed more fully below and should not be relied upon as an exhaustive summary of the material risks facing our business.

•Under most of our agreements with health plans, we assume some or all of the risk that the cost of providing services will exceed our compensation.

•Our revenues and operations are dependent upon a limited number of key existing payors and our continued relationship with those payors, and disruptions in those relationships (including renegotiation, non-renewal or termination of capitation agreements) or the inability of such payors to maintain their contracts with the Centers for Medicare and Medicaid Services could adversely affect our business.

•COVID-19 or other pandemic, epidemic, or outbreak of an infectious disease may have an adverse effect on our business, results of operations, financial condition and cash flows, the nature and extent of which are highly uncertain and unpredictable.

•Reductions in the quality ratings of the health plans we serve or our Medicare Risk Adjustment scores could have a material adverse effect on our business, results of operations, financial condition and cash flows.

•Our medical centers are concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions.

•We primarily depend on reimbursements by third-party payors, which could lead to delays and uncertainties in the reimbursement process.

•We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to achieve or maintain profitability.

•We depend on our senior management team and other key employees, and the loss of one or more of these employees or an inability to attract and retain other highly skilled employees could harm our business.

•If we fail to manage our growth effectively, we may be unable to execute our business plan, maintain high levels of service and member satisfaction or adequately address competitive challenges.

•We may not be able to identify suitable de novo expansion opportunities, engage with payors in new markets to continue extension of financial risk-sharing model agreements that have proved successful in our existing markets or cost-effectively develop, staff and establish such new medical centers in new markets.

iv

•We conduct business in a heavily regulated industry, and if we fail to comply with applicable state and federal healthcare laws and government regulations or lose governmental licenses, we could incur financial penalties, become excluded from participating in government healthcare programs, be required to make significant operational changes or experience adverse publicity, which could harm our business.

•We may not be able to identify suitable acquisition candidates, complete acquisitions or successfully integrate acquisitions, and acquisitions may not produce the intended results or may expose us to unknown or contingent liabilities.

•Reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program could have a material adverse effect on our financial condition and results of operations.

•Our business could be harmed if the Affordable Care Act (“ACA”) is overturned or by any legislative, regulatory or industry change that reduces healthcare spending or otherwise slows or limits the transition to more assumption of risk by healthcare providers.

•Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to the regulations implementing the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (“HIPPA”), and other federal and state privacy and security regulations. If we suffer a data breach or unauthorized disclosure, we could incur significant liability including government and private investigations and claims of privacy and security non-compliance. We could also suffer significant reputational harm as a result and, in turn, a material adverse effect on our member base and revenue.

•We may be subject to legal proceedings and litigation, including intellectual property, privacy and medical malpractice disputes, which are costly to defend and could materially harm our business and results of operations.

•Our existing indebtedness could adversely affect our business and growth prospects. The terms of the Credit Agreement (defined herein) restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.

If we are unable to adequately address these and other risks we face, our business, results of operations, financial condition and prospects may be harmed.

v

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

CANO HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in thousands, except share data)		September 30, 2021		December 31, 2020
Assets
Current assets:
Cash, cash equivalents and restricted cash	$	208,913	$	33,807
Accounts receivable, net of unpaid service provider costs (Related parties comprised $92 and $50,015 as of September 30, 2021 and December 31, 2020, respectively)		223,644		76,709
Inventory		1,777		922
Prepaid expenses and other current assets		30,788		8,937
Total current assets		465,122		120,375
Property and equipment, net (Related parties comprised $18,897 and $22,659 as of September 30, 2021 and December 31, 2020, respectively)		64,156		38,126
Goodwill		765,511		234,328
Payor relationships, net		584,265		189,570
Other intangibles, net		256,327		36,785
Other assets		4,703		4,362
Total assets	$	2,140,084	$	623,546
Liabilities and stockholders' equity / members' capital
Current liabilities:
Current portion of notes payable	$	6,493	$	4,800
Current portion of equipment loans		513		314
Current portion of capital lease obligations		1,006		876
Current portion of contingent consideration		8,406		—
Accounts payable and accrued expenses (Related parties comprised $0 and $112 as of September 30, 2021 and December 31, 2020, respectively)		76,654		33,180
Deferred revenue (Related parties comprised $0 and $988 as of September 30, 2021 and December 31, 2020, respectively)		1,815		988
Current portions due to sellers		24,687		27,129
Other current liabilities		20,000		1,333
Total current liabilities		139,574		68,620
Notes payable, net of current portion and debt issuance costs		916,111		456,745
Warrants liabilities		138,493		—
Equipment loans, net of current portion		1,454		873
Capital lease obligations, net of current portion		1,559		1,580
Deferred rent (Related parties comprised $0 and $92 as of September 30, 2021 and December 31, 2020, respectively)		5,387		3,111
Deferred revenue, net of current portion (Related parties comprised of $0 and $4,277 as of September 30, 2021 and December 31, 2020, respectively)		4,698		4,277
Due to sellers, net of current portion		170		13,976
Contingent consideration		38,300		5,172

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-6-

CANO HEALTH, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

Other liabilities (Related parties comprised $0 and $8,142 as of September 30, 2021 and December 31, 2020, respectively)		36,325		11,648
Total liabilities		1,282,071		566,002
Stockholders’ Equity / Members' Capital
Shares of Class A common stock $0.0001 par value (6,000,000,000 shares authorized and 171,594,914 shares issued and outstanding at September 30, 2021)		17		—
Shares of Class B common stock $0.0001 par value (1,000,000,000 shares authorized and 305,670,386 shares issued and outstanding at September 30, 2021)		31		—
Members' capital		—		157,591
Additional paid-in capital		363,060		—
Accumulated deficit		(52,547)		(99,913)
Notes receivable, related parties		—		(134)
Total Stockholders' Equity / Members’ Capital attributable to Class A common stockholders		310,561		57,544
Non-controlling interests		547,452		—
Total Stockholders' Equity / Members’ Capital		858,013		57,544
Total Liabilities and Stockholders' Equity / Members’ Capital	$	2,140,084	$	623,546

        

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-7-

CANO HEALTH, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands, except share and per share data)	2021		2020		2021		2020
Revenue:
Capitated revenue (Related parties comprised $0 and $131,945, and $335,383 and $239,692, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	$	501,780	$	252,974	$	1,148,041	$	544,617
Fee-for-service and other revenue (Related parties comprised $0 and $82, and $631 and $426, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	25,018		10,159		52,055		25,020
Total revenue	526,798		263,133		1,200,096		569,637
Operating expenses:
Third-party medical costs (Related parties comprised $0 and $90,166, and $249,819 and $167,109, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	379,316		184,926		866,177		382,279
Direct patient expense (Related parties comprised $6 and $1,016, and $1,502 and $2,161, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	57,708		31,108		135,777		71,441
Selling, general, and administrative expenses (Related parties comprised $4,225 and $3,289, and $9,814 and $8,428, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	75,926		27,391		157,348		70,234
Depreciation and amortization expense	16,955		5,379		30,746		12,741
Transaction costs and other (Related parties comprised $0 and $0, and $1,483 and $5,369 in the three months ended September 30, 2021 and 2020 and nine months ended September 30, 2021 and 2020, respectively)	6,528		7,716		32,140		29,854
Total operating expenses	536,433		256,520		1,222,188		566,549
Income (loss) from operations	(9,635)		6,613		(22,092)		3,088
Other income and expense:
Interest expense	(16,023)		(12,346)		(36,363)		(21,728)

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-8-

CANO HEALTH, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Interest income (Related parties comprised $0 and $0, and $0 and $236, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	1		80		4		239
Loss on extinguishment of debt	—		—		(13,225)		—
Change in fair value of embedded derivative	—		(5,138)		—		(5,444)
Change in fair value of warrant liabilities	(14,650)		—		24,565		—
Other expenses	(29)		—		(54)		(150)
Total other expense	(30,701)		(17,404)		(25,073)		(27,083)
Net loss before income tax benefit (expense)	(40,336)		(10,791)		(47,165)		(23,995)
Income tax benefit (expense)	(547)		(326)		762		(294)
Net loss	$	(40,883)	$	(11,117)	$	(46,403)	$	(24,289)
Net loss attributable to non-controlling interests	(26,246)		—		(41,283)		—
Net loss attributable to Class A common stockholders	$	(14,637)	$	—	$	(5,120)	$	—
Net loss per share attributable to Class A common stockholders, basic	$	(0.09)	N/A		$	(0.03)	N/A
Net loss per share attributable to Class A common stockholders, diluted	$	(0.09)	N/A		$	(0.08)	N/A
Weighted-average shares used in computation of earnings per share:
Basic	170,871,429		N/A		168,100,210		N/A
Diluted	170,871,429		N/A		169,312,258		N/A

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-9-

CANO HEALTH, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / MEMBERS' CAPITAL

(UNAUDITED)

Three Months Ended September 30, 2021
(in thousands, except shares)	Class A Shares			Class B Shares			Additional Paid-in Capital		Notes Receivable		Accumulated Deficit		Non-Controlling Interests		Total Equity
	Shares			Shares
BALANCE—June 30, 2021	170,299,189	$	17	306,843,662	$	31	$	389,892	$	(136)	$	(37,640)	$	536,187	$	888,351
Stock-based compensation expense	—	—		—	—		8,909		—		—		—		8,909
Issuance of common stock for acquisitions	122,449	—		—	—		1,500		—		(11)		11		1,500
Exchange of Class B common stock for Class A common stock	1,173,276	—		(1,173,276)	—		2,309		—		(259)		(2,050)		—
Impact of transactions affecting non-controlling interests	—	—		—	—		(39,550)		—		—		39,550		—
Settlement of notes receivable, net	—	—		—	—		—		136		—		—		136
Net loss	—	—		—	—		—		—		(14,637)		(26,246)		(40,883)
BALANCE—September 30, 2021	171,594,914	$	17	305,670,386	$	31	$	363,060	$	—	$	(52,547)	$	547,452	$	858,013

Three Months Ended September 30, 2020
(in thousands, except shares)	Members' Capital			Class A Shares			Class B Shares			Additional Paid-in Capital		Notes Receivable		Accumulated Deficit		Non-Controlling Interests		Total Equity
	Shares	Amount		Shares	Amount		Shares	Amount
BALANCE - June 30, 2020	—	$	261,718	—	$	—	—	$	—	$	—	$	(132)	$	(38,213)	$	392	$	223,765
Members distributions	—	(6,125)		—	—		—	—		—		—		—		—		(6,125)
Stock-based compensation expense	—	66		—	—		—	—		—		—		—		—		66
Interest on notes receivable	—	—		—	—		—	—		—		(1)		—		—		(1)
Net loss	—	—		—	—		—	—		—		—		(11,117)		—		(11,117)
BALANCE—September 30, 2020	—	$	255,659	—	$	—	—	$	—	$	—	$	(133)	$	(49,330)	$	392	$	206,588

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-10-

CANO HEALTH, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / MEMBERS' CAPITAL

(UNAUDITED)

Nine Months Ended September 30, 2021
(in thousands, except shares)	Members' Capital			Class A Shares			Class B Shares			Additional Paid-in Capital		Notes Receivable		Accumulated Deficit		Non-Controlling Interests		Total Equity
	Shares	Amount		Shares	Amount		Shares	Amount
BALANCE—December 31, 2020	14,629,533	$	157,591	—	$	—	—	$	—	$	—	$	(134)	$	(99,913)	$	—	$	57,544
Retrospective application of reverse recapitalization	292,214,129	(157,560)		—	—		—	—		157,560		—		—		—		—
ADJUSTED BALANCE - December 31, 2020	306,843,662	$	31	—	$	—	—	$	—	$	157,560	$	(134)	$	(99,913)	$	—	$	57,544
Net loss prior to business combination	—	—		—	—		—	—		—		—		(32,078)		—		(32,078)
Business combination and PIPE financing	(306,843,662)	(31)		166,243,491	17		306,843,662	31		169,093		—		85,663		518,320		773,093
Stock-based compensation expense	—	—		—	—		—	—		12,148		—		—		—		12,148
Issuance of common stock for acquisitions	—	—		4,178,147	—		—	—		61,500		—		(840)		840		61,500
Exchange of Class B common stock for Class A common stock	—	—		1,173,276	—		(1,173,276)	—		2,309		—		(259)		(2,050)		—
Impact of transactions affecting non-controlling interests	—	—		—	—		—	—		(39,550)		—		—		39,550		—
Settlement of notes receivable, net	—	—		—	—		—	—		—		134		—		—		134
Net loss	—	—		—	—		—	—		—		—		(5,120)		(9,208)		(14,328)
BALANCE—September 30, 2021	—	$	—	171,594,914	$	17	305,670,386	$	31	$	363,060	$	—	$	(52,547)	$	547,452	$	858,013

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-11-

CANO HEALTH, INC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / MEMBERS' CAPITAL

(UNAUDITED)

Nine Months Ended September 30, 2020
(in thousands, except shares)	Members' Capital			Class A Shares			Class B Shares			Additional Paid-in Capital		Notes Receivable		Accumulated Deficit		Non-Controlling Interests		Total Equity
	Shares	Amount		Shares	Amount		Shares	Amount
BALANCE - December 31, 2019	—	$	123,242	—	$	—	—	$	—	$	—	$	(130)	$	(25,041)	$	392	$	98,463
Members' contributions	—	95,782		—	—		—	—		—		—		—		—		95,782
Stock-based compensation expense	—	177		—	—		—	—		—		—		—		—		177
Issuance of common stock for acquisitions	—	34,300		—	—		—	—		—		—		—		—		34,300
Issuance of common stock for due to sellers balance	—	2,158		—	—		—	—		—		—		—		—		2,158
Interest on notes receivable	—	—		—	—		—	—		—		(3)		—		—		(3)
Net loss	—	—		—	—		—	—		—		—		(24,289)		—		(24,289)
BALANCE—September 30, 2020	—	$	255,659	—	$	—	—	$	—	$	—	$	(133)	$	(49,330)	$	392	$	206,588

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-12-

CANO HEALTH, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

		Nine Months Ended
		September 30,
(in thousands)		2021		2020
Cash Flows from Operating Activities:
Net loss	$	(46,403)	$	(24,289)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		30,746		12,741
Change in fair value of contingent consideration		(4,152)		—
Change in fair value of embedded derivative		—		5,444
Change in fair value of warrant liabilities		(24,565)		—
Loss on extinguishment of debt		13,225		—
Amortization of debt issuance costs		7,653		3,851
Write off of other receivables		—		531
Equity-based compensation		12,148		177
Changes in operating assets and liabilities:
Accounts receivable, net (Related parties comprised $(92) and $0 as of September 30, 2021 and 2020, respectively)		(95,991)		(33,286)
Inventory		(856)		(484)
Other assets		(6,578)		217
Prepaid expenses and other current assets		(27,358)		163
Accounts payable and accrued expenses (Related parties comprised $(112) and $(52) as of September 30, 2021 and 2020, respectively)		56,626		10,480
Deferred rent (Related parties comprised $(92) and $0 as of September 30, 2021 and 2020, respectively)		2,236		868
Deferred revenue		1,147		—
Other liabilities		(9,376)		2,544
Net cash used in operating activities		(91,498)		(21,043)
Cash Flows from Investing Activities:
Purchase of property and equipment (Related parties comprised $5,697 and $5,358 as of September 30, 2021 and 2020, respectively)		(23,221)		(9,442)
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired		(1,068,661)		(205,325)
Payments to sellers		(24,148)		(38,748)
Other		—		(39)
Net cash used in investing activities		(1,116,030)		(253,554)
Cash Flows from Financing Activities:
Contributions from member		—		95,782
Business combination and PIPE financing		935,362		—
Interest accrued due to sellers		1,208		1,082
Payments of long-term debt		(656,294)		(2,378)
Debt issuance costs		(17,689)		(5,655)
Proceeds from long-term debt		1,120,000		184,096

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-13-

CANO HEALTH, INC. and SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Proceeds from revolving credit facility		—		9,700
Repayments of revolving credit facility		—		(9,700)
Proceeds from insurance financing arrangements		4,401		2,864
Payments of principal on insurance financing arrangements		(3,939)		(2,388)
Repayments of equipment loans		(233)		(57)
Repayments of capital lease obligations		(316)		(518)
Settlement of note receivable, net		134		—
Net cash provided by financing activities		1,382,634		272,828
Net increase (decrease) in cash, cash equivalents and restricted cash		175,106		(1,769)
Cash, cash equivalents and restricted cash at beginning of year		33,807		29,192
Cash, cash equivalents and restricted cash at end of period	$	208,913	$	27,423
Supplemental cash flow information:
Interest paid		28,075		11,044
Income taxes paid		1,150		—
Non-cash investing and financing activities:
Issuance of securities by Cano Health, Inc. in connection with acquisitions		61,500		—
Issuance of securities in PCIH in connection with acquisitions		—		34,300
Contingent consideration in connection with acquisitions		47,900		—
Due to sellers in connection with acquisitions		1,295		16,216
Humana Affiliate Provider clinic leasehold improvements		5,605		—
Capital lease obligations entered into for property and equipment		225		—
Equipment loan obligations entered into for property and equipment		1,013		—

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements

-14-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.    NATURE OF BUSINESS AND OPERATIONS

Nature of Business

Cano Health, Inc. (“Cano Health”, or the “Company”), formerly known as Primary Care (ITC) Intermediate Holdings, LLC (“PCIH”), provides value-based medical care for its members through a network of primary care physicians across the U.S. and Puerto Rico. The Company focuses on high-touch population health and wellness services to Medicare Advantage, Medicare Global and Professional Direct Contracting ("DC") and Medicaid capitated members, particularly in underserved communities by leveraging a proprietary technology platform to deliver high-quality health care services, resulting in superior clinical outcomes at competitive costs. As of September 30, 2021, the Company provided services through its network of 113 owned medical centers and over 345 employed providers (physicians, nurse practitioners, and physician assistants), and maintained affiliate relationships with over 1,000 physicians. The Company also operates pharmacies in the network for the purpose of providing a full range of managed care services to its members.

On June 3, 2021 (the “Closing Date”), Jaws Acquisition, Corp. (“Jaws”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 11, 2020 (as amended, the “Business Combination Agreement”) by and among Jaws, Jaws Merger Sub, LLC, a Delaware limited liability company (“Merger Sub”), PCIH, and PCIH’s sole member, Primary Care (ITC) Holdings, LLC (“Seller” or "Parent"). Upon the closing of the Business Combination, Jaws was reincorporated in the State of Delaware and changed its name to "Cano Health, Inc."

Unless the context requires, "the Company", "we", "us", and "our" refer, for periods prior to the completion of the Business Combination, to PCIH and its consolidated subsidiaries, and for periods upon or after the completion of the Business Combination, to Cano Health, Inc. and its consolidated subsidiaries, including PCIH, and its subsidiaries.

Pursuant to the Business Combination Agreement, on the Closing Date, Jaws contributed cash to PCIH in exchange for 69.0 million common limited liability company units of PCIH ("PCIH Common Units") equal to the number of shares of Jaws' Class A ordinary shares outstanding on the Closing Date as well as 17.25 million Class B ordinary shares owned by Jaws Sponsor, LLC (the "Sponsor"). In connection with the Business Combination, the Company issued 306.8 million shares of the Company’s Class B common stock to existing shareholders of PCIH. The Company also issued 80.0 million shares of the Company’s Class A common stock in a private placement for $800.0 million (the "PIPE Investors").

Following the consummation of the Business Combination, substantially all of the Company’s assets and operations are held and conducted by PCIH and its subsidiaries. As the Company is a holding company with no material assets other than its ownership of PCIH Common Units and its managing member interest in PCIH, the Company has no independent means of generating revenue or cash flow. The Company’s ability to pay taxes and pay dividends depend on the financial results and cash flows of PCIH and the distributions it receives from PCIH. The Company’s only assets are equity interests in PCIH, which represented a 35.1% and 36.0% controlling ownership as of the Closing Date and September 30, 2021, respectively. Certain members of PCIH who retained their common unit interests in PCIH held the remaining 64.9% and 64.0% non-controlling ownership interests as of the Closing Date and September 30, 2021, respectively. These members hold economic interest in PCIH through PCIH Common Units and a corresponding number of non-economic Class B common stock, which enables the holder to one vote per share.

-15-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Our organizational structure following the completion of the Business Combination is commonly referred to as an umbrella partnership-C (or Up-C) corporation structure. This organizational structure allowed the Seller, the former sole owner and managing member of PCIH, to retain its equity ownership in PCIH, an entity that is classified as a partnership for U.S. federal income tax purposes, in the form of PCIH Common Units. The former stockholders of Jaws and the PIPE Investors who, prior to the Business Combination, held Class A ordinary shares or Class B ordinary shares of Jaws, by contrast, received equity ownership in Cano Health, Inc., a Delaware corporation that is a domestic corporation for U.S. federal income tax purposes.

Subject to the terms and conditions set forth in the Business Combination Agreement, the Seller and its equity holders received aggregate consideration with a value equal to $3,534.9 million, which consisted of (i) $466.5 million of cash and (ii) $3,068.4 million shares of Cano Health, Inc.'s common stock or 306.8 million shares of Class B common stock based on a reference stock price of $10.00 per share.

Following the closing of the Business Combination, Class A stockholders owned direct controlling interests in the combined results of PCIH and Cano Health, Inc. while the Seller as the sole Class B stockholder owned indirect economic interests in PCIH shown as non-controlling interests in the condensed consolidated financial statements of Cano Health, Inc. The indirect economic interests are held by the Seller in the form of PCIH Common Units that can be redeemed for Class A common stock together with the cancellation of an equal number of shares of Class B common stock in Cano Health, Inc. The non-controlling interests will decrease as shares of Class B common stock and PCIH Common Units are exchanged for shares of Class A common stock in Cano Health, Inc. Following the redemption of 6,509 public shares outstanding for $65,090 held in the trust account, the respective controlling interest and non-controlling interests in Cano Health, Inc. and PCIH were 35.1% and 64.9% resulting from the closing of the Business Combination.

On June 11, 2021, PCIH acquired University for a total consideration of $611.1 million. The equity issued on the acquisition close date equated to 4.1 million shares of Class A common stock in Cano Health, Inc. based on a share price of $14.79 per share. Further, in the third quarter of 2021, an additional 0.1 million shares of Class A common stock in Cano Health, Inc. were issued in connection with other acquisitions and 1.2 million PCIH Common Units were exchanged for shares of Class A common stock. As noted above, as of September 30, 2021, the controlling interest and non-controlling interest in Cano Health, Inc. and PCIH was 36.0% and 64.0%, respectively.

The following table reconciles the elements of the Business Combination to the condensed consolidated statements of cash flows and the condensed consolidated statements of changes in equity for the three and nine months ended September 30, 2021:

-16-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(in thousands)	Recapitalization
Cash - Jaws' trust and cash, net of redemptions	$	690,705
Cash - PIPE financing	800,000
Less: transaction costs and advisory fees paid	(88,745)
Less: Distribution to PCIH shareholders	(466,598)
Net Business Combination and PIPE financing	935,362
Plus: Non-cash net assets assumed	96
Plus: Accrued transaction costs	8,860
Less: Capitalized transaction costs	(8,167)
Less: Warrant liability assumed	(163,058)
Net contributions from Business Combination and PIPE financing	$	773,093

The number of shares of common stock issued immediately following the consummation of the Business Combination is as follows:

	Class A common stock	Class B common stock
Common stock outstanding prior to Business Combination	69,000,000	—
Less: redemption of Jaws shares	(6,509)	—
Ordinary shares of Jaws	68,993,491	—
Jaws Sponsor Shares	17,250,000	—
Shares issued in PIPE financing	80,000,000	—
Business Combination and PIPE financing shares	166,243,491	—
Shares to PCIH shareholders	—	306,843,662
Total shares of common stock outstanding immediately after the Business Combination	166,243,491	306,843,662

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The portion of an entity not wholly-owned by the Company is presented as non-controlling interest. All significant intercompany balances and transactions are eliminated in consolidation. The financial statements of the Company’s subsidiaries are prepared using accounting policies consistent with those of the Company.

The Company has interests in various entities and considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights (“variable interest entities” or “VIEs”) and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Included in the consolidated results of the Company are Cano Health Texas, PLLC and Cano Health Nevada, PLLC (collectively, the "Physicians Groups"), which the Company has concluded are both VIEs. All material intercompany accounts and transactions have been eliminated in consolidation.

Emerging Growth Company Status

-17-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to use this extended transition period until the Company is no longer an emerging growth company or until the Company affirmatively and irrevocably opts out of the extended transition period. Accordingly, our condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

The Company could be an emerging growth company for up to five years after the first sale of our Class A common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act"). If, however, certain events occur prior to the end of such five-year period, including if the Company becomes a “large accelerated filer,” our annual gross revenue exceeds $1.07 billion or the Company issues more than $1.0 billion of non-convertible debt securities in any three-year period, the Company would cease to be an emerging growth company prior to the end of such five-year period. The Company will become a “large accelerated filer,” as defined in Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and

will lose its “emerging growth company” status as of the end of the year ending December 31, 2021. After the Company loses its “emerging growth company” status, the Company expects to incur increased legal, accounting and other expenses.

Risks and Uncertainties

As of September 30, 2021, the Company’s coverage area is primarily in the State of Florida. Given this concentration, the Company is subject to adverse economic, regulatory, or other developments in the State of Florida that could have a material adverse effect on the Company’s financial conditions and operations. In addition, federal, state and local laws and regulations concerning healthcare affect the healthcare industry. The Company’s long-term success is dependent on the ability to successfully generate revenues; maintain or reduce operating costs; obtain additional funding when needed; and ultimately, achieve profitable operations. The Company is not able to predict the content or impact of future changes in laws and regulations affecting the healthcare industry; however, management believes that its existing cash position will be sufficient to fund operating and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements.

2.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position of the Company at September 30, 2021 and December 31, 2020, and the results of operations, cash flows and changes in equity for the three and nine months ended September 30, 2021 and 2020 have been included. The results of operations and cash flows for the three and nine months ended September 30, 2021 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2021 or any other future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the

-18-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

consolidated financial statements and notes thereto included in the Company’s audited consolidated financial statements for the year ended December 31, 2020.

The Company was deemed the accounting acquirer in the Business Combination of Jaws based on an analysis of the criteria outlined in Accounting Standards Codification ("ASC") Topic 805, "Business Combinations" ("ASC 805"), as the Company’s former owner retained control after the Business Combination. Refer to Note 1, "Nature of Business", for details surrounding the Business Combination. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Jaws, accompanied by a recapitalization. The net assets of Jaws were stated at historical cost, with no goodwill or other intangible assets recorded.

While Jaws was the legal acquirer in the Business Combination, because the Company was deemed the accounting acquirer, the historical financial statements of PCIH became the historical financial statements of the combined company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements reflect the historical operating results of PCIH prior to the Business Combination, the combined results of Jaws and the Company following the close of the Business Combination, the assets and liabilities of the Company at their historical cost, and the Company’s equity structure for all periods presented.

Pursuant to the Primary Care (ITC) Intermediate Holdings, LLC Second Amended and Restated Limited Liability Company Agreement, dated June 3, 2021, PCIH is required to issue limited liability company units to Cano Health, Inc. if Cano Health, Inc. issues any equity securities, on substantially the same terms, such that the capitalization structure of PCIH shall mirror the capitalization structure of Cano Health, Inc. During the quarters ended June 30, 2021 and September 30, 2021, Cano Health, Inc. issued in the aggregate 4,178,147 shares of Class A common stock in connection with certain acquisitions. Accordingly, in November 2021, PCIH issued 4,178,147 limited liability company units to Cano Health, Inc. The issuance of these Units resulted in a $39.6 million increase in the Company's non-controlling interests and a corresponding decrease in additional paid in capital with no effect on total stockholder's equity. The Company has reflected the November 2021 PCIH unit issuance related to the quarter ended June 30, 2021 totaling $38.6 million during the third quarter of 2021 as the amount was not material and did not impact total stockholders' equity / members’ capital.

Warrant Liabilities

The Company assumed 23.0 million public warrants ("Public Warrants") and 10.53 million private placement warrants ("Private Placement Warrants") upon the consummation of the Business Combination. The Company may issue or assume common stock warrants that are recorded as either liabilities or equity in accordance with the respective accounting guidance. Warrants recorded as equity are recorded at their relative fair value or fair value determined at the issuance date and remeasurement is not required. Warrants recorded as liabilities are recorded at their fair value, within warrant liability on the condensed consolidated balance sheets, and remeasured on each reporting date with changes recorded in revaluation of warrant liability on the Company’s condensed consolidated statements of operations.

The Public Warrants became exercisable 30 days after the consummation of the Business Combination, which occurred on June 3, 2021. The Public Warrants will expire five years after the consummation of the Business Combination, or earlier upon redemption or liquidation. The Private Placement Warrants are identical to the Public Warrants, except that so long as the Private Placement Warrants are held by the Sponsor or any of its permitted transferees, the Private Placement Warrants: (i) may be exercised for cash or on a “cashless basis”, (ii) may not be transferred, assigned or sold until 30 days after the completion of the initial Business Combination, (iii) shall not be redeemable by the Company when the Class A ordinary shares equal or exceed $18.00, and (iv) shall only be

-19-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

redeemable by the Company when the Class A ordinary shares are less than $18.00 per share, subject to certain adjustments.

The Company evaluated the Public Warrants and Private Placement Warrants and concluded that they do not meet the criteria to be classified as shareholders’ equity in accordance with ASC 815-40, “Derivatives and Hedging–Contracts in Entity’s Own Equity” ("ASC 815"). As the Public Warrants and Private Placement Warrants also meet the definition of a derivative under ASC 815, the Company has recorded these warrants as liabilities on its condensed consolidated balance sheets, with changes in their respective fair values recognized in the statement of operations at each reporting date.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts with Customers”, ASC 606 (“ASC 606”). On January 1, 2019, the Company adopted ASC 606, applying the full retrospective method as of the earliest period presented. The portfolio approach was used to apply the requirements of the standard to groups of contracts with similar characteristics.

Under ASC 606, the Company recognizes revenue when a customer obtains control of the promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company transfers to the customer (i.e., patient). At contract inception, once the contract is determined to be within the scope of ASC 606, management reviews the contract to determine which performance obligations must be satisfied and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

The Company derives its revenue primarily from its capitated fees for medical services provided under capitated arrangements, fee-for-service arrangements, and revenue from the sale of pharmaceutical drugs.

Capitated revenue is derived from fees for medical services provided by the Company under capitated arrangements with health maintenance organizations’ (“HMOs”) health plans. Capitated revenue consists of revenue earned through Medicare as well as through commercial and other non-Medicare governmental programs, such as Medicaid, which is captured as other capitated revenue. The Company is required to deliver primary care physician services to the enrolled member population and is responsible for medical expenses related to healthcare services required by that patient group, including services not provided by the Company. Since the Company controls the primary care physician services provided to enrolled members, the Company acts as a principal. The gross fees under these contracts are reported as revenue and the cost of provider care is included in third-party medical costs. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which they operate does not require such registration for risk-bearing providers.

Since contractual terms across these arrangements are similar, the Company groups them into one portfolio. The Company identifies a single performance obligation to stand-ready to provide healthcare services to enrolled members. Capitated revenue is recognized in the month in which the Company is obligated to provide medical care services. The transaction price for the Medicare Advantage and Medicare Direct Contracting services provided

-20-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

depends upon the pricing established by the Centers for Medicare & Medicaid (“CMS”) and includes rates that are based on the cost of medical care within a local market and the average utilization of healthcare services by the members enrolled. The transaction price is variable since the rates are risk adjusted for projected health status (acuity) of members and demographic characteristics of the enrolled members. The risk adjustment to the transaction price is presented as the Medicare Risk Adjustment (“MRA”) within accounts receivable on the accompanying condensed consolidated balance sheets. The fees are paid on an interim basis based on submitted enrolled member data for the previous year and are adjusted in subsequent periods after the final data is compiled by the CMS.

In 2020, the Company entered into multi-year agreements with Humana, Inc. (“Humana”), a managed care organization, to provide services only to members covered by Humana in certain centers. The agreements contain an administrative payment from Humana in exchange for the Company providing certain care coordination services during the contract term. The care coordination payments are refundable to Humana on a pro-rata basis if the Company ceases to provide services at the centers within the specified contract term. The Company identified one performance obligation to stand-ready to provide care coordination services to patients and will recognize revenue ratably over the contract term. Care coordination revenue is included in other revenue along with other ancillary healthcare revenues.

Fee-for-service revenue is generated from primary care services provided in the Company’s medical centers. During an office visit, a patient may receive a number of medical services from a healthcare provider. These healthcare services are not separately identifiable and are combined into a single performance obligation. The Company recognizes fee-for-service revenue at the net realizable amount at the time the patient is seen by a provider, and the Company’s performance obligation to the patient is complete.

Pharmacy revenue is generated from the sales of prescription medication to patients. Pharmacy contracts contain a single performance obligation. The Company satisfies its performance obligation and recognizes revenue at the time the patient takes possession of the merchandise. Other revenue includes revenue from certain third parties which include ancillary fees earned under contracts with certain care organizations for the provision of care coordination services.

The Company’s revenue from its revenue streams described in the preceding paragraphs for the three and nine months ended September 30, 2021 and 2020 was as follows:

-21-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

		Three Months Ended September 30,
(in thousands)		2021			2020
		Revenue $	Revenue %		Revenue $	Revenue %
Capitated revenue:
Medicare	$	447,250	84.9%	$	220,591	83.8	%
Other capitated revenue		54,530	10.4%		32,383	12.3	%
Total capitated revenue		501,780	95.3%		252,974	96.1	%
Fee-for-service and other revenue:
Fee-for-service		8,176	1.6%		3,258	1.2	%
Pharmacy		10,096	1.8%		6,154	2.4	%
Other		6,746	1.3%		747	0.3	%
Total fee-for-service and other revenue		25,018	4.7%		10,159	3.9	%
Total revenue	$	526,798	100.0%	$	263,133	100.0	%

		Nine Months Ended September 30,
		2021				2020
(in thousands)		Revenue $	Revenue %			Revenue $	Revenue %
Capitated revenue:
Medicare	$	1,008,329	84.0	%	$	455,986	80.0	%
Other capitated revenue		139,712	11.6	%		88,631	15.6	%
Total capitated revenue		1,148,041	95.7	%		544,617	95.6	%
Fee-for-service and other revenue:
Fee-for-service		17,113	1.4	%		6,269	1.1	%
Pharmacy		25,619	2.1	%		17,207	3.0	%
Other		9,323	0.8	%		1,544	0.3	%
Total fee-for-service and other revenue		52,055	4.3	%		25,020	4.4	%
Total revenue	$	1,200,096	100.0	%	$	569,637	100.0	%

As the performance obligations from the Company’s revenues are recognized at a point in time and the revenues recognized over time relate to contracts with a duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) which provides relief from the requirement to disclose the transaction price for remaining performance obligations at the end of each reporting period and the requirement to disclose when the Company expects to recognize the related revenue. The Company has de minimis performance obligations remaining at the end of the reporting period as patients are not contractually obligated to continue to receive medical care from the network of providers.

Third-Party Medical Costs

Third-party medical costs primarily consist of all medical expenses paid by the health plans or CMS, including inpatient and hospital care, specialists, and medicines for which the Company bears risk.

-22-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Direct Patient Expense

Direct patient expense primarily consists of costs incurred in the treatment of the patients, including the compensation related to medical service providers and technicians, medical supplies, purchased medical services, drug costs for pharmacy sales, and payments to third-party providers.

Third-party medical costs and direct patient expense collectively represent the cost of services provided.

Significant Vendor

The Company’s primary provider of pharmaceutical drugs and pharmacy supplies accounted for approximately 87% and 100%, and 96% and 100%, of the Company’s pharmaceutical drugs and supplies expense for the three months ended September 30, 2021, and 2020, respectively, and nine months ended September 30, 2021, and 2020, respectively.

Concentration of Risk

Contracts with three of the HMOs accounted for approximately 57.2% and 63.6% of total revenues for the three and nine months ended September 30, 2021, respectively, and approximately 39.8% of total accounts receivable as of September 30, 2021. Contracts with three of the HMOs accounted for approximately 70.2% and 67.5% of total revenues for the three and nine months ended September 30, 2020, respectively, and approximately 67.1% of total accounts receivable as of December 31, 2020. The loss of revenue from these contracts could have a material adverse effect on the Company. The percentage of accounts receivable related to the three HMOs decreased over the nine-month period ended September 31, 2021 due to an increase in acquisitions over that time period. The acquisitions significantly increased overall accounts receivable over this period, effectively diluting accounts receivable from the HMOs.

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash deposits in excess of the Federal Deposit Insurance Corporation insured limit of $0.3 million. At times, such cash balances may be in excess of insured amounts.

Cash and Restricted Cash

Cash and cash equivalents are highly liquid investments purchased with original maturities of three months or less. During the third quarter of 2021, two health plans required the Company to maintain restricted cash balances for an aggregate amount of $3.5 million. These restricted cash balances are included within the caption cash and restricted cash in the accompanying condensed consolidated balance sheets.

Inventory

Inventory consists entirely of pharmaceutical drugs and is valued at the lower of cost (under the first-in, first-out method) or net realizable value.

Accounts Receivable, Net of Unpaid Service Provider Costs

Accounts receivable are carried at amounts the Company deems collectible. Accordingly, an allowance is provided in the event an account is considered uncollectible. As of September 30, 2021 and December 31, 2020, the Company believes no allowance is necessary. The ultimate collectability of accounts receivable may differ from

-23-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

amounts estimated. The period between the time when the service is performed by the Company and the fees are received is usually one year or less and therefore, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust accounts receivable for the effect of a significant financing component.

Included in accounts receivable are MRA receivables which is an estimate derived from adjustments based on the health status of members and demographic characteristics of the plan. The health status of members is used to determine a risk score which is actuarially determined by comparing what was received from the CMS and what should have been received based on the health status of the enrolled member. Our accounts receivable included MRA receivables in the amount of $108.6 million and $18.1 million as of September 30, 2021 and December 31, 2020, respectively.

As of September 30, 2021 and December 31, 2020, the Company’s accounts receivable were presented net of the unpaid service provider costs. A right of offset exists when all of the following conditions are met: 1) each of the two parties owed the other determinable amounts; 2) the reporting party has the right to offset the amount owed with the amount owed to the other party; 3) the reporting party intends to offset; and 4) the right of offset is enforceable by law. The Company believes all of the aforementioned conditions existed as of September 30, 2021 and December 31, 2020.

Accounts receivable balances are summarized below:

		As of,
(in thousands)		September 30, 2021		December 31, 2020
Accounts receivable	$	242,086	$	113,089
Medicare risk adjustment		108,570		18,144
Unpaid service provider costs		(127,012)		(54,524)
Accounts receivable, net	$	223,644	$	76,709

Activity in unpaid service provider cost for the nine months ended September 30, 2021 and 2020 is summarized below:

		For the nine months ended September 30,
(in thousands)		2021		2020
Balance as at January 1,	$	54,524	$	19,968
Incurred related to:
Current year		566,473		216,044
Prior years		3,526		793
		569,999		216,837
Paid related to:
Current year		439,460		172,749
Prior years		58,051		20,761
		497,511		193,510
Balance as at September 30,	$	127,012	$	43,295

The foregoing reconciliation reflects a change in estimate during the nine months ended September 30, 2021 and September 30, 2020 related to unpaid service provider costs of approximately $3.5 million and $0.8 million, respectively.

-24-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Unpaid Service Provider Cost

Provider costs are accrued based on the date of services rendered to members, based in part on estimates, including an accrual for medical services incurred but not reported (“IBNR”). Liabilities for IBNR are estimated using standard actuarial methodologies including the Company’s accumulated statistical data, adjusted for current experience. These actuarially determined estimates are continually reviewed and updated. Differences between estimated IBNR and actual amounts incurred are adjusted as an increase or decrease to service provider cost in the condensed consolidated statements of operation in the period they become known.

The Company believes the amounts accrued to cover claims incurred and unpaid as of September 30, 2021 and December 31, 2020 are adequate. However, as the amount of unpaid service provider cost is based on estimates, the ultimate amounts paid to settle these liabilities might vary from recorded amounts, and these differences may be material.

The Company maintains a provider excess loss insurance policy to protect against claim expenses exceeding certain levels that were incurred by the Company on behalf of members. As of September 30, 2021 and December 31, 2020, the Company’s excess loss insurance deductible was $0.1 million and maximum coverage was $2.0 million per member per calendar year. The Company recorded excess loss insurance premiums of $1.9 million and $5.4 million, and insurance reimbursements of $3.6 million and $5.4 million, for the three and nine months ended September 30, 2021, respectively. The Company recorded excess loss insurance premiums of $1.3 million and $3.6 million, and no insurance reimbursements, for the three and nine months ended September 30, 2020, respectively. The Company recorded these amounts on a net basis in the caption third-party medical costs in the accompanying condensed consolidated statements of operations. The Company records excess loss insurance recoveries in accounts receivable on the accompanying condensed consolidated balance sheets. As of September 30, 2021 and December 31, 2020, the Company recorded insurance recoveries of $3.5 million and $2.5 million, respectively.

Debt Issuance Costs

Debt issuance costs represent fees incurred by the Company in connection with securing funding from a lender. These are lender fees and third-party professional fees that would not have been incurred if the Company did not pursue and secure financing. In circumstances where an embedded derivative is bifurcated from a host credit agreement and recorded as a standalone instrument at fair value, the debt issuance costs will reflect the initial fair value of such derivative. At inception of a credit agreement, these debt issuance costs are capitalized and presented net against the carrying amount of the related debt liabilities in the accompanying condensed consolidated balance sheets. Following recognition, they are amortized over the term of their related credit agreement through interest expense in the accompanying statements of operations through the effective interest method. In instances where there is no related debt drawn or outstanding, the debt issuance costs are presented in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets.

As of September 30, 2021 and December 31, 2020, the Company recorded capitalized deferred issuance cost balances of $24.2 million and $24.9 million, respectively, in the accompanying condensed consolidated balance sheets, as described in Note 9, “Long-Term Debt”. Of the balance as of September 30, 2021, $23.5 million was included in the caption notes payable, net of current portion and debt issuance costs, $0.2 million in prepaid expenses and other current assets, and $0.5 million in other assets on the accompanying condensed consolidated balance sheets. Of the balance as of December 31, 2020, $18.5 million was included in the caption notes payable,

-25-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

net of current portion and debt issuance costs, $5.8 million in prepaid expenses and other current assets, and $0.6 million in other assets on the accompanying condensed consolidated balance sheets.

As described in Note 9, “Long-Term Debt”, Term Loan 3 (as defined below) was partially repaid by the Company on June 3, 2021. The Company’s partial extinguishment of this Term Loan consisted of a cash payment to the lender for (1) $400.0 million of the outstanding principal amount, and (2) the outstanding accrued interest. The Company recorded a loss on extinguishment of debt of $13.2 million which related to unamortized debt issuance costs.

The Company recorded $4.0 million and $7.7 million of amortization of deferred financing costs for the three and nine months ended September 30, 2021, respectively. The Company recorded amortization expense of $3.0 million and $3.9 million for the three and nine months ended September 30, 2020, respectively. Amortization expense is reflected under the caption interest expense in the accompanying condensed consolidated statements of operations.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. The Company capitalizes asset purchases as well as major improvements that extend the useful life or add functionality, value, or productive capacity in amounts greater than one thousand dollars. Depreciation and amortization are computed using the straight-line method over the life of the assets, ranging from three to fifteen years. Leasehold improvements are amortized over the shorter of the estimated useful life of fifteen years or the term of the lease.

Repairs and maintenance are expensed as incurred. When property and equipment are retired, sold, or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in the accompanying condensed consolidated statements of operations.

Impairment of Long-Lived Assets

The Company periodically reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Business Acquisitions

The Company accounts for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. The Company uses various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, EBITDA growth rates, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. Refer to Note 3, "Business Acquisitions," for a discussion of the Company's recent acquisitions.

Goodwill

-26-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets acquired. The goodwill arising from acquisitions is a result of synergies that are expected to be derived from elimination of duplicative costs and the achievement of economies of scale. The Company assesses goodwill for impairment on an annual basis and between tests if events occur or circumstances exist that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual assessment on the first of October. Goodwill is evaluated for impairment at the reporting unit level. The Company has identified one reporting unit for the annual goodwill impairment testing. First, the Company performs a qualitative analysis to determine if it is more likely than not that the fair value of the reporting unit is less than its carrying value and a quantitative impairment test is required. If required, the Company applies the quantitative test to identify and measure the amount of impairment by comparing the fair value of the reporting unit, which the Company estimates on an income approach using the present value of expected future cash flows of the reporting unit to its carrying value.

The Company considered the effect of the COVID-19 pandemic on its business and the overall economy and resulting impact on its goodwill. As of October 1, 2020, the Company performed a quantitative goodwill impairment test and did not identify any impairment to goodwill. There was no impairment to goodwill during the nine months ended September 30, 2021 and 2020. The Company will perform its annual impairment analysis as of October 1, 2021.

Intangibles, Net

The Company’s intangibles consist of trade names, brand, non-compete, and customer, payor, and provider relationships. The Company amortizes its intangibles using the straight-line method over the estimated useful lives of the intangible, which ranges from one to twenty years. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

Deferred Rent

Minimum rent, including fixed escalations, is recorded on a straight-line basis over the lease term. The lease term commences when the Company takes possession of the leased premises and, in most cases, ends upon expiration of the initial non-cancelable term. When a lease provides for fixed escalations of the minimum rental payments during the lease term, the difference between the recorded straight-line rent and the amount payable under the lease is recognized as deferred rent obligation.

Professional and General Liability

As a healthcare provider, the Company is subject to medical malpractice claims and lawsuits. The Company may also be liable, as an employer, for the negligence of healthcare professionals it employs or the healthcare professionals it engages as independent contractors. To mitigate a portion of this risk, the Company maintains medical malpractice insurance, principally on a claims-made basis, with a reputable insurance provider. This policy contains a retroactive feature which covers claims incurred at the sites the Company operates, regardless if the claim was filed after the site’s respective policy term. The policy contains various limits and deductibles.

Loss contingencies, including medical malpractice claims and legal actions arising in the ordinary course of business, are recorded as liabilities when the likelihood of loss is probable, and an amount or range of loss can be reasonably estimated.

-27-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company maintains a malpractice insurance policy with a coverage limit of $1.0 million per occurrence and $3.0 million aggregate coverage, with an umbrella policy coverage of $5.0 million. Any amounts over that threshold, or for which the insurance policy will not cover, will be borne by the Company and may materially affect the Company’s future consolidated financial position, results of operations, and cash flows. As of September 30, 2021 and December 31, 2020, the Company has recorded claims liabilities of $0.5 million and $0.1 million, respectively, in other liabilities. Insurance recoverables were immaterial as of September 30, 2021 and December 31, 2020, and are recorded in other assets on the accompanying condensed consolidated balance sheets.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. Advertising and marketing costs expensed totaled approximately $4.9 million and $2.4 million for the three months ended September 30, 2021 and 2020, respectively, and $10.5 million and $4.9 million for the nine months ended September 30, 2021 and 2020, respectively. Advertising and marketing costs are included in the caption selling, general, and administrative expenses in the accompanying condensed consolidated statements of operations.

Management Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions based on available information. Such estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. However, actual results could differ from those estimates and these differences may be material. Significant estimates made by the Company include, but are not limited to, fair value allocations for intangible assets acquired as part of the Company’s numerous acquisitions, recoverability of goodwill and intangibles, fair value of contingent considerations, unpaid service provider cost liability, and respective revenues and expenses related to these estimates for the years reported.

COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. The rapid spread of COVID-19 around the world led to the shutdown of cities as national, state, and local authorities implemented social distancing, quarantine and self-isolation measures. [While the restrictions have been eased across the United States, some restrictions remain in place.] The full extent to which the COVID-19 pandemic has and will directly or indirectly impact the Company, future results of operations and financial condition will depend on future factors that are uncertain and cannot be accurately predicted. These factors include, but are not limited to, new information that may emerge concerning COVID-19, including the impact of new variants of the virus, the scope and duration of business closures and restrictions, government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Due to these and other uncertainties, management cannot estimate the length or severity of the impact of the pandemic on the Company. Additionally, because of the Company’s business model, the full impact of the COVID-19 pandemic may not be fully reflected in the Company’s results of operations and overall financial condition until future periods. The impact of COVID-19 variants cannot be predicted at this time, and could depend on numerous factors, [including vaccination rates among the population, the effectiveness of the COVID-19 vaccines and boosters against COVID-19 variants, and the actions taken to contain the COVID-19 pandemic and the economic impact on our business]. Management will continue to closely evaluate and monitor the nature and extent of these potential impacts to the Company, results of operations, and liquidity

Income Taxes

-28-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The acquisition of PCIH was implemented through an Up-C structure. Prior to the closing of the Business Combination, Jaws was reincorporated in the State of Delaware and became a U.S. domestic corporation named Cano Health, Inc. Merger Sub, a wholly owned subsidiary of Jaws, merged with and into PCIH, with PCIH as the surviving company in the merger. As of September 30, 2021, the Seller, the former sole owner and managing member of PCIH, held approximately 64.0% of voting rights in Cano Health, Inc. and 64.0% of economic rights in PCIH, while other investors, including the former stockholders of Jaws and PIPE Investors held approximately 36.0% of economic and voting rights in Cano Health, Inc. and 36.0% of economic and 100.0% of managing rights in PCIH. Subsequent to the closing of the Business Combination, income attributable to Cano Health, Inc. is taxed under Subchapter C while PCIH will continue to be treated as a partnership for tax purposes.

Prior to the close of the Business Combination, the Company was treated as a partnership for U.S. income tax purposes, whereby earnings and losses were included in the tax return of its members and taxed depending on the members’ tax situation. While the overall entity was previously treated as a partnership, the Company established in 2019 a subsidiary group that was taxed under Subchapter C with immaterial operations in 2019. The operations of the subsidiary group are conducted through a legal entity domiciled in Puerto Rico. The subsidiary group is subject to Puerto Rico and U.S. Federal taxes and Florida State taxes. Refer to Note 16, “Income Taxes”, for further details.

The Company recognizes and measures tax positions taken or expected to be taken in its tax return based on their technical merit and assesses the likelihood that the positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. Interest and penalties on tax liabilities, if any, would be recorded in the captions interest expense and other expenses, respectively, in the condensed consolidated statements of operations.

The U.S. Federal jurisdiction and the State of Florida are the major tax jurisdictions where the Company files income tax returns. The Company is generally subject to U.S. Federal or State examinations by tax authorities for all years since inception.

Recent Accounting Pronouncements 

In February 2016, the FASB established Topic 842, “Leases”, by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, “Land Easement Practical Expedient for Transition to Topic 842”, ASU No. 2018-10, “Codification Improvements to Topic 842, Leases”, ASU No. 2018-11, “Targeted Improvements”, ASU No. 2018-20, “Leases (Topic 842): Narrow-Scope Improvements for Lessors”, ASU No. 2021-05, “Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments”, and ASU No. 2020-05, “Leases (Topic 842): Effective Dates for Certain Entities” (collectively referred to as “ASC 842”). ASC 842 establishes a right of use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

Under ASC 842, a modified retrospective transition approach is required, and entities may choose to use either the effective date or the beginning of the earliest period presented in the financial statements as the date of initial application, with certain practical expedients available. The Company is in the process of evaluating the practical expedient options for adoption. ASC 842 is effective for fiscal years beginning after December 15, 2021 and for interim periods within fiscal years beginning after December 15, 2022, with early application permitted, and the Company expects to adopt the new standard on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier.

-29-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company has identified and contracted with a software vendor for the technology to support compliance with ASU 842. In addition, the Company is in the process of identifying the complete population of leases, which includes testing over contracts for any potential embedded leases. Based on the provisions of ASU 842, the Company anticipates a material increase in both assets and liabilities when the current operating lease contracts are recorded on the balance sheet. The Company does not yet have a dollar estimate of the impact; however, the Company does not anticipate the update having a material effect on its condensed consolidated statements of operations or cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU No. 2020-03, “Codification Improvements to Financial Instruments” (collectively referred to as “ASC 326”). which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. The standard has been further refined through subsequent releases by the FASB, including the extension of the effective date. As amended by ASU No. 2019-10, the standard is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those annual periods, with early adoption permitted, and the Company expects to adopt ASU 326 on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier. The Company is currently evaluating the effect that the standard will have on its condensed consolidated financial statements and related disclosures. The Company does not anticipate the update to have a material effect on the Company’s condensed consolidated statements of operations or cash flows.

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (“Topic 718”), which expands the scope of share-based compensation guidance to include share-based payment transactions for acquiring goods and services from nonemployees. The FASB has also issued an amendment to this update to include share-based payment awards granted to a customer. The update is effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (“Topic 820”): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which simplifies the fair value measurement disclosure requirements, including removing certain disclosures related to transfers between fair value hierarchy levels and adds certain disclosures to related level 3 investments. The update is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, with early adoption permitted. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In October 2018, the FASB issued ASU No. 2018-17, Consolidation (“Topic 810”) — Targeted Improvements to Related Party Guidance for Variable Interest Entities. The ASU creates a new private company accounting alternative in U.S. GAAP that allows a private company to not apply the VIE guidance to legal entities under common control if both the common control parent and the legal entity being evaluated for consolidation are not public business entities and other criteria are met. The new guidance also changes how all entities that apply the VIE guidance evaluate decision-making fees. For entities other than private companies, the guidance on decision-making fees is effective for annual periods beginning after December 15, 2019, and interim periods therein. The guidance is effective for private companies for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including in an interim period. The Company does not expect the update to have a material effect on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), “Simplifying the Accounting for Income Taxes.” This new standard simplifies various aspects related to the accounting for income taxes. The standard removes certain exceptions to the general principles in Topic 740 and also clarifies and modifies

-30-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

existing guidance to improve consistent application of Topic 740. The Company adopted this standard effective January 1, 2021 with no material impact to its condensed consolidated financial statements.

3.    BUSINESS ACQUISITIONS

Doctor’s Medical Center, LLC

On July 2, 2021, the Company acquired Doctor's Medical Center, LLC and its affiliates (“DMC”) for a purchase price of $300.7 million in cash. DMC sellers entered into non-compete agreements with the Company. The Company recorded non-compete intangible assets totaling $1.7 million with a weighted-average amortization period of five years.

The purchase price has been allocated to accounts receivable, net of unpaid service provider costs, property and equipment, net, other assets, favorable leasehold interest, non-compete intangibles, trade name, payor relationships, goodwill, and accounts payable and accrued expenses. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	6,641
Property and equipment, net		1,283
Other assets		142
Favorable leasehold interest		110
Non-compete intangibles		1,700
Trade name		25,500
Payor relationships		115,100
Goodwill		151,188
Accounts payable and accrued expenses		(1,001)
Total purchase price, including non-compete intangibles	$	300,663

Total revenues and net income attributable to the assets acquired in the DMC acquisition were approximately $45.6 million and $4.4 million, respectively, for the three and nine months ended September 30, 2021.

University Health Care and its affiliates

On June 11, 2021, the Company acquired University Health Care and its affiliates (collectively, “University”). The purchase price totaled $611.1 million, of which $541.5 million was paid in cash, $9.6 million in contingent consideration from forfeited acquisition add-ons based on terms negotiated by University prior to closing, and $60.0 million in 4,055,698 shares of the Company’s Class A common stock. University sellers entered into non-compete agreements with the Company. The Company recorded non-compete intangible assets totaling $45.2 million with a weighted-average amortization period of five years.

-31-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The purchase price has been allocated to accounts receivable, net of unpaid service provider costs, inventory, property and equipment, payor relationships, non-compete intangibles, other acquired intangibles, other assets, goodwill, and accounts payable and accrued expenses. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	2,217
Inventory		264
Property and equipment, net		1,636
Payor relationships		175,172
Non-compete intangibles		45,191
Other acquired intangibles		113,237
Other assets		116
Goodwill		273,427
Accounts payable and accrued expenses		(140)
Total purchase price, including non-compete intangibles	$	611,120

Total revenues attributable to the assets acquired in the University acquisition were approximately $89.3 million and $120.5 million for the three and nine months ended September 30, 2021, respectively. Net income attributable to the assets acquired in the University acquisition was approximately $10.6 million and $26.7 million for the three and nine months ended September 30, 2021, respectively.

HP Enterprises II, LLC and related entities

On June 1, 2020, the Company acquired all of the assets of HP Enterprises II, LLC and related entities (collectively, “Healthy Partners”). The purchase price totaled $195.4 million, of which $149.3 million was paid in cash (including $18.0 million paid to an escrow agent, of which $17.1 million was released on January 13, 2021 and $0.9 million is to be released on June 1, 2022), and $30.0 million in 923,076 Class A-4 Units of Primary Care (ITC) Intermediate Holdings, LLC’s securities. The remaining amount of $16.1 million related to payment reconciliations was held back, and is due no later than five days following January 31, 2022. The physicians entered into employment agreements with the Company which included covenants not to compete. The Company recorded non-compete intangible assets totaling $1.0 million with a weighted-average amortization period of five years.

The purchase price has been allocated to property and equipment, non-compete intangibles, acquired intangibles, goodwill, and other assets. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

-32-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(in thousands)
Property and equipment	$	2,409
Non-compete intangibles		1,022
Acquired intangibles		117,014
Goodwill		74,852
Other assets		87
Total purchase price, including non-compete intangibles	$	195,384

Total revenues attributable to the assets acquired in the Healthy Partners acquisition were approximately $95.0 million and $274.0 million for the three months and nine months ended September 30, 2021, respectively, and approximately $81.1 million and $114.7 million for the three months and nine months ended September 30, 2020, respectively. Net income attributable to the assets acquired in the Healthy Partners acquisition was approximately $15.8 million and $39.1 million for the three months and nine months ended September 30, 2021, respectively, and approximately $7.6 million and $9.8 million for the three months and nine months ended September 30, 2020.

Primary Care Physicians and related entities

On January 2, 2020, the Company acquired all of the assets of Primary Care Physicians and related entities (collectively, “PCP”). The purchase price totaled $60.2 million, of which $53.6 million was paid in cash and $4.0 million was paid in 123,077 Class A-4 Units of Primary Care (ITC) Intermediate Holdings, LLC. The remaining amount includes $1.5 million related to the pay-down of debt, and $1.1 million related to the pay-down of accounts payable and accrued expenses of PCP. The physicians entered into employment agreements with the Company and these agreements included covenants not to compete. The Company recorded non-compete intangible assets totaling $0.8 million with a weighted-average amortization period of three years.

The purchase price has been allocated to cash and cash equivalents, accounts receivable, inventory, property and equipment, non-compete intangibles, acquired intangibles, goodwill, and accounts payable. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Cash and cash equivalents	$	191
Accounts receivable		486
Inventory		155
Property and equipment		1,518
Non-compete intangibles		846
Acquired intangibles		43,549
Goodwill		13,738
Accounts payable		(274)
Total purchase price, including non-compete intangibles	$	60,209

Total revenues attributable to the assets acquired in the PCP acquisition were approximately $33.4 million and $33.0 million for the three months ended September 30, 2021 and 2020, respectively, and $78.4 million and $45.6 million for the nine months ended September 30, 2021 and 2020, respectively. Net income attributable to the

-33-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

assets acquired in the PCP acquisition was $4.9 million and $1.7 million for the three months ended September 30, 2021 and 2020, respectively, and $12.9 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively.

The net effect of acquisitions to the Company’s assets and liabilities and reconciliation of cash paid for net assets acquired for the nine months ended September 30, 2021 and 2020, including amounts related to acquisitions not disclosed above, was as follows:

		Nine Months Ended September 30,
(in thousands)		2021		2020
Assets Acquired
Accounts receivable	$	50,979	$	486
Other assets		2,050		433
Property and equipment		3,411		4,011
Goodwill		531,162		89,976
Intangibles		637,537		162,537
Total assets acquired		1,225,139		257,443
Liabilities Assumed
Due to sellers		1,295		16,288
Contingent consideration		47,900		—
Other liabilities		45,783		1,530
Total liabilities assumed		94,978		17,818
Net Assets Acquired		1,130,161		239,625
Issuance of Parent equity in connection with acquisitions		61,500		34,300
Acquisitions of subsidiaries, including non-compete intangibles, net of cash acquired	$	1,068,661	$	205,325

Pro forma information is not presented for all of the Company’s acquisitions during the three months and nine months ended September 30, 2021 and 2020 as historical financial results were unavailable for all businesses acquired. The following unaudited pro forma financial information summarizes the combined results of operations for the Company and its acquisitions of University and HP, as if the companies were combined as of January 1, 2020:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2021		2020		2021		2020
Revenue	$	526,798	$	350,976	$	1,354,547	$	979,355
Net loss	$	(40,883)	$	(14,398)	$	(53,592)	$	(8,566)

4.    PROPERTY AND EQUIPMENT, NET

The following is a summary of property and equipment, net and the related useful lives as of September 30, 2021 and December 31, 2020:

-34-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

			As of
(in thousands)			September 30,		December 31,
Assets Classification	Useful Life		2021		2020
Leasehold improvements	Lesser of lease term or 15 years	$	33,288	$	25,021
Machinery and equipment	3-12 years		14,403		8,288
Automobiles	3-5 years		6,679		4,900
Computer and equipment	5 years		5,950		4,475
Furniture and equipment	3-7 years		3,242		2,390
Construction in progress			19,057		4,155
Total			82,619		49,229
Less: Accumulated depreciation and amortization			(18,463)		(11,103)
Property and equipment, net		$	64,156	$	38,126

Depreciation expense was $2.7 million and $1.8 million for the three months ended September 30, 2021 and 2020, respectively, and $7.4 million and $4.5 million for the nine months ended September 30, 2021 and 2020, respectively. The Company paid a related party for construction in progress and leasehold improvements totaling $3.2 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and totaling $5.6 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively. The Company had $0.1 million due from the related party as of September 30, 2021 and $0.1 million due to the related party as of December 31, 2020, respectively, related to the construction in progress and leasehold improvements. These payments are included in the caption accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets.

The Company records construction in progress related to vehicles, computer equipment, medical equipment, furniture, and fixtures that have been acquired but have not yet been placed in service as of the reporting date, as well as leasehold improvements currently in progress.

5.    INTANGIBLES, NET

As of September 30, 2021, the Company’s total intangibles, net consisted of the following:

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(747)	$	662
Brand		183,217		(6,286)		176,931
Non-compete		75,626		(8,270)		67,356
Customer relationships		880		(171)		709
Payor relationships		609,322		(25,057)		584,265
Provider relationships		12,242		(1,573)		10,669
Total intangibles, net	$	882,696	$	(42,104)	$	840,592

As of December 31, 2020, the Company’s total intangibles, net consisted of the following:

-35-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(630)	$	779
Brand		29,486		(2,171)		27,315
Non-compete		7,733		(3,373)		4,360
Customer relationships		880		(135)		745
Payor relationships		201,530		(11,960)		189,570
Provider relationships		4,119		(533)		3,586
Total intangibles, net	$	245,157	$	(18,802)	$	226,355

The Company recorded amortization expense of $14.2 million and $3.6 million for the three months ended September 30, 2021 and 2020, respectively, and $23.3 million and $8.2 million for the nine months ended September 30, 2021 and 2020, respectively.

Expected amortization expense for the Company’s existing amortizable intangibles for the next five years, and thereafter, as of September 30, 2021 is as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	15,075
2022		59,423
2023		57,585
2024		55,644
2025		54,218
Thereafter		598,647
Total	$	840,592

6.    CAPITAL LEASE OBLIGATIONS

The Company enters into non-cancellable capital lease agreements with third parties, bearing interest at rates ranging from 4.1% to 12.1%, and expiring through the year 2026. The assets and liabilities under the capital leases are recorded at the present value of the minimum lease payments. The assets are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful lives. The assets under capital leases are included in the accompanying condensed consolidated balance sheets as property and equipment, net, with a gross asset value of $4.7 million and $4.2 million, and accumulated depreciation of $1.5 million and $1.5 million, as of September 30, 2021 and December 31, 2020, respectively. The depreciation of capital leases is included in depreciation and amortization.

Future minimum lease payments under the capital leases as of September 30, 2021 are due as noted below:

-36-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	307
2022		1,151
2023		819
2024		514
2025		76
2026		25
Total minimum lease payments		2,892
Less: amount representing interest		(327)
Total capital lease obligations		2,565
Less: current maturities		(1,006)
Total long-term capital lease obligations	$	1,559

Future minimum lease payments under the capital leases as of December 31, 2020 are due as noted below:

Year ending December 31,		Amount (in thousands)
2021	$	1,038
2022		919
2023		586
2024		271
Total minimum lease payments		2,814
Less: amount representing interest		(358)
Total capital lease obligations		2,456
Less: current maturities		(876)
Total long-term capital lease obligations	$	1,580

7.    EQUIPMENT LOANS

The Company has entered into various equipment loans to finance the purchases of property and equipment. Equipment loans were as follows as of September 30, 2021 and December 31, 2020:

-37-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Notes payable bearing interest at 17.2%; due July 2022, secured by certain property and equipment	$	28	$	51
Notes payable bearing interest at 12.5%, 12.8%, and 11.0%; all due June 2023, all secured by certain property and equipment	41		82
Notes payable bearing interest at 10.7%; due June 2023, secured by certain property and equipment	60		58
Notes payable bearing interest at 7.2%; due April 2025, secured by certain property and equipment	78		92
Notes payable bearing interest at 4.2%; due December 2024, secured by certain property and equipment	746		904
Notes payable bearing interest at 3.4%; due March 2026, secured by certain property and equipment	1,014		—
Total equipment loans	1,967		1,187
Less: Current portion	(513)		(314)
Total equipment loans, net of current portion	$	1,454	$	873

8.    CONTRACT LIABILITIES

As further explained in Note 13, “Related Party Transactions”, in the third quarter of 2020, the Company entered into an agreement with Humana under which they receive administrative payments in exchange for providing care coordination services at Humana Affiliate Provider (“HAP”) clinics over the term of such agreement. The Company’s contract liabilities balance related to these payments from Humana was $6.5 million and $5.3 million as of September 30, 2021 and December 31, 2020, respectively. The short-term portion is recorded in deferred revenue and the long-term portion is recorded in deferred revenue, net of current portion. The Company recognized $0.4 million and $1.0 million in revenue from contract liabilities recorded during the three months and nine months ended September 30, 2021, respectively.

A summary of significant changes in the contract liabilities balance during the period is as follows:

(in thousands)		For the three months ended September 30, 2021
Balance as at June 30, 2021	$	5,936
Increases due to amounts collected		990
Revenues recognized from current period increases		(413)
Balance as at September 30, 2021	$	6,513
(in thousands)		For the nine months ended September 30, 2021
Balance as at January 1, 2021	$	5,265
Increases due to amounts collected		2,290
Revenues recognized from current period increases		(1,042)
Balance as at September 30, 2021	$	6,513

-38-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Of the September 30, 2021 contract liabilities balance, the Company expects to recognize as revenue $0.5 million in the remainder of 2021, $1.9 million in 2022, $1.9 million in 2023, $1.8 million in 2024, and $0.4 million in 2025.

9.    LONG-TERM DEBT

The Company’s notes payable were as follows as of September 30, 2021 and December 31, 2020:

Long-Term Debt	As of,
(in thousands)	September 30, 2021		December 31, 2020
Term loan 3	$	252,531	$	480,000
Term loan 4	293,525		—
Term loan 5	100,000		—
Senior Notes	300,000		—
Less: Current portion of notes payable	(6,493)		(4,800)
	939,563		475,200
Less: debt issuance costs	(23,452)		(18,455)
Notes payable, net of current portion	$	916,111	$	456,745

Credit Facilities

Pursuant to a Credit Agreement with Credit Suisse and the other lenders party thereto (the “Credit Agreement”), the Company has entered into senior secured term loans (together with the revolving line of credit, the "Credit Facilities"). Obligations under the Credit Facilities are secured by substantially all of the Company’s assets. The Credit Facilities contain a financial maintenance covenant (which is for the benefit of the lenders under the revolving line of credit only), requiring the Company to not exceed a total first lien secured net debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio, which is tested quarterly only if the Company has exceeded a certain amount drawn under its revolving line of credit. As of September 30, 2021, the financial covenant did not apply.

Term Loan 1

On December 23, 2016, the Company entered into Term Loan 1, which bore interest at a variable rate equal to LIBOR plus an applicable margin (7.5% as of extinguishment on November 23, 2020). Beginning on March 31, 2017, the Company was required to make quarterly principal payments, which escalated every two years, with the final payment due on June 2, 2025.

Term Loan 1 was prepaid by the Company on November 23, 2020, which resulted in the Company’s legal relief from all obligations under Term Loan 1. The Company’s prepayment of Term Loan 1 consisted of a cash payment to the lender for (1) the outstanding principal, (2) the outstanding accrued interest, and (3) legal and prepayment fees.

Term Loan 2

On June 1, 2020, the Company entered into a term loan agreement with another lender for $130.0 million. Borrowings under Term Loan 2 bore cash interest at a rate of 5.0%, payable quarterly, in addition to interest paid in-kind ("PIK") of 11.5% per annum. Principal and PIK interest were due on December 1, 2022.

-39-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Term Loan 2 contained specific features that required the Company to pay the lender a make-whole amount in the event of a change in control of the Company or the issuance of additional debt by the Company (each a “make-whole event”). The make-whole amount was calculated as the present value of the scheduled interest between the date of a make-whole event and December 1, 2021 by utilizing a discount rate per annum equal to the United States Treasury securities rate three days prior to the date of the make-whole event plus 0.5%. These features met the criteria to be bifurcated from the host agreement as embedded derivatives under the guidance in ASC 815. At the time the Company entered into Term Loan 2, the likelihood of a make-whole event was deemed more than remote, and the Company determined these features contained substantial value to the lender. As such, the derivatives were bifurcated from the host agreement and recorded at the fair value on June 1, 2020 of $51.3 million. The embedded derivatives and the host agreement together represented the combined principal and interest obligations of the Company to the lender. The Company presented the embedded derivatives together with the debt obligation in the condensed consolidated balance sheets. The change in fair market value on embedded derivatives was $5.1 million for the three months ended September 30, 2020 and $5.4 million for the nine months ended September 30, 2020, and was recorded under the caption change in fair value of embedded derivative in the accompanying condensed consolidated statements of operations.

Term Loan 2 was prepaid by the Company on November 23, 2020, which resulted in the Company’s legal relief from all obligations under Term Loan 2. The Company’s prepayment of Term Loan 2 consisted of a cash payment to the lender for (1) the outstanding principal, (2) the outstanding accrued interest, and (3) legal and prepayment fees.

Term Loan 3

In conjunction with the Business Combination with Jaws, the Company entered into the Credit Agreement with Credit Suisse and the other lenders party thereto on November 23, 2020 under which Credit Suisse and the other lenders party thereto committed to extend credit to the Company in the initial amount of $685.0 million. The Credit Agreement initially consisted of (1) an initial term loan in the amount of $480.0 million (the “Initial Term Loan”), (2) delayed draw term loans (the “Delayed Draw Term Loans”) up to the aggregate amount of $175.0 million (the “Delayed Draw Term Commitments”), and (3) an initial revolving credit facility in the amount of $30.0 million (the “Initial Revolving Facility”).

On issuance, Term Loan 3 represented the principal amount of $480.0 million funded to the Company on November 23, 2020 by Credit Suisse and the other lenders. The Delayed Draw Term Commitments represented commitments from Credit Suisse and the other lenders to provide an aggregate amount of $175.0 million in additional term loans to the Company after November 23, 2020. As of September 30, 2021, the Company had fully drawn upon the Delayed Draw Term Commitments, and the $175.0 million of Delayed Draw Term Loans were combined with the Initial Term Loan into a single class of borrowings.

The Company is required to pay a commitment fee per annum (the “DDTL Ticking Fee”) on the unfunded Delayed Draw Term Commitments, depending on the days elapsed after December 15, 2020 (the “Ticking Fee Start Date”). The DDTL Ticking Fee is calculated on a 360-day year and payable in arrears on the last business day of each calendar quarter. The DDTL Ticking Fee is calculated as follows:

•No fee for the period commencing on the Ticking Fee Start Date until the date occurring 30 days thereafter.

•50% of the applicable margin for Delayed Draw Term Loans maintained as Eurodollar borrowings for the period commencing on the 31st day after the Ticking Fee Start Date until the date occurring 60 days after the Ticking Fee Start Date.

-40-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

•100% of the applicable margin for Delayed Draw Term Loans maintained as Eurodollar borrowings for the period commencing on the 61st day after the Ticking Fee Start Date thereafter.

The Initial Term Loan and the Delayed Draw Term Loans are subject to principal amortization repayments due on the last business day of each calendar quarter equal to 0.25% of the initial principal amount funded outstanding for the Initial Term Loan and each Delayed Draw Term Loan, as applicable, based on the funding date of each Delayed Draw Term Loan if and when issued. Amortization payments commenced on March 31, 2021. The outstanding amount of unpaid principal and interest associated with the Initial Term Loan and the Delayed Draw Term Loans is due on the maturity date of November 23, 2027. Prior to the maturity date, the Company may elect to prepay, in whole or in part, the Initial Term Loan and Delayed Draw Term Loans at any time without premium or penalty, other than in connection with certain repricing transactions and customary breakage costs.

The Company is also subject to mandatory prepayments on the Initial Term Loan and Delayed Draw Term Loans based on the occurrence of certain events after November 23, 2020 including, (1) an amount equal to a percentage between 50% and 0% of excess cash flow for the fiscal year ending December 31, 2021 and each subsequent fiscal year based on the Company’s first lien net leverage ratio (calculated as total consolidated debt secured by a first lien on any collateral, net of restricted cash. divided by consolidated Adjusted EBITDA (as defined in the Credit Agreement)) at the last day of the applicable fiscal year due only if and to the extent such calculated amount is greater than $3 million, (2) an amount equal to 100% of the net proceeds received in excess of $3 million individually in any fiscal year, or $10 million in the aggregate, pertaining to the disposition of assets that are not reinvested in assets useful to the Company’s business within 18 months of the disposition date, (3) an amount equal to 100% of the net proceeds received from the issuance of non-permitted indebtedness that is not intended to refinance the Credit Agreement with Credit Suisse, and (4) $400.0 million of the net cash proceeds received in a private placement of Class A common stock of the Company after the Business Combination with Jaws.

The Company maintains the right to choose between an applicable base rate (“ABR”) borrowing or a Eurodollar borrowing prior to the issuance of all credit by Credit Suisse and the other lenders. Interest is calculated on a 360-day year, or a 365-day year when Credit Suisse’s prime rate is utilized in an ABR borrowing, payable in arrears on the last business day of each calendar quarter (or, with respect to Eurodollar borrowings, on the last day of the applicable interest period, or, if the interest period is greater than three months, in three month intervals), and payable in arrears on the maturity date of each borrowing.

ABR borrowings are subject to interest at a rate per annum equal to (1) the greatest of (a) Credit Suisse’s prime rate in effect on such day, (b) the funds effective rate issued by the Federal Reserve Bank of New York in effect on such day plus 0.5%, (c) the LIBOR rate for a one month interest period on such day, as adjusted via multiplication by the Credit Suisse’s statutory reserve rate and subject to a floor of 0.75% on the adjusted rate only for the Initial Term Loan and the Delayed Draw Term Loans, plus 1%, and (d) solely with respect to the Initial Term Loans and Delayed Draw Term Loans, 1.75%, plus (2) the applicable rate of (a) 3.75% from between November 23, 2020 to the Closing Date of the Business Combination and (b) 3.5% after the Closing Date of the Business Combination, provided that if the Company achieves a public corporate rating from Standard and Poor's ("S&P") of at least B and a public credit rating from Moody’s Investors Service ("Moody's") of at least B2, then for as long as such ratings remain in effect, a rate of 3.25% shall be applicable.

Eurodollar borrowings are subject to interest at a rate per annum equal to (1) the LIBOR rate for a one month interest period on such day, as adjusted via multiplication by the Credit Suisse’s statutory reserve rate and subject to a floor of 0.75% on the adjusted rate only for the Initial Term Loan and the Delayed Draw Term Loans, plus (2) the applicable rate of (a) 4.75% and (b) 4.5% after the Closing Date of the Business Combination, provided that if the Company achieves a public corporate rating from S&P of at least B and a public credit rating from

-41-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Moody’s of at least B2, then for as long as such ratings remain in effect, a rate of 4.25% shall be applicable. Prior to November 23, 2020, the Company elected to treat the Initial Term Loan and the Initial Revolving Facility as Eurodollar borrowings. As of September 30, 2021, the stated interest rate for the Initial Term Loan and the Initial Revolving Facility was 5.25% and the effective interest rate for the Initial Term Loan was 5.74%. As of September 30, 2021, the Company’s Term Loan 3 bore interest of 5.25%.

Following the close of the Business Combination, the Company triggered the mandatory prepayment of $400.0 million of the outstanding principal on Term Loan 3 from the net cash proceeds received from the PIPE financing. The Company’s partial extinguishment of this Term Loan consisted of a cash payment to the lender for (1) $400.0 million of the outstanding principal amount, and (2) the outstanding accrued interest in the amount of $0.7 million. The Company recorded a loss on extinguishment of debt of $13.2 million in the nine months ended September 30, 2021, which related to unamortized debt issuance costs. The $400.0 million mandatory prepayment was made without premium or penalty.

On September 30, 2021, the Company and Credit Suisse amended Term Loan 3 to increase the Initial Revolving Facility by an additional $30.0 million.

As of September 30, 2021, no loans were drawn under the Initial Revolving Facility and its available balance was $56.2 million. As of September 30, 2021, the Company had two letters of credit outstanding in favor of two third parties in the amounts of $0.9 million and $2.9 million, respectively. As of December 31, 2020, no amounts were drawn from the Initial Revolving Facility and its available balance was $30.0 million. As of December 31, 2020, no letters of credit were issued. As of September 30, 2021, the Initial Revolving Facility bore interest at, and issued letters of credit were subject to fees equal to, the London Interbank offered rate (“LIBOR”) plus 4.5%.

Term Loan 4

On June 11, 2021, the Company entered into an amendment to the Credit Agreement with Credit Suisse and the other lenders for a principal amount of $295.0 million (“Term Loan 4”), subject to the same terms (including interest rate and maturity date) as Term Loan 3 above. The terms of the Term Loan 4, including interest rate and maturity, are equivalent to the terms of the Term Loan 3, and the Term Loan 3 and the Term Loan 4 form a single tranche of term loans under the Credit Agreement,

Term Loan 5

On September 30, 2021, the Company amended its Credit Agreement with Credit Suisse and the other lenders by adding an incremental term loan for a principal amount of $100.0 million (“Term Loan 5”), subject to the same terms (including interest rate and maturity date) as Term Loans 3 and 4 above. The terms of the Term Loan 5, including interest rate and maturity, are equivalent to the terms of the Term Loan 3 and the Term Loan 4, and the Term Loan 3, the Term Loan 4 and the Term Loan 5 form a single tranche of term loans under the Credit Agreement.

Term Loan 5 was issued with debt issuance costs of $1.0 million, which are included in the caption notes payable, net of current portion and debt issuance costs in the accompanying condensed consolidated balance sheets. The Company also incurred $0.1 million of third-party professional fees related to the issuance of Term Loan 5, which are included in the caption selling, general, and administrative expenses in the accompanying condensed consolidated statements of operations.

-42-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Bridge Loan

On July 2, 2021, the Company entered into a Bridge Loan Agreement (the "Bridge Loan Agreement") for a principal amount of $250.0 million ("Bridge Loan") to finance a business acquisition. Pursuant to the Bridge Loan Agreement, the Bridge Loan bore interest, payable quarterly in arrears (or, with respect to Eurodollar borrowings, on the last day of the applicable interest period, or, if the interest period is greater than three months, in three month intervals), at a rate equal to adjusted LIBOR plus 6.5% per annum, or 6.65%. Principal on the Bridge Loan is scheduled to mature on July 2, 2028.

The Bridge Loan was issued with debt issuance costs of $3.5 million, which fully amortized during the three months ended September 30, 2021 and is included in the caption interest expense in the accompanying condensed consolidated statements of operations.

On September 30, 2021, following the issuance of the Senior Notes, the Company repaid the Bridge Loan in full, consisting of (1) $250.0 million of principal and (2) $4.2 million of outstanding accrued interest.

Senior Notes

On September 30, 2021, the Company issued senior unsecured notes for a principal amount of $300.0 million (the "Senior Notes") in a private offering. Proceeds from the Senior Notes were used to repay the $250.0 million Bridge Loan in full. The Senior Notes bear interest at 6.25% per annum, payable semi-annually on April 1st and October 1st of each year, commencing April 1, 2022. As of September 30, 2021, the effective interest rate of the Senior Notes was 6.65%. Principal on the Senior Notes is due in full on October 1, 2028. The Senior Notes are not subject to any amortization payments.

Prior to October 1, 2024, the Company may redeem some or all of the notes at a price equal to 100% of the principal amount redeemed, plus accrued and unpaid interest, plus a make-whole premium. Prior to October 1, 2024, the Company may also redeem up to 40% of the aggregate principal amount of the notes with the net cash proceeds of certain equity offerings, at a redemption price of 106.25%, plus accrued and unpaid interest. On or after October 1, 2024, the Company may redeem some or all of the Notes at a redemption price of 100% - 103.13%, plus accrued and unpaid interest, depending on the date that the Senior Notes are redeemed.

The Senior Notes were issued with debt issuance costs of $6.8 million, which are included in the caption notes payable, net of current portion and debt discount in the accompanying condensed consolidated balance sheets.

The following table sets forth the Company’s future principal payments as of September 30, 2021, assuming another mandatory prepayment does not occur:

(in millions)
Year ending December 31,		Amount
Remainder of 2021	$	1,623
2022		6,493
2023		6,493
2024		6,493
2025		6,493
Thereafter		918,461
Total	$	946,056

-43-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As of September 30, 2021 and December 31, 2020, the balance of debt issuance costs totaled $24.2 million and $24.9 million, respectively, and were being amortized into interest expense over the life of the loan using the effective interest method. Of the balance as of September 30, 2021, $23.5 million was related to Term Loan 3, Term Loan 4, Term Loan 5, and the Senior Notes reflected as a direct reduction to the long-term debt balances, while the remaining $0.7 million was related to the Initial Revolving Facility, and reflected in prepaid expenses and other current assets. For the three and nine months ended September 30, 2021, the Company recognized interest expense of $16.0 million and $36.4 million, respectively, of which $4.0 million and $7.7 million were related to amortization of debt issuance costs.

For the three and nine months ended September 30, 2020, the Company recognized interest expense of $12.3 million and $21.7 million, respectively, of which $3.0 million and $3.9 million were related to the amortization of debt issuance costs.

10.    DUE TO SELLERS

The amounts due to sellers as of September 30, 2021 and December 31, 2020 were $24.9 million and $41.1 million, respectively. Included in the due to sellers balance, there are amounts recorded as part of the initial purchase price of acquisitions in 2021 and in prior years, including accrued interest and accrued bonuses payable to various sellers as part of their respective employment agreements, as well as other amounts due to sellers. The amount due to sellers was $16.4 million, and the total bonuses owed to sellers were $8.5 million, as of September 30, 2021. The amount due to sellers was $34.5 million, and the total bonuses owed to sellers were $6.6 million, as of December 31, 2020.

Total bonus charges to various sellers as part of their respective provider employment agreements amounted to a total of $2.5 million and $6.2 million for the three months and nine months ended September 30, 2021, respectively. These charges are included within the caption transaction costs and other within the accompanying condensed consolidated statements of operations.

11.    FAIR VALUE MEASUREMENTS

ASC 820, "Fair Value Measurements and Disclosures", provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy under the accounting standard are described as follows:

•Level 1    Inputs to the valuation methodology are unadjusted quoted prices for identical

assets or liabilities in active markets that the Company has the ability to access.

•Level 2    Inputs to the valuation methodology include:

•quoted prices for similar assets or liabilities in active markets;

•quoted prices for identical or similar assets or liabilities in inactive markets;

•inputs other than quoted prices that are observable for the asset or liability;

•inputs that are derived principally from or corroborated by observable market data by correlation or other means.

-44-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

•Level 3    Inputs to the valuation methodology are unobservable and significant to the fair

value measurement.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The carrying amounts of financial instruments including cash, accounts receivable, accounts payable, accrued liabilities, due to sellers and short-term borrowings approximate fair value due to the short maturities of such instruments. The fair value of the Company’s debt using Level 2 inputs was approximately $944.0 million and $474.0 million as of September 30, 2021 and December 31, 2020, respectively.

The following is a description of the valuation methodology used for liabilities measured at fair value.

Contingent Consideration: Consideration is earned by the sellers of two of the Company’s historical acquisitions based on the Company completing acquisitions of various targets specified at the time that business was acquired. The consideration is valued at fair value applying a Scenario Based method. The fair value considers transactions with the specified targets where a letter of intent is signed no later than September 30, 2021 and the acquisition is expected to be closed by December 31, 2021. The probability weighted average takes the probability of a given deal meeting this criteria and 20% of the preliminary consideration, discounted to present value using a risk-free/credit risk rate of 7.0%.

On August 11, 2021, the Company issued 2,720,966 shares of Class A common stock (the “escrowed shares”) to the escrow agent, on behalf of the seller, as part of the consideration in connection with an acquisition. The amount of shares was based on a $30.0 million purchase price divided by the average share price of the Company during the twenty consecutive trading days preceding the closing date of the transaction. The shares were deposited in escrow and will be released to the seller upon the satisfaction of certain performance metrics in 2022 and 2023. The final number of escrowed shares will be calculated by multiplying the initial share amount by an earned share percentage in accordance with the purchase agreement and subtracting any forfeited indemnity shares. The fair value of this contingent consideration is determined using a Monte-Carlo simulation model. These inputs are used to calculate the pay-off amount per the agreement which is then discounted to present value using the risk-free rate and the Company’s cost of debt.

The preceding methods described may produce fair value calculations that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

There was a decrease of $3.9 million and $4.2 million in the fair value of the contingent consideration during the three and nine months ended September 30, 2021, respectively, recorded in transaction costs and other in the consolidated statement of operations.

Embedded Derivative: In calculating the valuation of the embedded derivative, the Company considered the present value of the cash flows over the term of the debt agreement as impacted by (1) the probability of a debt

-45-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

issuance or a change in control event occurring that would trigger a prepayment penalty to the lender, (2) the market interest rate of the debt agreement without the embedded derivative, and (3) the interest rate premium associated with the embedded derivative. The embedded derivative was entered into on June 1, 2020 in connection with embedded features attached to Term Loan 2 and subsequently derecognized on November 23, 2020 when the Company refinanced its debt. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of June 1, 2020 and September 30, 2020:

	Range as of
Unobservable Input	June 1, 2020	September 30, 2020
Probability of change of control	90%	80%
Probability of issuance of debt	5%	15%
Expected date of event	Fourth Quarter 2020	Fourth Quarter 2020
Discount rate	39%	38%

The change in fair value of the embedded derivative of $5.1 million and $5.4 million was recorded during the three months and nine months ended September 30, 2020, respectively, and was included within change in fair value of embedded derivative. As noted in Note 9, "Long-Term Debt", the embedded derivative was derecognized as a result of the refinancing that took place on November 23, 2020.

Warrant Liabilities: As of June 3, 2021, the Closing Date of the Business Combination, and September 30, 2021, there were 23.0 million Public Warrants and 10.53 million Private Placement Warrants outstanding. The Company classifies its Public Warrants and Private Placement Warrants as liabilities in accordance with ASC 815 and measures them at fair value on a recurring basis. The Company’s valuation of the warrant liabilities utilized a binomial lattice in a risk-neutral framework (a special case of the Income Approach). The fair value of the Public Warrants and Private Placement Warrants utilized Level 1 and 3 inputs, respectively. The Private Placement Warrants are based on the significant inputs not observable in the market as of June 3, 2021 and September 30, 2021.

The following table provides quantitative information regarding the Level 3 inputs used for the fair value measurements of the warrants liabilities:

	As of
Unobservable Input	June 3, 2021	September 30, 2021
Exercise price	$11.50	$11.50
Stock price	$14.75	$12.68
Term (years)	5.0	4.7
Volatility	37.1%	—%
Risk free interest rate	0.8%	0.9%
Dividend yield	None	None
Public warrant price	None	$4.13

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of September 30, 2021:

-46-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	46,706	$	—	$	—	$	46,706
Public Warrant Liabilities		94,990		94,990		—		—
Private Placement Warrant Liabilities		43,503		—		—		43,503
Total Liabilities	$	185,199	$	94,990	$	—	$	90,209

There was an increase of $10.1 million and a decrease of $2.4 million in the fair value of the Public Warrant Liabilities during the three and nine months ended September 30, 2021, and an increase of $4.5 million and a decrease of $22.2 million in the fair value of the Private Placement Warrant Liabilities during the three and nine months ended September 30, 2021, respectively. The change in fair value of the warrant liabilities is recorded within the Change in fair value of warrant liabilities caption.

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of December 31, 2020:

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	5,172	$	—	$	—	$	5,172
Total Liabilities	$	5,172	$	—	$	—	$	5,172

Activity of the assets and liabilities measured at fair value using significant unobservable inputs was as follows:

-47-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

		Fair Value Measurements
		For the three months ended September 30,
		2021		2020
Opening balance as at July 1,	$	136,190	$	75,800
Change in fair value of embedded derivative		—		5,138
Change in fair value of contingent consideration		(3,940)		—
Contingent consideration recognized due to acquisitions		38,300		—
Change in fair value of warrants		14,649		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration payments		—		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879
		Fair Value Measurements
		For the nine months ended September 30,
		2021		2020
Opening balance as at January 1,	$	5,172	$	23,429
Embedded derivative recognized under Term Loan 2		—		51,328
Change in fair value of embedded derivative		—		5,444
Change in fair value of contingent consideration		(4,152)		—
Contingent consideration recognized due to acquisitions		47,900		2,695
Warrants acquired in the Business Combination		163,058		—
Change in fair value of warrants		(24,565)		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration settled through equity		—		(1,958)
Contingent consideration payments		(2,214)		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879

12.     VARIABLE INTEREST ENTITIES

The Physicians Groups were established to employ healthcare providers, to contract with managed care payors, and to deliver healthcare services to patients in the markets that the Company serves. The Company evaluated whether it has a variable interest in the Physicians Groups, whether the Physicians Groups are VIEs, and whether the Company has a controlling financial interest in the Physicians Groups. The Company concluded that it has variable interests in the Physicians Groups on the basis of each respective Master Service Agreement (“MSA”), which provides office space, consulting services, managerial and administrative services, billing and collection, personnel services, financial management, licensing, permitting, credentialing, and claims processing in exchange for a service fee and performance bonuses payable to the Company. Each respective MSA transfers substantially all the residual risks and rewards of ownership to the Company. The Physicians Groups’ equity at risk, as defined by U.S. GAAP, is insufficient to finance its activities without additional support, and therefore, the Physicians Groups are considered VIEs, and are not affiliates of the Company.

In order to determine whether the Company has a controlling financial interest in the Physicians Groups, and thus, whether the Company is the primary beneficiary, the Company considered whether it has i) the power to

-48-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

direct the activities that most significantly impact the Physicians Groups’ economic performance and ii) the obligation to absorb losses of the entities that could potentially be significant to it or the right to receive benefits from the Physicians Groups that could potentially be significant to it. The Company concluded that it may unilaterally remove the physician owners of the Physicians Groups at its discretion and is therefore considered to hold substantive kick-out rights over the decision maker of the Physicians Groups. Under each MSA, the Company is entitled to a management fee and a performance bonus that entitle the Company to substantially all of the residual returns or losses and is exposed to economics which could be significant to it. As a result, the Company concluded that it is the primary beneficiary of the Physicians Groups and therefore, consolidates the balance sheets, results of operations, and cash flows of these entities. The Company performs a qualitative assessment on an ongoing basis to determine if it continues to be the primary beneficiary.

The table below illustrates the aggregated VIE assets and liabilities and performance for the Physicians Groups:

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Total Assets	$	30,483	$	8,182
Total Liabilities	$	23,234	$	12,371

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2021		2020		2021		2020
Total revenue	$	12,321	$	79	$	14,621	$	79
Operating expenses:
Third-party medical costs	8,582		—		8,582		—
Direct patient expense	2,413		295		5,203		295
Selling, general and administrative expenses	7,277		1,125		12,540		1,324
Depreciation and amortization expense	353		—		860		—
Total operating expenses	18,625		1,420		27,185		1,619
Net loss	$	(6,304)	$	(1,341)	$	(12,564)	$	(1,540)

There are no restrictions on the Physicians Groups' assets or on the settlement of their liabilities. The assets of the Physicians Group can be used to settle obligations of the Company. The Physicians Groups are included in the Company’s creditor group; thus, creditors of the Company have recourse to the assets owned by the Physicians Groups. There are no liabilities for which creditors of the Physicians Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physicians Groups with respect to potential future distributions.

13.    RELATED PARTY TRANSACTIONS

Advisory Services Agreement

In December 2016, the Company and InTandem Capital Partners, LLC (“InTandem”) entered into an advisory services agreement whereby InTandem owned the majority voting and equity interest in Cano Health's Parent, Primary Care (ITC) Holdings, LLC, and provided financial and management consulting services to the

-49-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Company. Services provided included, but were not limited to (i) corporate strategy, (ii) legal advice, (iii) acquisitions and divestitures strategies, and (iv) debt and equity financings. InTandem was entitled to an annual fee equal to the greater of $0.3 million or 2% of EBITDA for the prior calendar year plus out-of-pocket expenses. In the event the Company completes an acquisition or is sold, an advisory fee of 2% of the enterprise value, as defined, would be due to InTandem. In addition, upon payment, an advisory fee equal to 2% of the deferred payment would be due to InTandem. In accordance with the terms of agreement, the advisory services agreement was terminated upon the consummation of the Business Combination disclosed in Note 1, “Nature of Business and Operations”.

Pursuant to the advisory services agreement, the Company incurred expenses which are included in the condensed consolidated statements of operations. The Company did not incur any related party transaction costs during the three months ended September 30, 2021 and 2020, respectively, and incurred related party transaction costs of approximately $1.5 and $5.4 million during the nine months ended September 30, 2021 and 2020, respectively, which are included in the transaction costs and other caption. The Company also incurred approximately $0.2 million during the three and nine months ended September 30, 2020, respectively, which is included in the selling, general, and administrative expenses caption. As of September 30, 2021 and December 31, 2020, no balance and an immaterial balance was owed to InTandem pursuant to this agreement, respectively.

Administrative Service Agreement

On April 23, 2018, the Company entered into an Administrative Service Agreement with Dental Excellence Partners, LLC, which merged with four other entities. Dental Excellence Partners, LLC also licensed the Cano Dental trademark from the Company. The administrative fee is a monthly fixed amount per office for providing comprehensive management and related administrative services to the dental practices. During April 2019, the Company entered into an amendment to this agreement and modified the administrative fee. The Company and Dental Excellence Partners, LLC terminated the Administrative Service Agreement in December 2020, effective immediately.

The Company recognized income from this agreement of approximately $0.1 million and $0.4 million during the nine months ended September 30, 2021 and 2020, and $0.1 million during the three months ended September 30, 2020, which was recorded within the caption fee-for-service and other revenues in the accompanying condensed consolidated statements of operations. As of December 31, 2020, an immaterial amount was due to the Company in relation to these agreements and recorded in the caption accounts receivable.

As part of this agreement, the Company agreed to have Dental Excellence Partners, LLC provide dental services for managed care members of the Company. The Company was charged approximately $1.2 million and $1.6 million during the nine months ended September 30, 2021 and 2020, and $0.7 million during the three months ended September 30, 2020 for these services. As of December 31, 2020, no balance was due to Dental Excellence Partners, LLC.

Dental Service Agreement

During 2019, the Company entered into a dental service agreement with Care Dental Group, LLC (“Belen Dental”), whereby the Company agreed to pay Belen Dental $15 per member per month, for each Medicare Advantage (“MA”) patient that is identified by the Company on a monthly enrollment roster to receive care at the legacy Belen Medical Centers. During the three months ended September 30, 2021, no payments were made and during the three months ended September 30, 2020 the Company paid Belen Dental approximately $0.3 million, in relation to this agreement. During the nine months ended September 30, 2021 and 2020, the Company paid Belen Dental approximately $0.3 million and $0.5 million, respectively, pursuant to this agreement.

-50-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Humana Relationships

In 2020, Cano Health and its Parent, Primary Care (ITC) Holdings, LLC, entered into multi-year agreements with Humana and its affiliates whereby the Parent entered into a note purchase agreement with Humana for a convertible note due October 2022 with an aggregate principal amount of $60.0 million. The note accrued interest at a rate of 8.0% per annum through March 2020 and 10.0% per annum thereafter, payable in kind. The note was convertible to Class A-4 units of the Parent at the option of Humana in the event the Parent and affiliates seek to consummate a sale transaction and could be settled in cash at the option of Humana. Accordingly, the note was converted and settled in cash upon the consummation of the Business Combination. Prior to the consummation of the Business Combination, Cano Health was not subject to any obligations under the convertible note, including payments of principal, interest, or fees under the terms of the instrument. As such, this instrument does not represent debt of the Company. Humana is not a related party subsequent to the Business Combination on June 3, 2021 due to the repayment of the note.

The Company licenses the use of Humana Affiliate Provider (“HAP”) clinics to provide services at the clinics. The multi-year agreements contain an administrative payment from Humana in exchange for the Company providing care coordination services over the term of the agreement. These payments are recognized as revenue ratably over the length of the term of the agreement and are refundable to Humana on a pro-rata basis if the Company ceases to provide care at the clinics during the specified service period in the agreements. The Company has identified one performance obligation to stand ready to provide care coordination services at the centers for the length of the term specified in the contracts.

The multi-year agreements also contain an arrangement for a license fee that is payable by the Company to Humana for the Company’s use of Humana owned or leased facilities to provide health care services. The agreement prohibits Cano from using the clinics for plans not sponsored by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the clinics, including rental payments, maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements, and other expenses identified by Humana. The Company has not paid license fees to Humana during the nine months ended September 30, 2021. The license, deferred revenue and deferred rent liability to Humana totaled $13.5 million as of December 31, 2020 while Humana was a related party. The Company also recorded $0.5 million in operating lease expense related to its use of Humana clinics in the nine months ended September 30, 2021 prior to repaying the note and while Humana was a related party.

Prior to entering into the agreements, the Company had existing payor relationships with Humana related to existing revenue arrangements within the Company. For the period that Humana was a related party to the Company, the Company recognized in its condensed consolidated statements of operations revenue from Humana, including its subsidiaries, of $131.9 million and $239.7 million for the three and nine months ended September 30, 2020, respectively, and $335.9 million for the nine months ended September 30, 2021. The Company recognized third-party medical expenses of and $90.2 million and $167.1 million for the three and nine months ended September 30, 2020, respectively, and $249.8 million for the nine months ended September 30, 2021.

Operating Leases

The Company leases several offices and medical spaces from certain employees and companies that are controlled by certain equity holders of Primary Care (ITC) Holdings, LLC. Monthly rent expense in aggregate totaled approximately $0.7 million and $0.7 million for the three months ended September 30, 2021 and 2020, respectively, and $2.1 million and $2.0 million for the nine months ended September 30, 2021 and 2020, respectively. These operating leases terminate through September 2024.

-51-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

General Contractor Agreements

As of December 31, 2018, the Company has entered into various general contractor agreements with a company that is controlled by a family member of the Chief Executive Officer of the Company to perform leasehold improvements at various Company locations as well as various repairs and related maintenance as deemed necessary. Payments made pursuant to the general contractor agreements as well as amounts paid for repairs and maintenance to this related party totaled approximately $3.2 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and $5.6 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively.

Other Related Party Transactions

The Company made payments to various related parties in relation to logistic software, medical supplies, housekeeping, and moving costs. During the three months ended September 30, 2021 and 2020 the Company paid approximately $0.4 million and $0.1 million, respectively, to such parties. During the nine months ended September 30, 2021 and 2020 the Company paid approximately $0.9 million and $0.4 million, respectively, to such parties.

On April 23, 2018, the Company advanced funds to an affiliated company, Dental Excellence Partners, LLC, in the amount of $4.5 million. The loan agreement calls for monthly interest-only payments to be received beginning May 1, 2018, and the entire outstanding principal balance shall be due and payable in full on April 23, 2023. The note receivable bears interest at 7.0%. For the three months and nine months ended September 30, 2020, the Company recognized $0.0 million and $0.2 million, respectively, of interest income related to this loan agreement. On December 17, 2020, Dental Excellence Partners made an early repayment of the outstanding balance to the Company. In connection with the early repayment, the Company wrote off $0.5 million, $0.4 million of which was due under the Administrative Service Agreement and $0.1 million was due for other services provided.

Additionally, during the year ended December 31, 2018, two executives of Cano Health obtained shares of the former Parent, Primary Care (ITC) Holdings, LLC, for a total amount of $0.4 million. As part of this transaction, the two executives paid cash and entered into promissory notes with the Parent in order to acquire the shares. On May 25, 2018, the first promissory note was obtained in the amount of $0.1 million, payable on May 25, 2026 with a fixed annual interest rate of 2.8%. On August 24, 2018, the second promissory note was obtained from the Company in the amount of $0.05 million, with a fixed annual interest rate of 2.8%. The loan and interest receivable was scheduled to be due on August 24, 2025. As of September 30, 2021, both of the promissory notes were paid in full.

14.    EQUITY-BASED COMPENSATION

2017 Profits Interest Units Plan

On September 30, 2017, the former Parent’s Limited Liability Agreement (“LLC Agreement”) created class B units, called Profit Interest Units (“PIU”), to provide additional incentives to attract and retain qualified, competent employees for the Company. All grants of PIUs vested upon the closing of the Business Combination on June 3, 2021 and resulted in an expense of $1.0 million recorded in the selling, general, and administrative caption.

2021 Stock Option and Incentive Plan

At the Company’s special meeting of stockholders held on June 2, 2021, the stockholders approved the 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“2021 ESPP”)

-52-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

to encourage and enable the current and future officers, employees, directors, and consultants of the Company and its affiliates to obtain ownership in the Company. The aggregate number of shares authorized for issuance under the 2021 Plan will not exceed 52.0 million shares of stock. The aggregate number of shares authorized for issuance under the 2021 ESPP will not exceed 4.7 million, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031 the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan shall be cumulatively increased by the lessor of (i) 15.0 million shares of Class A common stock, (ii) one percent 1.0% of the number of shares of Class A common stock issued and outstanding on the immediately preceding December 31st, or (iii) such lesser number of shares determined by the administrator appointed by the Board of Directors.

The 2021 Plan provides for the grant of incentive and nonqualified stock option, restricted stock units (“RSUs”), restricted share awards, stock appreciation awards, unrestricted stock awards, and cash-based awards to employees, directors, and consultants of the Company.

Market Condition Options

On June 3, 2021, in connection with the closing of the Business Combination, the Company granted 12.8 million stock options with market conditions (“Market Condition Awards”) to several executive officers and directors of the Company. The Market Condition Awards vest when the Company’s stock price meets specified hurdle prices and stays above those prices for 20 consecutive days. Once the market condition is satisfied, the applicable percentage of the Market Condition Awards will vest 50% on each of the first and second anniversaries so long as the optionee stays employed. The fair value of the Market Condition Awards is based on a Monte Carlo simulation for each hurdle price. The unrecognized compensation cost of the Market Condition Awards as of September 30, 2021 was $47.1 million, which is expected to be recognized over the weighted average remaining service period of 2.6 years.

The number of Market Condition Awards that vest is subject to the Company’s stock price equaling or exceeding certain hurdle prices for 20 consecutive trading days from June 3, 2021 to June 3, 2024 (i.e., the period from the grant date to the end date of the performance period).

Stock Option Valuation

The Monte-Carlo simulation model is used to estimate the fair value of the Market Condition Awards. The Monte-Carlo simulation model calculates multiple potential outcomes for an award and establishes a fair value based on the most likely outcome. Key assumptions for the Monte-Carlo simulation model include the risk-free rate, expected volatility, expected dividends and the expected cost of equity. The fair values were calculated using the Monte-Carlo model with the following assumptions as of the grant date on June 3, 2021:

	As of June 3, 2021
Closing Cano share price as of valuation date	$	14.75
Risk-free interest rate	1.68% - 2.0%
Expected volatility	45.0%
Expected dividend yield	0.0%
Expected cost of equity	9.0%

A summary of the status of unvested Market Condition Awards granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

-53-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	12,831,184	$4.23
Vested	—	—
Forfeitures	(97,486)	4.23
Balance, September 30, 2021	12,733,698	$4.23

Restricted Stock Units

In June 2021, the Company granted 2,590,472 time-based RSUs to several executive officers, directors and certain employees of the Company. An additional 2,249,972 time-based RSUs were granted in September 2021. The RSUs issued in June vest over a one-year period for directors and over a four-year period for employees commencing on the grant date, with one fourth of the RSUs vesting at the end of the first anniversary of the vesting commencement date and the remainder of the RSUs vesting yearly over the following three years. One fourth of the RSUs issued in September vest in August of 2022 with the remaining vesting on each of the next three subsequent anniversaries. The fair value of RSUs is based on the closing price of the Company’s Class A common stock on the grant date. The unrecognized compensation cost of the RSUs as of September 30, 2021 was $65.2 million, which is expected to be recognized over the weighted average remaining service period of 3.7 years. In addition, certain RSUs were granted to a nonemployee and included a discretionary performance condition which has been deemed not probable of being met and as such no expense has been recorded.

A summary of the status of unvested RSUs granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	4,840,444	$14.46
Vested	—	—
Forfeitures	(16,750)	14.75
Balance, September 30, 2021	4,823,694	$14.46

The Company recorded compensation expenses of $9.0 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively. The Company recorded compensation expenses of $12.1 million and $0.2 million for the nine months ended September 30, 2021 and 2020, respectively.

The total equity-based compensation expense related to all the equity-based awards granted by the former Parent is reported in the condensed consolidated statement of operations as compensation expense within the selling, general and administrative expense caption.

15.    COMMITMENTS AND CONTINGENCIES

Vendor Agreements

-54-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company, through its subsidiaries Comfort Pharmacy, LLC, Comfort Pharmacy 2, LLC, and Belen Pharmacy Group, LLC, entered into a multi-year Prime Vendor Agreement ("PVA") with a pharmaceutical wholesaler, effective November 1, 2020, that continues through October 31, 2023. This agreement extends on a month-to-month basis thereafter until either party gives 90 days' written notice to terminate. The pharmaceutical wholesaler serves as the Company’s primary wholesale supplier for branded and generic pharmaceuticals. The agreement contains a provision that requires average monthly net purchases of $0.8 million, and if the minimum is not met, the vendor may adjust the pricing of goods. A Joinder Agreement was entered into on December 1, 2020, which amended the PVA to include IFB Pharmacy, LLC, a fully consolidated subsidiary, under the agreement as of this date.

As a result of the University acquisition, the Company assumed the vendor agreement in 2021 that University, through its subsidiary University Health Care Pharmacy, Inc., had with a second pharmaceutical vendor. The agreement, effective through April 7, 2022, contains a provision that requires average monthly net purchases of $0.6 million, and if the minimum is not met, the vendor may adjust the pricing of goods.

Management believes for the nine months ended September 30, 2021 and 2020, the minimum requirements of the agreements in place were met.

Operating Leases

The Company leases office facilities and office equipment under non-cancellable operating leases expiring through the year 2028. Refer to Note 13, "Related Party Transactions", for operating leases that were entered into with related parties. Minimum future payments as of September 30, 2021 were approximately as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	3,876
2022		13,987
2023		12,763
2024		11,125
2025		9,451
Thereafter		27,908
Total	$	79,110

Rent expense for the three months ended September 30, 2021 and 2020 amounted to approximately $6.9 million and $3.1 million, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 amounted to approximately $15.9 million and $8.2 million, respectively.

Litigation

The Company is exposed to various asserted and unasserted potential claims encountered in the normal course of business. Management believes that the resolution of these matters will not have a material effect on the Company’s condensed consolidated financial position, results of their operations or cash flows.

16.     INCOME TAXES

-55-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company is subject to U.S. federal, state and local income taxes with respect to its taxable income, including its allocable share of any taxable income of its subsidiaries, and is taxed at prevailing corporate tax rates. PCIH is a multiple member limited liability company taxed as a partnership and accordingly any taxable income generated by PCIH is passed through to and included in the taxable income of its members, including the Company.

Prior to the close of the Business Combination, the Company was treated as a pass-through entity for tax purposes and no provision, except for certain subsidiaries which are taxed under Subchapter C, was made in the condensed consolidated financial statements for income taxes. The following income tax items for the periods prior to the close of the Business Combination are related to the applicable subsidiary company that is subject to income tax. Following the close of the Business Combination, the Company is taxed as a corporation.

The net loss for the three months and nine months ended September 30, 2021 and 2020 consisted of the following:

		For the Three Months Ended				For the Nine Months Ended
		September 30,				September 30,
(in thousands)		2021		2020		2021		2020
Jurisdictional earnings:
U.S. losses	$	(41,206)	$	(11,760)	$	(46,053)	$	(25,456)
Foreign income (losses)		870		969		(1,112)		1,461
Total losses		(40,336)		(10,791)		(47,165)		(23,995)
Current:
U.S. Federal		—		—		—		—
U.S. State and local		—		(29)		—		(26)
Foreign		—		(251)		—		(222)
Total current tax expense		—		(280)		—		(248)
Deferred:
U.S. Federal		—		—		—		—
U.S. State and local		(221)		—		282		—
Foreign		(326)		(46)		480		(46)
Total deferred tax benefit (expense)		(547)		(46)		762		(46)
Total tax benefit (expense)	$	(547)	$	(326)	$	762	$	(294)

Our effective tax rate for the third quarter of 2021 was 1.62% compared to (0.89)% for the year ended December 31, 2020. The effective tax rate for the periods presented differs from the statutory U.S. tax rate. This is primarily due to the Company’s pass-through entity treatment for tax purposes prior to the close of the Business Combination, including the Company’s full valuation allowance position which is further discussed below. In addition, for the Company’s taxable subsidiary operations, the effective tax rate differs due to mainly state income taxes and Puerto Rico taxes. The remaining rate differences are immaterial.

Deferred taxes for the applicable subsidiary companies are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences, operating losses and other tax credit carryforwards. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.

The Company does not believe it is more-likely-than-not all of its deferred tax assets will be realized and has therefore recorded a valuation allowance against its deferred tax assets which as of September 30, 2021 are not

-56-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

expected to be realized. The most significant deferred tax asset relates to the outside basis difference in the partnership which has a full valuation allowance through September 30, 2021. As of September 30, 2021, $0.7 million of deferred tax assets was included in other assets that are expected to be realized.

Management continuously assesses the likelihood that it is more likely than not that the deferred tax assets generated will be realized. In making such determinations, all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, and recent financial operations, are considered. In the event that management were to determine that the deferred income tax assets would be realized in the future for an amount equal to the net recorded amount, the valuation allowance and provision for income taxes would be adjusted.

The Company does not have any unrecognized tax positions (“UTPs”) as of September 30, 2021. While the Company currently does not have any UTPs, it is foreseeable that the calculation of the Company’s tax liabilities may involve dealing with uncertainties in the application of complex tax laws and regulations in multiple jurisdictions across the Company’s operations. ASC 740, "Income Taxes" ("ASC 740"), states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. Upon identification of a UTP, the Company would (1) record the UTP as a liability in accordance with ASC 740 and (2) adjust these liabilities if/when management’s judgment changes as a result of the evaluation of new information not previously available. Ultimate resolution of UTPs may produce a result that is materially different from a Company’s estimate of the potential liability. In accordance with ASC 740, the Company would reflect these differences as increases or decreases to income tax expense in the period in which new information is available. The Company’s accounting policy under ASC 740-10 is to include interest and penalties accrued on uncertain tax positions as a component of income tax expense in the event a material uncertain tax position is booked in the condensed consolidated financial statements.

The Company files income tax returns in the U.S. with Federal and State and local agencies, and in Puerto Rico. The Company is subject to U.S. Federal, state and local tax examinations for tax years starting in 2017. The Puerto Rico subsidiary group is subject to U.S. Federal, state and foreign tax examinations for tax years starting in 2019. The Company does not currently have any ongoing income tax examinations in any of its jurisdictions. The Company has analyzed filing positions in the Federal, State, local and foreign jurisdictions where it is required to file income tax returns for all open tax years and does not believe any tax uncertainties exist.

Tax Receivable Agreement

Upon the completion of the Business Combination, Cano Health, Inc. became a party to the Tax Receivable Agreement. Under the terms of that agreement, Cano Health, Inc. generally will be required to pay to the Seller and to each other person from time to time that becomes a “TRA Party” under the Tax Receivable Agreement, 85% of the tax savings, if any, that Cano Health, Inc. is deemed to realize in certain circumstances as a result of certain tax attributes that exist following the Business Combination and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. To the extent payments are made pursuant to the Tax Receivable Agreement, Cano Health, Inc. generally will be required to pay to the Sponsor and to each other person from time to time that becomes a “Sponsor Party” under the Tax Receivable Agreement such Sponsor Party’s proportionate share of, an amount equal to such payments multiplied by a fraction with the numerator 0.15 and the denominator 0.85. The term of the Tax Receivable Agreement will continue until all such tax benefits have been utilized or expired unless Cano Health, Inc. exercises its right to terminate the Tax Receivable Agreement for an amount representing the present value of anticipated future tax benefits under the Tax Receivable Agreement or certain other acceleration events occur. The Tax Receivable Agreement liability is determined and recorded under

-57-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

ASC 450, contingent liability; therefore, we are required to evaluate whether the liability is both probable and the amount can be estimated. Since the Tax Receivable Agreement liability is payable upon cash tax savings and we have determined that positive future taxable income is not probable based on the Cano Health, Inc’s historical loss position and other factors that make it difficult to rely on forecasts, we have not recorded the Tax Receivable Agreement liability as of September 30, 2021. We will evaluate this on a quarterly basis which may result in an adjustment in the future.

17.     NET LOSS PER SHARE

The following table sets forth the net loss for the three and nine months ended September 30, 2021 and 2020 and the computation of basic and diluted net loss per common stock for the three and nine months ended September 30, 2021:

	Three months ended September 30,				Nine months ended September 30,
(in thousands, except shares and per share data)	2021		2020		2021		2020
Numerator:
Net loss	$	(40,883)	$	(11,117)	$	(46,403)	$	(24,289)
Less: net loss attributable to non-controlling interests	(26,246)		—		(41,283)		—
Net loss attributable to Class A common stockholders	(14,637)		—		(5,120)		—
Dilutive effect of warrants on net loss to Class A common stockholders	—		N/A		(8,780)		N/A
Net loss attributable to Class A common stockholders - Diluted	(14,637)		N/A		(13,900)		N/A
Basic and Diluted Earnings Per Share denominator:
Weighted average common stock outstanding - basic	170,871,429		N/A		168,100,210		N/A
Net loss per share - basic	$	(0.09)	N/A		$	(0.03)	N/A
Diluted Earnings Per Share:
Dilutive effect of warrants on weighted average common stock outstanding	—		N/A		1,212,048		N/A
Weighted average common stock outstanding - diluted	170,871,429		N/A		169,312,258		N/A
Net loss per share - diluted	$	(0.09)	N/A		$	(0.08)	N/A

Prior to the consummation of the Business Combination, the Company’s ownership structure included equity interests held solely by the Parent. The Company analyzed the calculation of earnings per share for comparative periods presented and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, the earnings per share information has not been presented for the three and nine months ended September 30, 2020.

-58-

CANO HEALTH, INC. AND SUBSIDIARIES

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The outstanding Company’s Class B common stock does not represent economic interests in the Company, and as such, is not included in the denominator of the net loss per share calculation.

On August 11, 2021, the Company issued 2,720,966 shares of Class A common stock (the “escrowed shares”) to the escrow agent, on behalf of the seller, as part of the consideration in connection with an acquisition. The amount of shares was based on a $30.0 million purchase price divided by the average share price of the Company during the twenty consecutive trading days preceding the closing date of the transaction. The shares were deposited in escrow and will be released to the seller upon the satisfaction of certain performance metrics during 2022 and 2023. The final number of escrowed shares will be calculated by multiplying the initial share amount by an earned share percentage in accordance with the purchase agreement and subtracting any forfeited indemnity shares. The dilutive effects of these shares were excluded from the three and nine months ended September 30, 2021 because they were antidilutive.

The Company’s dilutive securities are derived from the Company’s Public Warrants and Private Placement Warrants using the treasury method and excluding the Class A stockholders' income statement effect of the change in fair value in warrant liability. The Public Warrants and Private Placement Warrants were included in the nine months ended September 30, 2021 dilutive earnings per share calculation. The warrants were excluded from the three months ended September 30, 2021 as they were antidilutive for the period. RSUs, stock options, and contingent shares were also excluded from the dilutive earning per share calculation as they had an anti-dilutive effect for the periods presented. The table below presents the Company’s potentially dilutive securities:

	As of September 30, 2021
Public Warrants	23,000,000
Private Placement Warrants	10,533,333
Restricted Stock Units	4,823,694
Stock Options	12,733,698
Contingent Shares Issued in Connection with Acquisitions	2,720,966
Potential Common Stock Equivalents	53,811,691

18.     SEGMENT INFORMATION

The Company organizes its operations into one reportable segment. The Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), reviews financial information and makes decisions about resource allocation based on the Company’s responsibility to deliver high quality primary medical care services to the Company’s patient population. For the periods presented, all of the Company’s revenues were earned in the United States, and all of the Company’s long lived assets were located in the United States.

19.    SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

-59-

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

Unless otherwise indicated or the context otherwise requires, references in this section to "the Company," "Cano Health,” “we,” “us,” “our,” and other similar terms refer, for periods prior to the completion of the Business Combination, to PCIH and its subsidiaries, and for periods upon or after the completion of the Business Combination, to the consolidated operations of Cano Health, Inc. and its subsidiaries, including PCIH and its subsidiaries. The following discussion and analysis is intended to help the reader understand our business, results of operations, financial condition, liquidity and capital resources. This discussion should be read in conjunction with Cano Health, Inc.'s unaudited condensed consolidated financial statements and related notes presented here in Part I, Item 1 included elsewhere in this Quarterly Report on Form 10-Q as well as PCIH's audited financial statements and the accompanying notes as well as “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Cano Health” included in our Form 8-K filed with the Securities and Exchange Commission on June 9, 2021.

The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report on Form 10-Q, particularly in the sections entitled "Forward-Looking Statements" and Part II, Item 1A, “Risk Factors.”

Overview

We are a primary care-centric, technology-powered healthcare delivery and population health management platform designed with a focus on clinical excellence. Our mission is simple: to improve patient health by delivering superior primary care medical services, while forging life-long bonds with our members. Our vision is clear: to become the national leader in primary care by improving the health, wellness and quality of life of the communities we serve, while reducing healthcare costs.

In 2016, we entered into a relationship with InTandem Capital Partners, LLC (“InTandem”) to provide financial support and guidance to fund platform investments and accelerate our growth. We have subsequently expanded our services from two markets in 2017 to 34 markets as of September 30, 2021, while growing membership from 13,685 members in 2017 to 210,663 members as of September 30, 2021. See “Management's Discussion and Analysis of Financial Condition and Results of Operations — Key Performance Metrics” for how we define our members and medical centers. Today, we are one of the largest and most sophisticated independent primary care platforms in the U.S., but still maintain significant growth runway. We have sought to address the fundamental problems with traditional healthcare payment models by leveraging our technology solutions and proven business model to align incentives among patients, payors and providers:

•Patients: Our members are offered services in modern, clean, and contemporary medical centers, with same or next day appointments, integrated virtual care, wellness services, ancillary services (such as physiotherapy), home services, transportation, telemedicine and a 24/7 urgency line, all without additional cost to them. This broad-based care model is critical to our success in delivering care to members of low-income communities, including large minority and immigrant populations, with complex care needs, many of whom previously had very limited or no access to quality healthcare. We are proud of the impact we have made in these underserved communities.

•Providers: We believe that providers want to be clinicians. Our employed physicians enjoy a collegial, near-academic environment and the tools and multi-disciplinary support they need to focus on medicine, their patients and their families rather than administrative matters like pre-authorizations, referrals, billing and coding. Our physicians receive ongoing training through regular clinical meetings to review the latest findings in primary care medicine. Furthermore, we offer above-average pay and no hospital call requirements. In addition, our physicians are eligible to receive a bonus based upon patient results, including reductions in patient emergency room visits and hospital admissions, among other metrics.

•Payors: Payors want three things: high-quality care, membership growth and effective medical cost management. We have a multi-year and multi-geography track record of delivering on all three. Our proven track record of high-quality ratings increases the premiums paid by the CMS to health plans, increases our quality primary-care-driven membership growth, and increases our scaled, highly professional value-based provider group that delivers quality care.

CanoPanorama, our proprietary population health management technology-powered platform, powers our efforts to deliver superior clinical care. Our platform provides the healthcare providers at our medical centers with a 360-degree view of their members, along with actionable insights to empower better care decisions and drive high member engagement. We leverage

-60-

our technology to risk-stratify members and apply a highly personalized approach to primary care, chronic care, preventive care and members’ broader healthcare needs. We believe our model is well-positioned to capitalize on the large and growing opportunity being driven by the marketplace’s shift to value-based care, demographic tailwinds in the market and the increased focus on improving health outcomes, care quality and the patient experience.

We predominantly enter into capitated contracts with the nation’s largest health plans to provide holistic, comprehensive healthcare. We predominantly recognize recurring per-member-per-month capitated revenue, which, in the case of health plans, is a pre-negotiated percentage of the premium that the health plan receives from the CMS. We also provide practice management and administrative support services to independent physicians and group practices that we do not own through our managed services organization relationships, which we refer to as our affiliate relationships. Our contracted recurring revenue model offers us highly predictable revenue and rewards us for providing high-quality care rather than driving a high volume of services. In this capitated arrangement, our goals are well-aligned with payors and patients alike — the more we improve health outcomes, the more profitable we will be over time.

Our capitated revenue is generally a function of the pre-negotiated percentage of the premium that the health plan receives from CMS as well as our ability to accurately and appropriately document member acuity and achieve quality metrics. Under this capitated contract structure, we are responsible for all members’ medical costs inside and outside of our medical centers. Keeping members healthy is our primary objective. When they need medical care, delivery of the right care in the right setting can greatly impact outcomes. Through members’ engagement with our entire suite of services, including high-frequency primary care and access to ancillary services like our wellness programs, Cano Life and Cano@Home, we aim to reduce the number of occasions that members need to seek specialty care in higher-cost environments. When care outside of our medical centers is needed, our primary care physicians control referrals to specialists and other third-party care, which are typically paid by us on a fee-for-service basis. This allows us to proactively manage members’ health within our medical centers first, prior to resorting to more costly care settings.

As of September 30, 2021, we employed approximately 345 providers (physicians, nurse practitioners, physician assistants) across our 113 owned medical centers, maintained affiliate relationships with over 1,000 physicians and approximately 600 clinical support employees focused on supporting physicians in enabling patient care and experience. For the nine months ended September 30, 2020 and 2021, our total revenue was $569.6 million and $1.2 billion, respectively, representing a period-over-period growth rate of 110.7%. Our net loss increased from $24.3 million for the nine months ended September 30, 2020 to $46.4 million for the nine months ended September 30, 2021.

Key Factors Affecting Our Performance

Our historical financial performance has been, and we expect our financial performance in the future to be, driven by our ability to:

Build Long-Term Relationships with our Existing Members

We focus on member satisfaction in order to build long-term relationships. Our members enjoy highly personalized value-based care and their visits to our medical centers cover primary care and ancillary programs such as pharmacy and dental services, in addition to wellness and social services, which lead to healthier and happier members. By integrating member engagement and the Cano Life wellness program within the CanoPanorama platform, we also help foster long-term relationships with members. Resulting word-of-mouth referrals contribute to our high organic growth rates. Patient satisfaction can also be measured by a provider’s Net Promoter Score ("NPS"), which measures the loyalty of customers to a company. Our member NPS score of 82 speaks to our ability to consistently deliver high-quality care with superior member satisfaction.

Add New Members in Existing Centers

Our ability to add new members organically is a key driver of our growth. We have a large embedded growth opportunity within our existing medical center base. As of December 31, 2020, our existing medical centers in South Florida operated at approximately 50% of capacity, providing us with the ability to significantly increase our membership without the need for significant capital expenditures. In medical centers that are approaching full capacity, we are able to augment our footprint by expanding our existing medical centers, opening de novo centers or acquiring centers that are a more convenient “medical home” for our members. We also believe that even after COVID-19 subsides, we will continue to conduct some visits

-61-

by telemedicine based on member preference and clinical need, which in turn could increase the average capacity of our medical centers. Additionally, as we add members to our existing medical centers, we expect these members to contribute significant incremental economics as we leverage our fixed cost base at each medical center.

Our payor partners also direct members to our medical centers by either assigning patients who have not yet selected a primary care provider or through insurance agents who inform their clients about our services. We believe this often results in the patient selecting us as their primary care provider when they select a Medicare Advantage plan. Due to our care delivery model’s patient-centric focus, we have been able to consistently help payors manage their costs while raising the quality of their plans, affording them quality bonuses that increase their revenue. We believe that we represent an attractive opportunity for payors to meaningfully improve their overall membership growth in a given market without assuming any financial downside.

Expand our Medical Center Base within Existing and New Markets

We have successfully entered 32 new markets since 2017 and as of September 30, 2021 were operating in 34 markets in Florida, Texas, Nevada, New Jersey, New York, New Mexico, Illinois, California and Puerto Rico. When entering a new market, we tailor our entry strategy to the characteristics of the specific market and provide a customized solution to meet that market’s needs. When choosing a market to enter, we look at various factors including (i) Medicare population density, (ii) underserved demographics, (iii) existing payor relationships, (iv) patient acuity and (v) specialist and hospital access/capacity. We typically choose a location that is highly visible and accessible and work to enhance brand development pre-entry. Our flexible medical center design allows us to adjust to local market needs by building medical centers that range from approximately 7,000 to 20,000 square feet that may include ancillary services such as pharmacies and dental services. We seek to grow member engagement through targeted multi-channel marketing, community outreach and use of mobile clinics to expand our reach. When entering a new market, based on its characteristics and economics, we decide whether it makes the most sense to buy existing medical centers, build de novo medical centers or to help manage members’ health care via affiliate relationships. This highly flexible model enables us to choose the right solution for each market.

When building or buying a medical center is the right solution, we own the medical facility and employ physicians. In our medical centers, we receive per-member-per-month capitated revenue, which, in the case of health plans, is a pre-negotiated percentage of the premium that the health plan receives from CMS. Although there is an upfront cost of development, historically approximately $1.3 to $1.8 million per medical center, the owned medical center model provides the best opportunity to drive improved health outcomes and allows us to practice full value-based care.

Alternatively, our affiliate relationships allow us to partner with independent physicians and group practices that we do not own and to provide them access to components of our population health management platform. As of September 30, 2021, we provided services to over 1,000 providers. As in the case of our owned medical centers, we receive per-member-per-month capitated revenue and a pre-negotiated percentage of the premium that the health plan receives from CMS. We pay the affiliate a primary care fee and a portion of the surplus of premium in excess of third-party medical costs. The surplus portion paid to affiliates is recorded as direct patient expense. This approach is extremely capital efficient as the costs of managing affiliates are minimal. Further, the affiliate model is an important growth avenue as it serves as a feeder into our acquisition pipeline, enabling us to evaluate and target affiliated practices for acquisition based on our operational experience with them.

Contracts with Payors

Our economic model relies on our capitated partnerships with payors, which manage Medicare members across the United States. We have established ourselves as a top quality provider across multiple Medicare and Medicaid health plans, including Humana, Anthem and UnitedHealthcare (or their respective affiliates). Our relationships with our payor partners go back as many as ten years and are generally evergreen in nature. We are viewed as a critical distributor of effective healthcare with market-leading clinical outcomes (led by primary care), and as such we believe our payor relationships will continue to be long-lasting and enduring. These plans and others are seeking further opportunities to expand their relationship with us beyond our current markets. Having payor relationships in place reduces the risk of entering into new markets. Maintaining, supporting and growing these relationships, particularly as we enter new geographies, is critical to our long-term success. Health plans look to achieve three goals when partnering with a provider: membership growth, clinical quality and medical cost management. We are capable of delivering all three based on our care coordination strategy, differentiated quality metrics and strong relationships with members. We believe this alignment of interests and our highly effective care model will ensure continued success with our payor partners.

-62-

Effectively Manage the Cost of Care for Our Members

The capitated nature of our contracting with payors requires us to invest in maintaining our members’ health while prudently managing the medical costs of our members. Third-party medical costs and direct patient expense are our largest expense categories, representing 82.0% of our total operating expenses for the nine months ended September 30, 2021. Our care model focuses on maintaining health and leveraging the primary care setting as a means of avoiding costly downstream healthcare costs. Our members, however, retain the freedom to seek care at emergency rooms or hospitals without the need for referrals; we do not restrict their access to care. Therefore, we are liable for potentially large medical claims should we not effectively manage our members’ health. To mitigate this exposure, we utilize stop-loss insurance for our members, protecting us from medical claims per episode in excess of certain levels.

Significant Acquisitions

We supplement our organic growth through our highly accretive acquisition strategy. We have a successful acquisition and integration track record. We have established a rigorous data-driven approach and the necessary infrastructure to identify, acquire and quickly integrate targets.

The acquisitions have all been accounted for in accordance with ASC 805, and the operations of the acquired entities are included in our historical results for the periods following the closing of the acquisition. See Note 3, “Business Acquisitions” in our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. The most significant of these acquisitions impacting the comparability of our operating results were:

•Primary Care Physicians and related entities. On January 2, 2020, we acquired Primary Care Physicians and related entities (collectively, "PCP") for total consideration of $60.2 million, consisting of $53.6 million in cash, $4.0 million of Class A-4 Units and $2.6 million in other closing payments. PCP is comprised of eleven primary care centers and a managed services organization serving populations in the Broward County region of South Florida.

•HP Enterprises II, LLC and related entities. On June 1, 2020 we acquired HP Enterprises II, LLC and related entities (collectively, "HP" or "Healthy Partners") for total consideration of $195.4 million, consisting of $149.3 million in cash, $30.0 million of Class A-4 Units and $16.1 million in deferred payments. Healthy Partners is comprised of sixteen primary care centers and a management services organization serving populations across Florida, including the Miami-Dade, Broward, Palm Beach, Treasure Coast and Central Florida areas.

•University Health Care and its affiliates. On June 11, 2021, we acquired University Health Care and its affiliates (collectively, "University") for total consideration of $611.1 million, consisting of $541.5 million in cash, $60.0 million of Class A common stock and $9.6 million in contingent consideration from acquisition add-ons based on additional acquired entities. University is comprised of thirteen primary care centers, a managed services organization and a pharmacy serving populations throughout various locations in South Florida.

•Doctor’s Medical Center, LLC and its affiliates. On July 2, 2021, the Company acquired Doctor's Medical Center, LLC and its affiliates ("DMC"). The purchase price totaled $300.7 million, which was paid in cash. DMC is comprised of fourteen primary care centers serving populations across Florida. In conjunction with the primary care centers, DMC also provides MSO services to affiliated medical centers, and operates a pharmacy.

Member Acuity and Quality Metrics

Medicare pays capitation using a risk-adjusted model, which compensates payors based on the health status, or acuity, of each individual member. Payors with higher acuity members receive a higher payment and those with lower acuity members receive a lower payment. Moreover, some of our capitated revenues also include adjustments for performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. Our capitated revenues are recognized based on projected member acuity and quality metrics and are subsequently adjusted to reflect actual member acuity and quality metrics. Our ability to accurately project and recognize member acuity and quality metric adjustments are affected by many factors. For instance, Medicare requires that a member’s health issues be documented semi-annually regardless of the permanence of the underlying causes. Historically, this documentation was required to be completed during an in-person visit with a member. As part of the Coronavirus Aid, Relief and Economic Security Act, Medicare is allowing documentation for

-63-

conditions identified during video visits with members. However, given the disruption caused by COVID-19, it is unclear whether we will be able to document the health conditions and quality metrics of our members as comprehensively as we did in prior years, which may adversely impact our capitated revenue. Similarly, our ability to accurately project member acuity and quality metrics may be more limited in the case of medical centers operating in new markets or which were recently acquired.

Seasonality to Our Business

Our operational and financial results experience some variability depending upon the time of year in which they are measured. This variability is most notable in the following areas:

Medical Costs

Medical costs vary seasonally depending on a number of factors. Typically, we experience higher utilization levels during the first quarter of the year. Medical costs also depend upon the number of business days in a period. Shorter periods will have lesser medical costs due to fewer business days. Business days can also create year-over-year comparability issues if one year has a different number of business days compared to another. Additionally, we accrue stop loss reimbursements from September through December which can result in reduced medical expenses during the fourth quarter due to recoveries.

Organic Member Growth

We experience the largest portion of our organic member growth during the first quarter, when plan enrollment selections made during the prior Annual Enrollment Period from October 15 through December 7 of the prior year take effect. We also add members throughout the year, including during Special Enrollment Periods when certain eligible individuals can enroll in Medicare Advantage midyear.

Per-Member Capitated Revenue

We experience some seasonality with respect to our per-member revenue, which generally declines over the course of the year. In January of each year, CMS revises the risk adjustment factor for each member based upon health conditions documented in the prior year, leading to an overall change in per-member premium. As the year progresses, our per-member revenue declines as new members join us, typically with less complete or accurate documentation (and therefore lower risk adjustment scores).

Key Performance Metrics

In addition to our U.S. GAAP and non-GAAP financial information, we review a number of operating and financial metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions.

	September 30, 2021	December 31, 2020	September 30, 2020
Members	210,663	105,707	102,767
Owned medical centers	113	71	71

Members

Members represent those Medicare, Medicaid, and Affordable Care Act ("ACA") patients for whom we receive a fixed per-member-per-month fee under capitation arrangements as of the end of a particular period.

Owned Medical Centers

We define our medical centers as those primary care medical centers open for business and attending to members at the end of a particular period in which we own the medical operations and the physicians are our employees.

Impact of COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. The rapid spread of COVID-19 around the world led to the shutdown of cities as national, state, and local authorities implemented social distancing,

-64-

quarantine and self-isolation measures. Many such restrictions remain in place, and some state and local governments are re-imposing certain restrictions due to the increasing rates of COVID-19 cases. Additionally, a new Delta variant of COVID-19, which appears to be the most transmissible variant to date, has begun to spread globally. The virus disproportionately impacts older adults, especially those with chronic illnesses, which describes many of our patients.

In response to COVID-19, we remained open and augmented our Cano@Home program, 24/7 urgency line and pharmacy home delivery to enable members to access needed care and support in the home. We successfully pivoted to a telemedicine offering for routine care in order to protect and better serve our patients, staff and community. Our centers remained open for urgent visits and necessary procedures. As COVID-19 cases grew nationally, we took immediate action and deployed a specific COVID-19 focused module under CanoPanorama that allowed our staff to screen patients for COVID-19 and related complications, as well as refer them to a specialized team that is dedicated to helping COVID-19 patients. The pandemic did not have a material impact on our results of operations, cash flows and financial position as of, and for the nine months ended, September 30, 2021. This is primarily attributable to the relatively fixed nature of our capitated revenue arrangements. Over 95% of our total gross revenues are recurring, consisting of fixed monthly per-member-per-month capitation payments we receive from healthcare providers. Additionally, during this time, we completed and integrated several acquisitions and expanded to new locations which had a positive impact on our revenues. Due to our recurring contracted revenue model, we experienced minimal impact to our revenue during 2020 and the first nine months of 2021.

We experienced both cost increases and cost savings due to COVID-19. Increases in operating expenses were primarily attributable to higher-than-budgeted payroll expenses, pharmacy prescription expenses, provider payments, rent, and marketing expenses. Deeply committed to our employees, we made a conscious decision not to furlough any of our employees, even if their function was disrupted by COVID-19. These higher costs were partially offset by lower referral fees, vehicle expenses, IT costs, professional fees, office and facility (ER) costs, and travel costs. We experienced a decrease in utilization of services during March through June of 2020. Medical centers were open for emergency visits, but we also expanded our at-home care services, resulting in lower emergency transportation costs, and facility service costs (including costs related to various wellness and activity services offered at clinics). Even as utilization increased month to month through the second half of 2020 and through 2021, we expect certain costs savings to remain permanent as some members continue to take advantage of telemedicine and Cano@Home care services.

The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, future results of operations and financial condition will depend on future factors that are highly uncertain and cannot be accurately predicted. These factors include, but are not limited to, new information that may emerge concerning COVID-19, the scope and duration of business closures and restrictions, government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Additionally, the impact of the COVID-19 variants cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the effectiveness of the COVID-19 vaccines against the variants, and the response by the governmental bodies and regulators. Due to these and other uncertainties, we cannot estimate the length or severity of the impact of the pandemic on our business. Additionally, because of our business model, the full impact of the COVID-19 pandemic may not be fully reflected in our results of operations and overall financial condition until future periods. We will continue to closely evaluate and monitor the nature and extent of these potential impacts to our business, results of operations and liquidity. However, based on our experience, we expect the overall negative impact from COVID-19 on our business will be immaterial. In addition, we expect to offer more telemedicine and mobile solutions which will create additional touchpoints to timely capture member medical data, which in turn provide actionable insights to empower better care decisions via our CanoPanorama system.

For additional information on the various risks posed by the COVID-19 pandemic, please see the section entitled "Risk Factors" included in this Quarterly Report on Form 10-Q.

Key Components of Results of Operations

Revenue

Capitated revenue. Our capitated revenue is derived from fees for medical services provided at our medical centers or affiliated practices under capitation arrangements made directly with various health plans or CMS. Fees consist of a per-member-per-month ("PMPM") amount paid on an interim basis for the delivery of healthcare services, and our rates are determined as a percent of the premium that the health plans receive from the CMS for our at-risk members. Those premiums are based upon the cost of care in a local market and the average utilization of services by the members enrolled. Medicare pays capitation using a “risk adjustment model,” which compensates providers based on the health status (acuity) of each individual patient. Groups with higher acuity patients receive more, and those with lower acuity patients receive less. Under the risk adjustment model, capitated premium is paid based on the acuity of members enrolled for the preceding year and subsequently adjusted once current year data is compiled. Our accrued revenue reflects the current period acuity of members. The amount of capitated revenue may be affected by certain factors outlined in the agreements with the health plans, such as administrative fees paid to the health plans and risk adjustments to premiums.

-65-

Generally, we enter into three types of capitation arrangements: non-risk arrangements, limited risk arrangements, and full risk arrangements. Under our non-risk arrangements, we receive monthly capitated payments without regard to the actual amount of services provided. Under our limited risk arrangements, we assume partial financial risk for covered members. Under our full risk arrangements, we assume full financial risk for covered members.

Fee-for-service and other revenue. We generate fee-for-service revenue from providing primary care services to patients in our medical centers and affiliates when we bill the member or their insurance plan on a fee-for-service basis as medical services are rendered. While substantially all of our patients are members, we occasionally also provide care to non-members. Fee-for-service amounts are recorded based on agreed-upon fee schedules determined within each contract.

Other revenue consists of sales from our pharmacies. We contract with an administrative services organization to collect and remit payments on our behalf from the sale of prescriptions and medications. We have pharmacies at some of our medical centers, where customers may fill prescriptions and retrieve their medications. Patients also have the option to fill their prescriptions with a third-party pharmacy of their choice.

Operating Expenses

Third-party medical costs. Third-party medical costs primarily consist of all medical expenses paid by the health plans or the CMS (contractually on behalf of Cano Health) including costs for inpatient and hospital care, specialists, and certain pharmacy purchases associated with the resale of third-party medicines. Provider costs are accrued based on the date of service to members, based in part on estimates, including an accrual for medical services incurred but not reported (“IBNR”). Liabilities for IBNR are estimated using standard actuarial methodologies including our accumulated statistical data, adjusted for current experience. These estimates are continually reviewed and updated, and we retain the services of an independent actuary to review IBNR on an annual basis. We expect our third-party medical costs to increase given the healthcare spending trends within the Medicare population and the increasing disease burden of our patients as they age, which is also consistent with what we indirectly receive (through capitated revenue) from the CMS.

Direct patient expense. Direct patient expense primarily consists of costs incurred in the treatment of our patients, at our medical centers and affiliated practices, including the compensation related to medical service providers and technicians, medical supplies, purchased medical services, and drug costs for pharmacy sales.

Selling, general, and administrative expense. Selling, general, and administrative expenses include employee-related expenses, including salaries and benefits, technology infrastructure, operations, clinical and quality support, finance, legal, human resources, and corporate development departments. In addition, selling, general, and administrative expenses include all corporate technology and occupancy costs. We expect our selling, general, and administrative expenses to increase over time following the closing of the Business Combination due to the additional legal, accounting, insurance, investor relations and other costs that we incur as a public company, as well as other costs associated with continuing to grow our business. However, we anticipate that these expenses will decrease as a percentage of revenue over the long term, although they may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses. For purposes of determining center-level economics, we allocate a portion of our selling, general, and administrative expenses to our medical centers and affiliated practices. The relative allocation of these expenses to each center depends upon a number of metrics, including (i) the number of centers open during a given period of time; (ii) the number of clinicians at each center at a given period of time; or (iii) if determinable, the center where the expense was incurred.

Depreciation and amortization expense. Depreciation and amortization expenses are primarily attributable to our capital investment and consist of fixed asset depreciation and amortization of intangibles considered to have finite lives.

Transaction costs and other. Transaction costs and other primarily consist of deal costs (including due diligence, integration, legal, internal staff, and other professional fees, incurred from acquisition activity), bonuses due to sellers, fair value adjustments in contingent consideration due to sellers, and management fees for financial and management consulting services from our advisory services agreement.

Other Income (Expense)

Interest expense. Interest expense primarily consists of interest incurred on our outstanding borrowings under our notes payable related to our equipment loans and credit facility. See “Liquidity and Capital Resources”. Costs incurred to obtain debt

-66-

financing are amortized and shown as a component of interest expense.

Interest income. Interest income consists of interest earned through a loan agreement with an affiliated company.

Loss on extinguishment of debt. Loss on extinguishment of debt primarily consists of unamortized debt issuance costs related to certain term loans in connection with our financing arrangements.

Change in fair value of embedded derivative. Change in fair value of embedded derivative consists primarily of changes to an embedded derivative identified in our debt agreement. The embedded derivative is revalued at each reporting period.

Change in fair value of warrant liabilities. Change in fair value of warrant liabilities consists primarily of changes to the Public Warrants and Private Placement Warrants assumed upon the consummation of the Business Combination. The liabilities are revalued at each reporting period.

Other expenses. Other expenses consist of legal settlement fees.

Results of Operations

The following table sets forth our consolidated statements of operations data for the periods indicated:

		Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)		2021		2020		2021		2020
Revenue:
Capitated revenue	$	501,780	$	252,974	$	1,148,041	$	544,617
Fee-for-service and other revenue		25,018		10,159		52,055		25,020
Total revenue		526,798		263,133		1,200,096		569,637
Operating expenses:
Third-party medical costs		379,316		184,926		866,177		382,279
Direct patient expense		57,708		31,108		135,777		71,441
Selling, general, and administrative expenses		75,926		27,391		157,348		70,234
Depreciation and amortization expense		16,955		5,379		30,746		12,741
Transaction costs and other		6,528		7,716		32,140		29,854
Total operating expenses		536,433		256,520		1,222,188		566,549
Income (loss) from operations		(9,635)		6,613		(22,092)		3,088
Other income and expense:
Interest expense		(16,023)		(12,346)		(36,363)		(21,728)
Interest income		1		80		4		239
Loss on extinguishment of debt		—		—		(13,225)		—
Change in fair value of embedded derivative		—		(5,138)		—		(5,444)
Change in fair value of warrant liabilities		(14,650)		—		24,565		—
Other expenses		(29)		—		(54)		(150)
Total other income (expense)		(30,701)		(17,404)		(25,073)		(27,083)
Net loss before income tax benefit (expenses)		(40,336)		(10,791)		(47,165)		(23,995)
Income tax benefit (expense)		(547)		(326)		762		(294)
Net loss		(40,883)		(11,117)		(46,403)		(24,289)
Net loss attributable to non-controlling interests		(26,246)		—		(41,283)		—
Net loss attributable to Class A common stockholders	$	(14,637)	$	—	$	(5,120)	$	—

The following table sets forth our consolidated statements of operations data expressed as a percentage of total revenues for the periods indicated:

-67-

	Three Months Ended September 30,				Nine Months Ended September 30,
(% of revenue)	2021		2020		2021		2020
Revenue:
Capitated revenue	95.3	%	96.1	%	95.7	%	95.6	%
Fee-for-service and other revenue	4.7	%	3.9	%	4.3	%	4.4	%
Total revenue	100.0	%	100.0	%	100.0	%	100.0	%
Operating expenses:
Third-party medical costs	72.0	%	70.3	%	72.2	%	67.1	%
Direct patient expense	11.0	%	11.8	%	11.3	%	12.5	%
Selling, general, and administrative expenses	14.4	%	10.4	%	13.1	%	12.3	%
Depreciation and amortization expense	3.2	%	2.0	%	2.6	%	2.2	%
Transaction costs and other	1.2	%	2.9	%	2.7	%	5.2	%
Total operating expenses	101.8	%	97.4	%	101.9	%	99.3	%
Loss from operations	(1.8)	%	2.6	%	(1.9)	%	0.7	%
Other income and expense:
Interest expense	(3.0)	%	(4.7)	%	(3.0)	%	(3.8)	%
Interest income	0.0	%	0.0	%	0.0	%	0.0	%
Loss on extinguishment of debt	0.0	%	0.0	%	(1.1)	%	0.0	%
Change in fair value of embedded derivative	0.0	%	(2.0)	%	0.0	%	(1.0)	%
Change in fair value of warrant liabilities	(2.8)	%	0.0	%	2.0	%	0.0	%
Other expenses	0.0	%	0.0	%	0.0	%	0.0	%
Total other income (expense)	(5.8)	%	(6.7)	%	(2.1)	%	(4.8)	%
Net loss before income tax benefit (expenses)	(7.6)	%	(4.1)	%	(4.0)	%	(4.1)	%
Income tax benefit (expense)	(0.1)	%	(0.1)	%	0.1	%	(0.1)	%
Net loss	(7.7)	%	(4.2)	%	(3.9)	%	(4.2)	%
Net loss attributable to non-controlling interests	(5.0)	%	—	%	(3.4)	%	—	%
Net loss attributable to Class A common stockholders	(2.7)	%	—	%	(0.5)	%	—	%

The following table sets forth the Company’s disaggregated revenue for the periods indicated:

		Three Months Ended September 30,
		2021				2020
($ in thousands)		Revenue $	Revenue %			Revenue $	Revenue %
Capitated revenue:
Medicare	$	447,250	84.9	%	$	220,591	83.8	%
Other capitated revenue		54,530	10.4	%		32,383	12.3	%
Total capitated revenue		501,780	95.3	%		252,974	96.1	%
Fee-for-service and other revenue:
Fee-for-service		8,176	1.6	%		3,258	1.2	%
Pharmacy		10,096	1.8	%		6,154	2.4	%
Other		6,746	1.3	%		747	0.3	%
Total fee-for-service and other revenue		25,018	4.7	%		10,159	3.9	%
Total revenue	$	526,798	100.0	%	$	263,133	100.0	%

-68-

		Nine Months Ended September 30,
		2021				2020
($ in thousands)		Revenue $	Revenue %			Revenue $	Revenue %
Capitated revenue:
Medicare	$	1,008,329	84.0	%	$	455,986	80.0	%
Other capitated revenue		139,712	11.6	%		88,631	15.6	%
Total capitated revenue		1,148,041	95.7	%		544,617	95.6	%
Fee-for-service and other revenue:
Fee-for-service		17,113	1.4	%		6,269	1.1	%
Pharmacy		25,619	2.1	%		17,207	3.0	%
Other		9,323	0.8	%		1,544	0.3	%
Total fee-for-service and other revenue		52,055	4.3	%		25,020	4.4	%
Total revenue	$	1,200,096	100.0	%	$	569,637	100.0	%

The following table sets forth the Company’s member and member month figures for the periods indicated:

		Three Months Ended September 30,
		2021		2020	% Change
Members:
Medicare		120,086		72,806	64.9	%
Medicaid		63,871		19,169	233.2	%
ACA		26,706		10,792	147.5	%
Total members		210,663		102,767	105.0	%
Member months:
Medicare		360,439		216,353	66.6	%
Medicaid		187,212		53,511	249.9	%
ACA		81,437		32,285	152.2	%
Total member months		629,088		302,149	108.2	%
Per Member Per Month ("PMPM"):
Medicare	$	1,241	$	1,020	21.7	%
Medicaid	$	271	$	585	(53.7)	%
ACA	$	47	$	33	42.4	%
Total PMPM	$	798	$	837	(4.7)	%
Owned medical centers		113		71

-69-

		Nine Months Ended September 30,
		2021		2020	% Change
Members:
Medicare		120,086		72,806	64.9	%
Medicaid		63,871		19,169	233.2	%
ACA		26,706		10,792	147.5	%
Total members		210,663		102,767	105.0	%
Member months:
Medicare		867,520		483,878	79.3	%
Medicaid		321,581		136,658	135.3	%
ACA		195,290		92,577	110.9	%
Total member months		1,384,391		713,113	94.1	%
Per Member Per Month ("PMPM"):
Medicare	$	1,162	$	942	23.4	%
Medicaid	$	414	$	631	(34.4)	%
ACA	$	36	$	26	38.5	%
Total PMPM	$	829	$	764	8.5	%
Owned medical centers		113		71

Comparison of the Three Months Ended September 30, 2021 and September 30, 2020

Revenue

		Three Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Revenue:
Capitated revenue	$	501,780	$	252,974	$	248,806	98.4	%
Fee-for-service and other revenue		25,018		10,159		14,859	146.3	%
Total revenue	$	526,798	$	263,133	$	263,665

Capitated revenue. Capitated revenue was $501.8 million for the three months ended September 30, 2021, an increase of $248.8 million, or 98.4%, compared to $253.0 million for the three months ended September 30, 2020. The increase was primarily driven by a 108.2% increase in the total member months, slightly offset by a 4.7% decrease in total revenue per member per month. The increase in member months was primarily due to an increase in the total number of members served and our acquisitions, primarily University in June 2021 and DMC in July 2021, which resulted in the addition of new members and new markets in Florida.

Fee-for-service and other revenue. Fee-for-service and other revenue was $25.0 million for the three months ended September 30, 2021, an increase of $14.9 million, or 146.3%, compared to $10.2 million for the three months ended September 30, 2020. The increase in fee-for-service revenue was primarily attributable to an increase in members served across existing centers and the acquisitions of affiliates in August 2021. We experienced a decrease in utilization of services due to the impact of COVID-19 in the third quarter of 2020, which contributed to lower fee-for service revenue in that period. Further, other revenue

-70-

increased in the third quarter of 2021 due to an acquisition that generated ancillary fees earned under contracts with certain care organizations for the provision of care coordination services. The increase in pharmacy revenue was driven by organic growth as we continued to increase the number of members served in our established pharmacies, as well as the addition of a new pharmacy from our acquisition of University in June 2021.

Operating Expenses

		Three Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Operating expenses:
Third-party medical costs	$	379,316	$	184,926	$	194,390	105.1	%
Direct patient expense		57,708		31,108		26,600	85.5	%
Selling, general, and administrative expenses		75,926		27,391		48,535	177.2	%
Depreciation and amortization expense		16,955		5,379		11,576	215.2	%
Transaction costs and other		6,528		7,716		(1,188)	(15.4)	%
Total operating expenses	$	536,433	$	256,520	$	279,913

Third-party medical costs. Third-party medical costs were $379.3 million for the three months ended September 30, 2021, an increase of $194.4 million, or 105.1%, compared to $184.9 million for the three months ended September 30, 2020. The increase was driven by a 108.2% increase in total member months, the addition of Direct Contracting Entity members with higher medical costs, and higher utilization of third party medical services as utilization normalized from lower levels related to the COVID-19 pandemic.

Direct patient expense. Direct patient expense was $57.7 million for the three months ended September 30, 2021, an increase of $26.6 million, or 85.5%, compared to $31.1 million for the three months ended September 30, 2020. The increase was driven by increases in payroll and benefits of $10.9 million, pharmacy drugs of $3.2 million, medical supplies of $1.1 million and provider payments of $11.4 million.

Selling, general, and administrative expense. Selling, general, and administrative expense was $75.9 million for the three months ended September 30, 2021, an increase of $48.5 million, or 177.2%, compared to $27.4 million for the three months ended September 30, 2020. The increase was driven by higher salaries and benefits of $19.3 million, stock-based compensation of $8.9 million, occupancy costs of $5.4 million, marketing expenses of $2.8 million, legal and professional services of $4.9 million, and other costs of $7.2 million. These increases were incurred to support the continued growth of our business and expansion into other states.

Depreciation and amortization expense. Depreciation and amortization expense was $17.0 million for the three months ended September 30, 2021, an increase of $11.6 million, or 215.2%, compared to $5.4 million for the three months ended September 30, 2020. The increase was driven by purchases of new property and equipment to support the growth of our business during the period as well as the addition of several new brand names, non-compete agreements, and payor relationships from our 2020 and 2021 acquisitions.

Transaction costs and other. Transaction costs and other were $6.5 million for the three months ended September 30, 2021, a decrease of $1.2 million, or 15.4%, compared to $7.7 million for the three months ended September 30, 2020. The decrease was due to lower integration, legal, internal staff, and other professional fees incurred subsequent to the closing of the Business Combination.

-71-

Other Income (Expense)

		Three Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Other income and expense:
Interest expense	$	(16,023)	$	(12,346)	$	(3,677)	29.8	%
Interest income		1		80		(79)	(98.8)	%
Change in fair value of embedded derivative		—		(5,138)		5,138	(100.0)	%
Change in fair value of warrant liabilities		(14,650)		—		(14,650)	0.0	%
Other expenses		(29)		—		(29)	0.0	%
Total other income (expense)	$	(30,701)	$	(17,404)	$	(13,297)

Interest expense. Interest expense was $16.0 million for the three months ended September 30, 2021, an increase of $3.7 million, or 29.8%, compared to $12.3 million for the three months ended September 30, 2020. The increase was primarily driven by interest incurred on our higher outstanding borrowings under our credit facility to fund our acquisitions.

Change in fair value of the embedded derivative. Change in fair value of the embedded derivative was $5.1 million for the three months ended September 30, 2020 which was due to a change in the fair value of the embedded derivative related to our term loan agreement in 2020. The embedded derivative was settled with the refinancing in November of 2020.

Change in fair value of warrant liabilities. Change in fair value of warrant liabilities was $14.7 million for the three months ended September 30, 2021. This expense is a result of the change in the fair value of the Public Warrants and Private Placement Warrants assumed in connection with the Business Combination.

Comparison of the Nine Months Ended September 30, 2021 and September 30, 2020

Revenue

		Nine Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Revenue:
Capitated revenue	$	1,148,041	$	544,617	$	603,424	110.8	%
Fee-for-service and other revenue		52,055		25,020		27,035	108.1	%
Total revenue	$	1,200,096	$	569,637	$	630,459	110.7	%

Capitated revenue. Capitated revenue was $1,148.0 million for the nine months ended September 30, 2021, an increase of $603.4 million, or 110.8%, compared to $544.6 million for the nine months ended September 30, 2020. The increase was primarily driven by a 94.1% increase in the total member months and an 8.5% increase in total revenue per member per month. The increase in member months was due to an increase in the total number of members served and our acquisitions, primarily Healthy Partners in June 2020 and University in June 2021, which resulted in the addition of new members and new markets in Florida.

Fee-for-service and other revenue. Fee-for-service and other revenue was $52.1 million for the nine months ended September 30, 2021, an increase of $27.0 million, or 108.1%, compared to $25.0 million for the nine months ended September 30, 2020. The increase in fee-for-service revenue was primarily attributable to an increase in members served across existing centers. We experienced a decrease in utilization of services due to the impact of COVID-19 through the third quarter of 2020, which contributed to lower fee-for service revenue in that period. Further, other revenue increased in the third quarter of 2021 due to an acquisition that generated ancillary fees earned under contracts with certain care organizations for the

-72-

provision of care coordination services. The increase in pharmacy revenue was driven by organic growth as we continued to increase the number of members served in our established pharmacies as well as the addition of a new pharmacy from our acquisition of University in June of 2021.

Operating Expenses

		Nine Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Operating expenses:
Third-party medical costs	$	866,177	$	382,279	$	483,898	126.6	%
Direct patient expense		135,777		71,441		64,336	90.1	%
Selling, general, and administrative expenses		157,348		70,234		87,114	124.0	%
Depreciation and amortization expense		30,746		12,741		18,005	141.3	%
Transaction costs and other		32,140		29,854		2,286	7.7	%
Total operating expenses	$	1,222,188	$	566,549	$	655,639

Third-party medical costs. Third-party medical costs were $866.2 million for the nine months ended September 30, 2021, an increase of $483.9 million, or 126.6%, compared to $382.3 million for the nine months ended September 30, 2020. The increase was driven by a 94.1% increase in total member months, the addition of Direct Contracting Entity members with higher medical costs, and higher utilization of third party medical services as utilization normalized from lower levels related to the COVID-19 pandemic.

Direct patient expense. Direct patient expense was $135.8 million for the nine months ended September 30, 2021, an increase of $64.3 million, or 90.1%, compared to $71.4 million for the nine months ended September 30, 2020. The increase was driven by increases in payroll and benefits of $22.5 million, pharmacy drugs of $6.4 million, medical supplies of $2.8 million and provider payments of $32.6 million.

Selling, general, and administrative expenses. Selling, general, and administrative expenses were $157.3 million for the nine months ended September 30, 2021, an increase of $87.1 million, or 124.0%, compared to $70.2 million for the nine months ended September 30, 2020. The increase was driven by higher salaries and benefits of $36.8 million, stock-based compensation of $11.2 million, occupancy costs of $11.2 million, marketing expenses of $6.0 million, legal and professional services of $7.3 million, and other costs of $14.6 million. These increases were incurred to support the continued growth of our business and expansion into other states.

Depreciation and amortization expense. Depreciation and amortization expense was $30.7 million for the nine months ended September 30, 2021, an increase of $18.0 million, or 141.3%, compared to $12.7 million for the nine months ended September 30, 2020. The increase was driven by purchases of new property and equipment to support the growth of our business during the period as well as the addition of several new brand names, non-compete agreements, and payor relationships from our 2020 and 2021 acquisitions.

Transaction costs and other. Transaction costs and other were $32.1 million for the nine months ended September 30, 2021, an increase of $2.3 million, or 7.7%, compared to $29.9 million for the nine months ended September 30, 2020. The increase was due to higher integration, legal, internal staff, and other professional fees incurred in the first half of 2021 in connection with the closing of the Business Combination.

Other Income (Expense)

-73-

		Nine Months Ended September 30,
($ in thousands)		2021		2020		$ Change	% Change
Other income and expense:
Interest expense	$	(36,363)	$	(21,728)	$	(14,635)	67.4	%
Interest income		4		239		(235)	(98.3)	%
Loss on extinguishment of debt		(13,225)		—		(13,225)	—	%
Change in fair value of embedded derivative		—		(5,444)		5,444	(100.0)	%
Change in fair value of warrant liabilities		24,565		—		24,565	—	%
Other expenses		(54)		(150)		96	(64.0)	%
Total other income (expense)	$	(25,073)	$	(27,083)	$	2,010

Interest expense. Interest expense was $36.4 million for the nine months ended September 30, 2021, an increase of $14.6 million, or 67.4%, compared to $21.7 million for the nine months ended September 30, 2020. The increase was primarily driven by interest incurred on our higher outstanding borrowings under our credit facility to fund our acquisitions.

Loss on extinguishment of debt. Loss on extinguishment of debt was $13.2 million for the nine months ended September 30, 2021 due to the partial extinguishment of Term Loan 3 following the closing of the Business Combination. The loss on extinguishment was related to unamortized debt issuance costs.

Change in fair value of the embedded derivative. Change in the fair value of the embedded derivative was $5.4 million for the three months ended September 30, 2021 due to a change in the fair value of the embedded derivative related to our term loan agreement in 2020. The embedded derivative was settled with the refinancing in November of 2020.

Change in fair value of warrant liabilities. Change in fair value of warrant liabilities was $24.6 million as a result of a change in the fair value of the Public Warrants and Private Placement Warrants assumed in connection with the Business Combination.

Liquidity and Capital Resources

General

To date, we have financed our operations principally through the issuance of equity and debt. As of September 30, 2021 and December 31, 2020, we had cash, cash equivalents and restricted cash of $208.9 million and $33.8 million, respectively. Our cash, cash equivalents and restricted cash primarily consist of highly liquid investments in money market funds and cash. Since our inception, we have generated significant operating losses from our operations, as reflected in our accumulated deficit of $52.5 million as of September 30, 2021 and negative cash flows from operations.

We expect to incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments we intend to continue to make in acquisitions, expansion of operations, and due to additional selling, general, and administrative costs we expect to incur in connection with operating as a public company. As a result, we may require additional capital resources to execute strategic initiatives to grow our business.

On November 23, 2020, we entered into the Credit Agreement with certain lenders, with Credit Suisse AG, Cayman Islands Branch, as the administrative agent, collateral agent and a letter of credit issuer, and Credit Suisse Loan Funding LLC, as the sole lead arranger and sole book runner. The Credit Agreement provided for an Initial Term Loan ("Term Loan 3") in an original aggregate principal amount of $480.0 million, a revolving credit facility with original commitments in an aggregate principal amount of $30.0 million (the "Revolving Credit Facility"), and a delayed draw term loan facility with commitments in an aggregate principal amount of $175.0 million (the" Delayed Draw Term Loan Facility"). The Revolving Credit Facility included a $10.0 million sub-limit for the issuance of letters of credit. Borrowings under the Revolving Credit Facility mature, and the revolving commitments thereunder terminate, on November 23, 2025. The Initial Term Loan and Delayed Draw Term Loans mature on November 23, 2027. In June 2021, we borrowed the remaining availability under our Delayed Draw Term Loan Facility and entered into the Third Amendment and Incremental Facility Amendment to the Credit Agreement pursuant to which we borrowed $295.0 million in incremental term loans ("Term Loan 4"), and made certain other amendments to our Credit Agreement. On September 30, 2021, the Company modified the Credit Agreement by adding an incremental term loan for a principal amount of $100.0 million ("Term Loan 5"), subject to the same terms (including interest rate and maturity date) as Term

-74-

Loans 3 and 4 above. As of September 30, 2021, the total amount of outstanding debt under our Term Loans under our Credit Agreement was $946.1 million.

The Business Combination closed on June 3, 2021. Pursuant to the Business Combination Agreement, on the Closing Date, Jaws contributed cash to PCIH in exchange for 69.0 million common limited liability company units of PCIH (“PCIH Common Units”) equal to the number of shares of Jaws' Class A ordinary shares outstanding on the Closing Date and 17.25 million Class B ordinary shares owned by Jaws Sponsor LLC (the “Sponsor”) . In connection with the Business Combination, the Company issued 306.8 million shares of Class B common stock to existing shareholders of PCIH. The Company also issued and sold 80.0 million shares of the Company’s Class A common stock in a private placement for $800.0 million. In aggregate, the Company generated approximately $935.4 million in net cash proceeds after transaction costs and advisory fees paid and distributions to PCIH shareholders. On June 4, 2021, the Company utilized $400.0 million of the net proceeds to pay off the Company’s debt under Term Loan 3 and the remainder of the net proceeds was held on the balance sheet for general corporate purposes. See further discussion related to the Business Combination in Note 1, "Nature of Business and Operations" in our unaudited condensed consolidated financial statements.

On June 11, 2021, we entered into a purchase agreement with University for total consideration of $611.1 million. The transaction was financed through $541.5 million of cash on hand, $60.0 million of Class A common stock issued to University's sellers and $9.6 million in contingent consideration from acquisition add-ons based on additional acquired entities.

On July 2, 2021, we entered into the Bridge Loan Agreement with certain lenders and Credit Suisse AG, Cayman Islands Branch, as administrative agent, pursuant to which the lenders provided a $250.0 million unsecured bridge term loan. We used the bridge term loan to acquire (“DMC”).

On September 30, 2021, the Company issued senior unsecured notes for a principal amount of $300.0 million (the "Senior Notes") in a private offering. Proceeds from the Senior Notes were used to repay in full the $250.0 million bridge term loan. The Senior Notes bear interest at 6.25% per annum, payable semi-annually on April 1st and October 1st of each year, commencing April 1, 2022. As of September 30, 2021, the effective interest rate of the Senior Notes was 6.65%. Principal on the Senior Notes is due in full on October 1, 2028.

The Company is a holding company with no material assets other than its ownership of the PCIH Common Units and its managing member interest in PCIH. As a result, we have no independent means of generating revenue or cash flow. Our ability to pay taxes, make payments under the Tax Receivable Agreement and pay dividends will depend on the financial results and cash flows of PCIH and the distributions we receive from PCIH. Deterioration in the financial condition, earnings or cash flow of PCIH for any reason could limit or impair PCIH’s ability to pay such distributions. Additionally, to the extent that we need funds and PCIH is restricted from making such distributions under applicable law or regulation or under the terms of any financing arrangements, or PCIH is otherwise unable to provide such funds, it could materially adversely affect our liquidity and financial condition. We anticipate that the distributions we will receive from PCIH may, in certain periods, exceed our actual tax liabilities and obligations to make payments under the Tax Receivable Agreement. Our Board, in its sole discretion, may make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, to pay dividends on our Class A common stock. We will have no obligation to distribute such cash (or other available cash other than any declared dividend) to our stockholders.

Dividends on our common stock, if any, will be paid at the discretion of our Board, which will consider, among other things, our available cash, available borrowings and other funds legally available therefore, taking into account the retention of any amounts necessary to satisfy our obligations that will not be reimbursed by PCIH, including taxes and amounts payable under the Tax Receivable Agreement and any restrictions in then applicable bank financing agreements. Financing arrangements may include restrictive covenants that restrict our ability to pay dividends or make other distributions to our stockholders. In addition, PCIH is generally prohibited under Delaware law from making a distribution to a member to the extent that, at the time of the distribution, after giving effect to the distribution, liabilities of PCIH (with certain exceptions) exceed the fair value of its assets. PCIH’s subsidiaries are generally subject to similar legal limitations on their ability to make distributions to PCIH. If PCIH does not have sufficient funds to make distributions, our ability to declare and pay cash dividends may also be restricted or impaired.

Under the terms of the Tax Receivable Agreement, we generally are required to pay to the Seller, and to each other person from time to time that becomes a “TRA Party” under the Tax Receivable Agreement, 85% of the tax savings, if any, that we are deemed to realize in certain circumstances as a result of certain tax attributes that exist following the Business

-75-

Combination and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. To the extent payments are made pursuant to the Tax Receivable Agreement, we generally will be required to pay to the Sponsor and to each other person from time to time that becomes a “Sponsor Party” under the Tax Receivable Agreement such Sponsor Party’s proportionate share of, an amount equal to such payments multiplied by a fraction with the numerator 0.15 and the denominator 0.85. The term of the Tax Receivable Agreement will continue until all such tax benefits have been utilized or expired unless we exercise our right to terminate the Tax Receivable Agreement for an amount representing the present value of anticipated future tax benefits under the Tax Receivable Agreement or certain other acceleration events occur. These payments are the obligation of the Company and not of PCIH. Any payments made by us under the Tax Receivable Agreement will generally reduce the amount of overall cash flow that might have otherwise been available to us or PCIH and, to the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, the unpaid amounts generally will be deferred and will accrue interest until paid by us.

We believe that the proceeds from the Business Combination, our Term Loans and our Revolving Credit Facility described above as well as our cash, cash equivalents and restricted cash will be sufficient to fund our operating and capital needs for at least the next 12 months. Our assessment of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties. Our actual results could vary because of, and our future capital requirements will depend on, many factors, including our growth rate, medical expenses, and the timing and extent of our expansion into new markets. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies, including intellectual property rights. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would be adversely affected.

Cash Flows

The following table presents a summary of our consolidated cash flows from operating, investing and financing activities for the periods indicated.

		Nine Months Ended September 30,
($ in thousands)		2021		2020
Net cash used in operating activities	$	(91,498)	$	(21,043)
Net cash used in investing activities		(1,116,030)		(253,554)
Net cash provided by financing activities		1,382,634		272,828
Net increase (decrease) in cash, cash equivalents and restricted cash		175,106		(1,769)
Cash, cash equivalents and restricted cash at beginning of year		33,807		29,192
Cash, cash equivalents and restricted cash at end of period	$	208,913	$	27,423

Operating Activities

For the nine months ended September 30, 2021, net cash used in operating activities was $91.5 million, an increase of $70.5 million in cash outflows compared to net cash used in operating activities of $21.0 million for the nine months ended September 30, 2020. Significant changes impacting net cash used in operating activities were as follows:

•Net loss for the nine months ended September 30, 2021 of $46.4 million compared to net loss for the nine months ended September 30, 2020 of $24.3 million;

•Increases in accounts receivable, net of $96.0 million for the nine months ended September 30, 2021 compared to increases in accounts receivable, net for the nine months ended September 30, 2020 of $33.3 million due to increased member counts across existing providers which was partially offset by the assumption of service provider liabilities from those acquisitions;

•Increases in accounts payable and accrued expenses for the nine months ended September 30, 2021 of $56.6 million compared to increases in accounts payable and accrued expenses for the nine months ended September 30, 2020 of $10.5 million due to the addition of new third-party provider payments related to businesses acquired after the first quarter of 2020 and higher accrued transaction costs; and

-76-

•Increases in prepaid expenses and other current assets of $27.4 million for the nine months ended September 30, 2021 compared to decreases in prepaid expenses and other current assets for the nine months ended September 30, 2020 of $0.2 million due to higher prepaid insurance payments and prepaid bonus incentives.

Investing Activities

For the nine months ended September 30, 2021, net cash used in investing activities was $1.1 billion, an increase of $862.5 million in cash outflows compared to net cash used in investing activities of $253.6 million for the nine months ended September 30, 2020 due primarily to an increase in capital expenditures and cash used for acquisitions of subsidiaries.

Financing Activities

Net cash provided by financing activities was $1.4 billion during the nine months ended September 30, 2021, an increase of $1.1 billion in cash inflows compared to net cash provided by financing activities of $272.8 million during the nine months ended September 30, 2020 due primarily to $935.4 million in connection with the Business Combination and PIPE financing as well as additional proceeds from long-term debt and Delayed Draw Term Loans.

Contractual Obligations and Commitments

Our principal commitments consist of obligations under operating and capital leases for our centers and equipment, repayments of long-term debt on notes payable, and payments due to sellers in connection with our acquisitions.

As of September 30, 2021, we had future minimum operating lease payments under non-cancellable leases through the year 2028 of $79.1 million related to office facilities and office equipment. We also had non-cancellable capital lease agreements with third parties through the year 2026 with future minimum payments of $2.9 million.

As of September 30, 2021, we have entered into various credit and guaranty agreements and the total amount of outstanding long-term debt on notes payable was $946.1 million. See Note 9 “Long-term Debt”, in our unaudited condensed consolidated financial statements for more information.

Additionally, we have amounts due to sellers in connection with our historical acquisitions of approximately $24.7 million as of September 30, 2021 that are due within the next twelve months.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2021.

Litigation

We are exposed to various asserted and unasserted potential claims encountered in the normal course of business. We believe that the resolution of these matters will not have a material effect on our consolidated financial position or the results of operations.

Non-GAAP Financial Metrics

The following discussion includes references to EBITDA and Adjusted EBITDA, which are non-GAAP financial measures. A non-GAAP financial measure is a performance metric that departs from U.S. GAAP because it excludes earnings components that are required under U.S. GAAP. Other companies may define non-GAAP financial measures differently and, as a result, our non-GAAP financial measures may not be directly comparable to those of other companies.

By definition, EBITDA consists of net loss before interest, income taxes, depreciation and amortization. Adjusted EBITDA is EBITDA adjusted to add back the effect of certain expenses, such as stock-based compensation expense, de novo losses (consisting of losses incurred in the twelve months after the opening of a new facility), acquisition transaction costs (consisting of transaction costs, fair value adjustments in contingent consideration, management fees and corporate development payroll costs), restructuring and other charges, loss on extinguishment of debt, changes in fair value of an embedded derivative, and changes in fair value of warrant liabilities. Adjusted EBITDA is a key measure used by our management to assess the operating and financial performance of our health centers in order to make decisions on allocation of resources.

-77-

The presentation of non-GAAP financial measures also provides additional information to investors regarding our results of operations and is useful for trending, analyzing and benchmarking the performance and value of our business. By excluding certain expenses and other items that may not be indicative of our core business operating results, these non-GAAP financial measures:

•allow investors to evaluate our performance from management’s perspective, resulting in greater transparency with respect to supplemental information used by us in our financial and operational decision making;

•provide better transparency as to the measures used by management and others who follow our industry to estimate the value of our company; and

•allow investors to view our financial performance and condition in the same manner that our significant lenders and landlords require us to report financial information to them in connection with determining our compliance with financial covenants.

Our use of EBITDA and Adjusted EBITDA have limitations as an analytical tool, and you should not consider them in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these limitations are as follows:

•although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;

•Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) net interest expense/income; and

•other companies, including companies in our industry, may calculate EBITDA and/or Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other U.S. GAAP-based financial performance measures, including net loss, cash flow metrics and our U.S. GAAP financial results.

The following table provides a reconciliation of net loss to non-GAAP financial information:

		Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)		2021		2020		2021		2020
Net loss	$	(40,883)	$	(11,117)	$	(46,403)	$	(24,289)
Interest income		(1)		(80)		(4)		(239)
Interest expense		16,023		12,346		36,363		21,728
Income tax expense (benefit)		547		326		(762)		294
Depreciation and amortization expense		16,955		5,379		30,746		12,741
EBITDA	$	(7,359)	$	6,854	$	19,940	$	10,235
Stock-based compensation		8,909		66		12,148		177
De novo losses (1)		9,016		2,025		21,496		4,373
Acquisition transaction costs (2)		7,825		7,827		35,163		30,121
Restructuring and other		2,123		1,113		5,513		1,829
Loss on extinguishment of debt		—		—		13,225		—
Change in fair value of embedded derivative		—		5,138		—		5,444
Change in fair value of warrant liabilities		14,650		—		(24,565)		—
Adjusted EBITDA	$	35,164	$	23,023	$	82,921	$	52,179

(1) De novo losses include those costs associated with the ramp up of new facilities and that are not expected to be incurred past the first 12 months after opening. These costs collectively are higher than comparable expenses incurred once such a facility has been open and generating revenue and would not have been incurred unless a new facility was being opened.

(2) Acquisition transaction costs included $1.3 million and $0.1 million of corporate development payroll costs for the three months ended September 30, 2021 and 2020, respectively, and $3.0 million and $0.3 million of corporate development payroll

-78-

costs for the nine months ended September 30, 2021 and 2020, respectively. Corporate development payroll costs include those expenses directly related to the additional staff needed to support our increased acquisition activity.

We experienced a 207.4% decrease in EBITDA and a 52.7% increase in Adjusted EBITDA between the three months ended September 30, 2021 and September 30, 2020. The decrease in EBITDA was primarily related to our acquisition activity, stock-based compensation, and changes in fair value of our warrant liabilities which all negatively impacted net income. The increase in Adjusted EBITDA related to overall growth in the business.

We experienced a 94.8% increase in EBITDA and a 58.9% increase in Adjusted EBITDA between the nine months ended September 30, 2021 and September 30, 2020. The increase in EDITDA and Adjusted EBITDA was primarily related to overall growth in the business.

Emerging Growth Company Status

We are an emerging growth company, as defined in the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period under the JOBS Act until the earlier of the date we (1) are no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Accordingly, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. The Company will become a “large accelerated filer,” as defined in Rule 12b-2 of the Exchange Act and will lose its "emerging growth company" status as of the end of the year ending December 31, 2021.

Recent Accounting Pronouncements

See Note 2, “Summary of Significant Accounting Policies—Recent Accounting Pronouncements” to our condensed consolidated financial statements for more information.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations is based upon our condensed consolidated financial statements and accompanying notes, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the amounts reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities at the date of our financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The future effects of the COVID-19 pandemic on our results of operations, cash flows and financial position are unclear; however, we believe we have made reasonable estimates and assumptions in preparing the financial statements. Actual results may differ from these estimates under different assumptions or conditions, impacting our reported results of operations and financial condition.

Certain accounting policies involve significant judgments and assumptions by management, which have a material impact on the carrying value of assets and liabilities and the recognition of income and expenses. Management considers these accounting policies to be critical accounting policies. The estimates and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described below. See Note 2 to our condensed consolidated financial statements “Summary of Significant Accounting Policies” in our condensed consolidated financial statements for more information.

Warrant Liabilities

We account for the Public Warrants and Private Placement Warrants in accordance with the guidance contained in ASC 815-40 under which the Public Warrants and Private Placement Warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the Public Warrants and Private Placement Warrants as liabilities at their fair value and adjust the Public Warrants and Private Placement Warrants to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement

-79-

of operations. The Public Warrants and the Private Placement Warrants for periods where no observable traded price was available are valued using a binomial lattice simulation model.

Revenue

Revenue consists primarily of fees for medical services provided under capitated arrangements with HMO health plans. Capitated revenue also consists of revenue earned through Medicare Advantage as well as through commercial and other non-Medicare governmental programs, such as Medicaid, which is captured as other capitated revenue. As we control the healthcare services provided to enrolled members, we act as the principal and the gross fees under these contracts are reported as revenue and the cost of provider care is included in third-party medical costs. Additionally, since contractual terms across these arrangements are similar, we group them into one portfolio.

Capitated revenues are recognized in the month in which we are obligated to provide medical care services. The transaction price for the services provided is variable and depends upon the terms of the arrangement provided by or negotiated with the health plan and include PMPM rates that may fluctuate. The rates are risk adjusted based on the health status (acuity) of members and demographic characteristics of the plan. The fees are paid on an interim basis based on submitted enrolled member data for the previous year and are adjusted in subsequent periods after the final data is compiled by the CMS.

Third-Party Medical Costs

Third-party medical costs primarily consist of all medical expenses paid by the health plans, including inpatient and hospital care, specialists, and medicines. Provider costs are accrued based on date of service to members, based in part on estimates, including an accrual for medical services incurred but not reported (“IBNR”). Actual claims expense will differ from the estimated liability due to factors in estimated and actual member utilization of health care services, the amount of charges, and other factors. Liabilities for IBNR are estimated using standard actuarial methodologies, including our accumulated statistical data, adjusted for current experience. These actuarially determined estimates are continually reviewed and updated; as the amount of unpaid service provider cost is based on estimates, the ultimate amounts paid to settle these liabilities might vary from recorded amounts and these differences may be material.

We have included IBNR claims of approximately $127.0 million and $54.5 million on our balance sheet as of September 30, 2021 and December 31, 2020, respectively.

Impairment of Long-Lived Assets

Long-lived assets are reviewed periodically for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Business Acquisitions

We account for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. We use various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. Refer to Note 3, “Business Acquisitions,” for a discussion of the Company's recent acquisitions.

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets acquired. We test goodwill for impairment annually on October 1st or more frequently if triggering events occur or other impairment indicators arise which might impair recoverability. These events or circumstances would

-80-

include a significant change in the business climate, legal factors, operating performance indicators, competition, sale, disposition of a significant portion of the business or other factors. Goodwill is evaluated for impairment at the reporting unit level and we have identified a single reporting unit.

ASC 350, "Intangibles—Goodwill and Other" allows entities to first use a qualitative approach to test goodwill for impairment by determining whether it is more likely than not (a likelihood of greater than 50%) that the fair value of a reporting unit is less than its carrying value. When we perform the quantitative goodwill impairment test, we compare the fair value of the reporting unit, which we primarily determine using an income approach based on the present value of expected future cash flows, to the respective carrying value, which includes goodwill. If the fair value of the reporting unit exceeds its carrying value, then goodwill is not considered impaired. If the carrying value is higher than the fair value, the difference would be recognized as an impairment loss. We considered the effect of the COVID-19 pandemic on our business and the overall economy and resulting impact on goodwill. There was no impairment to goodwill during the nine months ended September 30, 2021 and 2020.

Our intangibles consist of trade names, brands, non-compete agreements, and customer, payor, and provider relationships. We amortize intangibles using the straight-line method over the estimated useful lives of the intangible, which range from 1 to 20 years. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

The determination of fair values and useful lives requires us to make significant estimates and assumptions. These estimates include, but are not limited to, future expected cash flows from acquired capitation arrangements from a market participant perspective, discount rates, industry data and management’s prior experience. Unanticipated events or circumstances may occur that could affect the accuracy or validity of such assumptions, estimates or actual results.

Equity-Based Compensation

ASC 718, "Compensation—Stock Compensation" requires the measurement of the cost of the employee services received in exchange for an award of equity instruments based on the grant-date fair value or, in certain circumstances, the calculated value of the award. Under our unit-based incentive plan, we may reward employees with various types of awards, including but not limited to profits interests on a service-based or performance-based schedule. These awards may also contain market conditions. We have elected to account for forfeitures as they occur. We use the Black-Scholes pricing option model to estimate the fair value of each award as of the grant date.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.

Interest Rate Risk

As of September 30, 2021 and December 31, 2020, we had cash, cash equivalents and restricted cash of $208.9 million and $33.8 million, respectively, which are held for working capital purposes. We do not make investments for trading or speculative purposes.

As of September 30, 2021 the total amount of outstanding debt under Team Loan 3, Term Loan 4 and Term Loan 5 and the Senior Notes was $946.1 million. As of September 30, 2021, the Term Loan borrowings and Delayed Draw Term Commitments bore interest of 5.25%. The current stated interest rate for the Term Loan borrowings and Initial Revolving Facility was 5.5%. The effective interest rate for the Term Loan borrowings was 5.74% as of September 30, 2021. Term Loan borrowings are subject to interest at a rate per annum equal to (1) the LIBOR rate for a one month interest period on such day, as adjusted via multiplication by the Credit Suisse’s statutory reserve rate and subject to a floor of 0.75% on the adjusted rate only for the Initial Term Loan and the Delayed Draw Term Loans, plus (2) the applicable rate of (a) 4.75% and (b) 4.5% after the Closing Date of the Business Combination, provided that if the Company achieves a public corporate rating from S&P of at least B and a public credit rating from Moody’s of at least B2, then for as long as such ratings remain in effect, a rate of 4.25% shall be applicable. The Senior Notes bore interest at a fixed rate of 6.25%.

-81-

Inflation Risk

Based on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

Item 4.    Controls and Procedures

Evaluation of Disclosure Controls and Procedures

(a) Disclosure Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and the Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, has concluded that our disclosure controls and procedures were not effective as a result of the material weaknesses initially identified in our January 2021 filing of our S-4 Registration Statement and further identified below by management.                                            

The material weaknesses have not been remediated as of September 30, 2021. See “Part II. Other Information, Item 1A. Risk Factors, Risks Related to Being a Public Company". Our independent registered public accountants have identified a number of material weaknesses in our internal control over financial reporting. If we are unable to remediate the material weaknesses, or if other control deficiencies are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner.

The material weaknesses pertain to (i) our failure to establish controls to ensure the completeness and accuracy of information used to estimate and record certain accruals or make other closing adjustments in the financial statement close process, (ii) our failure in the process of accounting for business combinations related to the design and operation of controls to record and measure the identifiable assets acquired, the liabilities assumed and any non-controlling interest recognized as part of a business combination, (iii) JAWS’ failure in the process of accounting for a significant and unusual transaction related to the warrants it issued in connection with its initial public offering in May 2020, which resulted in a material misstatement of our warrant liabilities, transaction costs, change in fair value of warrant liabilities, additional paid-in-capital, accumulated deficit and related financial disclosures for the year ended December 31, 2020 and unaudited quarterly financial information as of and for the three and six months ended June 30, 2020 and the three and nine months ended September 30, 2020, and (iv) our failure to have a sufficient complement of personnel with an appropriate level of knowledge, experience and oversight commensurate with their financial reporting requirements to ensure proper selection and application of U.S. GAAP.

Our management is actively engaged in the implementation of remediation plans to address these material weaknesses. These plans include implementation of enhanced documentation policies and procedures, along with the allocation of resources dedicated to training and monitoring these policies and procedures and recruiting personnel with appropriate levels of skills commensurate with their roles.

As a result of these efforts, as of the date of the filing of this Quarterly Report on Form 10-Q, our management believes we have made progress toward remediating the underlying causes of the material weaknesses. Although we believe our remediation efforts will be effective in remediating the material weaknesses, there can be no assurance as to when the remediation plans will be fully implemented, or that the plans, as currently designed, will adequately remediate the material weaknesses. The material weaknesses will not be considered fully addressed until the enhanced policies and procedures over documentation have been in operation for a sufficient period of time for our management to conclude that the material weaknesses have been fully remediated.

-82-

Notwithstanding these identified material weaknesses, as of the date of the filing of this Quarterly Report on Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, believes that the unaudited consolidated financial statements contained in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows for the periods and such financial statements are presented in conformity with U.S GAAP.

(b) Changes in Internal Control over Financial Reporting

Other than the steps taken in our remediation efforts outlined above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

-83-

PART II. OTHER INFORMATION

Item 1.    Legal Proceedings

From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. As of September 30, 2021, we do not believe that the results of any such claims or litigation, individually or in the aggregate, will have a material adverse effect on our business, financial position, results of operations or cash flows.

Item 1A.    Risk Factors

Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with the other information in this Quarterly Report on Form 10-Q, including the section of this report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our unaudited condensed consolidated financial statements and the related notes. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of our Class A common stock could decline, and you could lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this quarterly report to our business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, the business, reputation, financial condition, results of operations, revenue and our future prospects. The material and other risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This quarterly report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See the section titled “Cautionary Note Regarding Forward-Looking Statements.”

Risks Related to Our Business

Under most of our agreements with health plans, we assume some or all of the risk that the cost of providing services will exceed our compensation.

Approximately 95.7% of our total revenue for the year ended December 31, 2020 and 95.6% and 95.7% of our total revenue for the nine months ended September 30, 2020 and 2021, respectively, is capitated revenue, which, in the case of health plans, is a pre-negotiated percentage of the premium that the health plan receives from CMS. We receive payments directly from CMS under our DCE model. While there are variations specific to each agreement, we generally contract with health plans to receive recurring per-member-per-month revenue and assume the financial responsibility for the healthcare expenses of our members. This type of contract is referred to as a “capitation” contract. To the extent that members require more care than is anticipated and/or the cost of care increases, aggregate fixed compensation amounts, or capitation payments, may be insufficient to cover the costs associated with treatment. If medical costs and expenses exceed estimates, except in very limited circumstances, we will not be able to increase the fee received under these capitation agreements during their then-current terms and we could suffer losses with respect to such agreements. While we maintain stop-loss insurance for our members, protecting us for medical claims per episode in excess of certain levels, future claims could exceed our applicable insurance coverage limits or potential increases in insurance premiums may require us to decrease our level of coverage.

Changes in our anticipated ratio of medical expense to revenue can significantly impact our financial results. Accordingly, the failure to adequately predict and control medical costs and expenses and to make reasonable estimates and maintain adequate accruals for incurred but not reported claims could have a material adverse effect on our business, results of operations, financial condition and cash flows. Additionally, the Medicare expenses of our members may be outside of our control in the event that members take certain actions that increase such expenses, such as unnecessary hospital visits.

Historically, our medical costs and expenses as a percentage of revenue have fluctuated. Factors that may cause medical expenses to exceed estimates include:

-84-

•the health status of our members;

•higher levels of hospitalization among our members;

•higher than expected utilization of new or existing healthcare services or technologies;

•an increase in the cost of healthcare services and supplies, whether as a result of inflation or otherwise;

•changes to mandated benefits or other changes in healthcare laws, regulations and practices;

•increased costs attributable to specialist physicians, hospitals and ancillary providers;

•changes in the demographics of our members and medical trends;

•contractual or claims disputes with providers, hospitals or other service providers within and outside a health plan’s network;

•the occurrence of catastrophes, major epidemics or pandemics, including COVID-19 and any variants thereof, or acts of terrorism; and

•the reduction of health plan premiums.

Our revenues and operations are dependent upon a limited number of key existing payors and our continued relationship with those payors, and disruptions in those relationships (including renegotiation, non-renewal or termination of capitation agreements) or the inability of such payors to maintain their contracts with CMS could adversely affect our business.

Our operations are dependent on a concentrated number of payors with whom we contract to provide services to members. Contracts with three such payors accounted for approximately 61.8% and 69.8% of total revenues for the years ended December 31, 2019 and 2020, respectively, and approximately 63.6% and 67.5% for the nine months ended September 30, 2021 and 2020, respectively. Contracts with three such payors accounted for approximately 44.1% and 67.1% of total accounts receivable as of December 31, 2019 and 2020, respectively, and approximately 39.8% as of September 30, 2021. The loss of revenue from these contracts could have a material adverse effect on our business, results of operations, financial condition and cash flows. We believe that a majority of our revenues will continue to be derived from a limited number of key payors, who may terminate their contracts with us or our physicians credentialed by them for convenience on short term notice, or upon the occurrence of certain events. The sudden loss of any of our payor partners or the renegotiation of any of our payor contracts could adversely affect our operating results. In particular, we have entered into expansion agreements with Humana which provide a roadmap to opening new Humana-funded medical centers in the southwestern U.S. by 2024. Humana may decline to fund additional medical centers, which would have an adverse effect on our growth and future prospects. In the ordinary course of business we engage in active discussions and renegotiations with payors in respect of the services we provide and the terms of our payor agreements. As the payors’ businesses respond to market dynamics and financial pressures, and as payors make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our payors may seek to renegotiate or terminate their agreements with us. These discussions could result in reductions to the fees and changes to the scope of services contemplated by our original payor contracts and consequently could negatively impact our revenues, business and prospects.

In the ordinary course of business, we engage in active discussions and renegotiations with payors in respect of the services we provide and the terms of our payor agreements. As the payors’ businesses respond to market dynamics and financial pressures, and as payors make strategic business decisions in respect to the lines of business they pursue and programs in which they participate, certain of our payors may seek to renegotiate or terminate their agreements with us. These discussions could result in reductions to the fees and changes to the scope of services contemplated by our original payor contracts and consequently could negatively impact our revenues, business and prospects.

Because we rely on a limited number of payors for a significant portion of our revenues, we depend on the creditworthiness of these payors. Our payors are subject to a number of risks, including reductions in payment rates from governmental programs, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations. If the financial condition of our payor partners declines, our credit risk could increase. Should one or more of our significant payor partners declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable, our bad debt reserves and our net income. If a plan with which we contract loses its Medicare contracts with CMS, receives reduced or insufficient government reimbursement under the Medicare

-85-

program, decides to discontinue its Medicare Advantage (“MA”), and/or commercial plans, decides to contract with another company to provide capitated care services to its members, or decides to directly provide care, our contract with that plan could be at risk and we could lose revenue.

Under most of our capitation agreements with health plans, the health plan is generally permitted to modify the benefit and risk obligations and compensation rights from time to time during the terms of the agreements. If a health plan exercises its right to amend its benefit and risk obligations and compensation rights, we are generally allowed a period of time to object to such amendment. If we so object, under some of the capitation agreements, either party may terminate the applicable agreement upon a certain period of prior written notice. If we enter into capitation contracts with unfavorable economic terms, or a capitation contract is amended to include unfavorable terms, we could suffer losses with respect to such contract. Since we do not negotiate with CMS or any health plan regarding the benefits to be provided under their plans, we often have just a few months to familiarize ourselves with each new annual package of benefits we are expected to offer. Depending on the health plan at issue and the amount of revenue associated with the health plan’s capitation agreement, the renegotiated terms or termination could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Although we have contracts with many payors, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. Certain of our contracts are terminable immediately upon the occurrence of certain events. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a payor were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such payor could in effect be terminated. In addition, certain of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our payors is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. If any of these contracts were terminated, certain members covered by such plans may choose to shift to another primary care provider within their health plan’s network. Moreover, our inability to maintain our agreements with health plans with respect to their members or to negotiate favorable terms for those agreements in the future could result in the loss of members and could have a material adverse effect on our profitability and business.

COVID-19 or another pandemic, epidemic, or outbreak of an infectious disease may have an adverse effect on our business, results of operations, financial condition and cash flows.

In March 2020, numerous state and local jurisdictions, including all markets in which we operate, imposed “shelter-in-place” orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. Such orders or restrictions have resulted in periods of remote operations at our headquarters and medical centers, work stoppages among some vendors and suppliers, slowdowns and delays, travel restrictions and cancellation of events and have restricted the ability of our front-line outreach teams to host and attend community events, among other effects, thereby negatively impacting our operations. Other disruptions or potential disruptions have included restrictions on the ability of our personnel to travel; inability of our suppliers to manufacture goods and to deliver these to us on a timely basis, or at all; inventory shortages or obsolescence; delays in actions of regulatory bodies; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business, including because of sickness of employees or their families or the desire of employees to avoid contact with groups of people; business adjustments or disruptions of certain third parties; and additional government requirements or other incremental mitigation efforts. The COVID-19 pandemic has had, and may continue to have, severe negative repercussions across local, state and national economies, financial markets and our industry. The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which remain uncertain and cannot be predicted, including, but not limited to additional waves of the virus, new information which may emerge concerning the severity and spread of COVID-19 and the actions to contain COVID-19 or treat its impact, including vaccination rates among the population, the effectiveness of the COVID-19 vaccines or boosters against COVID-19 variants, and the response by the governmental bodies and regulators. In addition, the COVID-19 virus disproportionately impacts older adults, especially those with chronic illnesses, which describes many of our members.

It remains difficult to project the direct impact of COVID-19 on our operating revenues and expenses. Key factors include the duration and extent of the outbreak in areas in which we operate as well as societal and governmental responses. Members may continue to be reluctant to seek necessary care given the risks of the COVID-19 pandemic. We also may experience increased internal and third-party medical costs as we provide care for members suffering from COVID-19. This increase in costs

-86-

may be particularly significant given the significant number of our members who are under capitation agreements. We may also incur liabilities related to our operations during the COVID-19 pandemic. For instance, in May 2020, we received a subpoena from the U.S. Department of Justice (the “DOJ”), seeking records relating to our prescription of hydroxychloroquine during the early days of the pandemic. We reached an agreement with DOJ to make a partial production of documents related to the matter, which we fulfilled in July 2020. We have not had any further interactions with DOJ on this matter. Further, we may face increased competition due to changes to our competitors’ products and services, including modifications to their terms, conditions, and pricing that could materially adversely impact our business, results of operations, and overall financial condition in future periods.

In response to the COVID-19 pandemic, we made operational changes to the staffing and operations of our medical centers to minimize potential exposure to COVID-19. If the COVID-19 pandemic worsens, including the spread of variants, especially in regions where we have offices or medical centers, our business activities originating from affected areas could be adversely affected. Disruptive activities could include business closures in impacted areas, further restrictions on our employees’ and service providers’ ability to travel, impacts to productivity if our employees or their family members experience health issues, and potential delays in hiring and onboarding of new employees. We are unable to predict the effect that an increased focus on providing COVID-19 vaccines or boosters to our members may have on our operations or our financial results. We may take further actions that alter our business operations as may be required by local, state, or federal authorities or that we determine are in the best interests of our employees. Such measures could negatively affect our sales and marketing efforts, employee productivity or member retention, any of which could harm our financial condition and business operations.

Due to the COVID-19 pandemic, we may not be able to document the health conditions of our members as completely as we have in the past. Medicare pays capitation using a “risk adjustment model,” which compensates providers based on the health status (acuity) of each individual member. Payors with higher acuity members receive more, and those with lower acuity members receive less. Medicare requires that a patient’s health issues be documented semi-annually regardless of the permanence of the underlying causes. Historically, this documentation was required to be completed during an in-person visit with a patient. As part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), Medicare is allowing documentation for conditions identified during video visits with patients. It remains unclear, given the disruption caused by COVID-19, whether we will be able to comprehensively document the health conditions of our members, which may adversely impact our revenue in future periods.

The COVID-19 pandemic could also cause our third-party data center hosting facilities and cloud computing platform providers, which are critical to our infrastructure, to shut down their business, experience security incidents that impact our business, delay or disrupt performance or delivery of services, or experience interference with the supply chain of hardware required by their systems and services, any of which could materially adversely affect our business. Further, the COVID-19 pandemic has resulted in our employees and those of many of our vendors working from home and conducting work via the internet, and if the network and infrastructure of internet providers becomes overburdened by increased usage or is otherwise unreliable or unavailable, our employees,’ and our vendors’ employees,’ access to the internet to conduct business could be negatively impacted. Limitations on access or disruptions to services or goods provided by or to some of our suppliers and vendors upon which our platform and business operations relies, could interrupt our ability to provide our platform, decrease the productivity of our workforce, and significantly harm our business operations, financial condition, and results of operations.

Our platform and the other systems or networks used in our business may experience an increase in attempted cyber-attacks, privacy breaches, targeted intrusion, ransomware, and phishing campaigns seeking to take advantage of shifts to employees working remotely using their household or personal internet networks and to leverage fears promulgated by the COVID-19 pandemic. The success of any of these unauthorized attempts could substantially impact our platform, the proprietary and other confidential data contained therein or otherwise stored or processed in our operations, and ultimately our business. Any actual or perceived security incident also may cause us to incur increased expenses to improve our security controls and to remediate security vulnerabilities.

While vaccines for COVID-19 have been developed and administered, and the spread of COVID-19 may eventually be contained or mitigated, we cannot predict the percentage of the population that becomes vaccinated, the efficacy of such vaccines (or boosters) against variants, and we do not yet know how businesses or our vendors, partners, members or employees will operate in a post COVID-19 environment. It is unclear how long the COVID-19 pandemic will last, how severe it will be, and what additional safety measures governments will impose in response to it and there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur. Public health officials and medical professionals have warned that COVID-19 cases may spike, particularly if vaccination rates do not increase or if additional, potent disease variants emerge. As of the date

-87-

of this report, the extent to which the COVID-19 pandemic may impact our business, results of operations and financial condition remains uncertain. Because of our business model, the full impact of the COVID-19 pandemic may not be fully reflected in our results of operations and overall financial condition until future periods.

To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this “Risk Factors” section, including but not limited to those relating to cyber-attacks and security vulnerabilities, interruptions or delays due to third parties or our ability to raise additional capital or generate sufficient cash flows necessary to fulfill our obligations under our existing indebtedness or to expand our operations.

Reductions in the quality ratings of the health plans we serve or our Medicare Risk Adjustment scores could have a material adverse effect on our business, results of operations, financial condition and cash flows.

As a result of the ACA, the level of reimbursement each health plan receives from CMS is dependent, in part, upon the quality rating of the Medicare plan. Under the Medicare Advantage plan’s star rating system, lower star ratings correspond to lower quality ratings. Such ratings impact the percentage of any cost savings rebate and any bonuses earned by such health plans. Since a significant portion of our revenue is expected to be calculated as a percentage of CMS reimbursements received by these health plans with respect to our members, reductions in the quality ratings of a health plan that we serve could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Given each health plan’s control of its local plans and the many other providers that serve such plans, we believe that we will have limited ability to influence the overall quality rating of any such plan. The Balanced Budget Act passed in February 2018 implemented certain changes to prevent artificial inflation of star ratings for Medicare Advantage plans offered by the same organization. In addition, CMS has terminated plans that have had a rating of less than three stars for three consecutive years, whereas Medicare Advantage plans with five stars are permitted to conduct enrollment throughout almost the entire year. Because low quality ratings can potentially lead to the termination of a plan that we serve, we may not be able to prevent the potential termination of a contracting plan or a shift of members to other plans based upon quality issues which could, in turn, have a material adverse effect on our business, results of operations, financial condition and cash flows.

Our medical centers and affiliate providers are concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions.

As of September 30, 2021, we provided care for our 210,663 members across 34 markets, of which approximately 200,000 members and 17 markets were in Florida, with the remainder in Texas, Nevada, and Puerto Rico, and had more than 345 employed providers (physicians, nurse practitioners, physician assistants) at our 113 owned medical centers and more than 1000 affiliate providers. Such geographic concentration makes us particularly sensitive to regulatory, economic, environmental and competitive conditions in the state of Florida. Any material changes in those factors in Florida could have a disproportionate effect on our business and results of operations. Due to the concentration of our operations in Florida, our business may be adversely affected by economic conditions that disproportionately affect Florida as compared to other states. In addition, our exposure to many of the risks described herein are not mitigated by a diversification of geographic focus.

Moreover, regions in and around the southeastern United States commonly experience hurricanes and other extreme weather conditions. As a result, certain of our medical centers, especially those in Florida, are susceptible to physical damage and business interruption from an active hurricane season or a single severe storm. Moreover, global climate change could increase the intensity of individual hurricanes or the number of hurricanes that occur each year. Even if our facilities are not directly damaged, we may experience considerable disruptions in our operations due to property damage or electrical outages experienced in storm-affected areas by our members, physicians, payors, vendors and others. Additionally, long-term adverse weather conditions, whether caused by global climate change or otherwise, could cause an outmigration of people from the communities where our medical centers are located. If any of the circumstances described above occurred, there could be a harmful effect on our business and our results of operations could be adversely affected.

As we expand into new markets in new states we must comply with a variety of health regulatory and other state laws. In California, for example, the Knox-Keene Act regulates healthcare service plans and requires registration or licensure if an organization: (i) contracts directly with a healthcare service plan or arranges for healthcare services for the healthcare service plan’s enrollees; (ii) assumes financial risk for the healthcare services provided to the plan’s employees; and (iii) is responsible for the processing and payment of claims made by providers for services rendered by those providers on behalf of a healthcare

-88-

service plan when those services are covered under risk-based payments made by the plan. Our business may require us to register with the California Department of Managed Health Care, meet certain solvency requirements, submit quarterly and annual financial reports (which will be publicly available), and submit quarterly survey reports.

We primarily depend on reimbursements by third-party payors, which could lead to delays and uncertainties in the reimbursement process.

The reimbursement process is complex and can involve lengthy delays. Although we recognize revenue when we provide services to our members, we may from time to time experience delays in receiving the associated capitation payments or, for our members on fee-for-service arrangements, the reimbursement for the service provided. In addition, third-party payors may disallow, in whole or in part, requests for reimbursement based on determinations that the member is not eligible for coverage, certain amounts are not reimbursable under plan coverage or were for services provided that were not medically necessary or additional supporting documentation is necessary. Retroactive adjustments may change amounts realized from third-party payors. As described below, we are subject to claims reviews and/or audits by such payors, including governmental audits of our Medicare claims, and may be required to repay these payors if a finding is made that we were incorrectly reimbursed. Delays and uncertainties in the reimbursement process may adversely affect accounts receivable, increase the overall costs of collection and cause us to incur additional borrowing costs. Third-party payors are also increasingly focused on controlling healthcare costs, and such efforts, including any revisions to reimbursement policies, may further complicate and delay our reimbursement claims.

In response to the COVID-19 pandemic, CMS has made several changes in the manner in which Medicare will pay for telehealth visits, many of which relax previous requirements, including site requirements for both the providers and patients, telehealth modality requirements and others. State law applicable to telehealth, particularly licensure requirements, has also been relaxed in many jurisdictions as a result of the COVID-19 pandemic. These relaxed regulations have allowed us to continue operating our business and delivering care to our members predominantly through telehealth modalities. While CMS in its December 1, 2020 Annual Physician Fee Schedule Final Rule permanently added to the list of telehealth services, it is still unclear which, if any, of these changes will remain in place permanently and which will be rolled-back following the COVID-19 pandemic or at a later date. If regulations change to restrict our ability to or prohibit us from delivering care through telehealth modalities, our financial condition and results of operations may be adversely affected.

Our relatively limited operating history makes it difficult to evaluate our current business and future prospects and increases the risk of your investment.

Our relatively limited operating history makes it difficult to evaluate our current business and plan for our future growth. We opened our first medical center in 2009, and our relationship with InTandem to provide financial support and guidance to fund platform investments and accelerate our growth began in 2016. We have encountered and will continue to encounter significant risks and uncertainties frequently experienced by new and growing companies in rapidly changing industries, such as determining appropriate investments for our limited resources, competition from other providers, acquiring and retaining members, hiring, integrating, training and retaining skilled personnel, determining prices for our services, unforeseen expenses, challenges in forecasting accuracy and successfully integrating practices that we acquire. Although we have successfully expanded our medical center footprint outside of Florida and intend to continue to expand into new geographic locations, we cannot provide assurance that any new medical centers we open or new geographic locations we enter will be successful. If we are unable to increase our member enrollment, successfully manage our third-party medical costs or successfully expand into new member services, our revenue and our ability to achieve and sustain profitability would be impaired. Additional risks include our ability to effectively manage growth of, process, store, protect and use personal data in compliance with governmental regulations, contractual obligations and other legal obligations related to privacy and security and manage our obligations as a provider of healthcare services under Medicare and Medicaid. If our assumptions regarding these and other similar risks and uncertainties, which we use to plan our business, are incorrect or change as we gain more experience operating our business or due to changes in our industry, or if we do not address these challenges successfully, our operating and financial results could differ materially from our expectations and our business could suffer.

We expect to continue to increase our headcount and to hire more physicians, nurses and other specialized medical personnel in the future as we grow our business and open new medical centers. We will need to continue to hire, train and manage additional qualified information technology, operations and marketing staff, and improve and maintain our technology and information systems to properly manage our growth. If our new hires perform poorly, or if we are unsuccessful in hiring,

-89-

training, managing and integrating these new employees, or if we are not successful in retaining our existing employees, our business may be adversely affected.

Labor shortages and constraints in the supply chain could adversely affect our results of operations.

In 2021, we experienced labor shortages and other labor-related issues, which were pronounced as a result of the COVID-19 pandemic. A number of factors may adversely affect the labor force available to us or increase labor costs, including high employment levels, federal unemployment subsidies, including unemployment benefits offered in response to the COVID-19 pandemic, increased wages offered by other employers, vaccine mandates and other government regulations and our responses thereto. As more employers offer remote work, we may have more difficulty recruiting for jobs that require on-site attendance. We have recently observed an overall tightening and increasingly competitive labor market. A sustained labor shortage or increased turnover rates within our employee base, caused by COVID-19 or as a result of general macroeconomic factors, could lead to increased costs, such as increased overtime or financial incentives to meet demand and increased wage rates to attract and retain employees, and could negatively affect our ability to efficiently operate our business. If we are unable to hire and retain employees capable of performing at a high-level, our business could be adversely affected. An overall labor shortage, lack of skilled labor, increased turnover or labor inflation, caused by COVID-19 or as a result of general macroeconomic factors, could have a material adverse impact on our business and operating results.

In addition, recent developments in the national and worldwide supply chain slowdown have resulted in increased cost and reduced supply for most supplies and materials, including healthcare supplies and equipment and building materials necessary for the build-out and completion of new medical centers. It is impossible to predict how long this supply chain slowdown will last or how much it will impact our business operations but it is likely that our costs will increase for supplies and equipment and our ability to quickly open new centers on budget will be impaired.

We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to achieve or maintain profitability.

We incurred a net loss of $(74.8) million for the year ended December 31, 2020 and net loss of $(24.3) million and $(46.4) million for the nine months ended September 30, 2020 and 2021. Our accumulated deficit was $99.9 million and $52.5 million as of December 31, 2020 and September 30, 2021, respectively. We expect our aggregate costs will increase substantially in the foreseeable future and our losses will continue as we expect to invest heavily in increasing our member base, expanding our operations, hiring additional employees and operating as a public company. These efforts may prove more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. Our cash flows from operating activities were negative for the year ended December 31, 2020 and the nine months ended September 30, 2021. We may not generate positive cash flow from operating activities in any given period, and our limited operating history may make it difficult for you to evaluate our current business and our future prospects. In addition, we have expended a significant amount of cash on acquisitions and investing in de novo medical centers. There is no guarantee that any such acquisition or investment is successful or generates a net profit. See “Risks Related to Our Growth.”

We depend on our senior management team and other key employees, and the loss of one or more of these employees or an inability to attract and retain other highly skilled employees could harm our business.

Our success depends largely upon the continued services of our senior management team and other key employees. We rely on our leadership team in the areas of operations, provision of medical services, information technology and security, marketing, compliance and general and administrative functions. From time to time, there may be changes in our executive management team resulting from the hiring or departure of executives, which could disrupt our business. Our employment agreements with our executive officers and other key personnel do not require them to continue to work for us for any specified period and, therefore, they could terminate their employment with us at any time. The loss (including as a result of a COVID-19 infection) of one or more of the members of our senior management team, or other key employees, could harm our business. In particular, the loss of the services of our founder and Chief Executive Officer, Dr. Marlow Hernandez, could significantly delay or prevent the achievement of our strategic objectives. Changes in our executive management team may also cause disruptions in, and harm to, our business.

Changes in the payor mix of members and potential decreases in our reimbursement rates could adversely affect our revenues and results of operations.

-90-

The amounts we receive for services provided to members are determined by a number of factors, including the payor mix of our members and the reimbursement methodologies and rates utilized by our members’ plans. Reimbursement rates are generally higher for capitation agreements than they are under fee-for-service arrangements, and capitation agreements provide us with an opportunity to capture any additional surplus we create by investing in preventive care to keep a particular member’s third-party medical expenses low. Under a capitated payor arrangement, we receive recurring per-member-per-month revenue and assume the financial responsibility for the healthcare expenses of our members. Under a fee-for-service payor arrangement, we collect fees directly from the payor as services are provided. Approximately 95.7% of our total revenue for the year ended December 31, 2020 and approximately 95.7% of our total revenue for the nine months ended September 30, 2021 is capitated revenue, with the remainder being fee-for-service and other revenue. A significant decrease in the number of capitation arrangements could adversely affect our revenues and results of operations.

The healthcare industry has also experienced a trend of consolidation, resulting in fewer but larger payors that have significant bargaining power, given their market share. Payments from payors are the result of negotiated rates. These rates may decline based on renegotiations and larger payors have significant bargaining power to negotiate higher discounted fee arrangements with healthcare providers. As a result, payors increasingly are demanding discounted fee structures or the assumption by healthcare providers of all or a portion of the financial risk related to paying for care provided through capitation agreements.

Via our management services organization relationships, we have relationships with affiliated independent physicians and group practices that we do not own or control to provide healthcare services, and our business could be harmed if a material number of those relationships were disrupted or if our arrangements with such providers become subject to legal challenges, liabilities or reputational harm.

In addition to our owned medical centers, we also provide practice management and administrative support services to independent physicians and group practices that we do not own through our managed services organization relationships, which we refer to as our affiliate providers. Our affiliate relationships allow us to partner with independent physicians and group practices and provides them access to components of our population health platform. As of September 30, 2021, we maintained relationships with over 1000 affiliate providers. As in the case of our owned medical centers, we receive per-member-per-month capitated revenue and a pre-negotiated percentage of the premium that the health plan receives from CMS. We pay the affiliate a primary care fee and a portion of the surplus of premium in excess of third-party medical costs. The surplus portion paid to affiliates is recorded as direct patient expense. However, we do not own our affiliated centers and our affiliated physicians are not our employees, and we have limited control over their operations. Accordingly, we do not exercise influence or control over the practice of medicine by our affiliated physicians, including, but not limited to, quality and cost of care. Our affiliated physicians and physician groups may not maintain standards of evidence-based medical practice and population health management that are consistent with our standards. If a material number of those relationships were disrupted or if our arrangements with such providers become subject to legal challenges, liabilities or reputational harm, our business could be harmed.

There are risks associated with estimating the amount of revenue that we recognize under our capitation agreements with health plans, and if our estimates of revenue are materially inaccurate, it could impact the timing and the amount of our revenue recognition or have a material adverse effect on our business, results of operations, financial condition and cash flows.

There are risks associated with estimating the amount of revenues that we recognize under our capitation agreements with health plans in a reporting period. Medicare pays capitation using a risk adjusted model, which compensates payors based on the health status, or acuity, of each individual member. Payors with higher acuity members receive a higher payment and those with lower acuity members receive a lower payment. Moreover, some of our capitated revenues also include adjustments for performance incentives or penalties based on the achievement of certain clinical quality metrics as contracted with payors. Our capitated revenues are recognized based on projected member acuity and quality metrics and are subsequently adjusted to reflect actual member acuity and quality metrics. Our ability to accurately project and recognize member acuity and quality metric adjustments are affected by many factors. For instance, our ability to accurately project member acuity and quality metrics may be more limited in the case of medical centers operating in new markets or medical centers that were recently acquired.

In addition, the billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues, such as ensuring appropriate documentation. Determining applicable primary and secondary coverage for our members, together with the changes in member coverage that

-91-

occur each month, requires complex, resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. If our estimates of revenues are materially inaccurate, it could impact the timing and the amount of our revenue recognition and have a material adverse impact on our business, results of operations, financial condition and cash flows.

A failure to accurately estimate incurred but not reported medical expense could adversely affect our results of operations.

Patient care costs include estimates of future medical claims that have been incurred by the patient but for which the provider has not yet billed. Our accrual for medical services incurred but not reported reflects our best estimates of unpaid medical expenses as of the end of any particular period. These claim estimates are made utilizing standard actuarial methodologies and are continually evaluated and adjusted by management based upon our historical claims experience and other factors, including regular independent assessments by a nationally recognized actuarial firm. Adjustments, if necessary, are made to medical claims expense and capitated revenues when the assumptions used to determine our claims liability change and when actual claim costs are ultimately determined.

Due to the inherent uncertainties associated with the factors used in these estimates and changes in the patterns and rates of medical utilization, materially different amounts could be reported in our financial statements for a particular period under different conditions or using different, but still reasonable, assumptions. It is possible that our estimates of this type of claim may be inadequate in the future. In such event, our results of operations could be adversely impacted. Further, the inability to estimate these claims accurately may also affect our ability to take timely corrective actions, further exacerbating the extent of any adverse effect on our results of operations.

Negative publicity regarding the managed healthcare industry generally could adversely affect our results of operations or business.

Negative publicity regarding the managed healthcare industry generally, or the Medicare Advantage program in particular, may result in increased regulation and legislative review of industry practices that further increase our costs of doing business and adversely affect our results of operations or business by:

•requiring us to change or increase our products and services provided to members;

•increasing the regulatory, including compliance, burdens under which we operate, which, in turn, may negatively impact the manner in which we provide services and increase our costs of providing services;

•adversely affecting our ability to market our products or services through the imposition of further regulatory restrictions regarding the manner in which plans and providers market to Medicare Advantage or traditional Medicare enrollees; or

•adversely affecting our ability to attract and retain members.

We lease all of our facilities and may experience risks relating to lease terminations, lease expense escalators, lease extensions and special charges.

We currently lease or license all of our medical centers. Generally, our lease or license agreements provide that the lessor may terminate the lease, subject to applicable cure provisions, for a number of reasons, including the defaults in any payment of rent, taxes or other payment obligations, the breach of any other covenant or agreement in the lease. Termination of certain of our lease agreements could result in a cross-default under our debt agreements or other lease agreements. If a lease agreement is terminated, there can be no assurance that we will be able to enter into a new lease agreement on similar or better terms or at all.

Our lease obligations often include annual fixed rent escalators or variable rent escalators based on a consumer price index. These escalators could impact our ability to satisfy certain obligations and financial covenants. If the results of our operations do not increase at or above the escalator rates, it would place an additional burden on our results of operations, liquidity and financial position.

As we continue to expand and have leases or licenses with different start dates, it is likely that some number of our leases and licenses will expire each year. Our lease or license agreements often provide for renewal or extension options. There can be no assurance that these rights will be exercised in the future or that we will be able to satisfy the conditions precedent to exercising any such renewal or extension. In addition, if we are unable to renew or extend any of our leases or licenses, we may

-92-

lose all of the facilities subject to that master lease agreement. If we are not able to renew or extend our leases or licenses at or prior to the end of the existing lease terms, or if the terms of such options are unfavorable or unacceptable to us, our business, financial condition and results of operations could be adversely affected.

Leasing facilities pursuant to binding lease or license agreements may limit our ability to exit markets. For instance, if one facility under a lease or license becomes unprofitable, we may be required to continue operating such facility or, if allowed by the landlord to close such facility, we may remain obligated for the lease payments on such facility. We could incur special charges relating to the closing of such facility, including lease termination costs, impairment charges and other special charges that would reduce our profits and could have a material adverse effect on our business, financial condition or results of operations.

Our failure to pay the rent or otherwise comply with the provisions of any of our lease agreements could result in an “event of default” under such lease agreement and agreements for our indebtedness. Upon an event of default, remedies available to our landlords generally include, without limitation, terminating such lease agreement, repossessing and reletting the leased properties and requiring us to remain liable for all obligations under such lease agreement, including the difference between the rent under such lease agreement and the rent payable as a result of reletting the leased properties, or requiring us to pay the net present value of the rent due for the balance of the term of such lease agreement. The exercise of such remedies would have a material adverse effect on our business, financial position, results of operations and liquidity.

If certain of our suppliers do not meet our needs, if there are material price increases on supplies, if we are not reimbursed or adequately reimbursed for drugs we purchase or if we are unable to effectively access new technology or superior products, it could negatively impact our ability to effectively provide the services we offer and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

We have significant suppliers that may be the sole or primary source of products critical to the services we provide, including our primary providers of pharmaceutical drugs and pharmacy supplies. If any of these suppliers do not meet our needs, including in the event of a product recall, shortage or dispute, and we are not able to find adequate alternative sources, if we experience material price increases from these suppliers (for instance, increases in the wholesale price of generic drugs) that we are unable to mitigate, or if some of the drugs that we purchase are not reimbursed or not adequately reimbursed by commercial or government payors, it could have a material adverse impact on our business, results of operations, financial condition and cash flows. In addition, the technology related to the products critical to the services we provide is subject to new developments which may result in superior products. If we are not able to access superior products on a cost-effective basis or if suppliers are not able to fulfill our requirements for such products, we could face member attrition and other negative consequences which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Our pharmacy business is subject to governmental regulations, procedures and requirements; our noncompliance or a significant regulatory change could adversely affect our business, the results of our operations or our financial condition.

Our pharmacy business is subject to numerous federal, state and local laws and regulations. Changes in these regulations may require extensive system and operating changes that may be difficult to implement. Untimely compliance or noncompliance with applicable regulations could result in the imposition of civil and criminal penalties that could adversely affect the continued operation of our pharmacy business, including: (i) suspension of payments from government programs; (ii) loss of required government certifications; (iii) loss of authorizations or changes in requirements for participating in, or exclusion from government reimbursement programs, such as the Medicare and Medicaid programs; (iv) loss of licenses; or (v) significant fines or monetary penalties. The regulations to which we are subject include, but are not limited to, federal, state and local registration and regulation of pharmacies; dispensing and sale of controlled substances and products containing pseudoephedrine; applicable Medicare and Medicaid regulations; regulations implementing the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (“HIPAA”); regulations implementing the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations (“HIPAA”); regulations relating to the protection of the environment and health and safety matters, including those governing exposure to and the management and disposal of hazardous substances; regulations enforced by the U. S. Federal Trade Commission, HHS and the Drug Enforcement Administration as well as state regulatory authorities, governing the sale, advertisement and promotion of products we sell; state and federal anti-kickback laws; false claims laws and federal and state laws governing the practice of the profession of pharmacy. We are also governed by federal and state laws of general applicability, including laws regulating wages and hours, working conditions, health and safety and equal employment opportunity. If we are unable to successfully provide pharmacy services, we may not be able to achieve the expected benefits of

-93-

our value-based care model where members have access to both primary care and ancillary programs such as pharmacy services at our medical centers, which may have a negative effect on our business and results of operations.

The continued conversion of various prescription drugs, including potential conversions of a number of popular medications, to over-the-counter medications may reduce our pharmacy sales and customers may seek to purchase such medications through other channels. Also, if the rate at which new prescription drugs become available slows or if new prescription drugs that are introduced into the market fail to achieve popularity, our pharmacy sales may be adversely affected. The withdrawal of certain drugs from the market or concerns about the safety or effectiveness of certain drugs or negative publicity surrounding certain categories of drugs may also have a negative effect on our pharmacy sales or may cause shifts in our pharmacy product mix.

Certain risks are inherent in providing pharmacy services; our insurance may not be adequate to cover any claims against us.

Pharmacies are exposed to risks inherent in the packaging and distribution of pharmaceuticals and other healthcare products, such as with respect to improper filling of prescriptions, labeling of prescriptions, adequacy of warnings, unintentional distribution of counterfeit drugs and expiration of drugs. In addition, federal and state laws that require our pharmacists to offer counseling, without additional charge, to customers about medication, dosage, delivery systems, common side effects and other information the pharmacists deem significant can impact our pharmacy business. Our pharmacists may also have a duty to warn customers regarding any potential negative effects of a prescription drug if the warning could reduce or negate these effects. Although we maintain professional liability and errors and omissions liability insurance, from time to time, claims result in the payment of significant amounts, some portions of which are not funded by insurance. We cannot assure you that the coverage limits under our insurance programs will be adequate to protect us against future claims, or that we will be able to maintain this insurance on acceptable terms in the future. Our results of operations, financial condition or cash flows may be adversely affected if in the future our insurance coverage proves to be inadequate or unavailable or there is an increase in liability for which we self-insure or we suffer reputational harm as a result of an error or omission.

We are subject to a right of first refusal in favor of Humana, Inc. and certain of its affiliates, which could impede our growth and adversely impact the potential value of the Company.

We are subject to an Amended and Restated Right of First Refusal Agreement (the “ROFR Agreement”), entered into by and among Humana and certain of its affiliates and PCIH, the Seller and the Company upon completion of the Business Combination. Under the ROFR Agreement, Humana has been granted a right of first refusal on any sale, lease, license or other disposition, in one transaction or a series of related transactions, of assets, businesses, divisions or subsidiaries that constitute 20% or more of the net revenues, net income or assets of, or any equity transaction (including by way of merger, consolidation, recapitalization, exchange offer, spin-off, split-off, reorganization or sale of securities) that results in a change of control of, PCIH, the Seller, or the Company or its subsidiary, HP MSO, LLC. If exercised, Humana would have the right to acquire the assets or equity interests by matching the terms of the proposed sale transaction.

The ability of Humana to elect to exercise its right of first refusal may limit or impede the Company’s ability to conduct its business on the terms and in the manner it considers most favorable, which may adversely affect its future growth opportunities. The existence of the right of first refusal may also deter potential acquirors from seeking to acquire the Company. If potential acquirors are deterred from considering an acquisition of it, the Company may receive less than fair market value acquisition offers or may not receive acquisition offers at all, which might have a substantial negative effect on the value of your investment in the Company and may impact the long-term value, growth and potential of the Company.

Our overall business results may suffer from an economic downturn.

During periods of high unemployment, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. These budget deficits at federal, state and local government entities have decreased, and may continue to decrease, spending for health and human service programs, including Medicare, Medicaid and similar programs, which represent significant payor sources for our medical centers together with payors with whom we contract to provide health plans to our members.

Risks Related to Our Growth

-94-

If we fail to manage our growth effectively, we may be unable to execute our business plan, maintain high levels of service and member satisfaction or adequately address competitive challenges.

We have experienced, and may continue to experience, rapid growth and organizational change, which has placed, and may continue to place, significant demands on our management and our operational and financial resources. Additionally, our organizational structure may become more complex as we improve our operational, financial and management controls, as well as our reporting systems and procedures. We may require significant capital expenditures and the allocation of valuable management resources to grow and change in these areas. We must effectively increase our headcount and continue to effectively train and manage our employees. We will be unable to manage our business effectively if we are unable to alleviate the strain on resources caused by growth in a timely and successful manner. If we fail to effectively manage our anticipated growth and change, the quality of our services may suffer, which could negatively affect our brand and reputation and harm our ability to attract and retain members and employees.

In addition, as we expand our business, it is important that we continue to maintain a high level of member service and satisfaction. As our member base continues to grow, we will need to expand our medical, member services and other personnel and our network of partners to provide personalized member service. If we are not able to continue to provide high quality medical care with high levels of member satisfaction, our reputation, as well as our business, results of operations and financial condition could be adversely affected.

We have encountered and will continue to encounter risks and difficulties frequently experienced by growing companies in rapidly changing industries, including increasing expenses as we continue to grow our business. We expect our operating expenses to increase significantly over the next several years as we continue to hire additional personnel, expand our operations and infrastructure, and continue to expand to reach more members. In addition to the expected costs to grow our business, we also expect to incur additional legal, accounting, investor relations and other expenses as a newly public company. These investments may be more costly than we expect, and if we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, they may not result in increased revenue or growth in our business. If our growth rate were to decline significantly or become negative, it could adversely affect our financial condition and results of operations. If we are not able to achieve or maintain positive cash flow in the long term, we may require additional financing, which may not be available on favorable terms or at all and/or which could be dilutive to our stockholders. If we are unable to successfully address these risks and challenges as we encounter them, our business, results of operations and financial condition would be adversely affected. Our failure to achieve or maintain profitability could negatively impact the value of our securities.

We may not be able to identify suitable de novo expansion opportunities, engage with payors in new markets to continue extension of financial risk-sharing model agreements that have proved successful in our existing markets or cost-effectively develop, staff and establish such new medical centers in new markets.

Our business strategy is to grow rapidly by expanding our network of medical centers and is significantly dependent on opening new medical centers in new geographic locations, recruiting new clinicians and members and partnering or contracting with payors, existing medical practices or other healthcare providers to provide primary care services. We seek growth opportunities both organically and through acquisitions or other partnerships with payors or other primary care providers. To continue to expand our operations to other regions of the United States, we will have to devote resources to identifying and exploring such perceived opportunities.

Our ability to grow depends upon a number of factors, including recruiting new members, entering into contracts with additional payors, establishing new relationships with physicians and other healthcare providers, identifying appropriate facilities, recruiting and retaining qualified personnel, obtaining leases and completing internal build-outs of new facilities within proposed timelines and budgets. We anticipate that further geographic expansion will require us to make a substantial investment of management time, capital and/or other resources. There can be no assurance that we will be able to continue to successfully expand our operations in any new geographic markets.

Our growth strategy in new markets involves a number of risks and uncertainties, including that:

-95-

•we may not be able to successfully enter into contracts with local payors on terms favorable to us or at all, including as a result of competition for payor relationships with other potential players, some of whom may have greater resources than we do, which competition may intensify due to the ongoing consolidation in the healthcare industry;

•we may not be able to recruit or retain a sufficient number of new members to execute our growth strategy, and we may incur substantial costs to recruit new members and we may be unable to recruit a sufficient number of new members to offset those costs;

•we may not be able to hire sufficient numbers of physicians and other staff and may fail to integrate our employees, particularly our medical personnel, into our care model;

•per-member revenue in new markets may be lower than in our existing markets, including as a result of geographic cost index-based adjustments by CMS;

•we may not be able to hire sufficient numbers of physicians and other staff and may fail to integrate our employees, particularly our medical personnel, into our care model;

•when expanding our business into new states, we may be required to comply with laws and regulations that may differ from states in which we currently operate; and

•depending upon the nature of the local market, we may not be able to implement our business model in every local market that we enter; for example, we may be unable to offer all services that we offer in our current markets (e.g., transportation), which could negatively impact our revenues and financial condition.

We cannot guarantee that we will be successful in pursuing our growth strategy. If we fail to evaluate and execute new business opportunities properly, we may not achieve anticipated benefits and may incur increased costs, which may negatively impact our business model, revenues, results of operations and financial condition.

We may not be able to identify suitable acquisition candidates, complete acquisitions or successfully integrate acquisitions, and acquisitions may not produce the intended results or may expose us to unknown or contingent liabilities.

Making selected acquisitions of complementary medical centers, physicians and group practices and successfully integrating them has been an important part of our growth to date, having completed a significant number of transactions since 2017, and we expect it to be a part of our strategy going forward. However, in the future, we may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully. In addition, acquisitions involve numerous risks, including difficulties in the integration of acquired operations and the diversion of management’s attention from other business concerns. In order to complete such strategic transactions, we may need to seek additional financing to fund these investments and acquisitions. Should we need to obtain financing for any acquisition or investment, there is no guarantee that we will be able to secure such financing, or obtain such financing on favorable terms, including due to general market conditions or the volatile nature of the healthcare marketplace. Should we issue equity securities as consideration in any acquisition, such issuance may be dilutive to our stockholders and the acquisition may not produce our desired results. If we incur additional debt, we may be subject to additional operating restrictions or be unable to generate sufficient cash flow to satisfy our debt obligations. See “Risks Related to Our Indebtedness.”

Even if we are successful in making an acquisition, the business that we acquire may not be successful or may require significantly greater resources and investments than we originally anticipated. We may expend extensive resources on an acquisition of a particular business that we are not able to successfully integrate into our operations, if at all, or where our expectations with respect to customer demands are not met.

Our ability to fully realize the anticipated benefits of both historical and future acquisitions will depend, to a large extent, on our ability to integrate the businesses we acquire. Integrating and coordinating aspects of the operations and personnel of acquisitions with ours involves complex operational and personnel-related challenges. This process is time-consuming and expensive, disrupts the businesses of both our business and the acquired business and may not result in the full benefits expected by us, including any cost synergies expected to arise from operational efficiencies and overlapping general and administrative functions.

-96-

The potential difficulties, and resulting costs and delays, include:

•managing a larger combined company and consolidating corporate and administrative infrastructures;

•the inability to realize any expected synergies and cost-savings;

•difficulties in managing geographically dispersed operations, including risks associated with entering markets in which we have no or limited prior experience;

•underperformance of any acquired business relative to our expectations and the price we paid;

•negative near-term impacts on financial results after an acquisition, including acquisition-related earnings charges;

•the assumption or incurrence of additional debt obligations or expenses, or use of substantial portions of our cash;

•the issuance of equity securities to finance or as consideration for any acquisitions that dilute the ownership of our stockholders;

•claims by terminated employees and shareholders of acquired companies or other third parties related to the transaction;

•problems maintaining uniform procedures, controls and policies with respect to our financial accounting systems;

•unanticipated issues in integrating information technology, communications and other systems; and

•risks associated with acquiring intellectual property, including potential disputes regarding acquired companies’ intellectual property.

Additionally, the integration of operations and personnel may place a significant burden on management and other internal resources. The attention of our management may be directed towards integration considerations and may be diverted from our day-to-day business operations, and matters related to the integration may require commitments of time and resources that could otherwise have been devoted to other opportunities that might have been beneficial to us and our business. The diversion of management’s attention, and any difficulties encountered in the transition and integration process, could harm our business, financial condition and results of operations.

We must attract and retain highly qualified personnel in order to execute our growth plan.

Competition for highly qualified personnel is intense, especially for physicians and other medical professionals who are experienced in providing care services to older adults. We have, from time to time, experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications. Many of the companies and healthcare providers with which we compete for experienced personnel have greater resources than we have. If we hire employees from competitors or other companies or healthcare providers, their former employers may attempt to assert that these employees or we have breached certain legal obligations, resulting in a diversion of our time and resources. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects could be harmed. Many of our senior employees are subject to non-competition and non-solicitation agreements with us. However, the enforceability of non-competition agreements may differ from state to state and by circumstance and if any of our non-competition agreements was found to be unenforceable, our business and growth prospects could be harmed.

If we are unable to attract new members, our revenue growth will be adversely affected.

To increase our revenue, our business strategy is to expand the number of medical centers in our network. In order to support such growth, we must continue to recruit and retain a sufficient number of new members. We are focused on the Medicare-eligible population and face competition from other primary healthcare providers in the recruitment of Medicare-eligible potential members. If we are unable to convince the Medicare-eligible population of the benefits of our platform or if potential or existing members prefer the care provider model of one of our competitors, we may not be able to effectively

-97-

implement our growth strategy, which depends on our ability to grow organically by attracting new members and retaining existing members. In addition, our growth strategy is dependent in part on patients electing to move from fee-for-service to capitated arrangements and selecting us as their primary care provider under their plan. The majority of plan enrollment selections are made during an annual enrollment period from November into December of each year; therefore, our ability to grow our member population with capitation arrangements is dependent in part on our ability to successfully recruit members during the annual enrollment period and to convince these patients to select us as their primary care provider and not subsequently change that election. Our inability to recruit new members and retain existing members, particularly those under capitation arrangements, would harm our ability to execute our growth strategy and may have a material adverse effect on our business operations and financial position.

We have limited experience serving as a Direct Contracting Entity with CMS and may not be able to realize the expected benefits thereof.

The CMS Center for Medicare and Medicaid Innovation recently announced a direct contracting model which began in 2021 to create value-based payment arrangements directly with DCEs, which is part of CMS’ strategy to drive broader healthcare reform and accelerate the shift from original Medicare toward value-based care models. A key aspect of direct contracting is providing new opportunities for a variety of different DCEs to participate in value-based care arrangements in Medicare fee-for-service. Our wholly owned subsidiary, American Choice Healthcare, LLC, was one of 41 unique companies chosen by CMS as a DCE to participate in the Implementation Period of the Direct Contracting Model for Global and Professional Options, which ran from October 1, 2020 through March 31, 2021. The Implementation Period provided us an opportunity to prepare for the first Performance Year, which began on April 1, 2021. We were assigned approximately 8,100 beneficiaries under this program. However, we have no experience serving as a DCE and may not be able to realize the expected benefits thereof. We can provide no assurances that direct contracting will allow us to achieve risk-like patient economics on original Medicare patients. For instance, we may not be able to calibrate our historical medical expense estimates to this new beneficiary population, who have not chosen to participate in value-based care and thus may utilize third-party medical services differently than our current members. Beneficiaries that we are assigned under the direct contracting model may not be profitable to us initially or at all. In addition, our management team has and may further invest considerable time and resources in adapting to the direct contracting model, but we may not be able to realize the expected benefits thereof. Adding additional members through direct contracting will require absorbing additional members into our existing medical centers, which may strain resources or negatively affect our quality of care. We can provide no assurances that the direct contracting model will continue for additional Performance Years beyond the initial five year period, including as a result of decreased political support for value-based care or the direct contracting model, or that it will expand our total addressable market in the manner that we expect.

Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.

We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, despite applicable restrictions on transfer of shares, liquidity available to our employee securityholders following the Business Combination could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth and our transition from a private company to a public company may result in a change to our corporate culture, which could harm our business.

We will be required to raise additional capital or generate cash flows to execute on our growth strategy, expand our operations and invest in new technologies in the future and our failure to do so could reduce our ability to compete successfully and harm our results of operations.

Our operations have consumed substantial amounts of cash since inception and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, expand our services in new geographic locations, build additional de novo medical centers and execute our accretive acquisition strategy. We will need to raise additional funds, and we may not be able to obtain additional debt or equity financing on favorable terms or at all. If we raise additional equity financing, our security holders may experience significant dilution of their ownership interests. If we engage in additional debt financing, we may be required to accept terms that restrict our ability to incur additional indebtedness,

-98-

force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. In addition, the covenants in the Credit Agreement may limit our ability to obtain additional debt, and any failure to adhere to these covenants could result in penalties or defaults that could further restrict our liquidity or limit our ability to obtain financing. If we need additional capital and cannot raise it on acceptable terms, or at all, we may not be able to, among other things:

•develop and enhance our member services;

•continue to expand our organization;

•hire, train and retain employees;

•respond to competitive pressures or unanticipated working capital requirements; or

•pursue acquisition opportunities.

Risks Related to Government Regulation

We conduct business in a heavily regulated industry, and if we fail to comply with applicable state and federal healthcare laws and government regulations or lose governmental licenses, we could incur financial penalties, become excluded from participating in government healthcare programs, be required to make significant operational changes or experience adverse publicity, which could harm our business.

Our operations are subject to extensive federal, state and local government laws and regulations, such as:

•Medicare and Medicaid reimbursement rules and regulations;

•federal Anti-Kickback Statute, which, subject to certain exceptions known as “safe harbors,” prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration for referring an individual, in return for ordering, leasing, purchasing or recommending or arranging for or to induce the referral of an individual or the ordering, purchasing or leasing of items or services covered, in whole or in part, by any federal healthcare program, such as Medicare and Medicaid. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act (the “FCA”);

•the federal physician self-referral law, commonly referred to as the Stark Law, and analogous state self-referral prohibition statutes, which, subject to limited exceptions, prohibit physicians from referring Medicare or Medicaid patients to an entity for the provision of certain “designated health services” if the physician or a member of such physician’s immediate family has a direct or indirect financial relationship (including an ownership interest or a compensation arrangement) with an entity, and prohibit the entity from billing Medicare or Medicaid for such “designated health services.” The Stark Law excludes certain ownership interests in an entity from the definition of a financial relationship, including ownership of investment securities that could be purchased on the open market when the designated health services referral was made and when the entity had stockholder equity exceeding $75 million at the end of the corporation’s most recent fiscal year or on average during the previous three fiscal years. “Stockholder equity” is the difference in value between a corporation’s total assets and total liabilities;

•federal civil and criminal false claims laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The FCA also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;

•the Civil Monetary Penalty statute and associated regulations, which authorizes the government agent to impose civil money penalties, an assessment, and program exclusion for various forms of fraud and abuse involving the Medicare and Medicaid programs;

-99-

•the criminal healthcare fraud provisions of HIPAA, and related rules that prohibit knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it;

•federal and state laws regarding telemedicine services, including necessary technological standards to deliver such services, coverage restrictions associated with such services, the amount of reimbursement for such services, the licensure of individuals providing such services;

•federal and state laws and policies related to the prescribing and dispensing of pharmaceuticals and controlled substances;

•federal and state laws related to the advertising and marketing of services by healthcare providers;

•state laws regulating the operations and financial condition of risk bearing providers, which may include capital requirements, licensing or certification, governance controls and other similar matters;

•state and federal statutes and regulations that govern workplace health and safety;

•federal and state laws and policies that require healthcare providers to maintain licensure, certification or accreditation to enroll and participate in the Medicare and Medicaid programs, to report certain changes in their operations to the agencies that administer these programs and, in some cases, to re-enroll in these programs when changes in direct or indirect ownership occur;

•state laws pertaining to kickbacks, fee splitting, self-referral and false claims, some of which are not consistent with comparable federal laws and regulations, including, for example, not being limited in scope to relationships involving government health care programs;

•state insurance laws governing what healthcare entities may bear financial risk and the allowable types of financial risks, including direct primary care programs, provider-sponsored organizations, Accountable Care Organizations, Independent Physician Associations, and provider capitation;

•federal and state laws pertaining to the provision of services by nurse practitioners and physician assistants in certain settings, physician supervision of those services, and reimbursement requirements that depend on the types of services provided and documented and relationships between physician supervisors and nurse practitioners and physician assistants; and

•federal and state laws pertaining to the privacy and security of protected health information (“PHI”) and other patient information.

In addition to the above laws, Medicare and Medicaid regulations, manual provisions, local coverage determinations, national coverage determinations and agency guidance also impose complex and extensive requirements upon healthcare providers. Moreover, the various laws and regulations that apply to our operations are often subject to varying interpretations and additional laws and regulations potentially affecting providers continue to be promulgated that may impact us. A violation or departure from any of the legal requirements implicated by our business may result in, among other things, government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. These legal requirements are civil, criminal and administrative in nature depending on the law or requirement.

We endeavor to comply with all legal requirements. We further endeavor to structure all of our relationships with physicians and providers to comply with state and federal anti-kickback physician and Stark laws and other applicable healthcare laws. On December 2, 2020, the HHS Office of Inspector General (the “OIG”), and CMS issued final rules expanding and

-100-

modifying existing and adding new regulatory Anti-Kickback Statute “safe harbors” and Stark Law exceptions, respectively. The rules are part of the “Regulatory Sprint to Coordinated Care” that HHS launched in 2018 in an effort to encourage innovative arrangements designed to improve the quality of care, health outcomes, and efficiency in the United States health care system. These final rules center on the concept of “value-based enterprises” (“VBEs”), and “value-based arrangements” between participants in VBEs. Both the Anti-Kickback Statute safe harbors and the Stark Law exceptions are broken down by the amount of financial risk assumed under the value-based arrangement, and the more risk assumed, the more flexibility offered under the safe harbors and exceptions. We continue to evaluate what effect, if any, these rules will have on our business. We utilize considerable resources to monitor laws and regulations and implement necessary changes. However, the laws and regulations in these areas are complex, changing and often subject to varying interpretations. As a result, there is no guarantee that we will be able to adhere to all of the laws and regulations that apply to our business, and any failure to do so could have a material adverse impact on our business, results of operations, financial condition, cash flows and reputation. Similarly, we may face penalties under the FCA, the federal Civil Monetary Penalty statute or otherwise related to failure to report and return overpayments within 60 days of when the overpayment is identified and quantified. These obligations to report and return overpayments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made investments in resources to decrease the time it takes to identify, quantify and process overpayments, and may be required to make additional investments in the future.

Additionally, the federal government has used the FCA to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare, Medicaid and other federally funded health care programs. Moreover, amendments to the federal Anti-Kickback Statute in the ACA make claims tainted by anti-kickback violations potentially subject to liability under the FCA, including qui tam or whistleblower suits. The penalties for a violation of the FCA range from $5,500 to $11,000 (adjusted for inflation) for each false claim plus three times the amount of damages caused by each such claim which generally means the amount received directly or indirectly from the government. On January 29, 2018, the DOJ issued a final rule announcing adjustments to FCA penalties, under which the per claim penalty range increases to a range from $11,665 to $23,331 per false claim or statement (as of June 19, 2020, and subject to annual adjustments for inflation). Given the high volume of claims processed by our various operating units, the potential is high for substantial penalties in connection with any alleged FCA violations.

In addition to the provisions of the FCA, which provide for civil enforcement, the federal government can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims for payment to the federal government.

In addition, with the various government shutdowns, stay at home orders, and restrictions on elective health care services brought about by the COVID-19 pandemic, our owned and affiliated practices have increasingly relied upon the availability of, and reimbursement for, telemedicine and other emerging technologies (such as digital health services) to generate revenue. Federal and state laws regarding such services, necessary technological standards to deliver such services, coverage restrictions associated with such services, and the amount of reimbursement for such services are subject to changing political, regulatory and other influences. During the first wave of the COVID-19 pandemic in the United States, many states loosened the restrictions in such laws and allowed providers to bill for such services at rates comparable to providing such services in a traditional office setting. These changes may be of short duration, may impede us in providing such services to our members in an economically viable manner in the future, and may harm our business. Failure to comply with these laws could result in denials of reimbursement for our affiliated providers’ services (to the extent such services are billed), recoupments of prior payments, professional discipline for our affiliated providers or civil or criminal penalties against our business.

If any of our operations are found to violate these or other government laws or regulations, we could suffer severe consequences that would have a material adverse effect on our business, results of operations, financial condition, cash flows, reputation and stock price, including:

•suspension or termination of our participation in government payment programs;

•refunds of amounts received in violation of law or applicable payment program requirements dating back to the applicable statute of limitation periods;

•loss of our required government certifications or exclusion from government payment programs;

-101-

•loss of our licenses required to operate healthcare facilities or administer pharmaceuticals in the states in which we operate;

•criminal or civil liability, fines, damages, exclusion from participation in federal and state health care programs and/or monetary penalties for violations of healthcare fraud and abuse laws, including the federal Anti-Kickback Statute, Civil Monetary Penalties Law, Stark Law and FCA, state laws and regulations, or other failures to meet regulatory requirements;

•enforcement actions by governmental agencies and/or state law claims for monetary damages by patients who believe their PHI has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including HIPAA and the Privacy Act of 1974;

•mandated changes to our practices or procedures that significantly increase operating expenses;

•imposition of and compliance with corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines, among other things;

•termination of various relationships and/or contracts related to our business, including payor agreements, joint venture arrangements, medical director agreements, real estate leases and consulting agreements with physicians;

•changes in and reinterpretation of rules and laws by a regulatory agency or court, such as state corporate practice of medicine laws, that could affect the structure and management of our business and its affiliated physician practice corporations;

•negative adjustments to government payment models including, but not limited to, Medicare Parts A, B, C and D and Medicaid; and

•harm to our reputation which could negatively impact our business relationships, affect our ability to attract and retain members and physicians, affect our ability to obtain financing and decrease access to new business opportunities, among other things.

We are, and may in the future be, a party to various lawsuits, demands, claims, qui tam suits, governmental investigations and audits (including investigations or other actions resulting from our obligation to self-report suspected violations of law) and other legal matters, any of which could result in, among other things, substantial financial penalties or awards against us, mandated refunds, substantial payments made by us, required changes to our business practices, exclusion from future participation in Medicare, Medicaid and other healthcare programs and possible criminal penalties, any of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and materially harm our reputation.

We may in the future be subject to investigations and audits by state or federal governmental agencies and/or private civil qui tam complaints filed by relators and other lawsuits, demands, claims and legal proceedings, including investigations or other actions resulting from our obligation to self-report suspected violations of law.

Responding to subpoenas, investigations and other lawsuits, claims and legal proceedings as well as defending ourselves in such matters will continue to require management’s attention and cause us to incur significant legal expense. Negative findings or terms and conditions that we might agree to accept as part of a negotiated resolution of pending or future legal or regulatory matters could result in, among other things, substantial financial penalties or awards against us, substantial payments made by us, harm to our reputation, required changes to our business practices, exclusion from future participation in the Medicare, Medicaid and other healthcare programs and, in certain cases, criminal penalties, any of which could have a material adverse effect on us. It is possible that criminal proceedings may be initiated against us and/or individuals in our business in connection with investigations by the federal government.

We, our employees, the facilities in which we operate and our affiliated physicians are subject to various federal, state and local licensing and certification laws and regulations and accreditation standards and other laws, relating to, among other things, the adequacy of medical care, equipment, privacy of patient information, physician relationships, personnel and operating

-102-

policies and procedures. Failure to comply with these licensing, certification and accreditation laws, regulations and standards could result in our services being found non-reimbursable or prior payments being subject to recoupment, requirements to make significant changes to our operations and can give rise to civil or, in extreme cases, criminal penalties. We routinely take the steps we believe are necessary to retain or obtain all requisite licensure and operating authorities. While we have made reasonable efforts to substantially comply with federal, state and local licensing and certification laws and regulations and standards as we interpret them, we cannot assure you that agencies that administer these programs will not find that we have failed to comply in some material respects.

Reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program could have a material adverse effect on our financial condition and results of operations.

We receive the majority of our revenue from Medicare, either directly or through Medicare Advantage plans, and revenue from Medicare accounted for 80.8% of our revenue for the year ended December 31, 2020 and 76.8% and 83.3% of our revenue for the nine months ended September 30, 2020 and 2021, respectively. In addition, many private payors base their reimbursement rates on the published Medicare rates or are themselves reimbursed by Medicare for the services we provide. As a result, our results of operations are, in part, dependent on government funding levels for Medicare programs, particularly Medicare Advantage programs. Any changes that limit or reduce Medicare Advantage or general Medicare reimbursement levels, such as reductions in or limitations of reimbursement amounts or rates under programs, reductions in funding of programs, expansion of benefits without adequate funding, elimination of coverage for certain benefits, or elimination of coverage for certain individuals or treatments under programs, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. For example, due to the federal sequestration, an automatic 2% reduction in Medicare spending took effect beginning in April 2013. The CARES Act, designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, and subsequent legislation temporarily suspended these reductions until December 31, 2021, and extended the sequester by one year, through 2030. Additional legislation extended this suspension until the end of the pandemic.

Each year, CMS issues a final rule to establish the Medicare Advantage benchmark payment rates for the following calendar year. Any reduction to Medicare Advantage rates impacting us that is greater compared to the industry average rate may have a material adverse effect on our business, results of operations, financial condition and cash flows. The final impact of the Medicare Advantage rates can vary from any estimate we may have and may be further impacted by the relative growth of our Medicare Advantage member volumes across markets as well as by the benefit plan designs submitted. It is possible that we may underestimate the impact of the Medicare Advantage rates on our business, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, our Medicare Advantage revenues may continue to be volatile in the future, which could have a material adverse impact on our business, results of operations, financial condition and cash flows.

In addition, CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes that could adversely affect our business include:

•administrative or legislative changes to base rates or the bases of payment;

•limits on the services or types of providers for which Medicare will provide reimbursement;

•changes in methodology for member assessment and/or determination of payment levels;

•the reduction or elimination of annual rate increases; or

•an increase in co-payments or deductibles payable by beneficiaries.

-103-

Recent legislative, judicial and executive efforts to enact further healthcare reform legislation have caused the future state of the exchanges, other reforms under the ACA, and many core aspects of the current U.S. health care system to be unclear. Since 2016, various administrative and legislative initiatives have been implemented that have had adverse impacts on the ACA and its programs. For example, in October 2017, the federal government announced that cost-sharing reduction payments to insurers would end, effective immediately, unless Congress appropriated the funds, and, in December 2017, Congress passed the Tax Cuts and Jobs Act, which includes a provision that eliminates the penalty under the ACA’s individual mandate for individuals who fail to obtain a qualifying health insurance plan and could impact the future state of the exchanges. On December 14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, and remanded the case to the lower court to reconsider its earlier invalidation of the full ACA. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case. Oral arguments, were held on November 10, 2020. The Supreme Court issued its decision in June 2021, ruling that the plaintiffs lacked standing to challenge the individual mandate provision, thus leaving the ACA in effect. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.

While specific changes and their timing are not yet apparent, enacted reforms and future legislative, regulatory, judicial, or executive changes, particularly any changes to the Medicare Advantage program, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Among the important statutory changes that are being implemented by CMS include provisions of the IMPACT Act. This law imposes a stringent timeline for implementing benchmark quality measures and data metrics across post-acute care providers. The enactment also mandates specific actions to design a unified payment methodology for post-acute providers. CMS is in the process of promulgating regulations to implement provisions of this enactment. Depending on the final details, the costs of implementation could be significant. The failure to meet implementation requirements could expose providers to fines and payment reductions.

There is also uncertainty regarding traditional Medicare and Medicare Advantage in both payment rates and beneficiary enrollment, which, if reduced, would reduce our overall revenues and net income. Although Medicare Advantage enrollment increased by approximately 15 million, or by 136%, between the enactment of the ACA in 2010 and 2021, there can be no assurance that this trend will continue. Further, fluctuation in Medicare Advantage payment rates is evidenced by CMS’s annual announcement of the expected average change in revenue from the prior year: for 2021, CMS announced an average increase of 1.66%; and for 2022, 4.08%. Uncertainty over traditional Medicare and Medicare Advantage enrollment and payment rates present a continuing risk to our business.

According to the Kaiser Family Foundation (“KFF”), Medicare Advantage enrollment continues to be highly concentrated among a few payors, both nationally and in local regions. In 2020, the KFF reported that three payors together accounted for more than half of Medicare Advantage enrollment and seven firms accounted for approximately 83% of the lives. Consolidation among Medicare Advantage plans in certain regions, or the Medicare program’s failure to attract additional plans to participate in the Medicare Advantage program, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Reductions in reimbursement rates or the scope of services being reimbursed, or an expansion of the scope of services to be provided under our contracts with payors without a corresponding increase in payment rates could have a material, adverse effect on our financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating expenses. Additionally, any delay or default by the government in making Medicare reimbursement payments could materially and adversely affect our business, financial condition and results of operations.

State and federal efforts to reduce Medicaid spending could adversely affect our financial condition and results of operations.

Approximately 50% of our medical center Medicare members are dual-eligible, qualifying for both Medicare and Medicaid. Medicaid is a joint federal-state program purchasing healthcare services for the low income and indigent as well as certain higher-income individuals with significant health needs. Under broad federal criteria, states establish rules for eligibility, services and payment. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets. This, combined with

-104-

slower state revenue growth, has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending.

For example, a number of states have adopted or are considering legislation designed to reduce their Medicaid expenditures, such as financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the provider’s total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states’ Medicaid expenditures, and as a result could have an adverse effect on our business.

As part of the movement to repeal, replace or modify the ACA and as a means to reduce the federal budget deficit, there are renewed congressional efforts to move Medicaid from an open-ended program with coverage and benefits set by the federal government to one in which states receive a fixed amount of federal funds, either through block grants or per capita caps, and have more flexibility to determine benefits, eligibility or provider payments. If those changes are implemented, we cannot predict whether the amount of fixed federal funding to the states will be based on current payment amounts, or if it will be based on lower payment amounts, which would negatively impact those states that expanded their Medicaid programs in response to the ACA.

We expect these state and federal efforts to continue for the foreseeable future. The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans.

Our business could be harmed if the ACA is overturned or by any legislative, regulatory or industry change that reduces healthcare spending or otherwise slows or limits the transition to more assumption of risk by healthcare providers.

Our operating model, our platform and our revenue are dependent on the healthcare industry’s continued movement towards providers assuming more risk from payors for the cost of patient care. Any legislative, regulatory or industry changes that slows or limits that movement or otherwise reduces the risk-based healthcare spending would most likely be detrimental to our business, revenue, financial projections and growth.

We are also impacted by the Medicare Access and CHIP Reauthorization Act, under which physicians must choose to participate in one of two payment formulas, the Merit-Based Incentive Payment System (“MIPS”), or Alternative Payment Models (“APMs”). Beginning in 2019, MIPS allows eligible physicians to receive upward or downward adjustments to their Medicare Part B payments based on certain quality and cost metrics, among other measures. As an alternative, physicians can choose to participate in an Advanced APM. Advanced APMs are exempt from the MIPS requirements, and physicians who are meaningful participants in APMs will receive bonus payments from Medicare pursuant to the law. CMS has proposed limiting the number of significant changes to the Quality Payment Program in 2021 by continuing a gradual implementation timeline for MIPS and APMs.

In addition, current and prior healthcare reform proposals have included the concept of creating a single payor or public option for health insurance. If enacted, these proposals could have an extensive impact on the healthcare industry, including us. We are unable to predict whether such reforms may be enacted or their impact on our operations.

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and private payors will pay for healthcare services, which could harm our business, financial condition and results of operations.

If we are unable to effectively adapt to changes in the healthcare industry or changes in state and federal laws and regulations affecting the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our business may be harmed.

-105-

Due to the importance of the healthcare industry in the lives of all Americans, federal, state, and local legislative bodies frequently pass legislation and promulgate regulations relating to healthcare reform or that affect the healthcare industry. As has been the trend in recent years, it is reasonable to assume that there will continue to be increased government oversight and regulation of the healthcare industry in the future. We cannot assure our stockholders as to the ultimate content, timing or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the impact of potential new legislation or regulations on our business. It is possible that future legislation enacted by Congress or state legislatures, or regulations promulgated by regulatory authorities at the federal or state level, could adversely affect our business or could change the operating environment of our medical centers. It is possible that the changes to the Medicare, Medicaid or other governmental healthcare program reimbursements may serve as precedent to possible changes in other payors’ reimbursement policies in a manner adverse to us. Similarly, changes in private payor reimbursements could lead to adverse changes in Medicare, Medicaid and other governmental healthcare programs, which could have a material adverse effect on our business, financial condition and results of operations.

While we believe that we have structured our agreements and operations in material compliance with applicable healthcare laws and regulations, there can be no assurance that we will be able to successfully address changes in the current regulatory environment. We believe that our business operations materially comply with applicable healthcare laws and regulations. However, some of the healthcare laws and regulations applicable to us are subject to limited or evolving interpretations, and a review of our business or operations by a court, law enforcement or a regulatory authority might result in a determination that could have a material adverse effect on us. Furthermore, the healthcare laws and regulations applicable to us may be amended or interpreted in a manner that could have a material adverse effect on our business, prospects, results of operations and financial condition.

Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal and state privacy and security regulations. If we suffer a data breach or unauthorized disclosure, we could incur significant liability including government and private investigations and claims of privacy and security non-compliance. We could also suffer significant reputational harm as a result and, in turn, a material adverse effect on our member base and revenue.

Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of protected health information (“PHI”), and other types of personal data or personally identifiable information (“PII”). These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of PHI by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services.

HIPAA requires covered entities, such as us, and their business associates to develop and maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA also implemented the use of standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including activities associated with the billing and collection of healthcare claims.

HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $100 per violation and, except in certain circumstances, are not to exceed $50,000 per violation, subject to a cap of $1.78 million for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys’ fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.

In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates for compliance with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator.

-106-

HIPAA further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees or authorized individuals. HIPAA specifies that such notifications must be made “without unreasonable delay and in no case later than 60 calendar days after discovery of the breach.” If a breach affects 500 patients or more, it must be reported to HHS without unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS at least annually.

In addition to HIPAA, numerous other federal and state laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. State statutes and regulations vary from state to state, and these laws and regulations in many cases are more restrictive than, and may not be preempted by, HIPAA and its implementing rules. These laws and regulations are often uncertain, contradictory, and subject to changed or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. In the event that new data security laws are implemented, we may not be able to timely comply with such requirements, or such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could subject us to liability for non-compliance. Some states may afford private rights of action to individuals who believe their PII has been misused. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and potentially restricts our ability to collect, use and disclose data and exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, and it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.

We also publish statements to our members and partners that describe how we handle and protect PHI. If federal or state regulatory authorities or private litigants consider any portion of these statements to be untrue, we may be subject to claims of deceptive practices, which could lead to significant liabilities and consequences, including, without limitation, costs of responding to investigations, defending against litigation, settling claims, and complying with regulatory or court orders. Any of the foregoing consequences could seriously harm our business and our financial results. Any of the foregoing consequences could have a material adverse impact on our business and our financial results.

We face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits could have adverse findings that may negatively affect our business, including our results of operations, liquidity, financial condition and reputation.

As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental inspections, reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. Payors may also reserve the right to conduct audits. We also periodically conduct internal audits and reviews of our regulatory compliance. An adverse inspection, review, audit or investigation could result in:

•refunding amounts we have been paid pursuant to the Medicare or Medicaid programs or from payors;

•state or federal agencies imposing fines, penalties and other sanctions on us;

•temporary suspension of payment for new patients to the facility or agency;

•decertification or exclusion from participation in the Medicare or Medicaid programs or one or more payor networks;

•self-disclosure of violations to applicable regulatory authorities;

•damage to our reputation;

-107-

•the revocation of a facility’s or agency’s license; and

•loss of certain rights under, or termination of, our contracts with payors.

We have in the past and will likely in the future be required to refund amounts we have been paid and/or pay fines and penalties as a result of these inspections, reviews, audits and investigations. If adverse inspections, reviews, audits or investigations occur and any of the results noted above occur, it could have a material adverse effect on our business and operating results. Furthermore, the legal, document production and other costs associated with complying with these inspections, reviews, audits or investigations could be significant.

Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties or require a restructuring of our business.

Some states have laws that prohibit business entities, such as us, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians or engaging in certain arrangements, such as fee-splitting, with physicians (such activities generally referred to as the “corporate practice of medicine”). In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. Certain of the states in which we currently operate, such as California, Illinois, Texas and Nevada, and certain of the states to which we may expand our operations, such as New York, generally prohibit the corporate practice of medicine, and other states may enact such restrictions as well.

Penalties for violations of the corporate practice of medicine vary by state and may result in physicians being subject to disciplinary action, as well as to forfeiture of revenues from payors for services rendered. For lay entities, violations may also bring both civil and, in more extreme cases, criminal liability for engaging in medical practice without a license. Some of the relevant laws, regulations and agency interpretations in states with corporate practice of medicine restrictions have been subject to limited judicial and regulatory interpretation. Moreover, state laws are subject to change. Regulatory authorities and other parties may assert that, despite the management agreements and other arrangements through which we operate, we are engaged in the prohibited corporate practice of medicine or that our arrangements constitute unlawful fee-splitting. If this were to occur, we could be subject to civil and/or criminal penalties, our agreements could be found legally invalid and unenforceable (in whole or in part) or we could be required to restructure our contractual arrangements. In markets where the corporate practice of medicine is prohibited, we have historically operated by maintaining long-term management contracts with multiple associated professional organizations which, in turn, employ or contract with physicians to provide those professional medical services required by the enrollees of the payors with which the professional organizations contract. Under these management agreements, our managed services organization performs only non-medical administrative services, does not represent that it offers medical services and does not exercise influence or control over the practice of medicine by the physicians or the associated physician groups with which it contracts. In addition, the professional organizations are all 100% owned by a member of our management team. In the event of death or disability or upon certain other triggering events, we maintain the right to direct the transfer of the ownership of the professional organizations to another licensed physician.

In addition to the above management arrangements, we have certain contractual rights relating to the orderly transfer of equity interests in our physician practices through succession agreements and other arrangements with their physician equity holders. Such equity interests cannot, however, be transferred to or held by us or by any non-professional organization. Accordingly, neither we nor our direct subsidiaries directly own any equity interests in any of our physician practices. In the event that any of the physician owners of our practices fail to comply with the management arrangement, if any management arrangement is terminated and/or we are unable to enforce our contractual rights over the orderly transfer of equity interests in any of our physician practices, such events could have a material adverse effect on our business, results of operations, financial condition and cash flows.

It is possible that a state regulatory agency or a court could determine that our agreements with physician equity holders of our practices and the way we carry out these arrangements as described above, either independently or coupled with the management services agreements with such associated physician practices, are in violation of prohibitions on the corporate practice of medicine. As a result, these arrangements could be deemed invalid, potentially resulting in a loss of revenues and an adverse effect on results of operations derived from such practices. Such a determination could force a restructuring of our management arrangements with the affected practices, which might include revisions of the management services agreements, including a modification of the management fee and/or establishing an alternative structure that would permit us to contract with

-108-

a physician network without violating prohibitions on the corporate practice of medicine. There can be no assurance that such a restructuring would be feasible, or that it could be accomplished within a reasonable time frame without a material adverse effect on our business, results of operations, financial condition and cash flows.

Our records and submissions to a health plan may contain inaccurate or unsupportable information regarding risk adjustment scores of members, which could cause us to overstate or understate our revenue and subject us to various penalties.

The claims and encounter records that we submit to health plans may impact data that support the Medicare Risk Adjustment Factor (“RAF”), scores attributable to members. These RAF scores determine, in part, the revenue to which the health plans and, in turn, we are entitled to the provision of medical care to such members. The data submitted to CMS by each health plan is based, in part, on medical charts and diagnosis codes that we prepare and submit to the health plans. Each health plan generally relies on us and our affiliated physicians to appropriately document and support such RAF data in our medical records. Each health plan also relies on us and our affiliated physicians to appropriately code claims for medical services provided to members. Erroneous claims and erroneous encounter records and submissions could result in inaccurate revenue and risk adjustment payments, which may be subject to correction or retroactive adjustment in later periods. This corrected or adjusted information may be reflected in financial statements for periods subsequent to the period in which the revenue was recorded. We might also need to refund a portion of the revenue that we received, which refund, depending on its magnitude, could damage our relationship with the applicable health plan and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Additionally, CMS audits Medicare Advantage plans for documentation to support RAF-related payments for members chosen at random. The Medicare Advantage plans ask providers to submit the underlying documentation for members that they serve. It is possible that claims associated with members with higher RAF scores could be subject to more scrutiny in a CMS or plan audit. There is a possibility that a Medicare Advantage plan may seek repayment from us should CMS make any payment adjustments to the Medicare Advantage plan as a result of its audits. The plans also may hold us liable for any penalties owed to CMS for inaccurate or unsupportable RAF scores provided by us or our affiliated physicians. In addition, we could be liable for penalties to the government under the FCA that range from $11,665 to $23,331 per false claim or statement (as of June 19, 2020, and subject to annual adjustments for inflation), plus up to three times the amount of damages caused by each false claim, which can be as much as the amounts received directly or indirectly from the government for each such false claim.

CMS has indicated that payment adjustments will not be limited to RAF scores for the specific Medicare Advantage enrollees for which errors are found but may also be extrapolated to the entire Medicare Advantage plan subject to a particular CMS contract. CMS has described its audit process as plan-year specific and stated that it will not extrapolate audit results for plan years prior to 2011. Because CMS has not stated otherwise, there is a risk that payment adjustments made as a result of one plan year’s audit would be extrapolated to prior plan years after 2011.

There can be no assurance that a health plan will not be randomly selected or targeted for review by CMS or that the outcome of such a review will not result in a material adjustment in our revenue and profitability, even if the information we submitted to the plan is accurate and supportable.

New physicians and other providers must be properly enrolled in governmental healthcare programs before we can receive reimbursement for their services, and there may be delays in the enrollment process.

Each time a new physician joins us, we must enroll the physician under our applicable group identification number for Medicare and Medicaid programs and for certain managed care and private insurance programs before we can receive reimbursement for services the physician renders to beneficiaries of those programs. The estimated time to receive approval for the enrollment is sometimes difficult to predict. These practices result in delayed reimbursement that may adversely affect our cash flows.

With respect to Medicare, providers can retrospectively bill Medicare for services provided 30 days prior to the effective date of the enrollment. In addition, the enrollment rules provide that the effective date of the enrollment will be the later of the date on which the enrollment application was filed and approved by the Medicare contractor, or the date on which the provider began providing services. If we are unable to properly enroll physicians and other applicable healthcare professionals within the 30 days after the provider begins providing services, we will be precluded from billing Medicare for any services which were

-109-

provided to a Medicare beneficiary more than 30 days prior to the effective date of the enrollment. With respect to Medicaid, new enrollment rules and whether a state will allow providers to retrospectively bill Medicaid for services provided prior to submitting an enrollment application varies by state. Failure to timely enroll providers could reduce our physician services segment total revenues and have a material adverse effect on the business, financial condition or results of operations of our physician services segment.

The ACA, as currently structured, added additional enrollment requirements for Medicare and Medicaid, which have been further enhanced through implementing regulations and increased enforcement scrutiny. Every enrolled provider must revalidate its enrollment at regular intervals and must update the Medicare contractors and many state Medicaid programs with significant changes on a timely basis. If we fail to provide sufficient documentation as required to maintain our enrollment, Medicare and Medicaid could deny continued future enrollment or revoke our enrollment and billing privileges.

The requirements for enrollment, licensure, certification, and accreditation may include notification or approval in the event of a transfer or change of ownership or certain other changes. Other agencies or payors with which we have contracts may have similar requirements, and some of these processes may be complex. Failure to provide required notifications or obtain necessary approvals may result in the delay or inability to complete an acquisition or transfer, loss of licensure, lapses in reimbursement, or other penalties. While we make reasonable efforts to substantially comply with these requirements, we cannot assure you that the agencies that administer these programs or have awarded us contracts will not find that we have failed to comply in some material respects. A finding of non-compliance and any resulting payment delays, refund demands or other sanctions could have a material adverse effect on our business, financial condition or results of operations.

Risks Related to Competition

The healthcare industry is highly competitive, and if we are not able to compete effectively, our business would be harmed.

We compete directly with national, regional and local providers of healthcare for members and physicians. There are many other companies and individuals currently providing healthcare services, many of which have been in business longer and/or have substantially more resources. There have been increased trends towards consolidation and vertical integration in the healthcare industry, including an influx of additional capital. Since there are virtually no substantial capital expenditures required for providing healthcare services, there are few financial barriers to entry in the healthcare industry. Other companies could enter the healthcare industry in the future and divert some or all of our business. Our ability to compete successfully varies from location to location and depends on a number of factors, including the number of competing primary care facilities in the local market and the types of services available at those facilities, our local reputation for quality care of members, the commitment and expertise of our medical staff, our local service offerings and community programs, the cost of care in each locality, and the physical appearance, location, age and condition of our facilities. If we are unable to attract members to our medical centers, our revenue and profitability will be adversely affected. Some of our competitors may have greater recognition and be more established in their respective communities than we are, and may have greater financial and other resources than we have. Competing primary care providers may also offer larger facilities or different programs or services than we do, which, combined with the foregoing factors, may result in our competitors being more attractive to our current members, potential members and referral sources. Furthermore, while we budget for routine capital expenditures at our facilities to keep them competitive in their respective markets, to the extent that competitive forces cause those expenditures to increase in the future, our financial condition may be negatively affected. In addition, our relationships with governmental and private third-party payors are not exclusive and our competitors have established or could seek to establish relationships with such payors to serve their covered patients. Additionally, as we expand into new geographies, we may encounter competitors with stronger relationships or recognition in the community in such new geography, which could give those competitors an advantage in obtaining new patients. Individual physicians, physician groups and companies in other healthcare industry segments, including those with which we have contracts, and some of which have greater financial, marketing and staffing resources, may become competitors in providing health care services, and this competition may have a material adverse effect on our business operations and financial position. In addition, established competitors in new markets (or new lines of business) may seek to increase competitive marketing, enrollment and recruiting practices in an effort to disrupt or slow our successful market entry. Such increased competitive activity could lead to competitive marketing and recruiting that could drive up the costs of entry and vigorous enforcement of contractual rights (e.g., non-compete agreements, etc.) that could impair our growth and increase the number lawsuits which could have a material adverse effect on our business, financial condition or results of operations.

Our performance depends on our ability to recruit and retain quality physicians, nurses and other personnel. Competitors in primary care markets may aggressively employ non-compete, non-solicitation and other restrictive covenant tools to chill the

-110-

entry of new operators. Competition for or shortages in quality physicians, nurses and other personnel, increases in labor costs or expiration of non-compete, non-solicitation and other restrictive covenants with past, present or future employees could adversely affect our revenue, profitability, cash flows, quality of care and member enrollment.

Our operations are dependent on the efforts, abilities and experience of our physicians and clinical personnel. We compete with other healthcare providers, primarily hospitals and other facilities, in attracting physicians, nurses and medical staff to support our medical centers, recruiting and retaining qualified management and support personnel responsible for the daily operations of each of our medical centers and in contracting with payors in each of our markets. Competitors in primary care markets may aggressively employ non-compete, non-solicitation and other restrictive covenant tools to chill the entry of new operators. In some markets, the lack of availability of clinical personnel, such as nurses and mental health professionals, has become a significant operating issue facing all healthcare providers. This shortage may require us to continue to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. We also depend on the available labor pool of semi-skilled and unskilled workers in each of the markets in which we operate.

Key primary care physicians with large member enrollment could retire, become disabled, terminate their provider contracts, get lured away by a competing independent physician association or medical group, or otherwise become unable or unwilling to continue practicing medicine or continue working with us. As a result, members who have been served by such physicians could choose to enroll with competitors’ physician organizations or could seek medical care elsewhere, which could reduce our revenues and profits. Moreover, we may not be able to attract new physicians to replace the services of terminating physicians or to service our growing membership.

We have employment contracts with physicians and other health professionals in many states. Some of these contracts include provisions preventing these physicians and other health professionals from competing with us both during and after the term of our contract with them. The law governing non-compete agreements and other forms of restrictive covenants varies from state to state. Some jurisdictions prohibit us from using non-competition covenants with our professional staff. Other states are reluctant to strictly enforce non-compete agreements and restrictive covenants applicable to physicians and other healthcare professionals. There can be no assurance that our non-compete agreements related to physicians and other health professionals will be found enforceable if challenged in certain states. In such event, we would be unable to prevent physicians and other health professionals formerly employed by us from competing with us, potentially resulting in the loss of some of our members.

If our labor costs increase, we may not be able to raise rates to offset these increased costs. Because a significant percentage of our revenue consists of fixed, prospective payments, our ability to pass along increased labor costs is limited. In particular, if labor costs rise at an annual rate greater than our net annual consumer price index basket update from Medicare, our results of operations and cash flows will likely be adversely affected. Any union activity at our facilities that may occur in the future could contribute to increased labor costs. Certain proposed changes in federal labor laws and the National Labor Relations Board’s modification of its election procedures could increase the likelihood of employee unionization attempts. Although none of our employees are currently represented by a collective bargaining agreement, to the extent a significant portion of our employee base unionizes, it is possible our labor costs could increase materially. Our failure to recruit and retain qualified management and medical personnel, or to control our labor costs, could have a material adverse effect on our business, prospects, results of operations and financial condition.

If we fail to cost-effectively develop widespread brand awareness and maintain our reputation, or if we fail to achieve and maintain market acceptance for our healthcare services, our business could suffer.

We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with both members and payors and to our ability to attract new members. The promotion of our brand may require us to make substantial investments and we anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of or provide quality medical care for our members, or any adverse publicity or litigation involving or surrounding us, one of our medical centers or our management, could make it substantially more difficult for us to attract new members. Similarly, because our existing members often act as references for us with prospective new members, any existing member that questions the quality of our care could impair our ability to secure additional new members. In addition, negative publicity resulting from any adverse government payor audit could injure our reputation. If we do not successfully maintain and

-111-

enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with members, which would harm our business, results of operations and financial condition.

The registered or unregistered trademarks or trade names that we own or license may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with members, payors and other partners. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to promote our business in certain relevant jurisdictions. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our brand recognition, reputation and results of operations may be adversely affected.

Our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems.

Our business is highly dependent on maintaining effective information systems as well as the integrity and timeliness of the data we use to serve our members, support our care teams and operate our business. Because of the large amount of data that we collect and manage, it is possible that hardware failures or errors in our systems could result in data loss or corruption or cause the information that we collect to be incomplete or contain inaccuracies that our partners regard as significant. If our data were found to be inaccurate or unreliable due to fraud or other error, or if we, or any of the third-party service providers we engage, were to fail to maintain information systems and data integrity effectively, we could experience operational disruptions that may impact our members and care teams and hinder our ability to provide services, establish appropriate pricing for services, retain and attract members, manage our member risk profiles, establish reserves, report financial results timely and accurately and maintain regulatory compliance, among other things.

Our information technology strategy and execution are critical to our continued success. We must continue to invest in long-term solutions that will enable us to anticipate member needs and expectations, enhance the member experience, act as a differentiator in the market and protect against cybersecurity risks and threats. Our success is dependent, in large part, on maintaining the effectiveness of existing technology systems and continuing to deliver and enhance technology systems that support our business processes in a cost-efficient and resource-efficient manner. Increasing regulatory and legislative changes will place additional demands on our information technology infrastructure that could have a direct impact on resources available for other projects tied to our strategic initiatives. In addition, recent trends toward greater patient engagement in health care require new and enhanced technologies, including more sophisticated applications for mobile devices. Connectivity among technologies is becoming increasingly important. We must also develop new systems to meet current market standards and keep pace with continuing changes in information processing technology, evolving industry and regulatory standards and patient needs. Failure to do so may present compliance challenges and impede our ability to deliver services in a competitive manner. Further, because system development projects are long-term in nature, they may be more costly than expected to complete and may not deliver the expected benefits upon completion. Our failure to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems could adversely affect our results of operations, financial position and cash flow.

Risks Related to Data Security and Intellectual Property

Our proprietary platform relies on third-party vendors, and disruptions in those relationships or other failures of our platform could damage our reputation, give rise to claims against us or divert the application of our resources from other purposes, any of which could harm our business.

CanoPanorama, our proprietary population health management technology-powered platform, contains components developed and maintained by third-party software vendors. Moreover, we use a third-party cloud-based electronic health record management system. The ability of these third-party suppliers to successfully provide reliable and high-quality services is subject to technical and operational uncertainties that are beyond our control. We may not be able to replace the functions provided by the third-party software currently used in CanoPanorama if that software becomes obsolete or defective or is not adequately maintained or updated. We may not be able to maintain our relationships with our third-party software vendors. Any significant interruption in the availability of these third-party software products or defects in these products could harm our business unless and until we can secure or develop an alternative source. In the event of failure in such third-party vendors’ systems and

-112-

processes, we could experience business interruptions or privacy and/or security breaches surrounding our data. Any of these outcomes could damage our reputation, give rise to claims against us or divert the application of our resources from other purposes, any of which could harm our business.

Data security breaches, loss of data and other disruptions could compromise sensitive information related to our business or our members, or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.

In the ordinary course of our business, we collect, store, use and disclose sensitive data, including PHI and other types of PII relating to our employees, members and others. We also process and store, and use third-party service providers to process and store, sensitive information, including intellectual property, confidential information and other proprietary business information. We manage and maintain such sensitive data and information utilizing a combination of on-site systems, managed data center systems and cloud-based computing center systems.

We are highly dependent on information technology networks and systems, including the internet, to securely process, transmit and store this sensitive data and information. Security breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches, and employee or contractor error, negligence or malfeasance, can create system disruptions, shutdowns or unauthorized disclosure or modifications of such sensitive data or information, causing PHI or other PII to be accessed or acquired without authorization or to become publicly available. We utilize third-party service providers for important aspects of the collection, storage, processing and transmission of employee, user and member information, and other confidential and sensitive information, and therefore rely on third parties to manage functions that have material cybersecurity risks. Because of the sensitivity of the PHI, other PII and other sensitive information that we and our service providers collect, store, transmit, and otherwise process, the security of our technology platform and other aspects of our services, including those provided or facilitated by our third-party service providers, are important to our operations and business strategy. We take certain administrative, physical and technological safeguards to address these risks, such as requiring contractors and other third-party service providers who handle this PHI, other PII and other sensitive information to enter into agreements that contractually obligate them to use reasonable efforts to safeguard such PHI, other PII, and other sensitive information. Measures taken to protect our systems, those of our contractors or third-party service providers, or the PHI, other PII, or other sensitive information we or contractors or third-party service providers process or maintain, may not adequately protect us from the risks associated with the collection, storage, processing and transmission of such sensitive data and information. We may be required to expend significant capital and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures, cyber-attacks are becoming more sophisticated and frequent. As a result, we or our third-party service providers may be unable to anticipate these techniques or implement adequate protective measures.

A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that prevents access to or otherwise impacts the confidentiality, security, or integrity of, member information, including PHI or other PII, or other sensitive information that we or our contractors or third-party service providers maintain or otherwise process, could harm our reputation, compel us to comply with breach notification laws, cause us to incur significant costs for remediation, fines, penalties, notification to individuals and for measures intended to repair or replace systems or technology and to prevent future occurrences, potential increases in insurance premiums, and require us to verify the accuracy of database contents, resulting in increased costs or loss of revenue. While we have not experienced any material system failure, accident or security breach to-date of which we are aware, we nevertheless have experienced from time to time, and continue to experience in the future, cyber-attacks on our information technology systems despite our best efforts to prevent them. For instance, in June 2020, we disclosed to the public a data breach resulting from a business email compromise by an unknown threat actor that affected Office 365 email accounts of certain employees. As some of the affected email inboxes contained PHI or PII, we notified all potentially affected individuals and the HHS Office of Civil Rights (“OCR”). In December 2020, we received a data request from OCR relating to this incident, to which we responded. In June 2021, OCR notified us that it has closed this inquiry with no findings. In addition, a class action lawsuit related to this incident was filed against us in the Miami-Dade County Court of the State of Florida. Our insurance carrier has reached a settlement with the class action plaintiffs and the settlement was approved by the Miami-Dade County Court at a hearing held on July 1, 2021. We may be subject to financial or reputational loss as a result of this data security incident.

If we are unable to prevent or mitigate such security breaches or privacy violations or implement satisfactory remedial measures, or if it is perceived that we have been unable to do so, our operations could be disrupted, we may be unable to provide access to our systems, we could suffer a loss of members and we may as a result suffer loss of reputation, adverse impacts on

-113-

member and investor confidence, financial loss, governmental investigations or other actions, regulatory or contractual penalties, and other claims and liability. In addition, security breaches and other inappropriate access to, or acquisition or processing of, information can be difficult to detect, and any delay in identifying such incidents or in providing any notification of such incidents may lead to increased harm.

Any such breach or interruption of our systems or those of any of our third-party service providers could compromise our networks or data security processes and sensitive information could be made inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption in access, improper access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws and regulations that protect the privacy of member information or other personal information, such as HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (HITECH) Act, and their implementing regulations and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to perform our services, access member health information, collect, process, and prepare company financial information, provide information about our current and future services and engage in other member and clinician education and outreach efforts. Any such breach could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our business and competitive position. While we maintain insurance that covers certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident.

Disruptions in our disaster recovery systems or management continuity planning could limit our ability to operate our business effectively.

Our information technology systems facilitate our ability to conduct our business. While we have disaster recovery systems and business continuity plans in place, any disruptions in our disaster recovery systems or the failure of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations. Despite our implementation of a variety of security measures, our information technology systems could be subject to physical or electronic break-ins, and similar disruptions from unauthorized tampering or any weather-related disruptions where our headquarters are located. In addition, in the event that a significant number of our management personnel are unavailable in the event of a disaster, our ability to effectively conduct business could be adversely affected.

If we are unable to obtain, maintain and enforce intellectual property protection for our content or if the scope of our intellectual property protection is not sufficiently broad, our business may be adversely affected.

Our business depends on certain internally developed content, including software, databases, confidential information and know-how, the protection of which is crucial to the success of our business. We rely on a combination of trademark, trade-secret, and copyright laws and confidentiality procedures and contractual provisions to protect our intellectual property rights in our internally developed content. We may, over time, increase our investment in protecting our intellectual property through additional trademark, patent and other intellectual property filings that could be expensive and time-consuming. Effective trademark, trade-secret and copyright protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of defending our rights. These measures, however, may not be sufficient to offer us meaningful protection. Additionally, we do not currently hold a patent or other registered or applied for intellectual property protection for CanoPanorama. If we are unable to protect our intellectual property and other rights, particularly with respect to CanoPanorama, our competitive position and our business could be harmed, as third parties may be able to commercialize and use technologies and software products that are substantially the same as ours without incurring the development and licensing costs that we have incurred. Any of our owned or licensed intellectual property rights could be challenged, invalidated, circumvented, infringed or misappropriated, our trade secrets and other confidential information could be disclosed in an unauthorized manner to third parties, or our intellectual property rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide us with competitive advantages, which could result in costly redesign efforts, discontinuance of certain offerings or other competitive harm.

Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors’ services, and may in the future seek to enforce our rights against potential infringement. However, the steps we have taken to protect our intellectual property rights may not be adequate to prevent infringement or misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual

-114-

property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our services. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms, or at all.

Uncertainty may result from changes to intellectual property legislation and from interpretations of intellectual property laws by applicable courts and agencies. Accordingly, despite our efforts, we may be unable to obtain and maintain the intellectual property rights necessary to provide us with a competitive advantage. Our failure to obtain, maintain and enforce our intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business, financial condition and results of operations.

Our commercial success depends on our ability to develop and commercialize our services and use our proprietary technology platform without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. As the market for healthcare in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our technology platform of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our vendors or licensors or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties. Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. It may be necessary for us to initiate litigation to defend ourselves in order to determine the scope, enforceability and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. We may not be able to successfully settle or otherwise resolve such adversarial proceedings or litigation. If we are unable to successfully settle future claims on terms acceptable to us we may be required to engage in or to continue claims, regardless of whether such claims have merit, which can be time-consuming, divert management’s attention and financial resources and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our technology platform, obtain licenses, modify our services and technology platform while we develop non-infringing substitutes or incur substantial damages, settlement costs or face a temporary or permanent injunction prohibiting us from marketing or providing the affected services. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, service fees, upfront fees or grant cross-licenses to intellectual property rights for our services. We may also have to redesign our services so they do not infringe on third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology platform may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology, license the technology on reasonable terms or obtain similar technology from another source, our revenue and earnings could be adversely impacted.

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. We are not currently subject to any claims from third parties asserting infringement of their intellectual property rights. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our securities. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.

If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary and internally developed information, the value of our technology platform could be adversely affected.

-115-

We may not be able to adequately protect our trade secrets, know-how and other internally developed information, including in relation to the CanoPanorama platform. Although we use reasonable efforts to protect this internally developed information and technology platform, our employees, consultants and other parties (including independent contractors and companies with which we conduct business) may unintentionally or willfully disclose our information or technology to competitors. Enforcing a claim that a third party illegally disclosed or obtained and is using any of our internally developed information or technology is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets, know-how and other proprietary information. We rely, in part, on non-disclosure and confidentiality agreements with our employees, independent contractors, consultants and companies with which we conduct business to protect our trade secrets, know-how and other intellectual property and internally developed information. These agreements may not be self-executing, or they may be breached and we may not have adequate remedies for such breaches. Moreover, third parties may independently develop similar or equivalent proprietary information or otherwise gain access to our trade secrets, know-how and other internally developed information.

Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.

We depend upon licenses from third parties for components of the technology and data used in CanoPanorama and for the platform upon which CanoPanorama is built and operates. We expect that we may need to obtain additional licenses from third parties in the future in connection with the development of our services. In addition, we obtain a portion of the data that we use from government entities, public records and our partners for specific partner engagements. We believe that we have all rights necessary to use the data that is incorporated into our services. We cannot, however, assure you that our licenses for information will allow us to use that information for all potential or contemplated applications. In addition, our ability to continue to offer integrated healthcare to our members depends on maintaining CanoPanorama, which is partially populated with data disclosed to us by our affiliates with their consent. If these affiliates revoke their consent for us to maintain, use, de-identify and share this data, consistent with applicable law, our data assets could be degraded.

In the future, data providers could withdraw their data from us or restrict our usage for any reason, including if there is a competitive reason to do so, if legislation is passed restricting the use of the data or if judicial interpretations are issued restricting use of the data that we currently use to support our services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide appropriate services to our members would be materially adversely impacted, which could have a material adverse effect on our business, financial condition and results of operations.

We also integrate our internally developed applications and use third-party software to support our technology infrastructure. Some of this software is proprietary and some is open source software. These technologies may not be available to us in the future on commercially reasonable terms, or at all, and could be difficult to replace once integrated into our own internally developed applications. Most of these licenses can be renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.

Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including but not limited to risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own internally developed technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.

We have in the past and may in the future be subject to legal proceedings and litigation, including intellectual property, privacy and medical malpractice disputes, which are costly to defend and could materially harm our business and results of operations.

-116-

We may be party to lawsuits and legal proceedings in the normal course of business. These matters are often expensive and disruptive to normal business operations. We may face allegations, lawsuits and regulatory inquiries, audits and investigations regarding data privacy, security, labor and employment, consumer protection and intellectual property infringement, including claims related to privacy, patents, publicity, trademarks, copyrights and other rights. We may also face allegations or litigation related to our acquisitions, securities issuances or business practices, including public disclosures about our business. Litigation and regulatory proceedings may be protracted and expensive, and the results are difficult to predict. Certain of these matters may include speculative claims for substantial or indeterminate amounts of damages and include claims for injunctive relief. Additionally, our litigation costs could be significant. Adverse outcomes with respect to litigation or any of these legal proceedings may result in significant settlement costs or judgments, penalties and fines, or require us to modify our services or require us to stop serving certain members or geographies, all of which could negatively impact our geographic expansion and revenue growth. We may also become subject to periodic audits, which would likely increase our regulatory compliance costs and may require us to change our business practices, which could negatively impact our revenue growth. Managing legal proceedings, litigation and audits, even if we achieve favorable outcomes, is time-consuming and diverts management’s attention from our business.

The results of regulatory proceedings, litigation, claims, and audits cannot be predicted with certainty, and determining reserves for pending litigation and other legal, regulatory and audit matters requires significant judgment. There can be no assurance that our expectations will prove correct, and even if these matters are resolved in our favor or without significant cash settlements, these matters, and the time and resources necessary to litigate or resolve them, could harm our reputation, business, financial condition, results of operations and the market price of our securities.

We also may be subject to lawsuits under the FCA and comparable state laws for submitting allegedly fraudulent or otherwise inappropriate bills for services to the Medicare and Medicaid programs. These lawsuits, which may be initiated by government authorities as well as private party relators, can involve significant monetary damages, fines, attorney fees and the award of bounties to private plaintiffs who successfully bring these suits, as well as to the government programs. In recent years, government oversight and law enforcement have become increasingly active and aggressive in investigating and taking legal action against potential fraud and abuse.

Furthermore, our business exposes us to potential medical malpractice, professional negligence or other related actions or claims that are inherent in the provision of healthcare services. These claims, with or without merit, could cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business, harm our reputation and adversely affect our ability to attract and retain members, any of which could have a material adverse effect on our business, financial condition and results of operations.

Although we maintain third-party directors’ and officers’ professional liability insurance coverage, it is possible that claims against us may exceed the coverage limits of our insurance policies. Even if any professional liability loss is covered by an insurance policy, these policies typically have substantial deductibles for which we are responsible. Professional liability claims in excess of applicable insurance coverage could have a material adverse effect on our business, financial condition and results of operations. In addition, any professional liability claim brought against us, with or without merit, could result in an increase of our professional liability insurance premiums. Insurance coverage varies in cost and can be difficult to obtain, and we cannot guarantee that we will be able to obtain insurance coverage in the future on terms acceptable to us or at all. If our costs of insurance and claims increase, then our earnings could decline.

Risks Related to Our Indebtedness

Our existing indebtedness could adversely affect our business and growth prospects.

Our existing indebtedness, or any additional indebtedness we may incur, could require us to divert funds identified for other purposes for debt service and impair our liquidity position. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our indebtedness, dispose of assets or issue equity to obtain necessary funds. We do not know whether we will be able to take any of these actions on a timely basis, on terms satisfactory to us or at all.

Our current and future levels of indebtedness and the cash flow needed to satisfy our indebtedness have important consequences, including:

-117-

•limiting funds otherwise available for financing our working capital, capital expenditures, acquisitions, investments and other general corporate purposes by requiring us to dedicate a portion of our cash flows from operations to the repayment of indebtedness and the interest on this indebtedness;

•making it more difficult for us to satisfy our obligations with respect to our indebtedness;

•increasing our vulnerability to general adverse economic and industry conditions;

•exposing us to the risk of increased interest rates as certain of our borrowings are at variable rates of interest;

•limiting our flexibility in planning for and reacting to changes in the industry in which we compete; and

•making us more vulnerable in the event of a downturn in our business.

Our level of indebtedness may place us at a competitive disadvantage to our competitors that are not as highly leveraged. Fluctuations in interest rates can increase borrowing costs. Increases in interest rates may directly impact the amount of interest we are required to pay and reduce earnings accordingly. In addition, developments in tax policy, such as the disallowance of tax deductions for interest paid on outstanding indebtedness, could have an adverse effect on our liquidity and our business, financial conditions and results of operations.

A substantial portion of our indebtedness, including the indebtedness under the Credit Agreement, is floating rate debt. As a result, an increase in interest rates generally would adversely affect our profitability. We may enter into pay-fixed interest rate swaps to limit our exposure to changes in floating interest rates. Such instruments may result in economic losses should interest rates decline to a point lower than our fixed rate commitments. We would be exposed to credit-related losses, which could impact the results of operations in the event of fluctuations in the fair value of the interest rate swaps due to a change in the creditworthiness or non-performance by the counterparties to the interest rate swaps.

We will be able to incur substantial additional indebtedness in the future. Although the agreements governing our existing indebtedness contain restrictions on the incurrence of additional indebtedness, these restrictions are subject to several significant qualifications and exceptions and, under certain circumstances, the amount of indebtedness that could be incurred in compliance with these restrictions could be substantial.

We expect to use cash flow from operations to meet current and future financial obligations, including funding our operations, indebtedness service requirements and capital expenditures. The ability to make these payments depends on our financial and operating performance, which is subject to prevailing economic, industry and competitive conditions and certain financial, business, economic and other factors beyond our control.

We may not be able to generate sufficient cash flow to service all of our indebtedness, and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.

Our ability to make scheduled payments or to refinance outstanding indebtedness obligations depends on our financial and operating performance, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. We may not be able to maintain a sufficient level of cash flow from operating activities to permit us to pay the principal, premium, if any, and interest on our indebtedness. Any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in penalties or defaults, which would also harm our ability to incur additional indebtedness.

If our cash flows and capital resources are insufficient to fund our indebtedness service obligations, we may be forced to reduce or delay capital expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Our ability to restructure or refinance our indebtedness will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants that could further restrict our business operations. These alternative measures may not be successful and may not permit us to meet our scheduled indebtedness service obligations. In the absence of such cash flows and resources, we could face substantial liquidity problems and might be required to sell material assets or operations to attempt to meet our indebtedness service obligations. If we cannot meet our indebtedness service obligations, the holders of our indebtedness may accelerate such

-118-

indebtedness, terminate their commitments to make additional loans, cease to make further loans, and, to the extent such indebtedness is secured, foreclose on our assets and we could be forced into bankruptcy or liquidation. In such an event, we may not have sufficient assets to repay all of our indebtedness.

We may be unable to refinance our indebtedness.

We may need to refinance all or a portion of our indebtedness before maturity. We cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all. There can be no assurance that we will be able to obtain sufficient funds to enable us to repay or refinance our debt obligations on commercially reasonable terms, or at all.

The terms of the Credit Agreement and the Indenture restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.

The Credit Agreement and the Indenture contain a number of restrictive covenants that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in our long-term best interests, including restrictions on our ability to:

•incur or guarantee additional indebtedness;

•incur liens;

•pay dividends and distributions on, or redeem, repurchase or retire our capital stock;

•make investments, acquisitions, loans, or advances;

•engage in mergers, consolidations, liquidations or dissolutions;

•sell, transfer or otherwise dispose of assets, including capital stock of subsidiaries;

•engage in certain transactions with affiliates;

•change of the nature of our business;

•prepay, redeem or repurchase certain indebtedness; and

•designate restricted subsidiaries as unrestricted subsidiaries.

Under certain circumstances, the restrictive covenants in the Credit Agreement require us to satisfy certain financial maintenance tests. Our ability to satisfy those tests can be affected by events beyond our control.

As a result of the restrictions described above, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants.

A breach of the covenants or restrictions under the Credit Agreement or the Indenture could result in an event of default thereunder. Such a default may allow the creditors to accelerate the related debt, which may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. In the event the holders of our indebtedness accelerate the repayment, we may not have sufficient assets to repay that indebtedness or be able to borrow sufficient funds to refinance it. Even if we are able to obtain new financing, it may not be on commercially reasonable terms or on terms acceptable to us. As a result of these restrictions, we may be:

•limited in how we conduct our business;

-119-

•unable to raise additional debt or equity financing to operate during general economic or business downturns; or

•unable to compete effectively or to take advantage of new business opportunities.

These restrictions, along with restrictions that may be contained in agreements evidencing or governing other future indebtedness, may affect our ability to grow in accordance with our growth strategy.

Any future credit facilities or debt instruments we may issue will likely contain similar, or potentially more expansive, events of default as compared to those set forth in the terms of the Credit Agreement, including those breaches or defaults with respect to any of our other outstanding debt instruments. All borrowings under the Revolving Credit Facility will be secured by a first priority pledge of and security interests in substantially all of our assets and any indebtedness we incur in the future may also be so secured.

A decline in our operating results or available cash could cause us to experience difficulties in complying with covenants contained in the Credit Agreement, which could result in our bankruptcy or liquidation.

If we were to sustain a decline in our operating results or available cash, we could experience difficulties in complying with the financial covenants contained in the Credit Agreement. The failure to comply with such covenants could result in an event of default under the Credit Agreement and by reason of cross-acceleration or cross-default provisions, other indebtedness may then become immediately due and payable. In addition, should an event of default occur, the lenders under the Credit Agreement could elect to terminate their commitments thereunder, cease making loans and institute foreclosure proceedings against our assets, and we could be forced into bankruptcy or liquidation. If our operating performance declines, we may in the future need to obtain waivers from the required lenders under our facilities or lines of credit to avoid being in default. If we breach our covenants under the Credit Agreement and seek a waiver, we may not be able to obtain a waiver from the required lenders. If this occurs, we would be in default under the Credit Agreement, the lenders could exercise their rights, as described above, and we could be forced into bankruptcy or liquidation.

The terms of the Credit Agreement and the indenture governing the Senior Notes restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.

The Credit Agreement and the indenture contain a number of restrictive covenants that impose significant operating and financial restrictions on us and may limit our ability to engage in acts that may be in our long-term best interests, including restrictions on our ability to:

•pay certain dividends on, repurchase, or make distributions in respect of capital stock or make other restricted payments;

•issue or sell capital stock of restricted subsidiaries;

•guarantee certain indebtedness;

•make certain investments;

•sell or exchange certain assets;

•enter into transactions with affiliates;

•create certain liens; and

•consolidate, merge, or transfer all or substantially all of our assets and the assets of our subsidiaries on a consolidated basis.

As a result of these covenants, we are limited in the manner in which we conduct our business, and we may be unable to raise additional debt or equity financing to operate during general economic or business downturns, engage in favorable business activities or finance future operations or capital needs or compete effectively or take advantage of new business opportunities. These restrictions may also hinder our ability to grow in accordance with our strategy.

-120-

As a result of the restrictions described above, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants.

A breach of the covenants or restrictions under the Credit Agreement or the indenture could result in an event of default under such document. Such a default may allow the creditors to accelerate the related debt, which may result in the acceleration of any other debt to which a cross-acceleration or cross-default provision applies. In the event the holders of our indebtedness accelerate the repayment, we may not have sufficient assets to repay that indebtedness or be able to borrow sufficient funds to refinance it. Even if we are able to obtain new financing, it may not be on commercially reasonable terms or on terms acceptable to us. As a result of these restrictions, we may be:

•limited in how we conduct our business;

•unable to raise additional debt or equity financing to operate during general economic or business downturns; or

•unable to compete effectively or to take advantage of new business opportunities.

These restrictions, along with restrictions that may be contained in agreements evidencing or governing other future indebtedness, may affect our ability to grow in accordance with our growth strategy.

Any future credit facilities or debt instruments we may issue will likely contain similar, or potentially more expansive, events of default as compared to those set forth in the terms of the Credit Agreement and the indenture governing the Senior Notes, including those breaches or defaults with respect to any of our other outstanding debt instruments.

Despite our substantial indebtedness, we are still able to incur significant additional amounts of debt.

We may be able to incur substantial additional indebtedness in the future. The Credit Agreement and the indenture governing the Senior Notes contain restrictions on the incurrence of additional indebtedness. However, these restrictions are subject to a number of significant qualifications and exceptions, and under certain circumstances, the amount of indebtedness that could be incurred in compliance with these restrictions could be substantial. Accordingly, we may be able to incur substantial additional indebtedness in the future.

If new debt is added to our existing debt levels, the related risks that we now face would increase. In addition, the Credit Agreement and the indenture governing the Senior Notes will not prevent us from incurring obligations that do not constitute indebtedness under those agreements, such as certain obligations to trade creditors.

Risks Related to Being a Public Company

InTandem has significant influence over us and its interests may conflict with ours or yours.

For so long as the investment entities affiliated with InTandem (the “Lead Investor”) continue to own a significant percentage of our stock, the Lead Investor will be able to significantly influence the composition of our Board and the approval of actions requiring shareholder approval. Accordingly, for such period of time, the Lead Investor will have significant influence with respect to our management, business plans and policies, including the appointment and removal of our officers, decisions on whether to raise future capital and amending our Certificate of Incorporation and Bylaws. In particular, for so long as the Lead Investor continues to own a significant percentage of our stock, the Lead Investor will be able to cause or prevent a change of control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of us. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares of Securities as part of a sale of us and ultimately might affect the market price of our Securities

-121-

The Lead Investor and its affiliates engage in a broad spectrum of activities, including investments in the healthcare industry generally. In the ordinary course of their business activities, the Lead Investor and its affiliates may engage in activities where their interests conflict with our interests or those of our other shareholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or businesses that are suppliers or customers of ours. In addition, the Lead Investor may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks to you.

The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an “emerging growth company.”

As a public company, we will incur legal, accounting and other expenses that we did not previously incur. We are subject to the reporting requirements of the Exchange Act, and the Sarbanes-Oxley Act, the listing requirements of the New York Stock Exchange and other applicable securities rules and regulations. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an “emerging growth company.” The Exchange Act requires that we file annual, quarterly and current reports with respect to our business, financial condition and results of operations. The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal controls and procedures for financial reporting. Furthermore, the need to establish the corporate infrastructure demanded of a public company may divert our management’s attention from implementing our growth strategy, which could prevent us from improving our business, financial condition and results of operations. We have made, and will continue to make, changes to our internal controls and procedures for financial reporting and accounting systems to meet our reporting obligations as a public company. However, the measures we take may not be sufficient to satisfy our obligations as a public company. In addition, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. These additional obligations could have a material adverse effect on our business, financial condition and results of operations.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations.

Our management team has limited experience managing a public company.

Most members of our management team have limited or no experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage us as a public company that is subject to significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, results of operations and financial condition.

Our independent registered public accountants have identified a number of material weaknesses in our internal controls over financial reporting. If we are unable to remediate the material weaknesses, or if other control deficiencies are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner.

-122-

Our independent registered public accountants have identified a number of material weaknesses in our internal controls over financial reporting. A “material weakness” is a deficiency, or a combination of deficiencies, in internal controls over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The material weaknesses that were identified were as follows:

•We failed to establish controls to ensure the completeness and accuracy of information used to estimate and record certain accruals or make other closing adjustments in the financial statement close process.

•We failed in the process of accounting for business combinations related to the design and operation of controls to record and measure the identifiable assets acquired, the liabilities assumed and any non-controlling interests recognized as part of a business combination.

•Jaws failed in the process of accounting for a significant and unusual transaction related to the warrants it issued in connection with its initial public offering in May 2020, which resulted in a material misstatement of our warrant liabilities, transaction costs, change in fair value of warrant liabilities, additional paid-in capital, accumulated deficit and related financial disclosures for the year ended December 31, 2020 and unaudited quarterly financial information as of and for the three and six months ended June 30, 2020 and three and nine months ended September 30, 2020.

•Furthermore, we did not have a sufficient complement of personnel with an appropriate level of knowledge, experience, and oversight commensurate with their financial reporting requirements to ensure proper selection and application of U.S. GAAP.

We have begun to take steps to remediate the material weaknesses, and to further strengthen our accounting staff and internal controls, by temporarily engaging external accounting and risk and control experts with the appropriate knowledge to supplement our internal resources. We plan to take additional steps to remediate the material weaknesses and improve our accounting function, including:

•hiring additional senior level and staff accountants to support the timely completion of financial close procedures and provide additional needed technical expertise;

•in the interim, continuing to engage third parties as required to assist with technical accounting, application of new accounting standards, tax matters and valuations and the technical accounting associated with business combinations resulting from potential future acquisitions; and

•implementing enhanced documentation of policies and procedures, along with allocating resources dedicated to training and monitoring these policies and procedures and recruiting personnel with appropriate levels of skills commensurate with their roles.

While we believe that these efforts will improve our internal controls over financial reporting, the implementation of these procedures is ongoing and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles. We cannot be certain that these measures will successfully remediate the material weaknesses or that other material weaknesses and control deficiencies will not be discovered in the future. If our efforts are not successful or other material weaknesses or control deficiencies occur in the future, we may be unable to report our financial results accurately on a timely basis or help prevent fraud, which could cause our reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause the market price of our securities to decline.

As a result of becoming a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting in order to comply with Section 404 of the Sarbanes-Oxley Act. We may not complete our analysis of our internal controls over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in us and, as a result, the value of our securities. In addition, because of our status as an emerging growth company, you will not be able to depend on any attestation from our independent registered public accountants as to our internal controls over financial reporting.

-123-

We will be required by Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal controls over financial reporting in our second annual report following the completion of the Business Combination. The process of designing and implementing internal controls over financial reporting required to comply with this requirement will be time-consuming, costly and complicated. If during the evaluation and testing process we identify one or more material weaknesses in our internal controls over financial reporting or determine that existing material weaknesses have not been remediated, our management will be unable to assert that our internal controls over financial reporting is effective. See “Our independent registered public accountants have identified a number of material weaknesses in our internal controls over financial reporting. If we are unable to remediate the material weaknesses, or if other control deficiencies are identified, we may not be able to report our financial results accurately, prevent fraud or file our periodic reports as a public company in a timely manner.” In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act.

Even if our management concludes that our internal controls over financial reporting are effective, our independent registered public accounting firm may issue a report that is qualified if it is not satisfied with our controls or the level at which our controls are documented, designed, operated or reviewed. However, our independent registered public accounting firm will not be required to attest formally to the effectiveness of our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until the later of the filing of our second annual report following the completion of the Business Combination or the date that we are no longer an “emerging growth company,” as defined in the JOBS Act. Accordingly, you will not be able to depend on any attestation concerning our internal controls over financial reporting from our independent registered public accountants.

We cannot be certain as to the timing of completion of our evaluation, testing and any remediation actions or the impact of the same on our operations. If we are not able to implement the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner or with adequate compliance, our independent registered public accounting firm may issue an adverse opinion due to ineffective internal controls over financial reporting, and we may be subject to sanctions or investigation by regulatory authorities, such as the SEC. As a result, there could be a negative reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, we may be required to incur costs in improving our internal controls system and hiring additional personnel. Any such action could negatively affect our results of operations and cash flows.

We are an “emerging growth company” and we expect to elect to comply with reduced public company reporting requirements, which could make our securities less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we are eligible for certain exemptions from various public company reporting requirements. These exemptions include, but are not limited to, (i) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, (iii) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved, (iv) not being required to provide audited financial statements for certain periods and (v) an extended transition period to comply with new or revised accounting standards applicable to public companies. We could be an emerging growth company for up to five years after the first sale of our securities pursuant to an effective registration statement under the Securities Act. If, however, certain events occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenue exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt securities in any three-year period, we would cease to be an emerging growth company prior to the end of such five-year period. In addition, for so long as we are an “emerging growth company,” we will choose to take advantage of the extended transition period to comply with new or revised accounting standards applicable to public companies. As a result, for so long as we are an “emerging growth company,” the information that we provide to holders of our securities may be different than you might receive from other public reporting companies in which you hold equity interests. We cannot predict if investors will find our securities less attractive as a result of reliance on these exemptions. If some investors find our securities less attractive as a result of any choice we make to reduce disclosure, there may be a less active trading market for our Class A common stock and the market price for our securities may be more volatile.

It is currently anticipated that we may lose our “emerging growth company” status as of the end of the year ending December 31, 2021. After we lose our “emerging growth company” status, we will incur legal, accounting and other expenses that we did not previously incur.

-124-

Provisions of our organizational documents could make an acquisition of us more difficult and may prevent attempts by our shareholders to replace or remove our current management, even if beneficial to our shareholders.

Our Certificate of Incorporation and Bylaws and the Delaware General Corporation Law (the “DGCL”) contain provisions that could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our shareholders. Among other things, these provisions:

•allow us to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without shareholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of shareholders;

•provide for a classified board of directors with staggered three-year terms;

•provide that any amendment, alteration, rescission or repeal of our Bylaws or certain provisions of our Certificate of Incorporation by our shareholders will require the affirmative vote of the holders of a majority of at least two-thirds (2/3) of the outstanding shares of capital stock entitled to vote thereon as a class; and

•establish advance notice requirements for nominations for elections to our Board or for proposing matters that can be acted upon by shareholders at shareholder meetings.

These provisions could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us to take other corporate actions you desire, including actions that you may deem advantageous, or negatively affect the trading price of our securities. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our shareholders to replace current members of our management team.

These and other provisions in our Certificate of Incorporation and Bylaws and Delaware law could make it more difficult for shareholders or potential acquirers to obtain control of our Board or initiate actions that are opposed by our then-current Board, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our securities and limit opportunities for you to realize value in a corporate transaction. For information regarding these and other provisions, see “Description of Capital Stock.”

Our Bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for disputes with us.

Pursuant to our Bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our shareholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws, (4) any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or our Bylaws, (5) any action or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware or (6) any other action asserting a claim against us that is governed by the internal affairs doctrine. The foregoing provisions will not apply to any claims arising under the Exchange Act or the Securities Act and, unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act.

This choice of forum provision in our Bylaws may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’ charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find the choice of forum

-125-

provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.

An active, liquid trading market for our Class A common stock may not be sustained, which may make it difficult to sell the shares of our Class A common stock that you purchase.

An active trading market for our Class A common stock may not be sustained, which would make it difficult for you to sell your shares of our Class A common stock at an attractive price (or at all). A public trading market that has the desirable characteristics of depth, liquidity, and orderliness depends upon the existence of willing buyers and sellers at any given time, and its existence is dependent upon the individual decisions of buyers and sellers over which neither we nor any market maker has control. The failure of an active and liquid trading market to develop and continue would likely have a material adverse effect on the value of our Class A common stock. The market price of our Class A common stock may decline below your purchase price, and you may not be able to sell your shares of our Class A common stock at or above the price you paid for such shares (or at all).

Our operating results and stock price may be volatile.

Our quarterly operating results are likely to fluctuate in the future. In addition, securities markets worldwide have experienced, and are likely to continue to experience, significant price and volume fluctuations. This market volatility, as well as general economic, market or political conditions, could subject the market price of our securities to wide price fluctuations regardless of our operating performance. Our operating results and the trading price of our securities may fluctuate in response to various factors, including:

•market conditions in our industry or the broader stock market;

•actual or anticipated fluctuations in our quarterly financial and operating results;

•issuances of new or changed securities analysts’ reports or recommendations;

•sales, or anticipated sales, of large blocks of our stock;

•additions or departures of key personnel;

•regulatory, legislative or political developments;

•litigation and governmental investigations;

•changing economic conditions;

•investors’ perception of us;

•events beyond our control such as weather and war; and

•any default on our indebtedness.

These and other factors, many of which are beyond our control, may cause our operating results and the market price and demand for our securities to fluctuate substantially. Fluctuations in our quarterly operating results could limit or prevent investors from readily selling their shares and may otherwise negatively affect the market price and liquidity of our securities. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the company that issued the stock. If any of our shareholders bring a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management from our business, which could significantly harm our profitability and reputation.

Because we have no current plans to pay regular cash dividends on our Class A common stock, you may not receive any return on investment unless you sell your Class A common stock for a price greater than that which you paid for it.

-126-

We do not anticipate paying any regular cash dividends on our Class A common stock. Any decision to declare and pay dividends in the future will be made at the discretion of our Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board may deem relevant. In addition, our ability to pay dividends is currently restricted by the Credit Agreement and may in the future be limited by covenants of existing and any future outstanding indebtedness we or our subsidiaries incur. Therefore, any return on investment in our Class A common stock is solely dependent upon the appreciation of the price of our Class A common stock on the open market, which may not occur.

If securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendations regarding our shares or if our results of operations do not meet their expectations, our stock price and trading volume could decline.

The trading market for our shares will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not have any control over these analysts. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock, or if our results of operations do not meet their expectations, our stock price could decline.

We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our Class A common stock, which could depress the price of our Class A common stock.

Our Certificate of Incorporation will authorize us to issue one or more series of preferred stock. Our Board will have the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our shareholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our Class A common stock. The potential issuance of preferred stock may delay or prevent a change in control of us, discouraging bids for our Class A common stock at a premium to the market price, and materially and adversely affect the market price and the voting and other rights of the holders of our Class A common stock.

Risks Related to Our Organizational Structure

We are a holding company and our only material asset is our interest in PCIH, and accordingly, we are dependent upon distributions made by our subsidiaries to pay taxes, make payments under the Tax Receivable Agreement and pay dividends.

We are a holding company with no material assets other than our ownership of the PCIH Common Units and our managing member interest in PCIH. As a result, we have no independent means of generating revenue or cash flow. Our ability to pay taxes, make payments under the Tax Receivable Agreement and pay dividends will depend on the financial results and cash flows of PCIH and the distributions we receive from PCIH. Deterioration in the financial condition, earnings or cash flow of PCIH for any reason could limit or impair PCIH’s ability to pay such distributions. Additionally, to the extent that we need funds and PCIH is restricted from making such distributions under applicable law or regulation or under the terms of any financing arrangements, or PCIH is otherwise unable to provide such funds, this could materially adversely affect our liquidity and financial condition.

PCIH will continue to be treated as a partnership for U.S. federal income tax purposes and as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, taxable income will be allocated to the holders of PCIH Common Units. Accordingly, we will be required to pay income taxes on our allocable share of any net taxable income of PCIH. Under the terms of the Second Amended and Restated Limited Liability Company Agreement, PCIH is obligated to make tax distributions to the holders of PCIH Common Units (including the Company), calculated at certain assumed tax rates. In addition to income taxes, we will also incur expenses related to our operations, including payment obligations under the Tax Receivable Agreement, which could be significant, some of which will be reimbursed by PCIH (excluding payment obligations under the Tax Receivable Agreement). We intend to cause PCIH to make ordinary distributions and tax distributions to holders of PCIH Common Units on a pro rata basis in amounts sufficient to cover all applicable taxes, relevant operating expenses, payments under the Tax Receivable Agreement and dividends, if any, declared by us. However, as discussed below, PCIH’s ability to make such distributions may be subject to various limitations and restrictions including, but not limited to, retention of amounts necessary to

-127-

satisfy the obligations of PCIH and restrictions on distributions that would violate any applicable restrictions contained in PCIH’s debt agreements, or any applicable law, or that would have the effect of rendering PCIH insolvent. To the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid; provided, however, that nonpayment for a specified period may constitute a material breach of a material obligation under the Tax Receivable Agreement and therefore accelerate payments under the Tax Receivable Agreement, which could be substantial.

Additionally, although PCIH generally will not be subject to any entity-level U.S. federal income tax, it may be liable for adjustments to its tax return, absent an election to the contrary, arising out of audits of its tax returns for 2018 and subsequent years. In the event that PCIH’s calculations of taxable income are incorrect, PCIH and/or its members, including us, may be subject to material liabilities in later years.

We anticipate that the distributions we will receive from PCIH may, in certain periods, exceed our actual tax liabilities and obligations to make payments under the Tax Receivable Agreement. Our Board, in its sole discretion, may make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, to pay dividends on our Class A common stock. We have no obligation to distribute such cash (or other available cash other than any declared dividend) to our stockholders.

Dividends on our Class A common stock, if any, will be paid at the discretion of our Board, which will consider, among other things, our available cash, available borrowings and other funds legally available therefor, taking into account the retention of any amounts necessary to satisfy our obligations that will not be reimbursed by PCIH, including taxes and amounts payable under the Tax Receivable Agreement and any restrictions in then-applicable bank financing agreements. Financing arrangements may include restrictive covenants that restrict our ability to pay dividends or make other distributions to its stockholders. In addition, PCIH is generally prohibited under Delaware law from making a distribution to a member to the extent that, at the time of the distribution, after giving effect to the distribution, liabilities of PCIH (with certain exceptions) exceed the fair value of its assets. PCIH’s subsidiaries are generally subject to similar legal limitations on their ability to make distributions to PCIH. If PCIH does not have sufficient funds to make distributions, our ability to declare and pay cash dividends may also be restricted or impaired.

Pursuant to the Tax Receivable Agreement, we generally will be required to pay each person from time to time that becomes a “TRA Party” under the Tax Receivable Agreement, 85% of the tax savings, if any, that we are deemed to realize in certain circumstances as a result of certain tax attributes that existed following the Business Combination and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement, and to the extent payments are made to Seller and to each other person that becomes a “TRA Party” to the agreement, we generally will be required to pay to the Sponsor, and to each other person from time to time that becomes a “Sponsor Party” under the Tax Receivable Agreement, such, Sponsor Party’s proportionate share of an amount equal to such payments multiplied by a fraction with the numerator 0.15 and the denominator 0.85, and those payments may be substantial.

We entered into the Tax Receivable Agreement, which generally provides for the payment by us to PCIH, and to each other person from time to time that becomes a “TRA Party” under the Tax Receivable Agreement, of 85% of the tax savings, if any, that we are deemed to realize in certain circumstances as a result of certain tax attributes that existed following the Business Combination and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. To the extent payments are made pursuant to the Tax Receivable Agreement, we generally will be required to pay to the Sponsor, and to each other person from time to time that becomes a “Sponsor Party” under the Tax Receivable Agreement such Sponsor Party’s proportionate share of, an amount equal to such payments multiplied by a fraction with the numerator 0.15 and the denominator 0.85. The term of the Tax Receivable Agreement will continue until all such tax benefits have been utilized or expired unless we exercise our right to terminate the Tax Receivable Agreement for an amount representing the present value of anticipated future tax benefits under the Tax Receivable Agreement or certain other acceleration events occur.

The Tax Receivable Agreement liability is determined and recorded under ASC 450, contingent liability; therefore, we are required to evaluate whether the liability is both probable and the amount can be estimated. Since the Tax Receivable Agreement liability is payable upon cash tax savings and we have determined that positive future taxable income is not probable based on the Cano Health, Inc’s historical loss position and other factors that make it difficult to rely on forecasts, we have not recorded the Tax Receivable Agreement liability as of September 30, 2021. We will evaluate this on a quarterly basis which may result in an adjustment in the future. If the Seller were to exchange their PCIH equity interests for our securities, we would recognize a

-128-

liability for the total amount owed to PCIH equity interests. These payments are our obligation and not of PCIH. The actual increase in our allocable share of PCIH’s tax basis in its assets, as well as the amount and timing of any payments under the Tax Receivable Agreement, will vary depending upon a number of factors, including the timing of exchanges, the market price of our Class A common stock at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the recognition of our income. While many of the factors that will determine the amount of payments that we will make under the Tax Receivable Agreement are outside of our control, we expect that the payments we will make under the Tax Receivable Agreement will be substantial and could have a material adverse effect on our financial condition. Any payments made by us under the Tax Receivable Agreement will generally reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make timely payments under the Tax Receivable Agreement for any reason, the unpaid amounts will be deferred and will accrue interest until paid; however, nonpayment for a specified period may constitute a material breach of a material obligation under the Tax Receivable Agreement and therefore accelerate payments due under the Tax Receivable Agreement, as further described below. Furthermore, our future obligation to make payments under the Tax Receivable Agreement could make it a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that may be deemed realized under the Tax Receivable Agreement.

In addition, by reason of the payments made to the Sponsor, we are not expected to retain any of the tax benefits stemming from events that gave rise to payments under the Tax Receivable Agreement.

In certain cases, payments under the Tax Receivable Agreement may exceed the actual tax benefits we realize or be accelerated.

Payments under the Tax Receivable Agreement will be based on the tax reporting positions that we determine, and the Internal Revenue Service or another taxing authority may challenge all or any part of the tax basis increases, as well as other tax positions that we take, and a court may sustain such a challenge. In the event that any tax benefits initially claimed by us are disallowed, the Seller and the exchanging holders will not be required to reimburse us for any excess payments that may previously have been made under the Tax Receivable Agreement, for example, due to adjustments resulting from examinations by taxing authorities. Rather, excess payments made to such holders will be netted against any future cash payments otherwise required to be made by us, if any, after the determination of such excess. However, a challenge to any tax benefits initially claimed by us may not arise for a number of years following the initial time of such payment or, even if challenged early, such excess cash payment may be greater than the amount of future cash payments that we might otherwise be required to make under the terms of the Tax Receivable Agreement and, as a result, there might not be future cash payments against which to net. As a result, in certain circumstances, we could make payments under the Tax Receivable Agreement in excess of our actual income or franchise tax savings, which could materially impair our financial condition.

Moreover, the Tax Receivable Agreement provides that, in the event that (i) we exercise our early termination rights under the Tax Receivable Agreement, (ii) certain changes of control of Cano Health, Inc. occur (as described in the Tax Receivable Agreement), or (iii) we breach any of our material obligations under the Tax Receivable Agreement, our obligations under the Tax Receivable Agreement will accelerate and we will be required to make a lump-sum cash payment to certain parties to the agreement, the Sponsor and/or other applicable parties to the Tax Receivable Agreement equal to the present value of all forecasted future payments that would have otherwise been made under the Tax Receivable Agreement, which lump-sum payment would be based on certain assumptions, including those relating to our future taxable income. The lump-sum payment could be substantial and could exceed the actual tax benefits that we realize subsequent to such payment because such payment would be calculated assuming, among other things, that we would have certain tax benefits available to it and that we would be able to use the potential tax benefits in future years.

There may be a material negative effect on our liquidity if the payments under the Tax Receivable Agreement exceed the actual income or franchise tax savings that we realize. Furthermore, our obligations to make payments under the Tax Receivable Agreement could also have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control.

These estimates and assumptions are also subject to various factors beyond our control, including, for example, changes in customer demand, increased costs in our supply chain, increased labor costs, changes in the regulatory environment, the adoption of future legislation, particularly with respect to Medicare, changes in regulations, the impact of global health crises (including the COVID-19 pandemic and COVID-19 variants) and changes in our executive team. There can be no assurance that the prospective results will be realized or that actual results will not be significantly higher or lower than estimated. Notably, our

-129-

financial projections reflect assumptions regarding contracts that are currently under negotiation with, as well as indications of interest from, potential customers, members, acquisition targets and strategic partners who may withdraw at any time. Accordingly, our future financial condition and results of operations may differ materially from our projections. Our failure to achieve our projected results could also harm the trading price of our securities and our financial position.

Delaware law, our Certificate of Incorporation and our Bylaws contain certain provisions, including anti-takeover provisions, that limit the ability of stockholders to take certain actions and could delay or discourage takeover attempts that stockholders may consider favorable.

Delaware law, our Certificate of Incorporation and our Bylaws contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by our Board and therefore depress the trading price of our securities. These provisions could also make it difficult for stockholders to take certain actions, including electing directors who are not nominated by the current members of our Board or taking other corporate actions, including effecting changes in management. Among other things, our Certificate of Incorporation and Bylaws include provisions regarding:

•a classified board of directors with three-year staggered terms, which could delay the ability of stockholders to change the membership of a majority of our Board;

•the ability of our Board to issue shares of preferred stock, including “blank check” preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;

•the limitation of the liability of, and the indemnification of, our directors and officers;

•the right of our Board to elect a director to fill a vacancy created by the expansion of our Board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board;

•the requirement that directors may only be removed from our Board for cause;

•the requirement that a special meeting of stockholders may be called only by a majority of our directors, whether not there exists any vacancies or unfilled seats, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors;

•controlling the procedures for the conduct and scheduling of our Board and stockholder meetings;

•the requirement for the affirmative vote of holders of (i) (a) at least 66-2/3%, in case of certain provisions, or (b) a majority, in case of other provisions, of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend, alter, change or repeal certain provisions of our Certificate of Incorporation, and (ii) (a) at least 66-2/3%, in case of certain provisions, or (b) a majority, in case of other provisions, of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, to amend, alter, change or repeal certain provisions of our Bylaws, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our Board and also may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt;

•the ability of our Board to amend the Bylaws, which may allow our Board to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt; and

•advance notice procedures with which stockholders must comply to nominate candidates to our Board or to propose matters to be acted upon at a stockholders’ meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our Board and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of the Company.

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our Board or management.

-130-

Any provision of our Certificate of Incorporation, our Bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for stockholders to receive a premium for their shares of our Class A common stock and could also affect the price that some investors are willing to pay for our Class A common stock.

Our Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.

Our Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee, agent or stockholder of the Company to the Company or the Company’s stockholders, or any claim for aiding and abetting such alleged breach; (iii) any action asserting a claim against the Company or any current or former director, officer, other employee, agent or stockholder of the Company (a) arising pursuant to any provision of the DGCL, our Certificate of Incorporation (as it may be amended or restated) or our Bylaws or (b) as to which the DGCL confers jurisdiction on the Delaware Court of Chancery; or (iv) any action asserting a claim against the Company or any current or former director, officer, other employee, agent or stockholder of the Company governed by the internal affairs doctrine of the law of the State of Delaware shall, as to any action in the foregoing clauses (i) through (iv), to the fullest extent permitted by law, be solely and exclusively brought in the Delaware Court of Chancery; provided, however, that the foregoing shall not apply to any claim (a) as to which the Delaware Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Delaware Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (b) which is vested in the exclusive jurisdiction of a court or forum other than the Delaware Court of Chancery, or (c) arising under federal securities laws, including the Securities Act as to which the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum. Notwithstanding the foregoing, the provisions of Article XII of our Certificate of Incorporation will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive forum.

Any person or entity purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to the forum provisions in our Certificate of Incorporation. If any action, the subject matter of which is within the scope of the forum provisions, is filed in a court other than a court located within the State of Delaware (a “foreign action”) in the name of any stockholder, such stockholder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”); and (y) having service of process made upon such stockholder in any such enforcement action by service upon such stockholder’s counsel in the foreign action as agent for such stockholder.

This choice-of-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, stockholders, agents or other employees, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our Certificate of Incorporation inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and Board of Directors.

Our business and operations could be negatively affected if we become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategy and impact our stock price.

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been brought against that company. Shareholder activism, which could take many forms or arise in a variety of situations, has been increasing recently. Volatility in the stock price of our Class A common stock or other securities or other reasons may in the future cause it to become the target of securities litigation or shareholder activism. Securities litigation and shareholder activism, including potential proxy contests, could result in substantial costs and divert management’s and the Board’s attention and resources from our business. Additionally, such securities litigation and shareholder activism could give rise to perceived uncertainties as to our future, adversely affect our relationships with service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to incur significant legal fees and other expenses related to any

-131-

securities litigation and activist shareholder matters. Further, our stock price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities litigation and shareholder activism.

Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business and results of operations.

We are subject to laws and regulations enacted by national, regional and local governments. In particular, we are required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

On August 11, 2021, the Company issued 2,720,966 shares of Class A common stock to the escrow agent, on behalf of the seller, as part of the consideration in connection with an acquisition. These shares were not registered under the Securities Act in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act.

On August 12, 2021, the Company issued an additional 122,449 shares of Class A common stock as part of the consideration in connection with an acquisition. These shares were not registered under the Securities Act in reliance upon the exemption provided in Section 4(a)(2) of the Securities Act.

Recent Purchases of Equity Securities

None.

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

Item 5.    Other Information

None.

-132-

Item 6.    Exhibits

Exhibits required by Item 601 of Regulation S-K are filed herewith or incorporated herein by reference and are listed in the following Exhibit Index:

Exhibit Index

Exhibit Number Description

2.1	Asset Purchase Agreement, dated July 2, 2021, by and among Doctor’s Medical Center, LLC, each Owner named therein, Cano Health, LLC, and Ventura De Paz in his capacity as Owners’ Representative (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on July 6, 2021).
3.1	Certificate of Incorporation of Cano Health, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 9, 2021).
3.2	By-laws of Cano Health, Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on June 9, 2021).
3.3	Second Amended And Restated Limited Liability Company Agreement of Primary Care (ITC) Intermediate Holdings, LLC, dated as of June 3, 2021 (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on June 9, 2021).
4.1	Indenture, dated as of September 30, 2021, by and among Cano Health, LLC, the guarantors party thereto and U.S. Bank, National Association, as trustee, relating to the 6.250% Senior Notes due 2028, including Form of Global Note (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 4, 2021)
4.2	Form of Global Note for 6.250% Senior Notes due 2028 (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 4, 2021)
10.1	Fourth Amendment and Incremental Facility Amendment to Credit Agreement, dated as of September 30, 2021, by and among Cano Health, LLC, Primary Care (ITC) Intermediate Holdings, LLC, Credit Suisse AG, Cayman Islands Branch and the lenders party thereto. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 4, 2021).
10.2	Bridge Loan Agreement, dated July 2, 2021, by and among Cano Health, LLC, Primary Care (ITC) Intermediate Holdings, LLC, Credit Suisse AG, Cayman Islands Branch and the lenders from time to time party thereto (incorporated by reference to Exhibit 10.15 to the Company’s quarterly report on Form 10-Q filed on August 15, 2021).
10.3	First Amendment to Cano Health, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.3 to the Company’s Registration Statement on Form S-8 filed on August 23, 2021).
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

-133-

101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)

*	Filed herewith.
**	Furnished herewith.
+	Indicates a management contract or any compensatory plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CANO HEALTH, INC.

November 9, 2021	By:	/s/ Dr. Marlow Hernandez	Chief Executive Officer
		Dr. Marlow Hernandez	(Principal Executive Officer)
November 9, 2021	By:	/s/ Brian D. Koppy	Chief Financial Officer
		Brian D. Koppy	(Principal Financial Officer)
November 9, 2021	By:	/s/ Mark Novell	Chief Accounting Officer
		Mark Novell	(Principal Accounting Officer)

-134-

EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d- 14(a)

OF THE SECURITIES AND EXCHANGE ACT, AS AMENDED AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dr. Marlow Hernandez, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cano Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/  Dr. Marlow Hernandez
	Dr. Marlow Hernandez Chief Executive Officer (Principal Executive Officer)

Date:  November 9, 2021

EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) AND RULE 15d- 14(a)

OF THE SECURITIES AND EXCHANGE ACT, AS AMENDED AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Brian D. Koppy, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cano Health, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/  Brian D. Koppy
	Brian D. Koppy Chief Financial Officer (Principal Financial Officer)

Date:  November 9, 2021

EX-32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Cano Health, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Marlow Hernandez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

By:	/s/ Dr. Marlow Hernandez
	Dr. Marlow Hernandez Chief Executive Officer (Principal Executive Officer)

Date: November 9, 2021

EX-32.2

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report on Form 10-Q of Cano Health, Inc. (the “Company”) for the period ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian D. Koppy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

By:	/s/ Brian D. Koppy
	Brian D. Koppy Chief Financial Officer (Principal Financial Officer)

Date: November 9, 2021

XML

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Registrant Name	Cano Health, Inc.
Entity File Number	001-39289
Entity Central Index Key	0001800682
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Tax Identification Number	98-1524224
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9725 NW 117th Avenue
Entity Address, Address Line Two	Suite #200
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33178
City Area Code	855
Local Phone Number	226-6633
Class A common stock, $0.0001 par value per share
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		180,410,977
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Trading Symbol	CANO
Security Exchange Name	NYSE
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	CANO/WS
Security Exchange Name	NYSE
Class B common stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		299,575,289

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash, cash equivalents and restricted cash	$ 208,913,000	$ 33,807,000
Accounts receivable, net of unpaid service provider costs (Related parties comprised $92 and $50,015 as of September 30, 2021 and December 31, 2020, respectively)	223,644,000	76,709,000
Inventory	1,777,000	922,000
Prepaid expenses and other current assets	30,788,000	8,937,000
Total current assets	465,122,000	120,375,000
Property and equipment, net (Related parties comprised $18,897 and $22,659 as of September 30, 2021 and December 31, 2020, respectively)	64,156,000	38,126,000
Goodwill	765,511,000	234,328,000
Payor relationships, net	584,265,000	189,570,000
Other intangibles, net	256,327,000	36,785,000
Other assets	4,703,000	4,362,000
Total assets	2,140,084,000	623,546,000
Current liabilities:
Current portion of notes payable	6,493,000	4,800,000
Current portion of equipment loans	513,000	314,000
Current portion of capital lease obligations	1,006,000	876,000
Current portion of contingent consideration	8,406,000	0
Accounts payable and accrued expenses (Related parties comprised $0 and $112 as of September 30, 2021 and December 31, 2020, respectively)	76,654,000	33,180,000
Deferred revenue (Related parties comprised $0 and $988 as of September 30, 2021 and December 31, 2020, respectively)	1,815,000	988,000
Current portions due to sellers	24,687,000	27,129,000
Other current liabilities	20,000,000	1,333,000
Total current liabilities	139,574,000	68,620,000
Notes payable, net of current portion and debt issuance costs	916,111,000	456,745,000
Warrants liabilities	138,493,000	0
Equipment loans, net of current portion	1,454,000	873,000
Capital lease obligations, net of current portion	1,559,000	1,580,000
Deferred rent (Related parties comprised $0 and $92 as of September 30, 2021 and December 31, 2020, respectively)	5,387,000	3,111,000
Deferred revenue, net of current portion (Related parties comprised of $0 and $4,277 as of September 30, 2021 and December 31, 2020, respectively)	4,698,000	4,277,000
Due to sellers, net of current portion	170,000	13,976,000
Contingent consideration	38,300,000	5,172,000
Other liabilities (Related parties comprised $0 and $8,142 as of September 30, 2021 and December 31, 2020, respectively)	36,325,000	11,648,000
Total liabilities	1,282,071,000	566,002,000
Stockholders’ Equity / Members' Capital
Members' capital	0	157,591,000
Additional paid-in capital	363,060,000	0
Accumulated deficit	(52,547,000)	(99,913,000)
Notes receivable, related parties	0	(134,000)
Total Stockholders' Equity / Members’ Capital attributable to Class A common stockholders	310,561,000	57,544,000
Non-controlling interests	547,452,000	0
Total Stockholders' Equity / Members’ Capital	858,013,000	57,544,000
Total Liabilities and Stockholders' Equity / Members’ Capital	2,140,084,000	623,546,000
Class A common stock
Stockholders’ Equity / Members' Capital
Common stock	17,000	0
Class B common stock
Stockholders’ Equity / Members' Capital
Common stock	$ 31,000	$ 0

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Accounts receivable, net of unpaid service provider costs, related parties	$ 92	$ 50,015
Property and equipment, net, related parties	18,897	22,659
Accounts payable and accrued expenses, related parties	0	112
Deferred revenue, related parties	0	988
Deferred rent, related parties	0	92
Deferred revenue, net of current portion, related parties	0	4,277
Other liabilities, related parties	$ 0	$ 8,142
Class A common stock
Common stock, par value (in dollars per share)	$ 0.0001
Common stock, shares authorized (in shares)	6,000,000,000
Common stock, shares issued (in shares)	171,594,914
Common stock, shares outstanding (in shares)	171,594,914
Class B common stock
Common stock, par value (in dollars per share)	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000
Common stock, shares issued (in shares)	305,670,386
Common stock, shares outstanding (in shares)	305,670,386

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Capitated revenue (Related parties comprised $0 and $131,945, and $335,383 and $239,692, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	$ 501,780	$ 252,974	$ 1,148,041	$ 544,617
Fee-for-service and other revenue (Related parties comprised $0 and $82, and $631 and $426, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	25,018	10,159	52,055	25,020
Total revenue	526,798	263,133	1,200,096	569,637
Operating expenses:
Third-party medical costs (Related parties comprised $0 and $90,166, and $249,819 and $167,109, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	379,316	184,926	866,177	382,279
Direct patient expense (Related parties comprised $6 and $1,016, and $1,502 and $2,161, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	57,708	31,108	135,777	71,441
Selling, general, and administrative expenses (Related parties comprised $4,225 and $3,289, and $9,814 and $8,428, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	75,926	27,391	157,348	70,234
Depreciation and amortization expense	16,955	5,379	30,746	12,741
Transaction costs and other (Related parties comprised $0 and $0, and $1,483 and $5,369 in the three months ended September 30, 2021 and 2020 and nine months ended September 30, 2021 and 2020, respectively)	6,528	7,716	32,140	29,854
Total operating expenses	536,433	256,520	1,222,188	566,549
Income (loss) from operations	(9,635)	6,613	(22,092)	3,088
Other income and expense:
Interest expense	(16,023)	(12,346)	(36,363)	(21,728)
Interest income (Related parties comprised $0 and $0, and $0 and $236, in the three months ended September 30, 2021 and 2020, and in the nine months ended September 30, 2021 and 2020, respectively)	1	80	4	239
Loss on extinguishment of debt	0	0	(13,225)	0
Change in fair value of embedded derivative	0	(5,138)	0	(5,444)
Change in fair value of warrant liabilities	(14,650)	0	24,565	0
Other expenses	(29)	0	(54)	(150)
Total other expense	(30,701)	(17,404)	(25,073)	(27,083)
Net loss before income tax benefit (expense)	(40,336)	(10,791)	(47,165)	(23,995)
Income tax benefit (expense)	(547)	(326)	762	(294)
Net loss	(40,883)	$ (11,117)	(46,403)	$ (24,289)
Net loss attributable to non-controlling interests	(26,246)		(41,283)
Net loss attributable to Class A common stockholders	$ (14,637)		$ (5,120)
Net income (loss) per common share:
Net income per share to Class A common stockholders, basic (in dollars per share)	$ (0.09)		$ (0.03)
Net loss per share to Class A common stockholders, diluted (in dollars per share)	$ (0.09)		$ (0.08)
Weighted-average shares used in computation of earnings per share:
Basic (in shares)	170,871,429		168,100,210
Diluted (in shares)	170,871,429		169,312,258

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Capitation revenues related parties	$ 0	$ 131,945	$ 335,383	$ 239,692
Revenue from service and other revenue related parties	0	82	631	426
Medical costs related parties	0	90,166	249,819	167,109
Direct patient expense related parties	6	1,016	1,502	2,161
Selling general and administrative expense related parties	4,225	3,289	9,814	8,428
Transaction costs and other related parties	0	0	1,483	5,369
Interest income related party	$ 0	$ 0	$ 0	$ 236

XML

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / MEMBERS' CAPITAL (UNAUDITED) - USD ($) $ in Thousands	Total	Notes Receivable	Class A common stock	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjusted Balance	Cumulative Effect, Period of Adoption, Adjusted Balance Notes Receivable	Members' Capital	Members' Capital Cumulative Effect, Period of Adoption, Adjustment	Members' Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock Class A common stock	Common Stock Class B common stock	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance Class A common stock	Common Stock Cumulative Effect, Period of Adoption, Adjusted Balance Class B common stock	Additional Paid-in Capital	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjusted Balance	Non-Controlling Interests	Non-Controlling Interests Cumulative Effect, Period of Adoption, Adjusted Balance
Balance at the beginning (in shares) at Dec. 31, 2019							0			0	0
Balance at the beginning at Dec. 31, 2019	$ 98,463	$ (130)					$ 123,242			$ 0	$ 0			$ 0			$ (25,041)		$ 392
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Members' contributions	95,782						95,782
Stock-based compensation expense	177						177
Issuance of common stock for acquisitions	34,300						34,300
Issuance of common stock for due to sellers balance	2,158						$ 2,158
Settlement of notes receivable, net	(3)	(3)
Net income (loss)	(24,289)																(24,289)		0
Balance at the end (in shares) at Sep. 30, 2020							0			0	0
Balance at the end at Sep. 30, 2020	206,588	(133)					$ 255,659			$ 0	$ 0			0			(49,330)		392
Balance at the beginning (in shares) at Jun. 30, 2020							0			0	0
Balance at the beginning at Jun. 30, 2020	223,765	(132)					$ 261,718			$ 0	$ 0			0			(38,213)		392
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Members distributions	(6,125)						(6,125)
Stock-based compensation expense	66						66
Interest on notes receivable	(1)	(1)
Net income (loss)	(11,117)						$ 0										(11,117)		0
Balance at the end (in shares) at Sep. 30, 2020							0			0	0
Balance at the end at Sep. 30, 2020	206,588	(133)					$ 255,659			$ 0	$ 0			0			(49,330)		392
Balance at the beginning (in shares) at Dec. 31, 2020							14,629,533,000	292,214,129,000	306,843,662,000	0	0	0	0
Balance at the beginning at Dec. 31, 2020	57,544	(134)		$ 0	$ 57,544	$ (134)	$ 157,591	$ (157,560)	$ 31	$ 0	$ 0	$ 0	$ 0	0	$ 157,560	$ 157,560	(99,913)	$ (99,913)	0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss prior to business combination	(32,078)																(32,078)
Business combination and PIPE financing (in shares)							(306,843,662,000)			166,243,491,000	306,843,662,000
Business combination and PIPE financing	773,093						$ (31)			$ 17	$ 31			169,093			85,663		518,320
Stock-based compensation expense	12,148													12,148
Issuance of common stock for acquisitions (in shares)										4,178,147,000
Issuance of common stock for acquisitions	61,500													61,500			(840)		840
Exchange of Class B common stock for Class A common stock (in shares)										1,173,276,000
Exchange of Class B common stock for Class A common stock	0										$ (1,173,276)			2,309			(259)		(2,050)
Impact of transactions affecting non-controlling interests	0													(39,550)					39,550
Settlement of notes receivable, net	134	134
Net income (loss)	(14,328)																(5,120)		(9,208)
Balance at the end (in shares) at Sep. 30, 2021							0			171,594,914,000	305,670,386,000
Balance at the end at Sep. 30, 2021	858,013	0					$ 0			$ 17	$ 31			363,060			(52,547)		547,452
Balance at the beginning (in shares) at Jun. 30, 2021										170,299,189,000	306,843,662,000
Balance at the beginning at Jun. 30, 2021	888,351	(136)								$ 17	$ 31			389,892			(37,640)		536,187
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	8,909													8,909
Issuance of common stock for acquisitions (in shares)			4,178,147							122,449,000
Issuance of common stock for acquisitions	1,500													1,500			(11)		11
Exchange of Class B common stock for Class A common stock (in shares)										1,173,276,000
Exchange of Class B common stock for Class A common stock	0										$ (1,173,276)			2,309			(259)		(2,050)
Impact of transactions affecting non-controlling interests	0													(39,550)					39,550
Settlement of notes receivable, net	136	136
Net income (loss)	(40,883)																(14,637)		(26,246)
Balance at the end (in shares) at Sep. 30, 2021							0			171,594,914,000	305,670,386,000
Balance at the end at Sep. 30, 2021	$ 858,013	$ 0					$ 0			$ 17	$ 31			$ 363,060			$ (52,547)		$ 547,452

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities:
Net loss	$ (46,403,000)	$ (24,289,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	30,746,000	12,741,000
Change in fair value of contingent consideration	(4,152,000)	0
Change in fair value of embedded derivative	0	5,444,000
Change in fair value of warrant liabilities	(24,565,000)	0
Loss on extinguishment of debt	13,225,000	0
Amortization of debt issuance costs	7,653,000	3,851,000
Write off of other receivables	0	531,000
Equity-based compensation	12,148,000	177,000
Changes in operating assets and liabilities:
Accounts receivable, net (Related parties comprised $(92) and $0 as of September 30, 2021 and 2020, respectively)	(95,991,000)	(33,286,000)
Inventory	(856,000)	(484,000)
Other assets	(6,578,000)	217,000
Prepaid expenses and other current assets	(27,358,000)	163,000
Accounts payable and accrued expenses (Related parties comprised $(112) and $(52) as of September 30, 2021 and 2020, respectively)	56,626,000	10,480,000
Deferred rent (Related parties comprised $(92) and $0 as of September 30, 2021 and 2020, respectively)	2,236,000	868,000
Deferred revenue	1,147,000	0
Other liabilities	(9,376,000)	2,544,000
Net cash used in operating activities	(91,498,000)	(21,043,000)
Cash Flows from Investing Activities:
Purchase of property and equipment (Related parties comprised $5,697 and $5,358 as of September 30, 2021 and 2020, respectively)	(23,221,000)	(9,442,000)
Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired	(1,068,661,000)	(205,325,000)
Payments to sellers	(24,148,000)	(38,748,000)
Other	0	(39,000)
Net cash used in investing activities	(1,116,030,000)	(253,554,000)
Net Cash Provided by (Used in) Financing Activities [Abstract]
Contributions from member	0	95,782,000
Business combination and PIPE financing	935,362,000	0
Interest accrued due to sellers	1,208,000	1,082,000
Payments of long-term debt	(656,294,000)	(2,378,000)
Debt issuance costs	(17,689,000)	(5,655,000)
Proceeds from long-term debt	1,120,000,000	184,096,000
Proceeds from revolving credit facility	0	9,700,000
Repayments of revolving credit facility	0	(9,700,000)
Proceeds from insurance financing arrangements	4,401,000	2,864,000
Payments of principal on insurance financing arrangements	(3,939,000)	(2,388,000)
Repayments of equipment loans	(233,000)	(57,000)
Repayments of capital lease obligations	(316,000)	(518,000)
Settlement of note receivable, net	134,000	0
Net cash provided by financing activities	1,382,634,000	272,828,000
Net increase (decrease) in cash, cash equivalents and restricted cash	175,106,000	(1,769,000)
Cash, cash equivalents and restricted cash at beginning of year	33,807,000	29,192,000
Cash, cash equivalents and restricted cash at end of period	208,913,000	27,423,000
Supplemental Cash Flow Information [Abstract]
Interest paid	28,075,000	11,044,000
Income taxes paid	1,150,000	0
Noncash Investing and Financing Items [Abstract]
Issuance of securities by Cano Health, Inc. in connection with acquisitions	61,500,000	0
Issuance of securities in PCIH in connection with acquisitions	0	34,300,000
Contingent consideration in connection with acquisitions	47,900,000	0
Due to sellers in connection with acquisitions	1,295,000	16,216,000
Humana Affiliate Provider clinic leasehold improvements	5,605,000	0
Capital lease obligations entered into for property and equipment	225,000	0
Equipment loan obligations entered into for property and equipment	$ 1,013,000	$ 0

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 30, 2020
Accounts receivable
Due from (to) related parties, current	$ (92)	$ 0
Accounts payable and accrued expense
Due from (to) related parties, current	(112)	(52)
Deferred rent
Due to related parties, non current	92	0
Purchase of property and equipment
Due to related parties	$ 5,697	$ 5,358

XML

Nature of Business and Operations

9 Months Ended

Sep. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business and Operations

NATURE OF BUSINESS AND OPERATIONS

Nature of Business

Cano Health, Inc. (“Cano Health”, or the “Company”), formerly known as Primary Care (ITC) Intermediate Holdings, LLC (“PCIH”), provides value-based medical care for its members through a network of primary care physicians across the U.S. and Puerto Rico. The Company focuses on high-touch population health and wellness services to Medicare Advantage, Medicare Global and Professional Direct Contracting ("DC") and Medicaid capitated members, particularly in underserved communities by leveraging a proprietary technology platform to deliver high-quality health care services, resulting in superior clinical outcomes at competitive costs. As of September 30, 2021, the Company provided services through its network of 113 owned medical centers and over 345 employed providers (physicians, nurse practitioners, and physician assistants), and maintained affiliate relationships with over 1,000 physicians. The Company also operates pharmacies in the network for the purpose of providing a full range of managed care services to its members.

On June 3, 2021 (the “Closing Date”), Jaws Acquisition, Corp. (“Jaws”), consummated the previously announced business combination (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 11, 2020 (as amended, the “Business Combination Agreement”) by and among Jaws, Jaws Merger Sub, LLC, a Delaware limited liability company (“Merger Sub”), PCIH, and PCIH’s sole member, Primary Care (ITC) Holdings, LLC (“Seller” or "Parent"). Upon the closing of the Business Combination, Jaws was reincorporated in the State of Delaware and changed its name to "Cano Health, Inc."

Unless the context requires, "the Company", "we", "us", and "our" refer, for periods prior to the completion of the Business Combination, to PCIH and its consolidated subsidiaries, and for periods upon or after the completion of the Business Combination, to Cano Health, Inc. and its consolidated subsidiaries, including PCIH, and its subsidiaries.

Pursuant to the Business Combination Agreement, on the Closing Date, Jaws contributed cash to PCIH in exchange for 69.0 million common limited liability company units of PCIH ("PCIH Common Units") equal to the number of shares of Jaws' Class A ordinary shares outstanding on the Closing Date as well as 17.25 million Class B ordinary shares owned by Jaws Sponsor, LLC (the "Sponsor"). In connection with the Business Combination, the Company issued 306.8 million shares of the Company’s Class B common stock to existing shareholders of PCIH. The Company also issued 80.0 million shares of the Company’s Class A common stock in a private placement for $800.0 million (the "PIPE Investors").

Following the consummation of the Business Combination, substantially all of the Company’s assets and operations are held and conducted by PCIH and its subsidiaries. As the Company is a holding company with no material assets other than its ownership of PCIH Common Units and its managing member interest in PCIH, the Company has no independent means of generating revenue or cash flow. The Company’s ability to pay taxes and pay dividends depend on the financial results and cash flows of PCIH and the distributions it receives from PCIH. The Company’s only assets are equity interests in PCIH, which represented a 35.1% and 36.0% controlling ownership as of the Closing Date and September 30, 2021, respectively. Certain members of PCIH who retained their common unit interests in PCIH held the remaining 64.9% and 64.0% non-controlling ownership interests as of the Closing Date and September 30, 2021, respectively. These members hold economic interest in PCIH through PCIH Common Units and a corresponding number of non-economic Class B common stock, which enables the holder to one vote per share.

Our organizational structure following the completion of the Business Combination is commonly referred to as an umbrella partnership-C (or Up-C) corporation structure. This organizational structure allowed the Seller, the former sole owner and managing member of PCIH, to retain its equity ownership in PCIH, an entity that is classified as a partnership for U.S. federal income tax purposes, in the form of PCIH Common Units. The former stockholders of Jaws and the PIPE Investors who, prior to the Business Combination, held Class A ordinary shares or Class B ordinary shares of Jaws, by contrast, received equity ownership in Cano Health, Inc., a Delaware corporation that is a domestic corporation for U.S. federal income tax purposes.

Subject to the terms and conditions set forth in the Business Combination Agreement, the Seller and its equity holders received aggregate consideration with a value equal to $3,534.9 million, which consisted of (i) $466.5 million of cash and (ii) $3,068.4 million shares of Cano Health, Inc.'s common stock or 306.8 million shares of Class B common stock based on a reference stock price of $10.00 per share.

Following the closing of the Business Combination, Class A stockholders owned direct controlling interests in the combined results of PCIH and Cano Health, Inc. while the Seller as the sole Class B stockholder owned indirect economic interests in PCIH shown as non-controlling interests in the condensed consolidated financial statements of Cano Health, Inc. The indirect economic interests are held by the Seller in the form of PCIH Common Units that can be redeemed for Class A common stock together with the cancellation of an equal number of shares of Class B common stock in Cano Health, Inc. The non-controlling interests will decrease as shares of Class B common stock and PCIH Common Units are exchanged for shares of Class A common stock in Cano Health, Inc. Following the redemption of 6,509 public shares outstanding for $65,090 held in the trust account, the respective controlling interest and non-controlling interests in Cano Health, Inc. and PCIH were 35.1% and 64.9% resulting from the closing of the Business Combination.

On June 11, 2021, PCIH acquired University for a total consideration of $611.1 million. The equity issued on the acquisition close date equated to 4.1 million shares of Class A common stock in Cano Health, Inc. based on a share price of $14.79 per share. Further, in the third quarter of 2021, an additional 0.1 million shares of Class A common stock in Cano Health, Inc. were issued in connection with other acquisitions and 1.2 million PCIH Common Units were exchanged for shares of Class A common stock. As noted above, as of September 30, 2021, the controlling interest and non-controlling interest in Cano Health, Inc. and PCIH was 36.0% and 64.0%, respectively.

The following table reconciles the elements of the Business Combination to the condensed consolidated statements of cash flows and the condensed consolidated statements of changes in equity for the three and nine months ended September 30, 2021:

(in thousands)	Recapitalization
Cash - Jaws' trust and cash, net of redemptions	$	690,705
Cash - PIPE financing	800,000
Less: transaction costs and advisory fees paid	(88,745)
Less: Distribution to PCIH shareholders	(466,598)
Net Business Combination and PIPE financing	935,362
Plus: Non-cash net assets assumed	96
Plus: Accrued transaction costs	8,860
Less: Capitalized transaction costs	(8,167)
Less: Warrant liability assumed	(163,058)
Net contributions from Business Combination and PIPE financing	$	773,093

The number of shares of common stock issued immediately following the consummation of the Business Combination is as follows:

	Class A common stock	Class B common stock
Common stock outstanding prior to Business Combination	69,000,000	—
Less: redemption of Jaws shares	(6,509)	—
Ordinary shares of Jaws	68,993,491	—
Jaws Sponsor Shares	17,250,000	—
Shares issued in PIPE financing	80,000,000	—
Business Combination and PIPE financing shares	166,243,491	—
Shares to PCIH shareholders	—	306,843,662
Total shares of common stock outstanding immediately after the Business Combination	166,243,491	306,843,662

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The portion of an entity not wholly-owned by the Company is presented as non-controlling interest. All significant intercompany balances and transactions are eliminated in consolidation. The financial statements of the Company’s subsidiaries are prepared using accounting policies consistent with those of the Company.

The Company has interests in various entities and considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights (“variable interest entities” or “VIEs”) and determines which business entity is the primary beneficiary of the VIE. The Company consolidates VIEs when it is determined that the Company is the primary beneficiary of the VIE. Included in the consolidated results of the Company are Cano Health Texas, PLLC and Cano Health Nevada, PLLC (collectively, the "Physicians Groups"), which the Company has concluded are both VIEs. All material intercompany accounts and transactions have been eliminated in consolidation.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to use this extended transition period until the Company is no longer an emerging growth company or until the Company affirmatively and irrevocably opts out of the extended transition period. Accordingly, our condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

The Company could be an emerging growth company for up to five years after the first sale of our Class A common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act"). If, however, certain events occur prior to the end of such five-year period, including if the Company becomes a “large accelerated filer,” our annual gross revenue exceeds $1.07 billion or the Company issues more than $1.0 billion of non-convertible debt securities in any three-year period, the Company would cease to be an emerging growth company prior to the end of such five-year period. The Company will become a “large accelerated filer,” as defined in Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and

will lose its “emerging growth company” status as of the end of the year ending December 31, 2021. After the Company loses its “emerging growth company” status, the Company expects to incur increased legal, accounting and other expenses.

Risks and Uncertainties

As of September 30, 2021, the Company’s coverage area is primarily in the State of Florida. Given this concentration, the Company is subject to adverse economic, regulatory, or other developments in the State of Florida that could have a material adverse effect on the Company’s financial conditions and operations. In addition, federal, state and local laws and regulations concerning healthcare affect the healthcare industry. The Company’s long-term success is dependent on the ability to successfully generate revenues; maintain or reduce operating costs; obtain additional funding when needed; and ultimately, achieve profitable operations. The Company is not able to predict the content or impact of future changes in laws and regulations affecting the healthcare industry; however, management believes that its existing cash position will be sufficient to fund operating and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements.

XML

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position of the Company at September 30, 2021 and December 31, 2020, and the results of operations, cash flows and changes in equity for the three and nine months ended September 30, 2021 and 2020 have been included. The results of operations and cash flows for the three and nine months ended September 30, 2021 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2021 or any other future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the

consolidated financial statements and notes thereto included in the Company’s audited consolidated financial statements for the year ended December 31, 2020.

The Company was deemed the accounting acquirer in the Business Combination of Jaws based on an analysis of the criteria outlined in Accounting Standards Codification ("ASC") Topic 805, "Business Combinations" ("ASC 805"), as the Company’s former owner retained control after the Business Combination. Refer to Note 1, "Nature of Business", for details surrounding the Business Combination. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Jaws, accompanied by a recapitalization. The net assets of Jaws were stated at historical cost, with no goodwill or other intangible assets recorded.

While Jaws was the legal acquirer in the Business Combination, because the Company was deemed the accounting acquirer, the historical financial statements of PCIH became the historical financial statements of the combined company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements reflect the historical operating results of PCIH prior to the Business Combination, the combined results of Jaws and the Company following the close of the Business Combination, the assets and liabilities of the Company at their historical cost, and the Company’s equity structure for all periods presented.

Pursuant to the Primary Care (ITC) Intermediate Holdings, LLC Second Amended and Restated Limited Liability Company Agreement, dated June 3, 2021, PCIH is required to issue limited liability company units to Cano Health, Inc. if Cano Health, Inc. issues any equity securities, on substantially the same terms, such that the capitalization structure of PCIH shall mirror the capitalization structure of Cano Health, Inc. During the quarters ended June 30, 2021 and September 30, 2021, Cano Health, Inc. issued in the aggregate 4,178,147 shares of Class A common stock in connection with certain acquisitions. Accordingly, in November 2021, PCIH issued 4,178,147 limited liability company units to Cano Health, Inc. The issuance of these Units resulted in a $39.6 million increase in the Company's non-controlling interests and a corresponding decrease in additional paid in capital with no effect on total stockholder's equity. The Company has reflected the November 2021 PCIH unit issuance related to the quarter ended June 30, 2021 totaling $38.6 million during the third quarter of 2021 as the amount was not material and did not impact total stockholders' equity / members’ capital.

Warrant Liabilities

The Company assumed 23.0 million public warrants ("Public Warrants") and 10.53 million private placement warrants ("Private Placement Warrants") upon the consummation of the Business Combination. The Company may issue or assume common stock warrants that are recorded as either liabilities or equity in accordance with the respective accounting guidance. Warrants recorded as equity are recorded at their relative fair value or fair value determined at the issuance date and remeasurement is not required. Warrants recorded as liabilities are recorded at their fair value, within warrant liability on the condensed consolidated balance sheets, and remeasured on each reporting date with changes recorded in revaluation of warrant liability on the Company’s condensed consolidated statements of operations.

The Public Warrants became exercisable 30 days after the consummation of the Business Combination, which occurred on June 3, 2021. The Public Warrants will expire five years after the consummation of the Business Combination, or earlier upon redemption or liquidation. The Private Placement Warrants are identical to the Public Warrants, except that so long as the Private Placement Warrants are held by the Sponsor or any of its permitted transferees, the Private Placement Warrants: (i) may be exercised for cash or on a “cashless basis”, (ii) may not be transferred, assigned or sold until 30 days after the completion of the initial Business Combination, (iii) shall not be redeemable by the Company when the Class A ordinary shares equal or exceed $18.00, and (iv) shall only be

redeemable by the Company when the Class A ordinary shares are less than $18.00 per share, subject to certain adjustments.

The Company evaluated the Public Warrants and Private Placement Warrants and concluded that they do not meet the criteria to be classified as shareholders’ equity in accordance with ASC 815-40, “Derivatives and Hedging–Contracts in Entity’s Own Equity” ("ASC 815"). As the Public Warrants and Private Placement Warrants also meet the definition of a derivative under ASC 815, the Company has recorded these warrants as liabilities on its condensed consolidated balance sheets, with changes in their respective fair values recognized in the statement of operations at each reporting date.

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts with Customers”, ASC 606 (“ASC 606”). On January 1, 2019, the Company adopted ASC 606, applying the full retrospective method as of the earliest period presented. The portfolio approach was used to apply the requirements of the standard to groups of contracts with similar characteristics.

Under ASC 606, the Company recognizes revenue when a customer obtains control of the promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company transfers to the customer (i.e., patient). At contract inception, once the contract is determined to be within the scope of ASC 606, management reviews the contract to determine which performance obligations must be satisfied and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

The Company derives its revenue primarily from its capitated fees for medical services provided under capitated arrangements, fee-for-service arrangements, and revenue from the sale of pharmaceutical drugs.

Capitated revenue is derived from fees for medical services provided by the Company under capitated arrangements with health maintenance organizations’ (“HMOs”) health plans. Capitated revenue consists of revenue earned through Medicare as well as through commercial and other non-Medicare governmental programs, such as Medicaid, which is captured as other capitated revenue. The Company is required to deliver primary care physician services to the enrolled member population and is responsible for medical expenses related to healthcare services required by that patient group, including services not provided by the Company. Since the Company controls the primary care physician services provided to enrolled members, the Company acts as a principal. The gross fees under these contracts are reported as revenue and the cost of provider care is included in third-party medical costs. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which they operate does not require such registration for risk-bearing providers.

Since contractual terms across these arrangements are similar, the Company groups them into one portfolio. The Company identifies a single performance obligation to stand-ready to provide healthcare services to enrolled members. Capitated revenue is recognized in the month in which the Company is obligated to provide medical care services. The transaction price for the Medicare Advantage and Medicare Direct Contracting services provided

depends upon the pricing established by the Centers for Medicare & Medicaid (“CMS”) and includes rates that are based on the cost of medical care within a local market and the average utilization of healthcare services by the members enrolled. The transaction price is variable since the rates are risk adjusted for projected health status (acuity) of members and demographic characteristics of the enrolled members. The risk adjustment to the transaction price is presented as the Medicare Risk Adjustment (“MRA”) within accounts receivable on the accompanying condensed consolidated balance sheets. The fees are paid on an interim basis based on submitted enrolled member data for the previous year and are adjusted in subsequent periods after the final data is compiled by the CMS.

In 2020, the Company entered into multi-year agreements with Humana, Inc. (“Humana”), a managed care organization, to provide services only to members covered by Humana in certain centers. The agreements contain an administrative payment from Humana in exchange for the Company providing certain care coordination services during the contract term. The care coordination payments are refundable to Humana on a pro-rata basis if the Company ceases to provide services at the centers within the specified contract term. The Company identified one performance obligation to stand-ready to provide care coordination services to patients and will recognize revenue ratably over the contract term. Care coordination revenue is included in other revenue along with other ancillary healthcare revenues.

Fee-for-service revenue is generated from primary care services provided in the Company’s medical centers. During an office visit, a patient may receive a number of medical services from a healthcare provider. These healthcare services are not separately identifiable and are combined into a single performance obligation. The Company recognizes fee-for-service revenue at the net realizable amount at the time the patient is seen by a provider, and the Company’s performance obligation to the patient is complete.

Pharmacy revenue is generated from the sales of prescription medication to patients. Pharmacy contracts contain a single performance obligation. The Company satisfies its performance obligation and recognizes revenue at the time the patient takes possession of the merchandise. Other revenue includes revenue from certain third parties which include ancillary fees earned under contracts with certain care organizations for the provision of care coordination services.

The Company’s revenue from its revenue streams described in the preceding paragraphs for the three and nine months ended September 30, 2021 and 2020 was as follows:

		Three Months Ended September 30,
(in thousands)		2021			2020
		Revenue $	Revenue %		Revenue $	Revenue %
Capitated revenue:
Medicare	$	447,250	84.9%	$	220,591	83.8	%
Other capitated revenue		54,530	10.4%		32,383	12.3	%
Total capitated revenue		501,780	95.3%		252,974	96.1	%
Fee-for-service and other revenue:
Fee-for-service		8,176	1.6%		3,258	1.2	%
Pharmacy		10,096	1.8%		6,154	2.4	%
Other		6,746	1.3%		747	0.3	%
Total fee-for-service and other revenue		25,018	4.7%		10,159	3.9	%
Total revenue	$	526,798	100.0%	$	263,133	100.0	%

		Nine Months Ended September 30,
		2021				2020
(in thousands)		Revenue $	Revenue %			Revenue $	Revenue %
Capitated revenue:
Medicare	$	1,008,329	84.0	%	$	455,986	80.0	%
Other capitated revenue		139,712	11.6	%		88,631	15.6	%
Total capitated revenue		1,148,041	95.7	%		544,617	95.6	%
Fee-for-service and other revenue:
Fee-for-service		17,113	1.4	%		6,269	1.1	%
Pharmacy		25,619	2.1	%		17,207	3.0	%
Other		9,323	0.8	%		1,544	0.3	%
Total fee-for-service and other revenue		52,055	4.3	%		25,020	4.4	%
Total revenue	$	1,200,096	100.0	%	$	569,637	100.0	%

As the performance obligations from the Company’s revenues are recognized at a point in time and the revenues recognized over time relate to contracts with a duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) which provides relief from the requirement to disclose the transaction price for remaining performance obligations at the end of each reporting period and the requirement to disclose when the Company expects to recognize the related revenue. The Company has de minimis performance obligations remaining at the end of the reporting period as patients are not contractually obligated to continue to receive medical care from the network of providers.

Third-Party Medical Costs

Third-party medical costs primarily consist of all medical expenses paid by the health plans or CMS, including inpatient and hospital care, specialists, and medicines for which the Company bears risk.

Direct Patient Expense

Direct patient expense primarily consists of costs incurred in the treatment of the patients, including the compensation related to medical service providers and technicians, medical supplies, purchased medical services, drug costs for pharmacy sales, and payments to third-party providers.

Third-party medical costs and direct patient expense collectively represent the cost of services provided.

Significant Vendor

The Company’s primary provider of pharmaceutical drugs and pharmacy supplies accounted for approximately 87% and 100%, and 96% and 100%, of the Company’s pharmaceutical drugs and supplies expense for the three months ended September 30, 2021, and 2020, respectively, and nine months ended September 30, 2021, and 2020, respectively.

Concentration of Risk

Contracts with three of the HMOs accounted for approximately 57.2% and 63.6% of total revenues for the three and nine months ended September 30, 2021, respectively, and approximately 39.8% of total accounts receivable as of September 30, 2021. Contracts with three of the HMOs accounted for approximately 70.2% and 67.5% of total revenues for the three and nine months ended September 30, 2020, respectively, and approximately 67.1% of total accounts receivable as of December 31, 2020. The loss of revenue from these contracts could have a material adverse effect on the Company. The percentage of accounts receivable related to the three HMOs decreased over the nine-month period ended September 31, 2021 due to an increase in acquisitions over that time period. The acquisitions significantly increased overall accounts receivable over this period, effectively diluting accounts receivable from the HMOs.

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash deposits in excess of the Federal Deposit Insurance Corporation insured limit of $0.3 million. At times, such cash balances may be in excess of insured amounts.

Cash and Restricted Cash

Cash and cash equivalents are highly liquid investments purchased with original maturities of three months or less. During the third quarter of 2021, two health plans required the Company to maintain restricted cash balances for an aggregate amount of $3.5 million. These restricted cash balances are included within the caption cash and restricted cash in the accompanying condensed consolidated balance sheets.

Inventory

Inventory consists entirely of pharmaceutical drugs and is valued at the lower of cost (under the first-in, first-out method) or net realizable value.

Accounts Receivable, Net of Unpaid Service Provider Costs

Accounts receivable are carried at amounts the Company deems collectible. Accordingly, an allowance is provided in the event an account is considered uncollectible. As of September 30, 2021 and December 31, 2020, the Company believes no allowance is necessary. The ultimate collectability of accounts receivable may differ from

amounts estimated. The period between the time when the service is performed by the Company and the fees are received is usually one year or less and therefore, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust accounts receivable for the effect of a significant financing component.

Included in accounts receivable are MRA receivables which is an estimate derived from adjustments based on the health status of members and demographic characteristics of the plan. The health status of members is used to determine a risk score which is actuarially determined by comparing what was received from the CMS and what should have been received based on the health status of the enrolled member. Our accounts receivable included MRA receivables in the amount of $108.6 million and $18.1 million as of September 30, 2021 and December 31, 2020, respectively.

As of September 30, 2021 and December 31, 2020, the Company’s accounts receivable were presented net of the unpaid service provider costs. A right of offset exists when all of the following conditions are met: 1) each of the two parties owed the other determinable amounts; 2) the reporting party has the right to offset the amount owed with the amount owed to the other party; 3) the reporting party intends to offset; and 4) the right of offset is enforceable by law. The Company believes all of the aforementioned conditions existed as of September 30, 2021 and December 31, 2020.

Accounts receivable balances are summarized below:

		As of,
(in thousands)		September 30, 2021		December 31, 2020
Accounts receivable	$	242,086	$	113,089
Medicare risk adjustment		108,570		18,144
Unpaid service provider costs		(127,012)		(54,524)
Accounts receivable, net	$	223,644	$	76,709

Activity in unpaid service provider cost for the nine months ended September 30, 2021 and 2020 is summarized below:

		For the nine months ended September 30,
(in thousands)		2021		2020
Balance as at January 1,	$	54,524	$	19,968
Incurred related to:
Current year		566,473		216,044
Prior years		3,526		793
		569,999		216,837
Paid related to:
Current year		439,460		172,749
Prior years		58,051		20,761
		497,511		193,510
Balance as at September 30,	$	127,012	$	43,295

The foregoing reconciliation reflects a change in estimate during the nine months ended September 30, 2021 and September 30, 2020 related to unpaid service provider costs of approximately $3.5 million and $0.8 million, respectively.

Unpaid Service Provider Cost

Provider costs are accrued based on the date of services rendered to members, based in part on estimates, including an accrual for medical services incurred but not reported (“IBNR”). Liabilities for IBNR are estimated using standard actuarial methodologies including the Company’s accumulated statistical data, adjusted for current experience. These actuarially determined estimates are continually reviewed and updated. Differences between estimated IBNR and actual amounts incurred are adjusted as an increase or decrease to service provider cost in the condensed consolidated statements of operation in the period they become known.

The Company believes the amounts accrued to cover claims incurred and unpaid as of September 30, 2021 and December 31, 2020 are adequate. However, as the amount of unpaid service provider cost is based on estimates, the ultimate amounts paid to settle these liabilities might vary from recorded amounts, and these differences may be material.

The Company maintains a provider excess loss insurance policy to protect against claim expenses exceeding certain levels that were incurred by the Company on behalf of members. As of September 30, 2021 and December 31, 2020, the Company’s excess loss insurance deductible was $0.1 million and maximum coverage was $2.0 million per member per calendar year. The Company recorded excess loss insurance premiums of $1.9 million and $5.4 million, and insurance reimbursements of $3.6 million and $5.4 million, for the three and nine months ended September 30, 2021, respectively. The Company recorded excess loss insurance premiums of $1.3 million and $3.6 million, and no insurance reimbursements, for the three and nine months ended September 30, 2020, respectively. The Company recorded these amounts on a net basis in the caption third-party medical costs in the accompanying condensed consolidated statements of operations. The Company records excess loss insurance recoveries in accounts receivable on the accompanying condensed consolidated balance sheets. As of September 30, 2021 and December 31, 2020, the Company recorded insurance recoveries of $3.5 million and $2.5 million, respectively.

Debt Issuance Costs

Debt issuance costs represent fees incurred by the Company in connection with securing funding from a lender. These are lender fees and third-party professional fees that would not have been incurred if the Company did not pursue and secure financing. In circumstances where an embedded derivative is bifurcated from a host credit agreement and recorded as a standalone instrument at fair value, the debt issuance costs will reflect the initial fair value of such derivative. At inception of a credit agreement, these debt issuance costs are capitalized and presented net against the carrying amount of the related debt liabilities in the accompanying condensed consolidated balance sheets. Following recognition, they are amortized over the term of their related credit agreement through interest expense in the accompanying statements of operations through the effective interest method. In instances where there is no related debt drawn or outstanding, the debt issuance costs are presented in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets.

As of September 30, 2021 and December 31, 2020, the Company recorded capitalized deferred issuance cost balances of $24.2 million and $24.9 million, respectively, in the accompanying condensed consolidated balance sheets, as described in Note 9, “Long-Term Debt”. Of the balance as of September 30, 2021, $23.5 million was included in the caption notes payable, net of current portion and debt issuance costs, $0.2 million in prepaid expenses and other current assets, and $0.5 million in other assets on the accompanying condensed consolidated balance sheets. Of the balance as of December 31, 2020, $18.5 million was included in the caption notes payable,

net of current portion and debt issuance costs, $5.8 million in prepaid expenses and other current assets, and $0.6 million in other assets on the accompanying condensed consolidated balance sheets.

As described in Note 9, “Long-Term Debt”, Term Loan 3 (as defined below) was partially repaid by the Company on June 3, 2021. The Company’s partial extinguishment of this Term Loan consisted of a cash payment to the lender for (1) $400.0 million of the outstanding principal amount, and (2) the outstanding accrued interest. The Company recorded a loss on extinguishment of debt of $13.2 million which related to unamortized debt issuance costs.

The Company recorded $4.0 million and $7.7 million of amortization of deferred financing costs for the three and nine months ended September 30, 2021, respectively. The Company recorded amortization expense of $3.0 million and $3.9 million for the three and nine months ended September 30, 2020, respectively. Amortization expense is reflected under the caption interest expense in the accompanying condensed consolidated statements of operations.

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. The Company capitalizes asset purchases as well as major improvements that extend the useful life or add functionality, value, or productive capacity in amounts greater than one thousand dollars. Depreciation and amortization are computed using the straight-line method over the life of the assets, ranging from three to fifteen years. Leasehold improvements are amortized over the shorter of the estimated useful life of fifteen years or the term of the lease.

Repairs and maintenance are expensed as incurred. When property and equipment are retired, sold, or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in the accompanying condensed consolidated statements of operations.

Impairment of Long-Lived Assets

The Company periodically reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Business Acquisitions

The Company accounts for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. The Company uses various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, EBITDA growth rates, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. Refer to Note 3, "Business Acquisitions," for a discussion of the Company's recent acquisitions.

Goodwill

Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets acquired. The goodwill arising from acquisitions is a result of synergies that are expected to be derived from elimination of duplicative costs and the achievement of economies of scale. The Company assesses goodwill for impairment on an annual basis and between tests if events occur or circumstances exist that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual assessment on the first of October. Goodwill is evaluated for impairment at the reporting unit level. The Company has identified one reporting unit for the annual goodwill impairment testing. First, the Company performs a qualitative analysis to determine if it is more likely than not that the fair value of the reporting unit is less than its carrying value and a quantitative impairment test is required. If required, the Company applies the quantitative test to identify and measure the amount of impairment by comparing the fair value of the reporting unit, which the Company estimates on an income approach using the present value of expected future cash flows of the reporting unit to its carrying value.

The Company considered the effect of the COVID-19 pandemic on its business and the overall economy and resulting impact on its goodwill. As of October 1, 2020, the Company performed a quantitative goodwill impairment test and did not identify any impairment to goodwill. There was no impairment to goodwill during the nine months ended September 30, 2021 and 2020. The Company will perform its annual impairment analysis as of October 1, 2021.

Intangibles, Net

The Company’s intangibles consist of trade names, brand, non-compete, and customer, payor, and provider relationships. The Company amortizes its intangibles using the straight-line method over the estimated useful lives of the intangible, which ranges from one to twenty years. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

Deferred Rent

Minimum rent, including fixed escalations, is recorded on a straight-line basis over the lease term. The lease term commences when the Company takes possession of the leased premises and, in most cases, ends upon expiration of the initial non-cancelable term. When a lease provides for fixed escalations of the minimum rental payments during the lease term, the difference between the recorded straight-line rent and the amount payable under the lease is recognized as deferred rent obligation.

Professional and General Liability

As a healthcare provider, the Company is subject to medical malpractice claims and lawsuits. The Company may also be liable, as an employer, for the negligence of healthcare professionals it employs or the healthcare professionals it engages as independent contractors. To mitigate a portion of this risk, the Company maintains medical malpractice insurance, principally on a claims-made basis, with a reputable insurance provider. This policy contains a retroactive feature which covers claims incurred at the sites the Company operates, regardless if the claim was filed after the site’s respective policy term. The policy contains various limits and deductibles.

Loss contingencies, including medical malpractice claims and legal actions arising in the ordinary course of business, are recorded as liabilities when the likelihood of loss is probable, and an amount or range of loss can be reasonably estimated.

The Company maintains a malpractice insurance policy with a coverage limit of $1.0 million per occurrence and $3.0 million aggregate coverage, with an umbrella policy coverage of $5.0 million. Any amounts over that threshold, or for which the insurance policy will not cover, will be borne by the Company and may materially affect the Company’s future consolidated financial position, results of operations, and cash flows. As of September 30, 2021 and December 31, 2020, the Company has recorded claims liabilities of $0.5 million and $0.1 million, respectively, in other liabilities. Insurance recoverables were immaterial as of September 30, 2021 and December 31, 2020, and are recorded in other assets on the accompanying condensed consolidated balance sheets.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. Advertising and marketing costs expensed totaled approximately $4.9 million and $2.4 million for the three months ended September 30, 2021 and 2020, respectively, and $10.5 million and $4.9 million for the nine months ended September 30, 2021 and 2020, respectively. Advertising and marketing costs are included in the caption selling, general, and administrative expenses in the accompanying condensed consolidated statements of operations.

Management Estimates

The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions based on available information. Such estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. However, actual results could differ from those estimates and these differences may be material. Significant estimates made by the Company include, but are not limited to, fair value allocations for intangible assets acquired as part of the Company’s numerous acquisitions, recoverability of goodwill and intangibles, fair value of contingent considerations, unpaid service provider cost liability, and respective revenues and expenses related to these estimates for the years reported.

COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. The rapid spread of COVID-19 around the world led to the shutdown of cities as national, state, and local authorities implemented social distancing, quarantine and self-isolation measures. [While the restrictions have been eased across the United States, some restrictions remain in place.] The full extent to which the COVID-19 pandemic has and will directly or indirectly impact the Company, future results of operations and financial condition will depend on future factors that are uncertain and cannot be accurately predicted. These factors include, but are not limited to, new information that may emerge concerning COVID-19, including the impact of new variants of the virus, the scope and duration of business closures and restrictions, government-imposed or recommended suspensions of elective procedures, and expenses required for supplies and personal protective equipment. Due to these and other uncertainties, management cannot estimate the length or severity of the impact of the pandemic on the Company. Additionally, because of the Company’s business model, the full impact of the COVID-19 pandemic may not be fully reflected in the Company’s results of operations and overall financial condition until future periods. The impact of COVID-19 variants cannot be predicted at this time, and could depend on numerous factors, [including vaccination rates among the population, the effectiveness of the COVID-19 vaccines and boosters against COVID-19 variants, and the actions taken to contain the COVID-19 pandemic and the economic impact on our business]. Management will continue to closely evaluate and monitor the nature and extent of these potential impacts to the Company, results of operations, and liquidity

Income Taxes

The acquisition of PCIH was implemented through an Up-C structure. Prior to the closing of the Business Combination, Jaws was reincorporated in the State of Delaware and became a U.S. domestic corporation named Cano Health, Inc. Merger Sub, a wholly owned subsidiary of Jaws, merged with and into PCIH, with PCIH as the surviving company in the merger. As of September 30, 2021, the Seller, the former sole owner and managing member of PCIH, held approximately 64.0% of voting rights in Cano Health, Inc. and 64.0% of economic rights in PCIH, while other investors, including the former stockholders of Jaws and PIPE Investors held approximately 36.0% of economic and voting rights in Cano Health, Inc. and 36.0% of economic and 100.0% of managing rights in PCIH. Subsequent to the closing of the Business Combination, income attributable to Cano Health, Inc. is taxed under Subchapter C while PCIH will continue to be treated as a partnership for tax purposes.

Prior to the close of the Business Combination, the Company was treated as a partnership for U.S. income tax purposes, whereby earnings and losses were included in the tax return of its members and taxed depending on the members’ tax situation. While the overall entity was previously treated as a partnership, the Company established in 2019 a subsidiary group that was taxed under Subchapter C with immaterial operations in 2019. The operations of the subsidiary group are conducted through a legal entity domiciled in Puerto Rico. The subsidiary group is subject to Puerto Rico and U.S. Federal taxes and Florida State taxes. Refer to Note 16, “Income Taxes”, for further details.

The Company recognizes and measures tax positions taken or expected to be taken in its tax return based on their technical merit and assesses the likelihood that the positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. Interest and penalties on tax liabilities, if any, would be recorded in the captions interest expense and other expenses, respectively, in the condensed consolidated statements of operations.

The U.S. Federal jurisdiction and the State of Florida are the major tax jurisdictions where the Company files income tax returns. The Company is generally subject to U.S. Federal or State examinations by tax authorities for all years since inception.

Recent Accounting Pronouncements 

In February 2016, the FASB established Topic 842, “Leases”, by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, “Land Easement Practical Expedient for Transition to Topic 842”, ASU No. 2018-10, “Codification Improvements to Topic 842, Leases”, ASU No. 2018-11, “Targeted Improvements”, ASU No. 2018-20, “Leases (Topic 842): Narrow-Scope Improvements for Lessors”, ASU No. 2021-05, “Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments”, and ASU No. 2020-05, “Leases (Topic 842): Effective Dates for Certain Entities” (collectively referred to as “ASC 842”). ASC 842 establishes a right of use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

Under ASC 842, a modified retrospective transition approach is required, and entities may choose to use either the effective date or the beginning of the earliest period presented in the financial statements as the date of initial application, with certain practical expedients available. The Company is in the process of evaluating the practical expedient options for adoption. ASC 842 is effective for fiscal years beginning after December 15, 2021 and for interim periods within fiscal years beginning after December 15, 2022, with early application permitted, and the Company expects to adopt the new standard on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier.

The Company has identified and contracted with a software vendor for the technology to support compliance with ASU 842. In addition, the Company is in the process of identifying the complete population of leases, which includes testing over contracts for any potential embedded leases. Based on the provisions of ASU 842, the Company anticipates a material increase in both assets and liabilities when the current operating lease contracts are recorded on the balance sheet. The Company does not yet have a dollar estimate of the impact; however, the Company does not anticipate the update having a material effect on its condensed consolidated statements of operations or cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU No. 2020-03, “Codification Improvements to Financial Instruments” (collectively referred to as “ASC 326”). which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. The standard has been further refined through subsequent releases by the FASB, including the extension of the effective date. As amended by ASU No. 2019-10, the standard is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those annual periods, with early adoption permitted, and the Company expects to adopt ASU 326 on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier. The Company is currently evaluating the effect that the standard will have on its condensed consolidated financial statements and related disclosures. The Company does not anticipate the update to have a material effect on the Company’s condensed consolidated statements of operations or cash flows.

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (“Topic 718”), which expands the scope of share-based compensation guidance to include share-based payment transactions for acquiring goods and services from nonemployees. The FASB has also issued an amendment to this update to include share-based payment awards granted to a customer. The update is effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (“Topic 820”): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which simplifies the fair value measurement disclosure requirements, including removing certain disclosures related to transfers between fair value hierarchy levels and adds certain disclosures to related level 3 investments. The update is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, with early adoption permitted. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In October 2018, the FASB issued ASU No. 2018-17, Consolidation (“Topic 810”) — Targeted Improvements to Related Party Guidance for Variable Interest Entities. The ASU creates a new private company accounting alternative in U.S. GAAP that allows a private company to not apply the VIE guidance to legal entities under common control if both the common control parent and the legal entity being evaluated for consolidation are not public business entities and other criteria are met. The new guidance also changes how all entities that apply the VIE guidance evaluate decision-making fees. For entities other than private companies, the guidance on decision-making fees is effective for annual periods beginning after December 15, 2019, and interim periods therein. The guidance is effective for private companies for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including in an interim period. The Company does not expect the update to have a material effect on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), “Simplifying the Accounting for Income Taxes.” This new standard simplifies various aspects related to the accounting for income taxes. The standard removes certain exceptions to the general principles in Topic 740 and also clarifies and modifies

existing guidance to improve consistent application of Topic 740. The Company adopted this standard effective January 1, 2021 with no material impact to its condensed consolidated financial statements.

XML

Business Acquisitions

9 Months Ended

Sep. 30, 2021

Business Combination and Asset Acquisition [Abstract]

Business Acquisitions

BUSINESS ACQUISITIONS

Doctor’s Medical Center, LLC

On July 2, 2021, the Company acquired Doctor's Medical Center, LLC and its affiliates (“DMC”) for a purchase price of $300.7 million in cash. DMC sellers entered into non-compete agreements with the Company. The Company recorded non-compete intangible assets totaling $1.7 million with a weighted-average amortization period of five years.

The purchase price has been allocated to accounts receivable, net of unpaid service provider costs, property and equipment, net, other assets, favorable leasehold interest, non-compete intangibles, trade name, payor relationships, goodwill, and accounts payable and accrued expenses. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	6,641
Property and equipment, net		1,283
Other assets		142
Favorable leasehold interest		110
Non-compete intangibles		1,700
Trade name		25,500
Payor relationships		115,100
Goodwill		151,188
Accounts payable and accrued expenses		(1,001)
Total purchase price, including non-compete intangibles	$	300,663

Total revenues and net income attributable to the assets acquired in the DMC acquisition were approximately $45.6 million and $4.4 million, respectively, for the three and nine months ended September 30, 2021.

University Health Care and its affiliates

On June 11, 2021, the Company acquired University Health Care and its affiliates (collectively, “University”). The purchase price totaled $611.1 million, of which $541.5 million was paid in cash, $9.6 million in contingent consideration from forfeited acquisition add-ons based on terms negotiated by University prior to closing, and $60.0 million in 4,055,698 shares of the Company’s Class A common stock. University sellers entered into non-compete agreements with the Company. The Company recorded non-compete intangible assets totaling $45.2 million with a weighted-average amortization period of five years.

The purchase price has been allocated to accounts receivable, net of unpaid service provider costs, inventory, property and equipment, payor relationships, non-compete intangibles, other acquired intangibles, other assets, goodwill, and accounts payable and accrued expenses. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	2,217
Inventory		264
Property and equipment, net		1,636
Payor relationships		175,172
Non-compete intangibles		45,191
Other acquired intangibles		113,237
Other assets		116
Goodwill		273,427
Accounts payable and accrued expenses		(140)
Total purchase price, including non-compete intangibles	$	611,120

Total revenues attributable to the assets acquired in the University acquisition were approximately $89.3 million and $120.5 million for the three and nine months ended September 30, 2021, respectively. Net income attributable to the assets acquired in the University acquisition was approximately $10.6 million and $26.7 million for the three and nine months ended September 30, 2021, respectively.

HP Enterprises II, LLC and related entities

On June 1, 2020, the Company acquired all of the assets of HP Enterprises II, LLC and related entities (collectively, “Healthy Partners”). The purchase price totaled $195.4 million, of which $149.3 million was paid in cash (including $18.0 million paid to an escrow agent, of which $17.1 million was released on January 13, 2021 and $0.9 million is to be released on June 1, 2022), and $30.0 million in 923,076 Class A-4 Units of Primary Care (ITC) Intermediate Holdings, LLC’s securities. The remaining amount of $16.1 million related to payment reconciliations was held back, and is due no later than five days following January 31, 2022. The physicians entered into employment agreements with the Company which included covenants not to compete. The Company recorded non-compete intangible assets totaling $1.0 million with a weighted-average amortization period of five years.

The purchase price has been allocated to property and equipment, non-compete intangibles, acquired intangibles, goodwill, and other assets. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Property and equipment	$	2,409
Non-compete intangibles		1,022
Acquired intangibles		117,014
Goodwill		74,852
Other assets		87
Total purchase price, including non-compete intangibles	$	195,384

Total revenues attributable to the assets acquired in the Healthy Partners acquisition were approximately $95.0 million and $274.0 million for the three months and nine months ended September 30, 2021, respectively, and approximately $81.1 million and $114.7 million for the three months and nine months ended September 30, 2020, respectively. Net income attributable to the assets acquired in the Healthy Partners acquisition was approximately $15.8 million and $39.1 million for the three months and nine months ended September 30, 2021, respectively, and approximately $7.6 million and $9.8 million for the three months and nine months ended September 30, 2020.

Primary Care Physicians and related entities

On January 2, 2020, the Company acquired all of the assets of Primary Care Physicians and related entities (collectively, “PCP”). The purchase price totaled $60.2 million, of which $53.6 million was paid in cash and $4.0 million was paid in 123,077 Class A-4 Units of Primary Care (ITC) Intermediate Holdings, LLC. The remaining amount includes $1.5 million related to the pay-down of debt, and $1.1 million related to the pay-down of accounts payable and accrued expenses of PCP. The physicians entered into employment agreements with the Company and these agreements included covenants not to compete. The Company recorded non-compete intangible assets totaling $0.8 million with a weighted-average amortization period of three years.

The purchase price has been allocated to cash and cash equivalents, accounts receivable, inventory, property and equipment, non-compete intangibles, acquired intangibles, goodwill, and accounts payable. The portion of the purchase price that is allocated to the non-compete is not considered part of the consideration transferred to acquire the business and is accounted for separately. The following table provides the allocation of the purchase price:

(in thousands)
Cash and cash equivalents	$	191
Accounts receivable		486
Inventory		155
Property and equipment		1,518
Non-compete intangibles		846
Acquired intangibles		43,549
Goodwill		13,738
Accounts payable		(274)
Total purchase price, including non-compete intangibles	$	60,209

Total revenues attributable to the assets acquired in the PCP acquisition were approximately $33.4 million and $33.0 million for the three months ended September 30, 2021 and 2020, respectively, and $78.4 million and $45.6 million for the nine months ended September 30, 2021 and 2020, respectively. Net income attributable to the

assets acquired in the PCP acquisition was $4.9 million and $1.7 million for the three months ended September 30, 2021 and 2020, respectively, and $12.9 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively.

The net effect of acquisitions to the Company’s assets and liabilities and reconciliation of cash paid for net assets acquired for the nine months ended September 30, 2021 and 2020, including amounts related to acquisitions not disclosed above, was as follows:

		Nine Months Ended September 30,
(in thousands)		2021		2020
Assets Acquired
Accounts receivable	$	50,979	$	486
Other assets		2,050		433
Property and equipment		3,411		4,011
Goodwill		531,162		89,976
Intangibles		637,537		162,537
Total assets acquired		1,225,139		257,443
Liabilities Assumed
Due to sellers		1,295		16,288
Contingent consideration		47,900		—
Other liabilities		45,783		1,530
Total liabilities assumed		94,978		17,818
Net Assets Acquired		1,130,161		239,625
Issuance of Parent equity in connection with acquisitions		61,500		34,300
Acquisitions of subsidiaries, including non-compete intangibles, net of cash acquired	$	1,068,661	$	205,325

Pro forma information is not presented for all of the Company’s acquisitions during the three months and nine months ended September 30, 2021 and 2020 as historical financial results were unavailable for all businesses acquired. The following unaudited pro forma financial information summarizes the combined results of operations for the Company and its acquisitions of University and HP, as if the companies were combined as of January 1, 2020:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2021		2020		2021		2020
Revenue	$	526,798	$	350,976	$	1,354,547	$	979,355
Net loss	$	(40,883)	$	(14,398)	$	(53,592)	$	(8,566)

XML

Property and Equipment, Net

9 Months Ended

Sep. 30, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

PROPERTY AND EQUIPMENT, NETThe following is a summary of property and equipment, net and the related useful lives as of September 30, 2021 and December 31, 2020:

			As of
(in thousands)			September 30,		December 31,
Assets Classification	Useful Life		2021		2020
Leasehold improvements	Lesser of lease term or 15 years	$	33,288	$	25,021
Machinery and equipment	3-12 years		14,403		8,288
Automobiles	3-5 years		6,679		4,900
Computer and equipment	5 years		5,950		4,475
Furniture and equipment	3-7 years		3,242		2,390
Construction in progress			19,057		4,155
Total			82,619		49,229
Less: Accumulated depreciation and amortization			(18,463)		(11,103)
Property and equipment, net		$	64,156	$	38,126

Depreciation expense was $2.7 million and $1.8 million for the three months ended September 30, 2021 and 2020, respectively, and $7.4 million and $4.5 million for the nine months ended September 30, 2021 and 2020, respectively. The Company paid a related party for construction in progress and leasehold improvements totaling $3.2 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and totaling $5.6 million and $5.4 million for the nine months ended September 30, 2021 and 2020, respectively. The Company had $0.1 million due from the related party as of September 30, 2021 and $0.1 million due to the related party as of December 31, 2020, respectively, related to the construction in progress and leasehold improvements. These payments are included in the caption accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets.

The Company records construction in progress related to vehicles, computer equipment, medical equipment, furniture, and fixtures that have been acquired but have not yet been placed in service as of the reporting date, as well as leasehold improvements currently in progress.

XML

Intangibles, Net

9 Months Ended

Sep. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangibles, Net

INTANGIBLES, NET

As of September 30, 2021, the Company’s total intangibles, net consisted of the following:

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(747)	$	662
Brand		183,217		(6,286)		176,931
Non-compete		75,626		(8,270)		67,356
Customer relationships		880		(171)		709
Payor relationships		609,322		(25,057)		584,265
Provider relationships		12,242		(1,573)		10,669
Total intangibles, net	$	882,696	$	(42,104)	$	840,592

As of December 31, 2020, the Company’s total intangibles, net consisted of the following:

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(630)	$	779
Brand		29,486		(2,171)		27,315
Non-compete		7,733		(3,373)		4,360
Customer relationships		880		(135)		745
Payor relationships		201,530		(11,960)		189,570
Provider relationships		4,119		(533)		3,586
Total intangibles, net	$	245,157	$	(18,802)	$	226,355

The Company recorded amortization expense of $14.2 million and $3.6 million for the three months ended September 30, 2021 and 2020, respectively, and $23.3 million and $8.2 million for the nine months ended September 30, 2021 and 2020, respectively.

Expected amortization expense for the Company’s existing amortizable intangibles for the next five years, and thereafter, as of September 30, 2021 is as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	15,075
2022		59,423
2023		57,585
2024		55,644
2025		54,218
Thereafter		598,647
Total	$	840,592

XML

Capital Lease Obligations

9 Months Ended

Sep. 30, 2021

Leases [Abstract]

Capital Lease Obligations

CAPITAL LEASE OBLIGATIONS

The Company enters into non-cancellable capital lease agreements with third parties, bearing interest at rates ranging from 4.1% to 12.1%, and expiring through the year 2026. The assets and liabilities under the capital leases are recorded at the present value of the minimum lease payments. The assets are depreciated on a straight-line basis over the shorter of the lease term or the estimated useful lives. The assets under capital leases are included in the accompanying condensed consolidated balance sheets as property and equipment, net, with a gross asset value of $4.7 million and $4.2 million, and accumulated depreciation of $1.5 million and $1.5 million, as of September 30, 2021 and December 31, 2020, respectively. The depreciation of capital leases is included in depreciation and amortization.

Future minimum lease payments under the capital leases as of September 30, 2021 are due as noted below:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	307
2022		1,151
2023		819
2024		514
2025		76
2026		25
Total minimum lease payments		2,892
Less: amount representing interest		(327)
Total capital lease obligations		2,565
Less: current maturities		(1,006)
Total long-term capital lease obligations	$	1,559

Future minimum lease payments under the capital leases as of December 31, 2020 are due as noted below:

Year ending December 31,		Amount (in thousands)
2021	$	1,038
2022		919
2023		586
2024		271
Total minimum lease payments		2,814
Less: amount representing interest		(358)
Total capital lease obligations		2,456
Less: current maturities		(876)
Total long-term capital lease obligations	$	1,580

XML

Equipment Loans

9 Months Ended

Sep. 30, 2021

Debt Disclosure [Abstract]

Equipment Loans

EQUIPMENT LOANSThe Company has entered into various equipment loans to finance the purchases of property and equipment. Equipment loans were as follows as of September 30, 2021 and December 31, 2020:

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Notes payable bearing interest at 17.2%; due July 2022, secured by certain property and equipment	$	28	$	51
Notes payable bearing interest at 12.5%, 12.8%, and 11.0%; all due June 2023, all secured by certain property and equipment	41		82
Notes payable bearing interest at 10.7%; due June 2023, secured by certain property and equipment	60		58
Notes payable bearing interest at 7.2%; due April 2025, secured by certain property and equipment	78		92
Notes payable bearing interest at 4.2%; due December 2024, secured by certain property and equipment	746		904
Notes payable bearing interest at 3.4%; due March 2026, secured by certain property and equipment	1,014		—
Total equipment loans	1,967		1,187
Less: Current portion	(513)		(314)
Total equipment loans, net of current portion	$	1,454	$	873

XML

Contract Liabilities

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Contract Liabilities

CONTRACT LIABILITIES

As further explained in Note 13, “Related Party Transactions”, in the third quarter of 2020, the Company entered into an agreement with Humana under which they receive administrative payments in exchange for providing care coordination services at Humana Affiliate Provider (“HAP”) clinics over the term of such agreement. The Company’s contract liabilities balance related to these payments from Humana was $6.5 million and $5.3 million as of September 30, 2021 and December 31, 2020, respectively. The short-term portion is recorded in deferred revenue and the long-term portion is recorded in deferred revenue, net of current portion. The Company recognized $0.4 million and $1.0 million in revenue from contract liabilities recorded during the three months and nine months ended September 30, 2021, respectively.

A summary of significant changes in the contract liabilities balance during the period is as follows:

(in thousands)		For the three months ended September 30, 2021
Balance as at June 30, 2021	$	5,936
Increases due to amounts collected		990
Revenues recognized from current period increases		(413)
Balance as at September 30, 2021	$	6,513
(in thousands)		For the nine months ended September 30, 2021
Balance as at January 1, 2021	$	5,265
Increases due to amounts collected		2,290
Revenues recognized from current period increases		(1,042)
Balance as at September 30, 2021	$	6,513

Of the September 30, 2021 contract liabilities balance, the Company expects to recognize as revenue $0.5 million in the remainder of 2021, $1.9 million in 2022, $1.9 million in 2023, $1.8 million in 2024, and $0.4 million in 2025.

XML

Long-Term Debt

9 Months Ended

Sep. 30, 2021

Debt Disclosure [Abstract]

Long-Term Debt

LONG-TERM DEBT

The Company’s notes payable were as follows as of September 30, 2021 and December 31, 2020:

Long-Term Debt	As of,
(in thousands)	September 30, 2021		December 31, 2020
Term loan 3	$	252,531	$	480,000
Term loan 4	293,525		—
Term loan 5	100,000		—
Senior Notes	300,000		—
Less: Current portion of notes payable	(6,493)		(4,800)
	939,563		475,200
Less: debt issuance costs	(23,452)		(18,455)
Notes payable, net of current portion	$	916,111	$	456,745

Credit Facilities

Pursuant to a Credit Agreement with Credit Suisse and the other lenders party thereto (the “Credit Agreement”), the Company has entered into senior secured term loans (together with the revolving line of credit, the "Credit Facilities"). Obligations under the Credit Facilities are secured by substantially all of the Company’s assets. The Credit Facilities contain a financial maintenance covenant (which is for the benefit of the lenders under the revolving line of credit only), requiring the Company to not exceed a total first lien secured net debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio, which is tested quarterly only if the Company has exceeded a certain amount drawn under its revolving line of credit. As of September 30, 2021, the financial covenant did not apply.

Term Loan 1

On December 23, 2016, the Company entered into Term Loan 1, which bore interest at a variable rate equal to LIBOR plus an applicable margin (7.5% as of extinguishment on November 23, 2020). Beginning on March 31, 2017, the Company was required to make quarterly principal payments, which escalated every two years, with the final payment due on June 2, 2025.

Term Loan 1 was prepaid by the Company on November 23, 2020, which resulted in the Company’s legal relief from all obligations under Term Loan 1. The Company’s prepayment of Term Loan 1 consisted of a cash payment to the lender for (1) the outstanding principal, (2) the outstanding accrued interest, and (3) legal and prepayment fees.

Term Loan 2

On June 1, 2020, the Company entered into a term loan agreement with another lender for $130.0 million. Borrowings under Term Loan 2 bore cash interest at a rate of 5.0%, payable quarterly, in addition to interest paid in-kind ("PIK") of 11.5% per annum. Principal and PIK interest were due on December 1, 2022.

Term Loan 2 contained specific features that required the Company to pay the lender a make-whole amount in the event of a change in control of the Company or the issuance of additional debt by the Company (each a “make-whole event”). The make-whole amount was calculated as the present value of the scheduled interest between the date of a make-whole event and December 1, 2021 by utilizing a discount rate per annum equal to the United States Treasury securities rate three days prior to the date of the make-whole event plus 0.5%. These features met the criteria to be bifurcated from the host agreement as embedded derivatives under the guidance in ASC 815. At the time the Company entered into Term Loan 2, the likelihood of a make-whole event was deemed more than remote, and the Company determined these features contained substantial value to the lender. As such, the derivatives were bifurcated from the host agreement and recorded at the fair value on June 1, 2020 of $51.3 million. The embedded derivatives and the host agreement together represented the combined principal and interest obligations of the Company to the lender. The Company presented the embedded derivatives together with the debt obligation in the condensed consolidated balance sheets. The change in fair market value on embedded derivatives was $5.1 million for the three months ended September 30, 2020 and $5.4 million for the nine months ended September 30, 2020, and was recorded under the caption change in fair value of embedded derivative in the accompanying condensed consolidated statements of operations.

Term Loan 2 was prepaid by the Company on November 23, 2020, which resulted in the Company’s legal relief from all obligations under Term Loan 2. The Company’s prepayment of Term Loan 2 consisted of a cash payment to the lender for (1) the outstanding principal, (2) the outstanding accrued interest, and (3) legal and prepayment fees.

Term Loan 3

In conjunction with the Business Combination with Jaws, the Company entered into the Credit Agreement with Credit Suisse and the other lenders party thereto on November 23, 2020 under which Credit Suisse and the other lenders party thereto committed to extend credit to the Company in the initial amount of $685.0 million. The Credit Agreement initially consisted of (1) an initial term loan in the amount of $480.0 million (the “Initial Term Loan”), (2) delayed draw term loans (the “Delayed Draw Term Loans”) up to the aggregate amount of $175.0 million (the “Delayed Draw Term Commitments”), and (3) an initial revolving credit facility in the amount of $30.0 million (the “Initial Revolving Facility”).

On issuance, Term Loan 3 represented the principal amount of $480.0 million funded to the Company on November 23, 2020 by Credit Suisse and the other lenders. The Delayed Draw Term Commitments represented commitments from Credit Suisse and the other lenders to provide an aggregate amount of $175.0 million in additional term loans to the Company after November 23, 2020. As of September 30, 2021, the Company had fully drawn upon the Delayed Draw Term Commitments, and the $175.0 million of Delayed Draw Term Loans were combined with the Initial Term Loan into a single class of borrowings.

The Company is required to pay a commitment fee per annum (the “DDTL Ticking Fee”) on the unfunded Delayed Draw Term Commitments, depending on the days elapsed after December 15, 2020 (the “Ticking Fee Start Date”). The DDTL Ticking Fee is calculated on a 360-day year and payable in arrears on the last business day of each calendar quarter. The DDTL Ticking Fee is calculated as follows:

•No fee for the period commencing on the Ticking Fee Start Date until the date occurring 30 days thereafter.

•50% of the applicable margin for Delayed Draw Term Loans maintained as Eurodollar borrowings for the period commencing on the 31st day after the Ticking Fee Start Date until the date occurring 60 days after the Ticking Fee Start Date.

•100% of the applicable margin for Delayed Draw Term Loans maintained as Eurodollar borrowings for the period commencing on the 61st day after the Ticking Fee Start Date thereafter.

The Initial Term Loan and the Delayed Draw Term Loans are subject to principal amortization repayments due on the last business day of each calendar quarter equal to 0.25% of the initial principal amount funded outstanding for the Initial Term Loan and each Delayed Draw Term Loan, as applicable, based on the funding date of each Delayed Draw Term Loan if and when issued. Amortization payments commenced on March 31, 2021. The outstanding amount of unpaid principal and interest associated with the Initial Term Loan and the Delayed Draw Term Loans is due on the maturity date of November 23, 2027. Prior to the maturity date, the Company may elect to prepay, in whole or in part, the Initial Term Loan and Delayed Draw Term Loans at any time without premium or penalty, other than in connection with certain repricing transactions and customary breakage costs.

The Company is also subject to mandatory prepayments on the Initial Term Loan and Delayed Draw Term Loans based on the occurrence of certain events after November 23, 2020 including, (1) an amount equal to a percentage between 50% and 0% of excess cash flow for the fiscal year ending December 31, 2021 and each subsequent fiscal year based on the Company’s first lien net leverage ratio (calculated as total consolidated debt secured by a first lien on any collateral, net of restricted cash. divided by consolidated Adjusted EBITDA (as defined in the Credit Agreement)) at the last day of the applicable fiscal year due only if and to the extent such calculated amount is greater than $3 million, (2) an amount equal to 100% of the net proceeds received in excess of $3 million individually in any fiscal year, or $10 million in the aggregate, pertaining to the disposition of assets that are not reinvested in assets useful to the Company’s business within 18 months of the disposition date, (3) an amount equal to 100% of the net proceeds received from the issuance of non-permitted indebtedness that is not intended to refinance the Credit Agreement with Credit Suisse, and (4) $400.0 million of the net cash proceeds received in a private placement of Class A common stock of the Company after the Business Combination with Jaws.

The Company maintains the right to choose between an applicable base rate (“ABR”) borrowing or a Eurodollar borrowing prior to the issuance of all credit by Credit Suisse and the other lenders. Interest is calculated on a 360-day year, or a 365-day year when Credit Suisse’s prime rate is utilized in an ABR borrowing, payable in arrears on the last business day of each calendar quarter (or, with respect to Eurodollar borrowings, on the last day of the applicable interest period, or, if the interest period is greater than three months, in three month intervals), and payable in arrears on the maturity date of each borrowing.

ABR borrowings are subject to interest at a rate per annum equal to (1) the greatest of (a) Credit Suisse’s prime rate in effect on such day, (b) the funds effective rate issued by the Federal Reserve Bank of New York in effect on such day plus 0.5%, (c) the LIBOR rate for a one month interest period on such day, as adjusted via multiplication by the Credit Suisse’s statutory reserve rate and subject to a floor of 0.75% on the adjusted rate only for the Initial Term Loan and the Delayed Draw Term Loans, plus 1%, and (d) solely with respect to the Initial Term Loans and Delayed Draw Term Loans, 1.75%, plus (2) the applicable rate of (a) 3.75% from between November 23, 2020 to the Closing Date of the Business Combination and (b) 3.5% after the Closing Date of the Business Combination, provided that if the Company achieves a public corporate rating from Standard and Poor's ("S&P") of at least B and a public credit rating from Moody’s Investors Service ("Moody's") of at least B2, then for as long as such ratings remain in effect, a rate of 3.25% shall be applicable.

Eurodollar borrowings are subject to interest at a rate per annum equal to (1) the LIBOR rate for a one month interest period on such day, as adjusted via multiplication by the Credit Suisse’s statutory reserve rate and subject to a floor of 0.75% on the adjusted rate only for the Initial Term Loan and the Delayed Draw Term Loans, plus (2) the applicable rate of (a) 4.75% and (b) 4.5% after the Closing Date of the Business Combination, provided that if the Company achieves a public corporate rating from S&P of at least B and a public credit rating from

Moody’s of at least B2, then for as long as such ratings remain in effect, a rate of 4.25% shall be applicable. Prior to November 23, 2020, the Company elected to treat the Initial Term Loan and the Initial Revolving Facility as Eurodollar borrowings. As of September 30, 2021, the stated interest rate for the Initial Term Loan and the Initial Revolving Facility was 5.25% and the effective interest rate for the Initial Term Loan was 5.74%. As of September 30, 2021, the Company’s Term Loan 3 bore interest of 5.25%.

Following the close of the Business Combination, the Company triggered the mandatory prepayment of $400.0 million of the outstanding principal on Term Loan 3 from the net cash proceeds received from the PIPE financing. The Company’s partial extinguishment of this Term Loan consisted of a cash payment to the lender for (1) $400.0 million of the outstanding principal amount, and (2) the outstanding accrued interest in the amount of $0.7 million. The Company recorded a loss on extinguishment of debt of $13.2 million in the nine months ended September 30, 2021, which related to unamortized debt issuance costs. The $400.0 million mandatory prepayment was made without premium or penalty.

On September 30, 2021, the Company and Credit Suisse amended Term Loan 3 to increase the Initial Revolving Facility by an additional $30.0 million.

As of September 30, 2021, no loans were drawn under the Initial Revolving Facility and its available balance was $56.2 million. As of September 30, 2021, the Company had two letters of credit outstanding in favor of two third parties in the amounts of $0.9 million and $2.9 million, respectively. As of December 31, 2020, no amounts were drawn from the Initial Revolving Facility and its available balance was $30.0 million. As of December 31, 2020, no letters of credit were issued. As of September 30, 2021, the Initial Revolving Facility bore interest at, and issued letters of credit were subject to fees equal to, the London Interbank offered rate (“LIBOR”) plus 4.5%.

Term Loan 4

On June 11, 2021, the Company entered into an amendment to the Credit Agreement with Credit Suisse and the other lenders for a principal amount of $295.0 million (“Term Loan 4”), subject to the same terms (including interest rate and maturity date) as Term Loan 3 above. The terms of the Term Loan 4, including interest rate and maturity, are equivalent to the terms of the Term Loan 3, and the Term Loan 3 and the Term Loan 4 form a single tranche of term loans under the Credit Agreement,

Term Loan 5

On September 30, 2021, the Company amended its Credit Agreement with Credit Suisse and the other lenders by adding an incremental term loan for a principal amount of $100.0 million (“Term Loan 5”), subject to the same terms (including interest rate and maturity date) as Term Loans 3 and 4 above. The terms of the Term Loan 5, including interest rate and maturity, are equivalent to the terms of the Term Loan 3 and the Term Loan 4, and the Term Loan 3, the Term Loan 4 and the Term Loan 5 form a single tranche of term loans under the Credit Agreement.

Term Loan 5 was issued with debt issuance costs of $1.0 million, which are included in the caption notes payable, net of current portion and debt issuance costs in the accompanying condensed consolidated balance sheets. The Company also incurred $0.1 million of third-party professional fees related to the issuance of Term Loan 5, which are included in the caption selling, general, and administrative expenses in the accompanying condensed consolidated statements of operations.

Bridge Loan

On July 2, 2021, the Company entered into a Bridge Loan Agreement (the "Bridge Loan Agreement") for a principal amount of $250.0 million ("Bridge Loan") to finance a business acquisition. Pursuant to the Bridge Loan Agreement, the Bridge Loan bore interest, payable quarterly in arrears (or, with respect to Eurodollar borrowings, on the last day of the applicable interest period, or, if the interest period is greater than three months, in three month intervals), at a rate equal to adjusted LIBOR plus 6.5% per annum, or 6.65%. Principal on the Bridge Loan is scheduled to mature on July 2, 2028.

The Bridge Loan was issued with debt issuance costs of $3.5 million, which fully amortized during the three months ended September 30, 2021 and is included in the caption interest expense in the accompanying condensed consolidated statements of operations.

On September 30, 2021, following the issuance of the Senior Notes, the Company repaid the Bridge Loan in full, consisting of (1) $250.0 million of principal and (2) $4.2 million of outstanding accrued interest.

Senior Notes

On September 30, 2021, the Company issued senior unsecured notes for a principal amount of $300.0 million (the "Senior Notes") in a private offering. Proceeds from the Senior Notes were used to repay the $250.0 million Bridge Loan in full. The Senior Notes bear interest at 6.25% per annum, payable semi-annually on April 1st and October 1st of each year, commencing April 1, 2022. As of September 30, 2021, the effective interest rate of the Senior Notes was 6.65%. Principal on the Senior Notes is due in full on October 1, 2028. The Senior Notes are not subject to any amortization payments.

Prior to October 1, 2024, the Company may redeem some or all of the notes at a price equal to 100% of the principal amount redeemed, plus accrued and unpaid interest, plus a make-whole premium. Prior to October 1, 2024, the Company may also redeem up to 40% of the aggregate principal amount of the notes with the net cash proceeds of certain equity offerings, at a redemption price of 106.25%, plus accrued and unpaid interest. On or after October 1, 2024, the Company may redeem some or all of the Notes at a redemption price of 100% - 103.13%, plus accrued and unpaid interest, depending on the date that the Senior Notes are redeemed.

The Senior Notes were issued with debt issuance costs of $6.8 million, which are included in the caption notes payable, net of current portion and debt discount in the accompanying condensed consolidated balance sheets.

The following table sets forth the Company’s future principal payments as of September 30, 2021, assuming another mandatory prepayment does not occur:

(in millions)
Year ending December 31,		Amount
Remainder of 2021	$	1,623
2022		6,493
2023		6,493
2024		6,493
2025		6,493
Thereafter		918,461
Total	$	946,056

As of September 30, 2021 and December 31, 2020, the balance of debt issuance costs totaled $24.2 million and $24.9 million, respectively, and were being amortized into interest expense over the life of the loan using the effective interest method. Of the balance as of September 30, 2021, $23.5 million was related to Term Loan 3, Term Loan 4, Term Loan 5, and the Senior Notes reflected as a direct reduction to the long-term debt balances, while the remaining $0.7 million was related to the Initial Revolving Facility, and reflected in prepaid expenses and other current assets. For the three and nine months ended September 30, 2021, the Company recognized interest expense of $16.0 million and $36.4 million, respectively, of which $4.0 million and $7.7 million were related to amortization of debt issuance costs.

For the three and nine months ended September 30, 2020, the Company recognized interest expense of $12.3 million and $21.7 million, respectively, of which $3.0 million and $3.9 million were related to the amortization of debt issuance costs.

XML

Due to Sellers

9 Months Ended

Sep. 30, 2021

Due to Sellers [Abstract]

Due to Sellers

DUE TO SELLERS

The amounts due to sellers as of September 30, 2021 and December 31, 2020 were $24.9 million and $41.1 million, respectively. Included in the due to sellers balance, there are amounts recorded as part of the initial purchase price of acquisitions in 2021 and in prior years, including accrued interest and accrued bonuses payable to various sellers as part of their respective employment agreements, as well as other amounts due to sellers. The amount due to sellers was $16.4 million, and the total bonuses owed to sellers were $8.5 million, as of September 30, 2021. The amount due to sellers was $34.5 million, and the total bonuses owed to sellers were $6.6 million, as of December 31, 2020.

Total bonus charges to various sellers as part of their respective provider employment agreements amounted to a total of $2.5 million and $6.2 million for the three months and nine months ended September 30, 2021, respectively. These charges are included within the caption transaction costs and other within the accompanying condensed consolidated statements of operations.

XML

Fair Value Measurements

9 Months Ended

Sep. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

ASC 820, "Fair Value Measurements and Disclosures", provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

The three levels of the fair value hierarchy under the accounting standard are described as follows:

•Level 1    Inputs to the valuation methodology are unadjusted quoted prices for identical

assets or liabilities in active markets that the Company has the ability to access.

•Level 2    Inputs to the valuation methodology include:

•quoted prices for similar assets or liabilities in active markets;

•quoted prices for identical or similar assets or liabilities in inactive markets;

•inputs other than quoted prices that are observable for the asset or liability;

•inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

•Level 3    Inputs to the valuation methodology are unobservable and significant to the fair

value measurement.

The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The carrying amounts of financial instruments including cash, accounts receivable, accounts payable, accrued liabilities, due to sellers and short-term borrowings approximate fair value due to the short maturities of such instruments. The fair value of the Company’s debt using Level 2 inputs was approximately $944.0 million and $474.0 million as of September 30, 2021 and December 31, 2020, respectively.

The following is a description of the valuation methodology used for liabilities measured at fair value.

Contingent Consideration: Consideration is earned by the sellers of two of the Company’s historical acquisitions based on the Company completing acquisitions of various targets specified at the time that business was acquired. The consideration is valued at fair value applying a Scenario Based method. The fair value considers transactions with the specified targets where a letter of intent is signed no later than September 30, 2021 and the acquisition is expected to be closed by December 31, 2021. The probability weighted average takes the probability of a given deal meeting this criteria and 20% of the preliminary consideration, discounted to present value using a risk-free/credit risk rate of 7.0%.

On August 11, 2021, the Company issued 2,720,966 shares of Class A common stock (the “escrowed shares”) to the escrow agent, on behalf of the seller, as part of the consideration in connection with an acquisition. The amount of shares was based on a $30.0 million purchase price divided by the average share price of the Company during the twenty consecutive trading days preceding the closing date of the transaction. The shares were deposited in escrow and will be released to the seller upon the satisfaction of certain performance metrics in 2022 and 2023. The final number of escrowed shares will be calculated by multiplying the initial share amount by an earned share percentage in accordance with the purchase agreement and subtracting any forfeited indemnity shares. The fair value of this contingent consideration is determined using a Monte-Carlo simulation model. These inputs are used to calculate the pay-off amount per the agreement which is then discounted to present value using the risk-free rate and the Company’s cost of debt.

The preceding methods described may produce fair value calculations that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

There was a decrease of $3.9 million and $4.2 million in the fair value of the contingent consideration during the three and nine months ended September 30, 2021, respectively, recorded in transaction costs and other in the consolidated statement of operations.

Embedded Derivative: In calculating the valuation of the embedded derivative, the Company considered the present value of the cash flows over the term of the debt agreement as impacted by (1) the probability of a debt

issuance or a change in control event occurring that would trigger a prepayment penalty to the lender, (2) the market interest rate of the debt agreement without the embedded derivative, and (3) the interest rate premium associated with the embedded derivative. The embedded derivative was entered into on June 1, 2020 in connection with embedded features attached to Term Loan 2 and subsequently derecognized on November 23, 2020 when the Company refinanced its debt. The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of June 1, 2020 and September 30, 2020:

	Range as of
Unobservable Input	June 1, 2020	September 30, 2020
Probability of change of control	90%	80%
Probability of issuance of debt	5%	15%
Expected date of event	Fourth Quarter 2020	Fourth Quarter 2020
Discount rate	39%	38%

The change in fair value of the embedded derivative of $5.1 million and $5.4 million was recorded during the three months and nine months ended September 30, 2020, respectively, and was included within change in fair value of embedded derivative. As noted in Note 9, "Long-Term Debt", the embedded derivative was derecognized as a result of the refinancing that took place on November 23, 2020.

Warrant Liabilities: As of June 3, 2021, the Closing Date of the Business Combination, and September 30, 2021, there were 23.0 million Public Warrants and 10.53 million Private Placement Warrants outstanding. The Company classifies its Public Warrants and Private Placement Warrants as liabilities in accordance with ASC 815 and measures them at fair value on a recurring basis. The Company’s valuation of the warrant liabilities utilized a binomial lattice in a risk-neutral framework (a special case of the Income Approach). The fair value of the Public Warrants and Private Placement Warrants utilized Level 1 and 3 inputs, respectively. The Private Placement Warrants are based on the significant inputs not observable in the market as of June 3, 2021 and September 30, 2021.

The following table provides quantitative information regarding the Level 3 inputs used for the fair value measurements of the warrants liabilities:

	As of
Unobservable Input	June 3, 2021	September 30, 2021
Exercise price	$11.50	$11.50
Stock price	$14.75	$12.68
Term (years)	5.0	4.7
Volatility	37.1%	—%
Risk free interest rate	0.8%	0.9%
Dividend yield	None	None
Public warrant price	None	$4.13

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of September 30, 2021:

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	46,706	$	—	$	—	$	46,706
Public Warrant Liabilities		94,990		94,990		—		—
Private Placement Warrant Liabilities		43,503		—		—		43,503
Total Liabilities	$	185,199	$	94,990	$	—	$	90,209

There was an increase of $10.1 million and a decrease of $2.4 million in the fair value of the Public Warrant Liabilities during the three and nine months ended September 30, 2021, and an increase of $4.5 million and a decrease of $22.2 million in the fair value of the Private Placement Warrant Liabilities during the three and nine months ended September 30, 2021, respectively. The change in fair value of the warrant liabilities is recorded within the Change in fair value of warrant liabilities caption.

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of December 31, 2020:

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	5,172	$	—	$	—	$	5,172
Total Liabilities	$	5,172	$	—	$	—	$	5,172

Activity of the assets and liabilities measured at fair value using significant unobservable inputs was as follows:

		Fair Value Measurements
		For the three months ended September 30,
		2021		2020
Opening balance as at July 1,	$	136,190	$	75,800
Change in fair value of embedded derivative		—		5,138
Change in fair value of contingent consideration		(3,940)		—
Contingent consideration recognized due to acquisitions		38,300		—
Change in fair value of warrants		14,649		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration payments		—		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879
		Fair Value Measurements
		For the nine months ended September 30,
		2021		2020
Opening balance as at January 1,	$	5,172	$	23,429
Embedded derivative recognized under Term Loan 2		—		51,328
Change in fair value of embedded derivative		—		5,444
Change in fair value of contingent consideration		(4,152)		—
Contingent consideration recognized due to acquisitions		47,900		2,695
Warrants acquired in the Business Combination		163,058		—
Change in fair value of warrants		(24,565)		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration settled through equity		—		(1,958)
Contingent consideration payments		(2,214)		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879

XML

Variable Interest Entities

9 Months Ended

Sep. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Variable Interest Entities

VARIABLE INTEREST ENTITIES

The Physicians Groups were established to employ healthcare providers, to contract with managed care payors, and to deliver healthcare services to patients in the markets that the Company serves. The Company evaluated whether it has a variable interest in the Physicians Groups, whether the Physicians Groups are VIEs, and whether the Company has a controlling financial interest in the Physicians Groups. The Company concluded that it has variable interests in the Physicians Groups on the basis of each respective Master Service Agreement (“MSA”), which provides office space, consulting services, managerial and administrative services, billing and collection, personnel services, financial management, licensing, permitting, credentialing, and claims processing in exchange for a service fee and performance bonuses payable to the Company. Each respective MSA transfers substantially all the residual risks and rewards of ownership to the Company. The Physicians Groups’ equity at risk, as defined by U.S. GAAP, is insufficient to finance its activities without additional support, and therefore, the Physicians Groups are considered VIEs, and are not affiliates of the Company.

In order to determine whether the Company has a controlling financial interest in the Physicians Groups, and thus, whether the Company is the primary beneficiary, the Company considered whether it has i) the power to

direct the activities that most significantly impact the Physicians Groups’ economic performance and ii) the obligation to absorb losses of the entities that could potentially be significant to it or the right to receive benefits from the Physicians Groups that could potentially be significant to it. The Company concluded that it may unilaterally remove the physician owners of the Physicians Groups at its discretion and is therefore considered to hold substantive kick-out rights over the decision maker of the Physicians Groups. Under each MSA, the Company is entitled to a management fee and a performance bonus that entitle the Company to substantially all of the residual returns or losses and is exposed to economics which could be significant to it. As a result, the Company concluded that it is the primary beneficiary of the Physicians Groups and therefore, consolidates the balance sheets, results of operations, and cash flows of these entities. The Company performs a qualitative assessment on an ongoing basis to determine if it continues to be the primary beneficiary.

The table below illustrates the aggregated VIE assets and liabilities and performance for the Physicians Groups:

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Total Assets	$	30,483	$	8,182
Total Liabilities	$	23,234	$	12,371

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2021		2020		2021		2020
Total revenue	$	12,321	$	79	$	14,621	$	79
Operating expenses:
Third-party medical costs	8,582		—		8,582		—
Direct patient expense	2,413		295		5,203		295
Selling, general and administrative expenses	7,277		1,125		12,540		1,324
Depreciation and amortization expense	353		—		860		—
Total operating expenses	18,625		1,420		27,185		1,619
Net loss	$	(6,304)	$	(1,341)	$	(12,564)	$	(1,540)

There are no restrictions on the Physicians Groups' assets or on the settlement of their liabilities. The assets of the Physicians Group can be used to settle obligations of the Company. The Physicians Groups are included in the Company’s creditor group; thus, creditors of the Company have recourse to the assets owned by the Physicians Groups. There are no liabilities for which creditors of the Physicians Groups do not have recourse to the general credit of the Company. There are no restrictions placed on the retained earnings or net income of the Physicians Groups with respect to potential future distributions.

XML

Related Party Transactions

9 Months Ended

Sep. 30, 2021

Related Party Transactions [Abstract]

Related Party Transactions

RELATED PARTY TRANSACTIONS

Advisory Services Agreement

In December 2016, the Company and InTandem Capital Partners, LLC (“InTandem”) entered into an advisory services agreement whereby InTandem owned the majority voting and equity interest in Cano Health's Parent, Primary Care (ITC) Holdings, LLC, and provided financial and management consulting services to the

Company. Services provided included, but were not limited to (i) corporate strategy, (ii) legal advice, (iii) acquisitions and divestitures strategies, and (iv) debt and equity financings. InTandem was entitled to an annual fee equal to the greater of $0.3 million or 2% of EBITDA for the prior calendar year plus out-of-pocket expenses. In the event the Company completes an acquisition or is sold, an advisory fee of 2% of the enterprise value, as defined, would be due to InTandem. In addition, upon payment, an advisory fee equal to 2% of the deferred payment would be due to InTandem. In accordance with the terms of agreement, the advisory services agreement was terminated upon the consummation of the Business Combination disclosed in Note 1, “Nature of Business and Operations”.

Pursuant to the advisory services agreement, the Company incurred expenses which are included in the condensed consolidated statements of operations. The Company did not incur any related party transaction costs during the three months ended September 30, 2021 and 2020, respectively, and incurred related party transaction costs of approximately $1.5 and $5.4 million during the nine months ended September 30, 2021 and 2020, respectively, which are included in the transaction costs and other caption. The Company also incurred approximately $0.2 million during the three and nine months ended September 30, 2020, respectively, which is included in the selling, general, and administrative expenses caption. As of September 30, 2021 and December 31, 2020, no balance and an immaterial balance was owed to InTandem pursuant to this agreement, respectively.

Administrative Service Agreement

On April 23, 2018, the Company entered into an Administrative Service Agreement with Dental Excellence Partners, LLC, which merged with four other entities. Dental Excellence Partners, LLC also licensed the Cano Dental trademark from the Company. The administrative fee is a monthly fixed amount per office for providing comprehensive management and related administrative services to the dental practices. During April 2019, the Company entered into an amendment to this agreement and modified the administrative fee. The Company and Dental Excellence Partners, LLC terminated the Administrative Service Agreement in December 2020, effective immediately.

The Company recognized income from this agreement of approximately $0.1 million and $0.4 million during the nine months ended September 30, 2021 and 2020, and $0.1 million during the three months ended September 30, 2020, which was recorded within the caption fee-for-service and other revenues in the accompanying condensed consolidated statements of operations. As of December 31, 2020, an immaterial amount was due to the Company in relation to these agreements and recorded in the caption accounts receivable.

As part of this agreement, the Company agreed to have Dental Excellence Partners, LLC provide dental services for managed care members of the Company. The Company was charged approximately $1.2 million and $1.6 million during the nine months ended September 30, 2021 and 2020, and $0.7 million during the three months ended September 30, 2020 for these services. As of December 31, 2020, no balance was due to Dental Excellence Partners, LLC.

Dental Service Agreement

During 2019, the Company entered into a dental service agreement with Care Dental Group, LLC (“Belen Dental”), whereby the Company agreed to pay Belen Dental $15 per member per month, for each Medicare Advantage (“MA”) patient that is identified by the Company on a monthly enrollment roster to receive care at the legacy Belen Medical Centers. During the three months ended September 30, 2021, no payments were made and during the three months ended September 30, 2020 the Company paid Belen Dental approximately $0.3 million, in relation to this agreement. During the nine months ended September 30, 2021 and 2020, the Company paid Belen Dental approximately $0.3 million and $0.5 million, respectively, pursuant to this agreement.

Humana Relationships

In 2020, Cano Health and its Parent, Primary Care (ITC) Holdings, LLC, entered into multi-year agreements with Humana and its affiliates whereby the Parent entered into a note purchase agreement with Humana for a convertible note due October 2022 with an aggregate principal amount of $60.0 million. The note accrued interest at a rate of 8.0% per annum through March 2020 and 10.0% per annum thereafter, payable in kind. The note was convertible to Class A-4 units of the Parent at the option of Humana in the event the Parent and affiliates seek to consummate a sale transaction and could be settled in cash at the option of Humana. Accordingly, the note was converted and settled in cash upon the consummation of the Business Combination. Prior to the consummation of the Business Combination, Cano Health was not subject to any obligations under the convertible note, including payments of principal, interest, or fees under the terms of the instrument. As such, this instrument does not represent debt of the Company. Humana is not a related party subsequent to the Business Combination on June 3, 2021 due to the repayment of the note.

The Company licenses the use of Humana Affiliate Provider (“HAP”) clinics to provide services at the clinics. The multi-year agreements contain an administrative payment from Humana in exchange for the Company providing care coordination services over the term of the agreement. These payments are recognized as revenue ratably over the length of the term of the agreement and are refundable to Humana on a pro-rata basis if the Company ceases to provide care at the clinics during the specified service period in the agreements. The Company has identified one performance obligation to stand ready to provide care coordination services at the centers for the length of the term specified in the contracts.

The multi-year agreements also contain an arrangement for a license fee that is payable by the Company to Humana for the Company’s use of Humana owned or leased facilities to provide health care services. The agreement prohibits Cano from using the clinics for plans not sponsored by Humana. The license fee is a reimbursement to Humana for its costs of owning or leasing and maintaining the clinics, including rental payments, maintenance or repair expenses, equipment expenses, special assessments, cost of upgrades, taxes, leasehold improvements, and other expenses identified by Humana. The Company has not paid license fees to Humana during the nine months ended September 30, 2021. The license, deferred revenue and deferred rent liability to Humana totaled $13.5 million as of December 31, 2020 while Humana was a related party. The Company also recorded $0.5 million in operating lease expense related to its use of Humana clinics in the nine months ended September 30, 2021 prior to repaying the note and while Humana was a related party.

Prior to entering into the agreements, the Company had existing payor relationships with Humana related to existing revenue arrangements within the Company. For the period that Humana was a related party to the Company, the Company recognized in its condensed consolidated statements of operations revenue from Humana, including its subsidiaries, of $131.9 million and $239.7 million for the three and nine months ended September 30, 2020, respectively, and $335.9 million for the nine months ended September 30, 2021. The Company recognized third-party medical expenses of and $90.2 million and $167.1 million for the three and nine months ended September 30, 2020, respectively, and $249.8 million for the nine months ended September 30, 2021.

Operating Leases

The Company leases several offices and medical spaces from certain employees and companies that are controlled by certain equity holders of Primary Care (ITC) Holdings, LLC. Monthly rent expense in aggregate totaled approximately $0.7 million and $0.7 million for the three months ended September 30, 2021 and 2020, respectively, and $2.1 million and $2.0 million for the nine months ended September 30, 2021 and 2020, respectively. These operating leases terminate through September 2024.

General Contractor Agreements

As of December 31, 2018, the Company has entered into various general contractor agreements with a company that is controlled by a family member of the Chief Executive Officer of the Company to perform leasehold improvements at various Company locations as well as various repairs and related maintenance as deemed necessary. Payments made pursuant to the general contractor agreements as well as amounts paid for repairs and maintenance to this related party totaled approximately $3.2 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and $5.6 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively.

Other Related Party Transactions

The Company made payments to various related parties in relation to logistic software, medical supplies, housekeeping, and moving costs. During the three months ended September 30, 2021 and 2020 the Company paid approximately $0.4 million and $0.1 million, respectively, to such parties. During the nine months ended September 30, 2021 and 2020 the Company paid approximately $0.9 million and $0.4 million, respectively, to such parties.

On April 23, 2018, the Company advanced funds to an affiliated company, Dental Excellence Partners, LLC, in the amount of $4.5 million. The loan agreement calls for monthly interest-only payments to be received beginning May 1, 2018, and the entire outstanding principal balance shall be due and payable in full on April 23, 2023. The note receivable bears interest at 7.0%. For the three months and nine months ended September 30, 2020, the Company recognized $0.0 million and $0.2 million, respectively, of interest income related to this loan agreement. On December 17, 2020, Dental Excellence Partners made an early repayment of the outstanding balance to the Company. In connection with the early repayment, the Company wrote off $0.5 million, $0.4 million of which was due under the Administrative Service Agreement and $0.1 million was due for other services provided.

Additionally, during the year ended December 31, 2018, two executives of Cano Health obtained shares of the former Parent, Primary Care (ITC) Holdings, LLC, for a total amount of $0.4 million. As part of this transaction, the two executives paid cash and entered into promissory notes with the Parent in order to acquire the shares. On May 25, 2018, the first promissory note was obtained in the amount of $0.1 million, payable on May 25, 2026 with a fixed annual interest rate of 2.8%. On August 24, 2018, the second promissory note was obtained from the Company in the amount of $0.05 million, with a fixed annual interest rate of 2.8%. The loan and interest receivable was scheduled to be due on August 24, 2025. As of September 30, 2021, both of the promissory notes were paid in full.

XML

Equity-Based Compensation

9 Months Ended

Sep. 30, 2021

Share-based Payment Arrangement [Abstract]

Equity-Based Compensation

EQUITY-BASED COMPENSATION

2017 Profits Interest Units Plan

On September 30, 2017, the former Parent’s Limited Liability Agreement (“LLC Agreement”) created class B units, called Profit Interest Units (“PIU”), to provide additional incentives to attract and retain qualified, competent employees for the Company. All grants of PIUs vested upon the closing of the Business Combination on June 3, 2021 and resulted in an expense of $1.0 million recorded in the selling, general, and administrative caption.

2021 Stock Option and Incentive Plan

At the Company’s special meeting of stockholders held on June 2, 2021, the stockholders approved the 2021 Omnibus Equity Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“2021 ESPP”)

to encourage and enable the current and future officers, employees, directors, and consultants of the Company and its affiliates to obtain ownership in the Company. The aggregate number of shares authorized for issuance under the 2021 Plan will not exceed 52.0 million shares of stock. The aggregate number of shares authorized for issuance under the 2021 ESPP will not exceed 4.7 million, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031 the number of shares of Class A common stock reserved and available for issuance under the 2021 Plan shall be cumulatively increased by the lessor of (i) 15.0 million shares of Class A common stock, (ii) one percent 1.0% of the number of shares of Class A common stock issued and outstanding on the immediately preceding December 31st, or (iii) such lesser number of shares determined by the administrator appointed by the Board of Directors.

The 2021 Plan provides for the grant of incentive and nonqualified stock option, restricted stock units (“RSUs”), restricted share awards, stock appreciation awards, unrestricted stock awards, and cash-based awards to employees, directors, and consultants of the Company.

Market Condition Options

On June 3, 2021, in connection with the closing of the Business Combination, the Company granted 12.8 million stock options with market conditions (“Market Condition Awards”) to several executive officers and directors of the Company. The Market Condition Awards vest when the Company’s stock price meets specified hurdle prices and stays above those prices for 20 consecutive days. Once the market condition is satisfied, the applicable percentage of the Market Condition Awards will vest 50% on each of the first and second anniversaries so long as the optionee stays employed. The fair value of the Market Condition Awards is based on a Monte Carlo simulation for each hurdle price. The unrecognized compensation cost of the Market Condition Awards as of September 30, 2021 was $47.1 million, which is expected to be recognized over the weighted average remaining service period of 2.6 years.

The number of Market Condition Awards that vest is subject to the Company’s stock price equaling or exceeding certain hurdle prices for 20 consecutive trading days from June 3, 2021 to June 3, 2024 (i.e., the period from the grant date to the end date of the performance period).

Stock Option Valuation

The Monte-Carlo simulation model is used to estimate the fair value of the Market Condition Awards. The Monte-Carlo simulation model calculates multiple potential outcomes for an award and establishes a fair value based on the most likely outcome. Key assumptions for the Monte-Carlo simulation model include the risk-free rate, expected volatility, expected dividends and the expected cost of equity. The fair values were calculated using the Monte-Carlo model with the following assumptions as of the grant date on June 3, 2021:

	As of June 3, 2021
Closing Cano share price as of valuation date	$	14.75
Risk-free interest rate	1.68% - 2.0%
Expected volatility	45.0%
Expected dividend yield	0.0%
Expected cost of equity	9.0%

A summary of the status of unvested Market Condition Awards granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	12,831,184	$4.23
Vested	—	—
Forfeitures	(97,486)	4.23
Balance, September 30, 2021	12,733,698	$4.23

Restricted Stock Units

In June 2021, the Company granted 2,590,472 time-based RSUs to several executive officers, directors and certain employees of the Company. An additional 2,249,972 time-based RSUs were granted in September 2021. The RSUs issued in June vest over a one-year period for directors and over a four-year period for employees commencing on the grant date, with one fourth of the RSUs vesting at the end of the first anniversary of the vesting commencement date and the remainder of the RSUs vesting yearly over the following three years. One fourth of the RSUs issued in September vest in August of 2022 with the remaining vesting on each of the next three subsequent anniversaries. The fair value of RSUs is based on the closing price of the Company’s Class A common stock on the grant date. The unrecognized compensation cost of the RSUs as of September 30, 2021 was $65.2 million, which is expected to be recognized over the weighted average remaining service period of 3.7 years. In addition, certain RSUs were granted to a nonemployee and included a discretionary performance condition which has been deemed not probable of being met and as such no expense has been recorded.

A summary of the status of unvested RSUs granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	4,840,444	$14.46
Vested	—	—
Forfeitures	(16,750)	14.75
Balance, September 30, 2021	4,823,694	$14.46

The Company recorded compensation expenses of $9.0 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively. The Company recorded compensation expenses of $12.1 million and $0.2 million for the nine months ended September 30, 2021 and 2020, respectively.

The total equity-based compensation expense related to all the equity-based awards granted by the former Parent is reported in the condensed consolidated statement of operations as compensation expense within the selling, general and administrative expense caption.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIESVendor Agreements

The Company, through its subsidiaries Comfort Pharmacy, LLC, Comfort Pharmacy 2, LLC, and Belen Pharmacy Group, LLC, entered into a multi-year Prime Vendor Agreement ("PVA") with a pharmaceutical wholesaler, effective November 1, 2020, that continues through October 31, 2023. This agreement extends on a month-to-month basis thereafter until either party gives 90 days' written notice to terminate. The pharmaceutical wholesaler serves as the Company’s primary wholesale supplier for branded and generic pharmaceuticals. The agreement contains a provision that requires average monthly net purchases of $0.8 million, and if the minimum is not met, the vendor may adjust the pricing of goods. A Joinder Agreement was entered into on December 1, 2020, which amended the PVA to include IFB Pharmacy, LLC, a fully consolidated subsidiary, under the agreement as of this date.

As a result of the University acquisition, the Company assumed the vendor agreement in 2021 that University, through its subsidiary University Health Care Pharmacy, Inc., had with a second pharmaceutical vendor. The agreement, effective through April 7, 2022, contains a provision that requires average monthly net purchases of $0.6 million, and if the minimum is not met, the vendor may adjust the pricing of goods.

Management believes for the nine months ended September 30, 2021 and 2020, the minimum requirements of the agreements in place were met.

Operating Leases

The Company leases office facilities and office equipment under non-cancellable operating leases expiring through the year 2028. Refer to Note 13, "Related Party Transactions", for operating leases that were entered into with related parties. Minimum future payments as of September 30, 2021 were approximately as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	3,876
2022		13,987
2023		12,763
2024		11,125
2025		9,451
Thereafter		27,908
Total	$	79,110

Rent expense for the three months ended September 30, 2021 and 2020 amounted to approximately $6.9 million and $3.1 million, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 amounted to approximately $15.9 million and $8.2 million, respectively.

Litigation

The Company is exposed to various asserted and unasserted potential claims encountered in the normal course of business. Management believes that the resolution of these matters will not have a material effect on the Company’s condensed consolidated financial position, results of their operations or cash flows.

XML

Income Taxes

9 Months Ended

Sep. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company is subject to U.S. federal, state and local income taxes with respect to its taxable income, including its allocable share of any taxable income of its subsidiaries, and is taxed at prevailing corporate tax rates. PCIH is a multiple member limited liability company taxed as a partnership and accordingly any taxable income generated by PCIH is passed through to and included in the taxable income of its members, including the Company.

Prior to the close of the Business Combination, the Company was treated as a pass-through entity for tax purposes and no provision, except for certain subsidiaries which are taxed under Subchapter C, was made in the condensed consolidated financial statements for income taxes. The following income tax items for the periods prior to the close of the Business Combination are related to the applicable subsidiary company that is subject to income tax. Following the close of the Business Combination, the Company is taxed as a corporation.

The net loss for the three months and nine months ended September 30, 2021 and 2020 consisted of the following:

		For the Three Months Ended				For the Nine Months Ended
		September 30,				September 30,
(in thousands)		2021		2020		2021		2020
Jurisdictional earnings:
U.S. losses	$	(41,206)	$	(11,760)	$	(46,053)	$	(25,456)
Foreign income (losses)		870		969		(1,112)		1,461
Total losses		(40,336)		(10,791)		(47,165)		(23,995)
Current:
U.S. Federal		—		—		—		—
U.S. State and local		—		(29)		—		(26)
Foreign		—		(251)		—		(222)
Total current tax expense		—		(280)		—		(248)
Deferred:
U.S. Federal		—		—		—		—
U.S. State and local		(221)		—		282		—
Foreign		(326)		(46)		480		(46)
Total deferred tax benefit (expense)		(547)		(46)		762		(46)
Total tax benefit (expense)	$	(547)	$	(326)	$	762	$	(294)

Our effective tax rate for the third quarter of 2021 was 1.62% compared to (0.89)% for the year ended December 31, 2020. The effective tax rate for the periods presented differs from the statutory U.S. tax rate. This is primarily due to the Company’s pass-through entity treatment for tax purposes prior to the close of the Business Combination, including the Company’s full valuation allowance position which is further discussed below. In addition, for the Company’s taxable subsidiary operations, the effective tax rate differs due to mainly state income taxes and Puerto Rico taxes. The remaining rate differences are immaterial.

Deferred taxes for the applicable subsidiary companies are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences, operating losses and other tax credit carryforwards. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.

The Company does not believe it is more-likely-than-not all of its deferred tax assets will be realized and has therefore recorded a valuation allowance against its deferred tax assets which as of September 30, 2021 are not

expected to be realized. The most significant deferred tax asset relates to the outside basis difference in the partnership which has a full valuation allowance through September 30, 2021. As of September 30, 2021, $0.7 million of deferred tax assets was included in other assets that are expected to be realized.

Management continuously assesses the likelihood that it is more likely than not that the deferred tax assets generated will be realized. In making such determinations, all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, and recent financial operations, are considered. In the event that management were to determine that the deferred income tax assets would be realized in the future for an amount equal to the net recorded amount, the valuation allowance and provision for income taxes would be adjusted.

The Company does not have any unrecognized tax positions (“UTPs”) as of September 30, 2021. While the Company currently does not have any UTPs, it is foreseeable that the calculation of the Company’s tax liabilities may involve dealing with uncertainties in the application of complex tax laws and regulations in multiple jurisdictions across the Company’s operations. ASC 740, "Income Taxes" ("ASC 740"), states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. Upon identification of a UTP, the Company would (1) record the UTP as a liability in accordance with ASC 740 and (2) adjust these liabilities if/when management’s judgment changes as a result of the evaluation of new information not previously available. Ultimate resolution of UTPs may produce a result that is materially different from a Company’s estimate of the potential liability. In accordance with ASC 740, the Company would reflect these differences as increases or decreases to income tax expense in the period in which new information is available. The Company’s accounting policy under ASC 740-10 is to include interest and penalties accrued on uncertain tax positions as a component of income tax expense in the event a material uncertain tax position is booked in the condensed consolidated financial statements.

The Company files income tax returns in the U.S. with Federal and State and local agencies, and in Puerto Rico. The Company is subject to U.S. Federal, state and local tax examinations for tax years starting in 2017. The Puerto Rico subsidiary group is subject to U.S. Federal, state and foreign tax examinations for tax years starting in 2019. The Company does not currently have any ongoing income tax examinations in any of its jurisdictions. The Company has analyzed filing positions in the Federal, State, local and foreign jurisdictions where it is required to file income tax returns for all open tax years and does not believe any tax uncertainties exist.

Tax Receivable Agreement

Upon the completion of the Business Combination, Cano Health, Inc. became a party to the Tax Receivable Agreement. Under the terms of that agreement, Cano Health, Inc. generally will be required to pay to the Seller and to each other person from time to time that becomes a “TRA Party” under the Tax Receivable Agreement, 85% of the tax savings, if any, that Cano Health, Inc. is deemed to realize in certain circumstances as a result of certain tax attributes that exist following the Business Combination and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. To the extent payments are made pursuant to the Tax Receivable Agreement, Cano Health, Inc. generally will be required to pay to the Sponsor and to each other person from time to time that becomes a “Sponsor Party” under the Tax Receivable Agreement such Sponsor Party’s proportionate share of, an amount equal to such payments multiplied by a fraction with the numerator 0.15 and the denominator 0.85. The term of the Tax Receivable Agreement will continue until all such tax benefits have been utilized or expired unless Cano Health, Inc. exercises its right to terminate the Tax Receivable Agreement for an amount representing the present value of anticipated future tax benefits under the Tax Receivable Agreement or certain other acceleration events occur. The Tax Receivable Agreement liability is determined and recorded under

ASC 450, contingent liability; therefore, we are required to evaluate whether the liability is both probable and the amount can be estimated. Since the Tax Receivable Agreement liability is payable upon cash tax savings and we have determined that positive future taxable income is not probable based on the Cano Health, Inc’s historical loss position and other factors that make it difficult to rely on forecasts, we have not recorded the Tax Receivable Agreement liability as of September 30, 2021. We will evaluate this on a quarterly basis which may result in an adjustment in the future.

XML

Net Loss Per Share

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

NET LOSS PER SHARE

The following table sets forth the net loss for the three and nine months ended September 30, 2021 and 2020 and the computation of basic and diluted net loss per common stock for the three and nine months ended September 30, 2021:

	Three months ended September 30,				Nine months ended September 30,
(in thousands, except shares and per share data)	2021		2020		2021		2020
Numerator:
Net loss	$	(40,883)	$	(11,117)	$	(46,403)	$	(24,289)
Less: net loss attributable to non-controlling interests	(26,246)		—		(41,283)		—
Net loss attributable to Class A common stockholders	(14,637)		—		(5,120)		—
Dilutive effect of warrants on net loss to Class A common stockholders	—		N/A		(8,780)		N/A
Net loss attributable to Class A common stockholders - Diluted	(14,637)		N/A		(13,900)		N/A
Basic and Diluted Earnings Per Share denominator:
Weighted average common stock outstanding - basic	170,871,429		N/A		168,100,210		N/A
Net loss per share - basic	$	(0.09)	N/A		$	(0.03)	N/A
Diluted Earnings Per Share:
Dilutive effect of warrants on weighted average common stock outstanding	—		N/A		1,212,048		N/A
Weighted average common stock outstanding - diluted	170,871,429		N/A		169,312,258		N/A
Net loss per share - diluted	$	(0.09)	N/A		$	(0.08)	N/A

Prior to the consummation of the Business Combination, the Company’s ownership structure included equity interests held solely by the Parent. The Company analyzed the calculation of earnings per share for comparative periods presented and determined that it resulted in values that would not be meaningful to the users of these condensed consolidated financial statements. Therefore, the earnings per share information has not been presented for the three and nine months ended September 30, 2020.

The outstanding Company’s Class B common stock does not represent economic interests in the Company, and as such, is not included in the denominator of the net loss per share calculation.

On August 11, 2021, the Company issued 2,720,966 shares of Class A common stock (the “escrowed shares”) to the escrow agent, on behalf of the seller, as part of the consideration in connection with an acquisition. The amount of shares was based on a $30.0 million purchase price divided by the average share price of the Company during the twenty consecutive trading days preceding the closing date of the transaction. The shares were deposited in escrow and will be released to the seller upon the satisfaction of certain performance metrics during 2022 and 2023. The final number of escrowed shares will be calculated by multiplying the initial share amount by an earned share percentage in accordance with the purchase agreement and subtracting any forfeited indemnity shares. The dilutive effects of these shares were excluded from the three and nine months ended September 30, 2021 because they were antidilutive.

The Company’s dilutive securities are derived from the Company’s Public Warrants and Private Placement Warrants using the treasury method and excluding the Class A stockholders' income statement effect of the change in fair value in warrant liability. The Public Warrants and Private Placement Warrants were included in the nine months ended September 30, 2021 dilutive earnings per share calculation. The warrants were excluded from the three months ended September 30, 2021 as they were antidilutive for the period. RSUs, stock options, and contingent shares were also excluded from the dilutive earning per share calculation as they had an anti-dilutive effect for the periods presented. The table below presents the Company’s potentially dilutive securities:

	As of September 30, 2021
Public Warrants	23,000,000
Private Placement Warrants	10,533,333
Restricted Stock Units	4,823,694
Stock Options	12,733,698
Contingent Shares Issued in Connection with Acquisitions	2,720,966
Potential Common Stock Equivalents	53,811,691

XML

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATIONThe Company organizes its operations into one reportable segment. The Chief Executive Officer, who is our Chief Operating Decision Maker (“CODM”), reviews financial information and makes decisions about resource allocation based on the Company’s responsibility to deliver high quality primary medical care services to the Company’s patient population. For the periods presented, all of the Company’s revenues were earned in the United States, and all of the Company’s long lived assets were located in the United States.

XML

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTSThe Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

XML

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

These financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the financial position of the Company at September 30, 2021 and December 31, 2020, and the results of operations, cash flows and changes in equity for the three and nine months ended September 30, 2021 and 2020 have been included. The results of operations and cash flows for the three and nine months ended September 30, 2021 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2021 or any other future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the

consolidated financial statements and notes thereto included in the Company’s audited consolidated financial statements for the year ended December 31, 2020.

The Company was deemed the accounting acquirer in the Business Combination of Jaws based on an analysis of the criteria outlined in Accounting Standards Codification ("ASC") Topic 805, "Business Combinations" ("ASC 805"), as the Company’s former owner retained control after the Business Combination. Refer to Note 1, "Nature of Business", for details surrounding the Business Combination. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of the Company issuing stock for the net assets of Jaws, accompanied by a recapitalization. The net assets of Jaws were stated at historical cost, with no goodwill or other intangible assets recorded.

While Jaws was the legal acquirer in the Business Combination, because the Company was deemed the accounting acquirer, the historical financial statements of PCIH became the historical financial statements of the combined company upon the consummation of the Business Combination. As a result, the condensed consolidated financial statements reflect the historical operating results of PCIH prior to the Business Combination, the combined results of Jaws and the Company following the close of the Business Combination, the assets and liabilities of the Company at their historical cost, and the Company’s equity structure for all periods presented.

Warrant Liabilities

Warrant Liabilities

The Company assumed 23.0 million public warrants ("Public Warrants") and 10.53 million private placement warrants ("Private Placement Warrants") upon the consummation of the Business Combination. The Company may issue or assume common stock warrants that are recorded as either liabilities or equity in accordance with the respective accounting guidance. Warrants recorded as equity are recorded at their relative fair value or fair value determined at the issuance date and remeasurement is not required. Warrants recorded as liabilities are recorded at their fair value, within warrant liability on the condensed consolidated balance sheets, and remeasured on each reporting date with changes recorded in revaluation of warrant liability on the Company’s condensed consolidated statements of operations.

The Public Warrants became exercisable 30 days after the consummation of the Business Combination, which occurred on June 3, 2021. The Public Warrants will expire five years after the consummation of the Business Combination, or earlier upon redemption or liquidation. The Private Placement Warrants are identical to the Public Warrants, except that so long as the Private Placement Warrants are held by the Sponsor or any of its permitted transferees, the Private Placement Warrants: (i) may be exercised for cash or on a “cashless basis”, (ii) may not be transferred, assigned or sold until 30 days after the completion of the initial Business Combination, (iii) shall not be redeemable by the Company when the Class A ordinary shares equal or exceed $18.00, and (iv) shall only be

redeemable by the Company when the Class A ordinary shares are less than $18.00 per share, subject to certain adjustments.The Company evaluated the Public Warrants and Private Placement Warrants and concluded that they do not meet the criteria to be classified as shareholders’ equity in accordance with ASC 815-40, “Derivatives and Hedging–Contracts in Entity’s Own Equity” ("ASC 815"). As the Public Warrants and Private Placement Warrants also meet the definition of a derivative under ASC 815, the Company has recorded these warrants as liabilities on its condensed consolidated balance sheets, with changes in their respective fair values recognized in the statement of operations at each reporting date.

Revenue Recognition

Revenue Recognition

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts with Customers”, ASC 606 (“ASC 606”). On January 1, 2019, the Company adopted ASC 606, applying the full retrospective method as of the earliest period presented. The portfolio approach was used to apply the requirements of the standard to groups of contracts with similar characteristics.

Under ASC 606, the Company recognizes revenue when a customer obtains control of the promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services the Company transfers to the customer (i.e., patient). At contract inception, once the contract is determined to be within the scope of ASC 606, management reviews the contract to determine which performance obligations must be satisfied and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.

The Company derives its revenue primarily from its capitated fees for medical services provided under capitated arrangements, fee-for-service arrangements, and revenue from the sale of pharmaceutical drugs.

Capitated revenue is derived from fees for medical services provided by the Company under capitated arrangements with health maintenance organizations’ (“HMOs”) health plans. Capitated revenue consists of revenue earned through Medicare as well as through commercial and other non-Medicare governmental programs, such as Medicaid, which is captured as other capitated revenue. The Company is required to deliver primary care physician services to the enrolled member population and is responsible for medical expenses related to healthcare services required by that patient group, including services not provided by the Company. Since the Company controls the primary care physician services provided to enrolled members, the Company acts as a principal. The gross fees under these contracts are reported as revenue and the cost of provider care is included in third-party medical costs. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which they operate does not require such registration for risk-bearing providers.

Since contractual terms across these arrangements are similar, the Company groups them into one portfolio. The Company identifies a single performance obligation to stand-ready to provide healthcare services to enrolled members. Capitated revenue is recognized in the month in which the Company is obligated to provide medical care services. The transaction price for the Medicare Advantage and Medicare Direct Contracting services provided

depends upon the pricing established by the Centers for Medicare & Medicaid (“CMS”) and includes rates that are based on the cost of medical care within a local market and the average utilization of healthcare services by the members enrolled. The transaction price is variable since the rates are risk adjusted for projected health status (acuity) of members and demographic characteristics of the enrolled members. The risk adjustment to the transaction price is presented as the Medicare Risk Adjustment (“MRA”) within accounts receivable on the accompanying condensed consolidated balance sheets. The fees are paid on an interim basis based on submitted enrolled member data for the previous year and are adjusted in subsequent periods after the final data is compiled by the CMS.

In 2020, the Company entered into multi-year agreements with Humana, Inc. (“Humana”), a managed care organization, to provide services only to members covered by Humana in certain centers. The agreements contain an administrative payment from Humana in exchange for the Company providing certain care coordination services during the contract term. The care coordination payments are refundable to Humana on a pro-rata basis if the Company ceases to provide services at the centers within the specified contract term. The Company identified one performance obligation to stand-ready to provide care coordination services to patients and will recognize revenue ratably over the contract term. Care coordination revenue is included in other revenue along with other ancillary healthcare revenues.

Fee-for-service revenue is generated from primary care services provided in the Company’s medical centers. During an office visit, a patient may receive a number of medical services from a healthcare provider. These healthcare services are not separately identifiable and are combined into a single performance obligation. The Company recognizes fee-for-service revenue at the net realizable amount at the time the patient is seen by a provider, and the Company’s performance obligation to the patient is complete.

Pharmacy revenue is generated from the sales of prescription medication to patients. Pharmacy contracts contain a single performance obligation. The Company satisfies its performance obligation and recognizes revenue at the time the patient takes possession of the merchandise. Other revenue includes revenue from certain third parties which include ancillary fees earned under contracts with certain care organizations for the provision of care coordination services.

As the performance obligations from the Company’s revenues are recognized at a point in time and the revenues recognized over time relate to contracts with a duration of one year or less, the Company elected the practical expedient in ASC 606-10-50-14(a) which provides relief from the requirement to disclose the transaction price for remaining performance obligations at the end of each reporting period and the requirement to disclose when the Company expects to recognize the related revenue. The Company has de minimis performance obligations remaining at the end of the reporting period as patients are not contractually obligated to continue to receive medical care from the network of providers.

Third-Party Medical Costs

Third-Party Medical Costs

Third-party medical costs primarily consist of all medical expenses paid by the health plans or CMS, including inpatient and hospital care, specialists, and medicines for which the Company bears risk.

Direct Patient Expense

Direct Patient Expense

Direct patient expense primarily consists of costs incurred in the treatment of the patients, including the compensation related to medical service providers and technicians, medical supplies, purchased medical services, drug costs for pharmacy sales, and payments to third-party providers.

Third-party medical costs and direct patient expense collectively represent the cost of services provided.

Significant Vendor

Significant VendorThe Company’s primary provider of pharmaceutical drugs and pharmacy supplies accounted for approximately 87% and 100%, and 96% and 100%, of the Company’s pharmaceutical drugs and supplies expense for the three months ended September 30, 2021, and 2020, respectively, and nine months ended September 30, 2021, and 2020, respectively.

Concentration of Risk

Concentration of Risk

Contracts with three of the HMOs accounted for approximately 57.2% and 63.6% of total revenues for the three and nine months ended September 30, 2021, respectively, and approximately 39.8% of total accounts receivable as of September 30, 2021. Contracts with three of the HMOs accounted for approximately 70.2% and 67.5% of total revenues for the three and nine months ended September 30, 2020, respectively, and approximately 67.1% of total accounts receivable as of December 31, 2020. The loss of revenue from these contracts could have a material adverse effect on the Company. The percentage of accounts receivable related to the three HMOs decreased over the nine-month period ended September 31, 2021 due to an increase in acquisitions over that time period. The acquisitions significantly increased overall accounts receivable over this period, effectively diluting accounts receivable from the HMOs.

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash deposits in excess of the Federal Deposit Insurance Corporation insured limit of $0.3 million. At times, such cash balances may be in excess of insured amounts.

Cash and Restricted Cash

Cash and Restricted CashCash and cash equivalents are highly liquid investments purchased with original maturities of three months or less. During the third quarter of 2021, two health plans required the Company to maintain restricted cash balances for an aggregate amount of $3.5 million. These restricted cash balances are included within the caption cash and restricted cash in the accompanying condensed consolidated balance sheets.

Inventory

Inventory Inventory consists entirely of pharmaceutical drugs and is valued at the lower of cost (under the first-in, first-out method) or net realizable value.

Accounts Receivable, Net of Unpaid Service Provider Costs

Accounts Receivable, Net of Unpaid Service Provider Costs

Accounts receivable are carried at amounts the Company deems collectible. Accordingly, an allowance is provided in the event an account is considered uncollectible. As of September 30, 2021 and December 31, 2020, the Company believes no allowance is necessary. The ultimate collectability of accounts receivable may differ from

amounts estimated. The period between the time when the service is performed by the Company and the fees are received is usually one year or less and therefore, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust accounts receivable for the effect of a significant financing component.

Included in accounts receivable are MRA receivables which is an estimate derived from adjustments based on the health status of members and demographic characteristics of the plan. The health status of members is used to determine a risk score which is actuarially determined by comparing what was received from the CMS and what should have been received based on the health status of the enrolled member. Our accounts receivable included MRA receivables in the amount of $108.6 million and $18.1 million as of September 30, 2021 and December 31, 2020, respectively.

As of September 30, 2021 and December 31, 2020, the Company’s accounts receivable were presented net of the unpaid service provider costs. A right of offset exists when all of the following conditions are met: 1) each of the two parties owed the other determinable amounts; 2) the reporting party has the right to offset the amount owed with the amount owed to the other party; 3) the reporting party intends to offset; and 4) the right of offset is enforceable by law. The Company believes all of the aforementioned conditions existed as of September 30, 2021 and December 31, 2020.The foregoing reconciliation reflects a change in estimate during the nine months ended September 30, 2021 and September 30, 2020 related to unpaid service provider costs of approximately $3.5 million and $0.8 million, respectively.

Unpaid Service Provider Cost

Unpaid Service Provider Cost

Provider costs are accrued based on the date of services rendered to members, based in part on estimates, including an accrual for medical services incurred but not reported (“IBNR”). Liabilities for IBNR are estimated using standard actuarial methodologies including the Company’s accumulated statistical data, adjusted for current experience. These actuarially determined estimates are continually reviewed and updated. Differences between estimated IBNR and actual amounts incurred are adjusted as an increase or decrease to service provider cost in the condensed consolidated statements of operation in the period they become known.

The Company believes the amounts accrued to cover claims incurred and unpaid as of September 30, 2021 and December 31, 2020 are adequate. However, as the amount of unpaid service provider cost is based on estimates, the ultimate amounts paid to settle these liabilities might vary from recorded amounts, and these differences may be material.

The Company maintains a provider excess loss insurance policy to protect against claim expenses exceeding certain levels that were incurred by the Company on behalf of members. As of September 30, 2021 and December 31, 2020, the Company’s excess loss insurance deductible was $0.1 million and maximum coverage was $2.0 million per member per calendar year. The Company recorded excess loss insurance premiums of $1.9 million and $5.4 million, and insurance reimbursements of $3.6 million and $5.4 million, for the three and nine months ended September 30, 2021, respectively. The Company recorded excess loss insurance premiums of $1.3 million and $3.6 million, and no insurance reimbursements, for the three and nine months ended September 30, 2020, respectively. The Company recorded these amounts on a net basis in the caption third-party medical costs in the accompanying condensed consolidated statements of operations. The Company records excess loss insurance recoveries in accounts receivable on the accompanying condensed consolidated balance sheets.

Debt Issuance Costs

Debt Issuance Costs

Debt issuance costs represent fees incurred by the Company in connection with securing funding from a lender. These are lender fees and third-party professional fees that would not have been incurred if the Company did not pursue and secure financing. In circumstances where an embedded derivative is bifurcated from a host credit agreement and recorded as a standalone instrument at fair value, the debt issuance costs will reflect the initial fair value of such derivative. At inception of a credit agreement, these debt issuance costs are capitalized and presented net against the carrying amount of the related debt liabilities in the accompanying condensed consolidated balance sheets. Following recognition, they are amortized over the term of their related credit agreement through interest expense in the accompanying statements of operations through the effective interest method. In instances where there is no related debt drawn or outstanding, the debt issuance costs are presented in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets.

As of September 30, 2021 and December 31, 2020, the Company recorded capitalized deferred issuance cost balances of $24.2 million and $24.9 million, respectively, in the accompanying condensed consolidated balance sheets, as described in Note 9, “Long-Term Debt”. Of the balance as of September 30, 2021, $23.5 million was included in the caption notes payable, net of current portion and debt issuance costs, $0.2 million in prepaid expenses and other current assets, and $0.5 million in other assets on the accompanying condensed consolidated balance sheets. Of the balance as of December 31, 2020, $18.5 million was included in the caption notes payable,

net of current portion and debt issuance costs, $5.8 million in prepaid expenses and other current assets, and $0.6 million in other assets on the accompanying condensed consolidated balance sheets.

As described in Note 9, “Long-Term Debt”, Term Loan 3 (as defined below) was partially repaid by the Company on June 3, 2021. The Company’s partial extinguishment of this Term Loan consisted of a cash payment to the lender for (1) $400.0 million of the outstanding principal amount, and (2) the outstanding accrued interest. The Company recorded a loss on extinguishment of debt of $13.2 million which related to unamortized debt issuance costs.

The Company recorded $4.0 million and $7.7 million of amortization of deferred financing costs for the three and nine months ended September 30, 2021, respectively. The Company recorded amortization expense of $3.0 million and $3.9 million for the three and nine months ended September 30, 2020, respectively. Amortization expense is reflected under the caption interest expense in the accompanying condensed consolidated statements of operations.

Property and Equipment, Net

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. The Company capitalizes asset purchases as well as major improvements that extend the useful life or add functionality, value, or productive capacity in amounts greater than one thousand dollars. Depreciation and amortization are computed using the straight-line method over the life of the assets, ranging from three to fifteen years. Leasehold improvements are amortized over the shorter of the estimated useful life of fifteen years or the term of the lease.

Repairs and maintenance are expensed as incurred. When property and equipment are retired, sold, or otherwise disposed of, the asset’s carrying amount and related accumulated depreciation and amortization are removed from the accounts and any gain or loss is included in the accompanying condensed consolidated statements of operations.

Impairment of Long-Lived Assets

Impairment of Long-Lived AssetsThe Company periodically reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Business Acquisitions

Business Acquisitions

The Company accounts for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. The Company uses various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, EBITDA growth rates, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. Refer to Note 3, "Business Acquisitions," for a discussion of the Company's recent acquisitions.

Goodwill

GoodwillGoodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets acquired. The goodwill arising from acquisitions is a result of synergies that are expected to be derived from elimination of duplicative costs and the achievement of economies of scale. The Company assesses goodwill for impairment on an annual basis and between tests if events occur or circumstances exist that would reduce the fair value of a reporting unit below its carrying amount. The Company performs its annual assessment on the first of October. Goodwill is evaluated for impairment at the reporting unit level. The Company has identified one reporting unit for the annual goodwill impairment testing. First, the Company performs a qualitative analysis to determine if it is more likely than not that the fair value of the reporting unit is less than its carrying value and a quantitative impairment test is required. If required, the Company applies the quantitative test to identify and measure the amount of impairment by comparing the fair value of the reporting unit, which the Company estimates on an income approach using the present value of expected future cash flows of the reporting unit to its carrying value. The Company considered the effect of the COVID-19 pandemic on its business and the overall economy and resulting impact on its goodwill. As of October 1, 2020, the Company performed a quantitative goodwill impairment test and did not identify any impairment to goodwill.

Intangibles, Net

Intangibles, Net

The Company’s intangibles consist of trade names, brand, non-compete, and customer, payor, and provider relationships. The Company amortizes its intangibles using the straight-line method over the estimated useful lives of the intangible, which ranges from one to twenty years. Intangible assets are reviewed for impairment in conjunction with long-lived assets.

Deferred Rent

Deferred RentMinimum rent, including fixed escalations, is recorded on a straight-line basis over the lease term. The lease term commences when the Company takes possession of the leased premises and, in most cases, ends upon expiration of the initial non-cancelable term. When a lease provides for fixed escalations of the minimum rental payments during the lease term, the difference between the recorded straight-line rent and the amount payable under the lease is recognized as deferred rent obligation.

Professional and General Liability

Professional and General Liability

As a healthcare provider, the Company is subject to medical malpractice claims and lawsuits. The Company may also be liable, as an employer, for the negligence of healthcare professionals it employs or the healthcare professionals it engages as independent contractors. To mitigate a portion of this risk, the Company maintains medical malpractice insurance, principally on a claims-made basis, with a reputable insurance provider. This policy contains a retroactive feature which covers claims incurred at the sites the Company operates, regardless if the claim was filed after the site’s respective policy term. The policy contains various limits and deductibles.

Loss contingencies, including medical malpractice claims and legal actions arising in the ordinary course of business, are recorded as liabilities when the likelihood of loss is probable, and an amount or range of loss can be reasonably estimated.

The Company maintains a malpractice insurance policy with a coverage limit of $1.0 million per occurrence and $3.0 million aggregate coverage, with an umbrella policy coverage of $5.0 million. Any amounts over that threshold, or for which the insurance policy will not cover, will be borne by the Company and may materially affect the Company’s future consolidated financial position, results of operations, and cash flows. As of September 30, 2021 and December 31, 2020, the Company has recorded claims liabilities of $0.5 million and $0.1 million, respectively, in other liabilities. Insurance recoverables were immaterial as of September 30, 2021 and December 31, 2020, and are recorded in other assets on the accompanying condensed consolidated balance sheets.

Advertising and Marketing Costs

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred. Advertising and marketing costs expensed totaled approximately $4.9 million and $2.4 million for the three months ended September 30, 2021 and 2020, respectively, and $10.5 million and $4.9 million for the nine months ended September 30, 2021 and 2020, respectively. Advertising and marketing costs are included in the caption selling, general, and administrative expenses in the accompanying condensed consolidated statements of operations.

Management Estimates

Management EstimatesThe preparation of the condensed consolidated financial statements requires management to make estimates and assumptions based on available information. Such estimates are based on historical experience and other assumptions that are considered appropriate in the circumstances. However, actual results could differ from those estimates and these differences may be material. Significant estimates made by the Company include, but are not limited to, fair value allocations for intangible assets acquired as part of the Company’s numerous acquisitions, recoverability of goodwill and intangibles, fair value of contingent considerations, unpaid service provider cost liability, and respective revenues and expenses related to these estimates for the years reported.

Income Taxes

Income Taxes

The acquisition of PCIH was implemented through an Up-C structure. Prior to the closing of the Business Combination, Jaws was reincorporated in the State of Delaware and became a U.S. domestic corporation named Cano Health, Inc. Merger Sub, a wholly owned subsidiary of Jaws, merged with and into PCIH, with PCIH as the surviving company in the merger. As of September 30, 2021, the Seller, the former sole owner and managing member of PCIH, held approximately 64.0% of voting rights in Cano Health, Inc. and 64.0% of economic rights in PCIH, while other investors, including the former stockholders of Jaws and PIPE Investors held approximately 36.0% of economic and voting rights in Cano Health, Inc. and 36.0% of economic and 100.0% of managing rights in PCIH. Subsequent to the closing of the Business Combination, income attributable to Cano Health, Inc. is taxed under Subchapter C while PCIH will continue to be treated as a partnership for tax purposes.

Prior to the close of the Business Combination, the Company was treated as a partnership for U.S. income tax purposes, whereby earnings and losses were included in the tax return of its members and taxed depending on the members’ tax situation. While the overall entity was previously treated as a partnership, the Company established in 2019 a subsidiary group that was taxed under Subchapter C with immaterial operations in 2019. The operations of the subsidiary group are conducted through a legal entity domiciled in Puerto Rico. The subsidiary group is subject to Puerto Rico and U.S. Federal taxes and Florida State taxes. Refer to Note 16, “Income Taxes”, for further details.

The Company recognizes and measures tax positions taken or expected to be taken in its tax return based on their technical merit and assesses the likelihood that the positions will be sustained upon examination based on the facts, circumstances and information available at the end of each period. Interest and penalties on tax liabilities, if any, would be recorded in the captions interest expense and other expenses, respectively, in the condensed consolidated statements of operations.

The U.S. Federal jurisdiction and the State of Florida are the major tax jurisdictions where the Company files income tax returns. The Company is generally subject to U.S. Federal or State examinations by tax authorities for all years since inception.

Recent Accounting Pronouncements

Recent Accounting Pronouncements 

In February 2016, the FASB established Topic 842, “Leases”, by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, “Land Easement Practical Expedient for Transition to Topic 842”, ASU No. 2018-10, “Codification Improvements to Topic 842, Leases”, ASU No. 2018-11, “Targeted Improvements”, ASU No. 2018-20, “Leases (Topic 842): Narrow-Scope Improvements for Lessors”, ASU No. 2021-05, “Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments”, and ASU No. 2020-05, “Leases (Topic 842): Effective Dates for Certain Entities” (collectively referred to as “ASC 842”). ASC 842 establishes a right of use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations.

Under ASC 842, a modified retrospective transition approach is required, and entities may choose to use either the effective date or the beginning of the earliest period presented in the financial statements as the date of initial application, with certain practical expedients available. The Company is in the process of evaluating the practical expedient options for adoption. ASC 842 is effective for fiscal years beginning after December 15, 2021 and for interim periods within fiscal years beginning after December 15, 2022, with early application permitted, and the Company expects to adopt the new standard on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier.

The Company has identified and contracted with a software vendor for the technology to support compliance with ASU 842. In addition, the Company is in the process of identifying the complete population of leases, which includes testing over contracts for any potential embedded leases. Based on the provisions of ASU 842, the Company anticipates a material increase in both assets and liabilities when the current operating lease contracts are recorded on the balance sheet. The Company does not yet have a dollar estimate of the impact; however, the Company does not anticipate the update having a material effect on its condensed consolidated statements of operations or cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU No. 2020-03, “Codification Improvements to Financial Instruments” (collectively referred to as “ASC 326”). which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. The standard has been further refined through subsequent releases by the FASB, including the extension of the effective date. As amended by ASU No. 2019-10, the standard is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those annual periods, with early adoption permitted, and the Company expects to adopt ASU 326 on the effective date or the date it no longer qualifies as an emerging growth company, whichever is earlier. The Company is currently evaluating the effect that the standard will have on its condensed consolidated financial statements and related disclosures. The Company does not anticipate the update to have a material effect on the Company’s condensed consolidated statements of operations or cash flows.

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (“Topic 718”), which expands the scope of share-based compensation guidance to include share-based payment transactions for acquiring goods and services from nonemployees. The FASB has also issued an amendment to this update to include share-based payment awards granted to a customer. The update is effective for fiscal years beginning after December 15, 2019 and for interim periods within fiscal years beginning after December 15, 2020. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (“Topic 820”): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which simplifies the fair value measurement disclosure requirements, including removing certain disclosures related to transfers between fair value hierarchy levels and adds certain disclosures to related level 3 investments. The update is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years, with early adoption permitted. The Company adopted the standard on January 1, 2020 and it did not have a material effect on its condensed consolidated financial statements.

In October 2018, the FASB issued ASU No. 2018-17, Consolidation (“Topic 810”) — Targeted Improvements to Related Party Guidance for Variable Interest Entities. The ASU creates a new private company accounting alternative in U.S. GAAP that allows a private company to not apply the VIE guidance to legal entities under common control if both the common control parent and the legal entity being evaluated for consolidation are not public business entities and other criteria are met. The new guidance also changes how all entities that apply the VIE guidance evaluate decision-making fees. For entities other than private companies, the guidance on decision-making fees is effective for annual periods beginning after December 15, 2019, and interim periods therein. The guidance is effective for private companies for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including in an interim period. The Company does not expect the update to have a material effect on its condensed consolidated financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), “Simplifying the Accounting for Income Taxes.” This new standard simplifies various aspects related to the accounting for income taxes. The standard removes certain exceptions to the general principles in Topic 740 and also clarifies and modifies

existing guidance to improve consistent application of Topic 740. The Company adopted this standard effective January 1, 2021 with no material impact to its condensed consolidated financial statements.

XML

Nature of Business and Operations (Tables) - Jaws Acquisition Corp

9 Months Ended

Sep. 30, 2021

Business Acquisition [Line Items]

Summary of Elements of Business Combination to the Consolidated Statement of Cash Flows

The following table reconciles the elements of the Business Combination to the condensed consolidated statements of cash flows and the condensed consolidated statements of changes in equity for the three and nine months ended September 30, 2021:

(in thousands)	Recapitalization
Cash - Jaws' trust and cash, net of redemptions	$	690,705
Cash - PIPE financing	800,000
Less: transaction costs and advisory fees paid	(88,745)
Less: Distribution to PCIH shareholders	(466,598)
Net Business Combination and PIPE financing	935,362
Plus: Non-cash net assets assumed	96
Plus: Accrued transaction costs	8,860
Less: Capitalized transaction costs	(8,167)
Less: Warrant liability assumed	(163,058)
Net contributions from Business Combination and PIPE financing	$	773,093

Summary of the Reconcile Number of Shares of Common Stock Issued Through Business Combination

The number of shares of common stock issued immediately following the consummation of the Business Combination is as follows:

	Class A common stock	Class B common stock
Common stock outstanding prior to Business Combination	69,000,000	—
Less: redemption of Jaws shares	(6,509)	—
Ordinary shares of Jaws	68,993,491	—
Jaws Sponsor Shares	17,250,000	—
Shares issued in PIPE financing	80,000,000	—
Business Combination and PIPE financing shares	166,243,491	—
Shares to PCIH shareholders	—	306,843,662
Total shares of common stock outstanding immediately after the Business Combination	166,243,491	306,843,662

XML

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2021

Accounting Policies [Abstract]

Summary of Revenue

The Company’s revenue from its revenue streams described in the preceding paragraphs for the three and nine months ended September 30, 2021 and 2020 was as follows:

		Three Months Ended September 30,
(in thousands)		2021			2020
		Revenue $	Revenue %		Revenue $	Revenue %
Capitated revenue:
Medicare	$	447,250	84.9%	$	220,591	83.8	%
Other capitated revenue		54,530	10.4%		32,383	12.3	%
Total capitated revenue		501,780	95.3%		252,974	96.1	%
Fee-for-service and other revenue:
Fee-for-service		8,176	1.6%		3,258	1.2	%
Pharmacy		10,096	1.8%		6,154	2.4	%
Other		6,746	1.3%		747	0.3	%
Total fee-for-service and other revenue		25,018	4.7%		10,159	3.9	%
Total revenue	$	526,798	100.0%	$	263,133	100.0	%

		Nine Months Ended September 30,
		2021				2020
(in thousands)		Revenue $	Revenue %			Revenue $	Revenue %
Capitated revenue:
Medicare	$	1,008,329	84.0	%	$	455,986	80.0	%
Other capitated revenue		139,712	11.6	%		88,631	15.6	%
Total capitated revenue		1,148,041	95.7	%		544,617	95.6	%
Fee-for-service and other revenue:
Fee-for-service		17,113	1.4	%		6,269	1.1	%
Pharmacy		25,619	2.1	%		17,207	3.0	%
Other		9,323	0.8	%		1,544	0.3	%
Total fee-for-service and other revenue		52,055	4.3	%		25,020	4.4	%
Total revenue	$	1,200,096	100.0	%	$	569,637	100.0	%

Summary of Account Receivable Balance

Accounts receivable balances are summarized below:

		As of,
(in thousands)		September 30, 2021		December 31, 2020
Accounts receivable	$	242,086	$	113,089
Medicare risk adjustment		108,570		18,144
Unpaid service provider costs		(127,012)		(54,524)
Accounts receivable, net	$	223,644	$	76,709

Summary of Activity in Unpaid Service Provider Cost For The Period

Activity in unpaid service provider cost for the nine months ended September 30, 2021 and 2020 is summarized below:

		For the nine months ended September 30,
(in thousands)		2021		2020
Balance as at January 1,	$	54,524	$	19,968
Incurred related to:
Current year		566,473		216,044
Prior years		3,526		793
		569,999		216,837
Paid related to:
Current year		439,460		172,749
Prior years		58,051		20,761
		497,511		193,510
Balance as at September 30,	$	127,012	$	43,295

XML

Business Acquisitions (Tables)

9 Months Ended

Sep. 30, 2021

Business Combination and Asset Acquisition [Abstract]

Summary of Allocation of the Purchase Price

The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	6,641
Property and equipment, net		1,283
Other assets		142
Favorable leasehold interest		110
Non-compete intangibles		1,700
Trade name		25,500
Payor relationships		115,100
Goodwill		151,188
Accounts payable and accrued expenses		(1,001)
Total purchase price, including non-compete intangibles	$	300,663

The following table provides the allocation of the purchase price:

(in thousands)
Accounts receivable, net of unpaid service provider costs	$	2,217
Inventory		264
Property and equipment, net		1,636
Payor relationships		175,172
Non-compete intangibles		45,191
Other acquired intangibles		113,237
Other assets		116
Goodwill		273,427
Accounts payable and accrued expenses		(140)
Total purchase price, including non-compete intangibles	$	611,120

The following table provides the allocation of the purchase price:

(in thousands)
Property and equipment	$	2,409
Non-compete intangibles		1,022
Acquired intangibles		117,014
Goodwill		74,852
Other assets		87
Total purchase price, including non-compete intangibles	$	195,384

The following table provides the allocation of the purchase price:

(in thousands)
Cash and cash equivalents	$	191
Accounts receivable		486
Inventory		155
Property and equipment		1,518
Non-compete intangibles		846
Acquired intangibles		43,549
Goodwill		13,738
Accounts payable		(274)
Total purchase price, including non-compete intangibles	$	60,209

Summary of Company's Assets and Liabilities and Reconciliation of Cash Paid for Net Assets Acquired

The net effect of acquisitions to the Company’s assets and liabilities and reconciliation of cash paid for net assets acquired for the nine months ended September 30, 2021 and 2020, including amounts related to acquisitions not disclosed above, was as follows:

		Nine Months Ended September 30,
(in thousands)		2021		2020
Assets Acquired
Accounts receivable	$	50,979	$	486
Other assets		2,050		433
Property and equipment		3,411		4,011
Goodwill		531,162		89,976
Intangibles		637,537		162,537
Total assets acquired		1,225,139		257,443
Liabilities Assumed
Due to sellers		1,295		16,288
Contingent consideration		47,900		—
Other liabilities		45,783		1,530
Total liabilities assumed		94,978		17,818
Net Assets Acquired		1,130,161		239,625
Issuance of Parent equity in connection with acquisitions		61,500		34,300
Acquisitions of subsidiaries, including non-compete intangibles, net of cash acquired	$	1,068,661	$	205,325

Summary of Pro Forma Information of the Combined Results of Operations

The following unaudited pro forma financial information summarizes the combined results of operations for the Company and its acquisitions of University and HP, as if the companies were combined as of January 1, 2020:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2021		2020		2021		2020
Revenue	$	526,798	$	350,976	$	1,354,547	$	979,355
Net loss	$	(40,883)	$	(14,398)	$	(53,592)	$	(8,566)

XML

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2021

Property, Plant and Equipment [Abstract]

Summary of Property And Equipment, Net and The Related Useful Lives

The following is a summary of property and equipment, net and the related useful lives as of September 30, 2021 and December 31, 2020:

			As of
(in thousands)			September 30,		December 31,
Assets Classification	Useful Life		2021		2020
Leasehold improvements	Lesser of lease term or 15 years	$	33,288	$	25,021
Machinery and equipment	3-12 years		14,403		8,288
Automobiles	3-5 years		6,679		4,900
Computer and equipment	5 years		5,950		4,475
Furniture and equipment	3-7 years		3,242		2,390
Construction in progress			19,057		4,155
Total			82,619		49,229
Less: Accumulated depreciation and amortization			(18,463)		(11,103)
Property and equipment, net		$	64,156	$	38,126

XML

Intangibles, Net (Tables)

9 Months Ended

Sep. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Total Intangible, Net

As of September 30, 2021, the Company’s total intangibles, net consisted of the following:

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(747)	$	662
Brand		183,217		(6,286)		176,931
Non-compete		75,626		(8,270)		67,356
Customer relationships		880		(171)		709
Payor relationships		609,322		(25,057)		584,265
Provider relationships		12,242		(1,573)		10,669
Total intangibles, net	$	882,696	$	(42,104)	$	840,592

As of December 31, 2020, the Company’s total intangibles, net consisted of the following:

(in thousands)		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangibles:
Trade names	$	1,409	$	(630)	$	779
Brand		29,486		(2,171)		27,315
Non-compete		7,733		(3,373)		4,360
Customer relationships		880		(135)		745
Payor relationships		201,530		(11,960)		189,570
Provider relationships		4,119		(533)		3,586
Total intangibles, net	$	245,157	$	(18,802)	$	226,355

Summary of Expected Amortization Expense of The Intangible Assets

Expected amortization expense for the Company’s existing amortizable intangibles for the next five years, and thereafter, as of September 30, 2021 is as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	15,075
2022		59,423
2023		57,585
2024		55,644
2025		54,218
Thereafter		598,647
Total	$	840,592

XML

Capital Lease Obligations (Tables)

9 Months Ended

Sep. 30, 2021

Leases [Abstract]

Schedule of Future Minimum Lease Payments Under The Capital Leases

Future minimum lease payments under the capital leases as of September 30, 2021 are due as noted below:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	307
2022		1,151
2023		819
2024		514
2025		76
2026		25
Total minimum lease payments		2,892
Less: amount representing interest		(327)
Total capital lease obligations		2,565
Less: current maturities		(1,006)
Total long-term capital lease obligations	$	1,559

Future minimum lease payments under the capital leases as of December 31, 2020 are due as noted below:

Year ending December 31,		Amount (in thousands)
2021	$	1,038
2022		919
2023		586
2024		271
Total minimum lease payments		2,814
Less: amount representing interest		(358)
Total capital lease obligations		2,456
Less: current maturities		(876)
Total long-term capital lease obligations	$	1,580

XML

Equipment Loans (Tables)

9 Months Ended

Sep. 30, 2021

Debt Disclosure [Abstract]

Summary of Equipment Loans

Equipment loans were as follows as of September 30, 2021 and December 31, 2020:

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Notes payable bearing interest at 17.2%; due July 2022, secured by certain property and equipment	$	28	$	51
Notes payable bearing interest at 12.5%, 12.8%, and 11.0%; all due June 2023, all secured by certain property and equipment	41		82
Notes payable bearing interest at 10.7%; due June 2023, secured by certain property and equipment	60		58
Notes payable bearing interest at 7.2%; due April 2025, secured by certain property and equipment	78		92
Notes payable bearing interest at 4.2%; due December 2024, secured by certain property and equipment	746		904
Notes payable bearing interest at 3.4%; due March 2026, secured by certain property and equipment	1,014		—
Total equipment loans	1,967		1,187
Less: Current portion	(513)		(314)
Total equipment loans, net of current portion	$	1,454	$	873

XML

Contract Liabilities (Tables)

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Summary of Significant Changes In The Contract Liabilities

A summary of significant changes in the contract liabilities balance during the period is as follows:

(in thousands)		For the three months ended September 30, 2021
Balance as at June 30, 2021	$	5,936
Increases due to amounts collected		990
Revenues recognized from current period increases		(413)
Balance as at September 30, 2021	$	6,513
(in thousands)		For the nine months ended September 30, 2021
Balance as at January 1, 2021	$	5,265
Increases due to amounts collected		2,290
Revenues recognized from current period increases		(1,042)
Balance as at September 30, 2021	$	6,513

XML

Long-Term Debt (Tables)

9 Months Ended

Sep. 30, 2021

Debt Disclosure [Abstract]

Schedule of Notes Payable

The Company’s notes payable were as follows as of September 30, 2021 and December 31, 2020:

Long-Term Debt	As of,
(in thousands)	September 30, 2021		December 31, 2020
Term loan 3	$	252,531	$	480,000
Term loan 4	293,525		—
Term loan 5	100,000		—
Senior Notes	300,000		—
Less: Current portion of notes payable	(6,493)		(4,800)
	939,563		475,200
Less: debt issuance costs	(23,452)		(18,455)
Notes payable, net of current portion	$	916,111	$	456,745

Schedule of Maturities of Long-term Debt

The following table sets forth the Company’s future principal payments as of September 30, 2021, assuming another mandatory prepayment does not occur:

(in millions)
Year ending December 31,		Amount
Remainder of 2021	$	1,623
2022		6,493
2023		6,493
2024		6,493
2025		6,493
Thereafter		918,461
Total	$	946,056

XML

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2021

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of September 30, 2021:

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	46,706	$	—	$	—	$	46,706
Public Warrant Liabilities		94,990		94,990		—		—
Private Placement Warrant Liabilities		43,503		—		—		43,503
Total Liabilities	$	185,199	$	94,990	$	—	$	90,209

The following table sets forth by level, within the fair value hierarchy, the Company’s liabilities measured at fair value on a recurring basis as of December 31, 2020:

(in thousands)		Carrying Value		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities measured at fair value on a recurring basis:
Contingent consideration	$	5,172	$	—	$	—	$	5,172
Total Liabilities	$	5,172	$	—	$	—	$	5,172

Summary of Liabilities Measured At Fair Value Using Significant Unobservable Inputs

Activity of the assets and liabilities measured at fair value using significant unobservable inputs was as follows:

		Fair Value Measurements
		For the three months ended September 30,
		2021		2020
Opening balance as at July 1,	$	136,190	$	75,800
Change in fair value of embedded derivative		—		5,138
Change in fair value of contingent consideration		(3,940)		—
Contingent consideration recognized due to acquisitions		38,300		—
Change in fair value of warrants		14,649		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration payments		—		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879
		Fair Value Measurements
		For the nine months ended September 30,
		2021		2020
Opening balance as at January 1,	$	5,172	$	23,429
Embedded derivative recognized under Term Loan 2		—		51,328
Change in fair value of embedded derivative		—		5,444
Change in fair value of contingent consideration		(4,152)		—
Contingent consideration recognized due to acquisitions		47,900		2,695
Warrants acquired in the Business Combination		163,058		—
Change in fair value of warrants		(24,565)		—
Contingent consideration reclassified to due to seller		—		(16,059)
Contingent consideration settled through equity		—		(1,958)
Contingent consideration payments		(2,214)		(3,000)
Closing balance as at September 30,	$	185,199	$	61,879

Embedded Derivative Liability

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements

The recurring Level 3 fair value measurements of the embedded derivative liability included the following significant unobservable inputs as of June 1, 2020 and September 30, 2020:

	Range as of
Unobservable Input	June 1, 2020	September 30, 2020
Probability of change of control	90%	80%
Probability of issuance of debt	5%	15%
Expected date of event	Fourth Quarter 2020	Fourth Quarter 2020
Discount rate	39%	38%

Warrant Liabilities

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements

The following table provides quantitative information regarding the Level 3 inputs used for the fair value measurements of the warrants liabilities:

	As of
Unobservable Input	June 3, 2021	September 30, 2021
Exercise price	$11.50	$11.50
Stock price	$14.75	$12.68
Term (years)	5.0	4.7
Volatility	37.1%	—%
Risk free interest rate	0.8%	0.9%
Dividend yield	None	None
Public warrant price	None	$4.13

XML

Variable Interest Entities (Tables)

9 Months Ended

Sep. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Aggregated VIE Assets and Liabilities and Performance

The table below illustrates the aggregated VIE assets and liabilities and performance for the Physicians Groups:

	As of,
(in thousands)	September 30, 2021		December 31, 2020
Total Assets	$	30,483	$	8,182
Total Liabilities	$	23,234	$	12,371

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2021		2020		2021		2020
Total revenue	$	12,321	$	79	$	14,621	$	79
Operating expenses:
Third-party medical costs	8,582		—		8,582		—
Direct patient expense	2,413		295		5,203		295
Selling, general and administrative expenses	7,277		1,125		12,540		1,324
Depreciation and amortization expense	353		—		860		—
Total operating expenses	18,625		1,420		27,185		1,619
Net loss	$	(6,304)	$	(1,341)	$	(12,564)	$	(1,540)

XML

Equity-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2021

Share-based Payment Arrangement [Abstract]

Schedule of Fair Value of Stock Options Granted Using e Monte-Carlo model

The fair values were calculated using the Monte-Carlo model with the following assumptions as of the grant date on June 3, 2021:

	As of June 3, 2021
Closing Cano share price as of valuation date	$	14.75
Risk-free interest rate	1.68% - 2.0%
Expected volatility	45.0%
Expected dividend yield	0.0%
Expected cost of equity	9.0%

Summary of Activity of Unvested Market Condition Awards Granted

A summary of the status of unvested Market Condition Awards granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	12,831,184	$4.23
Vested	—	—
Forfeitures	(97,486)	4.23
Balance, September 30, 2021	12,733,698	$4.23

Summary of Unvested Restricted Stock Units Activity

A summary of the status of unvested RSUs granted under the 2021 Plan from January 1, 2021 through September 30, 2021 is presented below:

	Shares	Weighted Average Grant Date Fair Value
Balance, January 1, 2021	—	—
Granted	4,840,444	$14.46
Vested	—	—
Forfeitures	(16,750)	14.75
Balance, September 30, 2021	4,823,694	$14.46

XML

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Schedule of Minimum Future Payments

Minimum future payments as of September 30, 2021 were approximately as follows:

Year ending December 31,		Amount (in thousands)
Remainder of 2021	$	3,876
2022		13,987
2023		12,763
2024		11,125
2025		9,451
Thereafter		27,908
Total	$	79,110

XML

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2021

Income Tax Disclosure [Abstract]

Summary of Income Tax Expense From Continuing Operations

The net loss for the three months and nine months ended September 30, 2021 and 2020 consisted of the following:

		For the Three Months Ended				For the Nine Months Ended
		September 30,				September 30,
(in thousands)		2021		2020		2021		2020
Jurisdictional earnings:
U.S. losses	$	(41,206)	$	(11,760)	$	(46,053)	$	(25,456)
Foreign income (losses)		870		969		(1,112)		1,461
Total losses		(40,336)		(10,791)		(47,165)		(23,995)
Current:
U.S. Federal		—		—		—		—
U.S. State and local		—		(29)		—		(26)
Foreign		—		(251)		—		(222)
Total current tax expense		—		(280)		—		(248)
Deferred:
U.S. Federal		—		—		—		—
U.S. State and local		(221)		—		282		—
Foreign		(326)		(46)		480		(46)
Total deferred tax benefit (expense)		(547)		(46)		762		(46)
Total tax benefit (expense)	$	(547)	$	(326)	$	762	$	(294)

XML

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2021

Earnings Per Share [Abstract]

Summary of Basic and Diluted Net Loss Per Common Share

The following table sets forth the net loss for the three and nine months ended September 30, 2021 and 2020 and the computation of basic and diluted net loss per common stock for the three and nine months ended September 30, 2021:

	Three months ended September 30,				Nine months ended September 30,
(in thousands, except shares and per share data)	2021		2020		2021		2020
Numerator:
Net loss	$	(40,883)	$	(11,117)	$	(46,403)	$	(24,289)
Less: net loss attributable to non-controlling interests	(26,246)		—		(41,283)		—
Net loss attributable to Class A common stockholders	(14,637)		—		(5,120)		—
Dilutive effect of warrants on net loss to Class A common stockholders	—		N/A		(8,780)		N/A
Net loss attributable to Class A common stockholders - Diluted	(14,637)		N/A		(13,900)		N/A
Basic and Diluted Earnings Per Share denominator:
Weighted average common stock outstanding - basic	170,871,429		N/A		168,100,210		N/A
Net loss per share - basic	$	(0.09)	N/A		$	(0.03)	N/A
Diluted Earnings Per Share:
Dilutive effect of warrants on weighted average common stock outstanding	—		N/A		1,212,048		N/A
Weighted average common stock outstanding - diluted	170,871,429		N/A		169,312,258		N/A
Net loss per share - diluted	$	(0.09)	N/A		$	(0.08)	N/A

Summary of Diluted Net Loss Per Share

The table below presents the Company’s potentially dilutive securities:

	As of September 30, 2021
Public Warrants	23,000,000
Private Placement Warrants	10,533,333
Restricted Stock Units	4,823,694
Stock Options	12,733,698
Contingent Shares Issued in Connection with Acquisitions	2,720,966
Potential Common Stock Equivalents	53,811,691

XML

Nature of Business and Operations - Additional Information (Details) $ / shares in Units, physician in Thousands			3 Months Ended		9 Months Ended
	Jun. 11, 2021 USD ($) $ / shares shares	Jun. 03, 2021 USD ($) $ / shares shares	Sep. 30, 2021 shares	Jun. 30, 2021 shares	Sep. 30, 2021 vote medical_provider physician medical_center shares
Nature Of Business And Operations [Line Items]
Number of owned medical centers | medical_center					113
Number of service providers | medical_provider					345
Number of physicians | physician					1
Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Percentage of controlling ownership		35.10%
Percentage of non controlling ownership		64.90%
Jaws Acquisition Corp
Nature Of Business And Operations [Line Items]
Stock shares redeemed during the period (in shares)		6,509
Payments for Repurchase of Redeemable Noncontrolling Interest | $		$ 65,090
Jaws Acquisition Corp | PIPE Financing
Nature Of Business And Operations [Line Items]
Payment to acquire business | $		800,000,000
Jaws Acquisition Corp | Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Payment to acquire business | $		$ 466,500,000
Business acquistion share price | $ / shares		$ 10.00
Business acquistion equity interests issued or issuable shares (in shares)		3,068,400,000
Business combination, consideration transferred | $		$ 3,534,900,000
University Health Care And Its Affiliates
Nature Of Business And Operations [Line Items]
Payment to acquire business | $	$ 541,500,000
University Health Care And Its Affiliates | Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Percentage of controlling ownership			36.00%		36.00%
Percentage of non controlling ownership			64.00%		64.00%
Business acquistion share price | $ / shares	$ 14.79
Business acquistion equity interests issued or issuable shares (in shares)	4,100,000
Business combination, consideration transferred | $	$ 611,100,000
Class A common stock, $0.0001 par value per share
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)			171,594,914		171,594,914
Stock issued during period, acquisitions (in shares)			4,178,147	4,178,147
Class A common stock, $0.0001 par value per share | Jaws Acquisition Corp
Nature Of Business And Operations [Line Items]
Stock shares redeemed during the period (in shares)		6,509
Class A common stock, $0.0001 par value per share | Jaws Acquisition Corp | PIPE Financing
Nature Of Business And Operations [Line Items]
Stock issued during period shares (in shares)		80,000,000
Class A common stock, $0.0001 par value per share | Jaws Acquisition Corp | Founder Shares
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)		17,250,000
Class A common stock, $0.0001 par value per share | Jaws Acquisition Corp | Stock Outstanding Prior To Business Combination
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)		69,000,000
Class A common stock, $0.0001 par value per share | University Health Care And Its Affiliates
Nature Of Business And Operations [Line Items]
Business acquistion equity interests issued or issuable shares (in shares)	4,055,698
Business acquisition, conversion of stock, shares issues (in shares)			1,200,000
Class A common stock, $0.0001 par value per share | Other acquisitions | Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Business acquistion equity interests issued or issuable shares (in shares)			100,000
Class B common stock
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)			305,670,386		305,670,386
Class B common stock | Jaws Acquisition Corp
Nature Of Business And Operations [Line Items]
Stock shares redeemed during the period (in shares)		0
Class B common stock | Jaws Acquisition Corp | PCIH Shareholders
Nature Of Business And Operations [Line Items]
Stock issued during period, acquisitions (in shares)		306,800,000
Class B common stock | Jaws Acquisition Corp | PIPE Financing
Nature Of Business And Operations [Line Items]
Stock issued during period shares (in shares)		0
Class B common stock | Jaws Acquisition Corp | Founder Shares
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)		0
Class B common stock | Jaws Acquisition Corp | Founder Shares | Jaws Sponsor LLC
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)		17,250,000
Class B common stock | Jaws Acquisition Corp | Stock Outstanding Prior To Business Combination
Nature Of Business And Operations [Line Items]
Common stock outstanding (in shares)		0
Class B common stock | Jaws Acquisition Corp | Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Business acquistion equity interests issued or issuable shares (in shares)		306,800,000
Class B common stock | University Health Care And Its Affiliates
Nature Of Business And Operations [Line Items]
Business acquisition, conversion of stock, shares converted (in shares)			1,200,000
Class B common stock | Primary Care ITC Intermediate Holdings LLC
Nature Of Business And Operations [Line Items]
Common stock, voting rights (in dollars per share) | vote					1

XML

Nature of Business and Operations - Summary of Elements of Business Combination to the Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash - Jaws' trust and cash, net of redemptions	$ 690,705	$ 690,705
Cash - PIPE financing	800,000	800,000
Less: transaction costs and advisory fees paid	(88,745)	(88,745)
Less: Distribution to PCIH shareholders	(466,598)	(466,598)
Net Business Combination and PIPE financing	935,362	935,362
Plus: Non-cash net assets assumed	96	96
Plus: Accrued transaction costs	8,860	8,860
Less: Capitalized transaction costs	(8,167)	(8,167)
Less: Warrant liability assumed	(163,058)	(163,058)
Net contributions from Business Combination and PIPE financing	$ 773,093	$ 773,093

XML

Nature of Business and Operations - Summary of the Reconcile Number of Shares of Common Stock Issued Through Business Combination (Details) - shares		3 Months Ended		9 Months Ended
	Jun. 03, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2021
Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)		171,594,914		171,594,914
Issuance of common stock for acquisitions (in shares)		4,178,147	4,178,147
Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)		305,670,386		305,670,386
Jaws Acquisition Corp
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Less: redemption of Jaws shares (in shares)	(6,509)
Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Less: redemption of Jaws shares (in shares)	(6,509)
Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Less: redemption of Jaws shares (in shares)	0
Jaws Acquisition Corp | PCIH Shareholders | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Issuance of common stock for acquisitions (in shares)	0
Jaws Acquisition Corp | PCIH Shareholders | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Issuance of common stock for acquisitions (in shares)	306,843,662
Jaws Acquisition Corp | PIPE Financing | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Shares issued in PIPE financing (in shares)	80,000,000
Jaws Acquisition Corp | PIPE Financing | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Shares issued in PIPE financing (in shares)	0
Common Stock | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Issuance of common stock for acquisitions (in shares)		122,449,000		4,178,147,000
Common Stock | Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	68,993,491
Common Stock | Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	0
Founder Shares | Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	17,250,000
Founder Shares | Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	0
PIPE Financing Shares | Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Issuance of common stock for acquisitions (in shares)	166,243,491
PIPE Financing Shares | Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Issuance of common stock for acquisitions (in shares)	0
Stock Outstanding Prior To Business Combination | Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	69,000,000
Stock Outstanding Prior To Business Combination | Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	0
Stock Outstanding After Business Combination | Jaws Acquisition Corp | Class A common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	166,243,491
Stock Outstanding After Business Combination | Jaws Acquisition Corp | Class B common stock
Schedule Of Reconcile Number Of Shares Of Common Stock Issued Through Business Combination [Line Items]
Common stock outstanding (in shares)	306,843,662

XML

Summary of Significant Accounting Policies - Additional Information (Details) $ / shares in Units, $ in Thousands				3 Months Ended			9 Months Ended		12 Months Ended
	Nov. 09, 2021 USD ($) shares	Jun. 11, 2021	Jun. 03, 2021 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) plan shares	Jun. 30, 2021 USD ($) shares	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) plan shares	Sep. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Impact of transactions affecting non-controlling interests				$ 0			$ 0
Class of Warrant or Right [Line Items]
Number of days from which warrants become exercisable after the consummation of business combination			30 days
Warrants and rights outstanding term			5 years
Share price | $ / shares			$ 18.00
Concentration Risk [Line Items]
Concentration risk percentage				100.00%		100.00%	100.00%	100.00%
Cash FDIC Insured Amount				$ 300			$ 300
Number of health plan | plan				2			2
Restricted cash balances				$ 3,500			$ 3,500
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable				0			0		$ 0
Accounts receivable				223,644			223,644		76,709
Unpaid service cost incurred in previous year							3,526	$ 793
Malpractice Insurance [Line Items]
Loss contingency insurance policy, deductible							100		100
Loss contingency insurance policy, Maximum Coverage limit									2,000
Loss contingency insurance policy, Premiums				1,900		$ 1,300	5,400	3,600
Loss contingency insurance policy, insurance reimbursements				3,600		0	5,400	0
Insurance recoveries							3,500		2,500
Extinguishment of Debt [Line Items]
Debt issuance costs and debt discounts premium, net				24,200			24,200		24,900
Extinguishment of debt			$ 400,000
Loss on extinguishment of debt				0		0	13,225	0
Amortization of debt issuance costs				4,000		3,000	7,700	3,900
Extinguishment of debt			$ 400,000
Loss on extinguishment of debt				$ 0		0	13,225	0
Property, Plant and Equipment [Line Items]
Impairment to goodwill							$ 0	0
Class A common stock
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Stock issued during period, acquisitions (in shares) | shares				4,178,147	4,178,147
Income Tax Disclosure [Line Items]
Issuance of common stock for acquisitions (in shares) | shares				4,178,147	4,178,147
Issuance of common stock for acquisitions (in shares) | shares				4,178,147	4,178,147
Subsequent Event | Primary Care Intermediate Holdings, LLC
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Number of shares of equity interests issued to acquire entity (in shares) | shares	4,178,147
Minimum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets							1 year
Maximum
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets							20 years
University Health Care And Its Affiliates
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets		5 years
Medicare risk adjustment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable				$ 108,600			$ 108,600		18,100
Primary Care ITC Intermediate Holdings LLC
Income Tax Disclosure [Line Items]
Percentage of non controlling ownership			64.90%
Percentage of controlling ownership			35.10%
Primary Care ITC Intermediate Holdings LLC | University Health Care And Its Affiliates
Income Tax Disclosure [Line Items]
Percentage of non controlling ownership				64.00%			64.00%
Percentage of controlling ownership				36.00%			36.00%
Former Stock Holders Of Jaws And Pipe Investors
Income Tax Disclosure [Line Items]
Percentage of managing rights				100.00%			100.00%
Leaseholds and Leasehold Improvements | Minimum
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life							3 years
Leaseholds and Leasehold Improvements | Maximum
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life							15 years
Professional and General Liability
Malpractice Insurance [Line Items]
Malpractice insurance policy with a coverage limit							$ 1,000
Malpractice insurance policy with a aggregate coverage limit							3,000
Umbrella Insurance policy coverage							5,000
Insurance claim liabilities				$ (500)			(500)		$ (100)
Selling, General and Administrative Expenses
Schedule of Marketing and Advertising Expense [Line Items]
Advertising and marketing expense				4,900		$ 2,400	10,500	$ 4,900
Non-Controlling Interests
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Impact of transactions affecting non-controlling interests				(39,550)	$ (38,600)		(39,550)
Non-Controlling Interests | Subsequent Event
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Impact of transactions affecting non-controlling interests	$ (39,600)
Additional Paid-in Capital
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Impact of transactions affecting non-controlling interests				$ 39,550	$ 38,600		$ 39,550
Additional Paid-in Capital | Subsequent Event
Distribution Made to Limited Liability Company (LLC) Member [Line Items]
Impact of transactions affecting non-controlling interests	$ 39,600
Supplier Benchmark | Significant Vendor | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk percentage				87.00%		100.00%	96.00%	100.00%
Revenue Benchmark | Customer Concentration Risk | Three HMOs
Concentration Risk [Line Items]
Concentration risk percentage				57.20%		70.20%	63.60%	67.50%
Accounts receivable | Customer Concentration Risk | Three HMOs
Concentration Risk [Line Items]
Concentration risk percentage							39.80%		67.10%
Public Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares) | shares			23,000,000.0	23,000,000.0			23,000,000.0
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares) | shares			10,530,000	10,530,000			10,530,000
Notes Payable
Extinguishment of Debt [Line Items]
Debt issuance costs and debt discounts premium, net				$ 23,500			$ 23,500		$ 18,500
Prepaid Expenses and Other Current Assets
Extinguishment of Debt [Line Items]
Debt issuance costs and debt discounts premium, net				200			200		5,800
Other Assets
Extinguishment of Debt [Line Items]
Debt issuance costs and debt discounts premium, net				$ 500			$ 500		$ 600

XML

Summary of Significant Accounting Policies - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Capital revenue	$ 501,780	$ 252,974	$ 1,148,041	$ 544,617
Fee-for-service and other revenue	25,018	10,159	52,055	25,020
Total revenue	$ 526,798	$ 263,133	$ 1,200,096	$ 569,637
Percentage of capital revenue	95.30%	96.10%	95.70%	95.60%
Percentage of fee for service and other revenue	4.70%	3.90%	4.30%	4.40%
Total revenue	100.00%	100.00%	100.00%	100.00%
Medicare
Disaggregation of Revenue [Line Items]
Capital revenue	$ 447,250	$ 220,591	$ 1,008,329	$ 455,986
Percentage of capital revenue	84.90%	83.80%	84.00%	80.00%
Other capitated revenue
Disaggregation of Revenue [Line Items]
Capital revenue	$ 54,530	$ 32,383	$ 139,712	$ 88,631
Percentage of capital revenue	10.40%	12.30%	11.60%	15.60%
Fee-for-service
Disaggregation of Revenue [Line Items]
Fee-for-service and other revenue	$ 8,176	$ 3,258	$ 17,113	$ 6,269
Percentage of fee for service and other revenue	1.60%	1.20%	1.40%	1.10%
Pharmacy
Disaggregation of Revenue [Line Items]
Fee-for-service and other revenue	$ 10,096	$ 6,154	$ 25,619	$ 17,207
Percentage of fee for service and other revenue	1.80%	2.40%	2.10%	3.00%
Other
Disaggregation of Revenue [Line Items]
Fee-for-service and other revenue	$ 6,746	$ 747	$ 9,323	$ 1,544
Percentage of fee for service and other revenue	1.30%	0.30%	0.80%	0.30%

XML

Summary of Significant Accounting Policies - Summary of Account Receivable Balance (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Schedule of Account Receivable [Line Items]
Accounts receivable, net	$ 223,644	$ 76,709
Accounts receivable
Schedule of Account Receivable [Line Items]
Accounts receivable, net	242,086	113,089
Medicare risk adjustment
Schedule of Account Receivable [Line Items]
Accounts receivable, net	108,570	18,144
Unpaid service provider costs
Schedule of Account Receivable [Line Items]
Accounts receivable, net	$ (127,012)	$ (54,524)

XML

Summary of Significant Accounting Policies - Summary of Activity in Unpaid Service Provider Cost For The Period (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Unpaid Service Cost [Roll Forward]
Beginning balance	$ 54,524	$ 19,968
Unpaid service cost incurred in current year	566,473	216,044
Unpaid service cost incurred in previous year	3,526	793
Total	569,999	216,837
Unpaid service cost paid in current year	439,460	172,749
Unpaid service cost paid in previous year	58,051	20,761
Total	497,511	193,510
Ending balance	$ 127,012	$ 43,295

XML

Business Acquisitions - Additional Information (Details) - USD ($) $ in Thousands							3 Months Ended		9 Months Ended
	Jun. 01, 2022	Jul. 02, 2021	Jun. 11, 2021	Jan. 13, 2021	Jun. 01, 2020	Jan. 02, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Revenues							$ 526,798	$ 263,133	$ 1,200,096	$ 569,637
Net income							(14,637)		(5,120)
University Health Care and Its Affiliates
Business Acquisition [Line Items]
Purchase price			$ 541,500
Non-compete intangibles			45,191
Revenues							89,300		120,500
Business combination, contingent consideration			9,600
Intangible assets			$ 45,200
Weighted-average amortization period			5 years
Net income							10,600		26,700
University Health Care and Its Affiliates | Primary Care ITC Intermediate Holdings LLC
Business Acquisition [Line Items]
Business combination, consideration transferred			$ 611,100
Number of shares of equity interests issued to acquire entity (in shares)			4,100,000
University Health Care and Its Affiliates | Class A common stock
Business Acquisition [Line Items]
Business acquisition, equity interest issued value assigned			$ 60,000
Number of shares of equity interests issued to acquire entity (in shares)			4,055,698
HP Enterprises II LLC and Related Entities
Business Acquisition [Line Items]
Purchase price					$ 149,300
Non-compete intangibles					1,022
Revenues							95,000	81,100	274,000	114,700
Business combination, consideration transferred					195,400
Intangible assets					$ 1,000
Weighted-average amortization period					5 years
Payments made for an escrow agent				$ 18,000
Other payments to acquire businesses				$ 17,100
Business combination, consideration transferred, liabilities incurred					$ 16,100
Business combination, contingent consideration arrangements, description					due no later than five days following January 31, 2022
Net income							15,800	7,600	39,100	9,800
HP Enterprises II LLC and Related Entities | Forecast
Business Acquisition [Line Items]
Other payments to acquire businesses	$ 900
HP Enterprises II LLC and Related Entities | Class A-4 Units
Business Acquisition [Line Items]
Business acquisition, equity interest issued value assigned					$ 30,000
Number of shares of equity interests issued to acquire entity (in shares)					923,076
Primary Care Physicians and Related Entities
Business Acquisition [Line Items]
Purchase price						$ 53,600
Non-compete intangibles						846
Revenues							33,400	33,000	78,400	45,600
Business combination, consideration transferred						60,200
Intangible assets						$ 800
Weighted-average amortization period						3 years
Net income							4,900	$ 1,700	12,900	$ 5,400
Business combination, pay-down of long-term debt						$ 1,500
Pay down of accounts payable and accrued expenses						1,100
Primary Care Physicians and Related Entities | Class A-4 Units
Business Acquisition [Line Items]
Business acquisition, equity interest issued value assigned						$ 4,000
Number of shares of equity interests issued to acquire entity (in shares)						123,077
Doctor's Medical Center, LLC
Business Acquisition [Line Items]
Purchase price		$ 300,700
Revenues							45,600		45,600
Net income							$ 4,400		$ 4,400
Doctor's Medical Center, LLC | Non-compete
Business Acquisition [Line Items]
Non-compete intangibles		$ 1,700

XML

Business Acquisitions - Summary of Allocation of the Purchase Price (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jul. 02, 2021	Jun. 11, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 01, 2020	Jan. 02, 2020
Business Acquisition [Line Items]
Goodwill	$ 765,511			$ 234,328
Doctor's Medical Center, LLC
Business Acquisition [Line Items]
Accounts receivable, net of unpaid service provider costs		$ 6,641
Property and equipment, net		1,283
Other assets		142
Favorable leasehold interest		110
Payor relationships		115,100
Goodwill		151,188
Accounts payable and accrued expenses		(1,001)
Total purchase price, including non-compete intangibles		300,663
Doctor's Medical Center, LLC | Non-compete
Business Acquisition [Line Items]
Non-compete intangibles		1,700
Doctor's Medical Center, LLC | Trade names
Business Acquisition [Line Items]
Trade name		$ 25,500
University Health Care And Its Affiliates
Business Acquisition [Line Items]
Accounts receivable, net of unpaid service provider costs			$ 2,217
Inventory			264
Property and equipment, net			1,636
Other acquired intangibles			113,237
Other assets			116
Non-compete intangibles			45,191
Payor relationships			175,172
Goodwill			273,427
Accounts payable and accrued expenses			(140)
Total purchase price, including non-compete intangibles			$ 611,120
HP Enterprises II LLC and Related Entities
Business Acquisition [Line Items]
Property and equipment, net						$ 2,409
Other acquired intangibles						117,014
Other assets						87
Non-compete intangibles						1,022
Goodwill						74,852
Total purchase price, including non-compete intangibles						$ 195,384
Primary Care Physicians And Related Entities
Business Acquisition [Line Items]
Cash and cash equivalents							$ 191
Accounts receivable, net of unpaid service provider costs	50,979				$ 486		486
Inventory							155
Property and equipment, net	3,411				4,011		1,518
Other acquired intangibles	637,537				162,537		43,549
Other assets	2,050				433
Non-compete intangibles							846
Goodwill	531,162				89,976		13,738
Accounts payable and accrued expenses	$ (1,295)				$ (16,288)		(274)
Total purchase price, including non-compete intangibles							$ 60,209

XML

Business Acquisitions - Summary of Company's Assets and Liabilities and Reconciliation of Cash Paid for Net Assets Acquired (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jan. 02, 2020
Business Acquisition [Line Items]
Goodwill	$ 765,511		$ 234,328
Acquisitions of subsidiaries, including non-compete intangibles, net of cash acquired	1,068,661	$ 205,325
Primary Care Physicians and Related Entities
Business Acquisition [Line Items]
Accounts receivable	50,979	486		$ 486
Other assets	2,050	433
Property and equipment	3,411	4,011		1,518
Goodwill	531,162	89,976		13,738
Intangibles	637,537	162,537		43,549
Total assets acquired	1,225,139	257,443
Due to sellers	1,295	16,288		$ 274
Contingent consideration	47,900	0
Other liabilities	45,783	1,530
Total liabilities assumed	94,978	17,818
Net Assets Acquired	1,130,161	239,625
Issuance of Parent equity in connection with acquisitions	61,500	34,300
Acquisitions of subsidiaries, including non-compete intangibles, net of cash acquired	$ 1,068,661	$ 205,325

XML

Business Acquisitions - Summary of Pro Forma Information of the Combined Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 526,798	$ 350,976	$ 1,354,547	$ 979,355
Net loss	$ (40,883)	$ (14,398)	$ (53,592)	$ (8,566)

XML

Property and Equipment, Net - Summary of Property And Equipment, Net And The Related Useful Lives (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 82,619	$ 49,229
Less: Accumulated depreciation and amortization	(18,463)	(11,103)
Property and equipment, net	$ 64,156	38,126
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Property and equipment, total	$ 33,288	25,021
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 14,403	8,288
Machinery and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Machinery and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	12 years
Automobiles
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 6,679	4,900
Automobiles | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Automobiles | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Computer and equipment
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Property and equipment, total	$ 5,950	4,475
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 3,242	2,390
Furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, total	$ 19,057	$ 4,155

XML

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation	$ 2.7	$ 1.8	$ 7.4	$ 4.5
Construction in Progress and Leasehold Improvements
Property, Plant and Equipment [Line Items]
Transactions with related party	3.2	$ 2.1	5.6	$ 5.4
Due to related parties	$ 0.1		$ 0.1		$ 0.1

XML

Intangibles, Net - Summary of Total Intangible, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 882,696	$ 245,157
Accumulated Amortization	(42,104)	(18,802)
Net Carrying Amount	840,592	226,355
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,409	1,409
Accumulated Amortization	(747)	(630)
Net Carrying Amount	662	779
Brand
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	183,217	29,486
Accumulated Amortization	(6,286)	(2,171)
Net Carrying Amount	176,931	27,315
Non-compete
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	75,626	7,733
Accumulated Amortization	(8,270)	(3,373)
Net Carrying Amount	67,356	4,360
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	880	880
Accumulated Amortization	(171)	(135)
Net Carrying Amount	709	745
Payor relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	609,322	201,530
Accumulated Amortization	(25,057)	(11,960)
Net Carrying Amount	584,265	189,570
Provider relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	12,242	4,119
Accumulated Amortization	(1,573)	(533)
Net Carrying Amount	$ 10,669	$ 3,586

XML

Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 14.2	$ 3.6	$ 23.3	$ 8.2

XML

Intangibles, Net - Summary of Expected Amortization Expense of The Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 15,075
2022	59,423
2023	57,585
2024	55,644
2025	54,218
Thereafter	598,647
Net Carrying Amount	$ 840,592	$ 226,355

XML

Capital Lease Obligations - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Capital Lease Obligations [Line Items]
Gross asset value	$ 82,619	$ 49,229
Accumulated depreciation	$ 18,463	11,103
Minimum
Capital Lease Obligations [Line Items]
Capital Lease interest rate	4.10%
Maximum
Capital Lease Obligations [Line Items]
Capital Lease interest rate	12.10%
Assets Held under Capital Leases
Capital Lease Obligations [Line Items]
Gross asset value	$ 4,700	4,200
Accumulated depreciation	$ 1,500	$ 1,500

XML

Capital Lease Obligations - Schedule of Future Minimum Lease Payments Under The Capital Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 307
2022 / 2021	1,151	$ 1,038
2023 / 2022	819	919
2024 / 2023	514	586
2025 / 2024	76	271
2026	25
Total minimum lease payments	2,892	2,814
Less: amount representing interest	(327)	(358)
Capital Lease Obligations	2,565	2,456
Less: current maturities	(1,006)	(876)
Total long-term capital lease obligations	$ 1,559	$ 1,580

XML

Equipment Loans - Summary of Equipment loans (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long term debt	$ 946,056
Asset Pledged as Collateral
Debt Instrument [Line Items]
Long term debt	1,967	$ 1,187
Less: Current portion	(513)	(314)
Long-term debt, excluding current maturities	$ 1,454	873
Notes payable bearing interest at 17.2%; due July 2022, secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	17.20%
Long term debt	$ 28	51
Notes payable bearing interest at 12.5%, 12.8%, and 11.0%; all due June 2023, all secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Long term debt	$ 41	82
Note Payable Bearing Interest At 12.5% Due June 2023 | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.50%
Note Payable Bearing Interest At 12.8% Due June 2023 | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.80%
Note Payable Bearing Interest At 11.0% Due June 2023 | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	11.00%
Notes payable bearing interest at 10.7%; due June 2023, secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	10.70%
Long term debt	$ 60	58
Notes payable bearing interest at 7.2%; due April 2025, secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	7.20%
Long term debt	$ 78	92
Notes payable bearing interest at 4.2%; due December 2024, secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.20%
Long term debt	$ 746	904
Notes payable bearing interest at 3.4%; due March 2026, secured by certain property and equipment | Asset Pledged as Collateral
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.40%
Long term debt	$ 1,014	$ 0

XML

Contract Liabilities - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Change In Contract With Customer Liability [Line Items]
Contract liabilities	$ 6,513	$ 6,513	$ 5,936	$ 5,265
Revenues recognized from current period increases	413	1,042
Humana Affiliate Provider
Change In Contract With Customer Liability [Line Items]
Contract liabilities	6,500	6,500		$ 5,300
Revenues recognized from current period increases	$ 400	$ 1,000

XML

Contract Liabilities - Summary of Significant Changes In The Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Contract with Customer, Liability [Roll Forward]
Balance	$ 5,936	$ 5,265
Increases due to amounts collected	990	2,290
Revenues recognized from current period increases	(413)	(1,042)
Balance	$ 6,513	$ 6,513

XML

Contract Liabilities - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Details) $ in Millions	Sep. 30, 2021 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 0.5
Revenue, remaining performance obligation, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1.9
Revenue, remaining performance obligation, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1.9
Revenue, remaining performance obligation, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 1.8
Revenue, remaining performance obligation, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, amount	$ 0.4
Revenue, remaining performance obligation, period	1 year

XML

Long-Term Debt - Schedule of Notes Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Less: Current portion of notes payable	$ (6,493)	$ (4,800)
Long-term debt, gross	939,563	475,200
Less: debt issuance costs	(23,452)	(18,455)
Notes payable, net of current portion	916,111	456,745
Term loan 3
Debt Instrument [Line Items]
Term loans	252,531	480,000
Term loan 4
Debt Instrument [Line Items]
Term loans	293,525	0
Term loan 5
Debt Instrument [Line Items]
Term loans	100,000	0
Less: debt issuance costs	(1,000)
Senior Notes
Debt Instrument [Line Items]
Senior Notes	300,000	$ 0
Less: debt issuance costs	$ (6,800)

XML

Long-Term Debt - Additional Information (Details) - USD ($)							3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jul. 02, 2021	Jun. 03, 2021	Nov. 23, 2020	Jun. 01, 2020	Mar. 17, 2017	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Jun. 11, 2021	Dec. 31, 2020	Dec. 15, 2020
Debt Instrument [Line Items]
Change in fair value of embedded derivative							$ 0	$ (5,138,000)	$ 0	$ (5,444,000)
Extinguishment of debt			$ 400,000,000
Interest paid									28,075,000	11,044,000
Loss on extinguishment of debt							0	0	13,225,000	0
Debt issuance fees	$ 23,452,000						23,452,000		23,452,000				$ 18,455,000
Debt issuance costs and debt discounts premium, net	24,200,000						24,200,000		24,200,000				24,900,000
Interest expenses							16,023,000	12,346,000	36,363,000	21,728,000
Amortization of debt issuance costs							4,000,000.0	3,000,000.0	7,700,000	3,900,000
Notes Payable
Debt Instrument [Line Items]
Debt issuance costs and debt discounts premium, net	23,500,000						23,500,000		23,500,000				18,500,000
Prepaid Expenses and Other Current Assets
Debt Instrument [Line Items]
Debt issuance costs and debt discounts premium, net	200,000						200,000		200,000				5,800,000
Term loan 3
Debt Instrument [Line Items]
Extinguishment of debt									400,000,000
Interest paid									700,000
DDTL Ticking Fees | Interest On The Initial Term Loan Delayed Draw Term Loans And Initial Revolving Facility
Debt Instrument [Line Items]
Percentage of fee to applicable interest rate														50.00%
Revolving Credit Facility | Prepaid Expenses and Other Current Assets
Debt Instrument [Line Items]
Debt issuance costs and debt discounts premium, net	700,000						700,000		700,000
Revolving Credit Facility | New Credit Suisse Agreement
Debt Instrument [Line Items]
Line of credit facility, remaining borrowing capacity	56,200,000						56,200,000		$ 56,200,000				30,000,000
Debt instrument, basis spread on variable rate									4.50%
Line of credit	0						0		$ 0				$ 0
Revolving Credit Facility | New Credit Suisse Agreement | Letter of Credit | Third Party One
Debt Instrument [Line Items]
Line of credit	900,000						900,000		900,000
Revolving Credit Facility | New Credit Suisse Agreement | Letter of Credit | Third Party Two
Debt Instrument [Line Items]
Line of credit	$ 2,900,000						$ 2,900,000		$ 2,900,000
Delayed Draw Term Loans Maintained As Euro Dollar Borrowings | DDTL Ticking Fees
Debt Instrument [Line Items]
Percentage of fee to applicable interest rate														100.00%
Initial Term Loan And Each Delayed Draw Term Loan
Debt Instrument [Line Items]
Percentage of principal payment outstanding				0.25%
Initial Term Loan And Delayed Draw Term Loan
Debt Instrument [Line Items]
Debt instrument interest rate				3.75%
Debt instrument, basis spread on variable rate									1.75%
Initial Term Loan And Delayed Draw Term Loan | Forecast
Debt Instrument [Line Items]
Minimum amount determining mandatory prepayments											$ 3,000,000
Percentage of amount to net proceed, Determining mandatory prepayment											100.00%
Initial Term Loan And Delayed Draw Term Loan | Basis Spread Determined By Credit Rating
Debt Instrument [Line Items]
Debt instrument interest rate				3.50%
Initial Term Loan And Delayed Draw Term Loan | Basis Spread Determined By Credit Rating Existence
Debt Instrument [Line Items]
Debt instrument interest rate				3.25%
Initial Term Loan And Delayed Draw Term Loan | Common Stock | Forecast
Debt Instrument [Line Items]
Proceeds from private placement											$ 400,000,000
Initial Term Loan And Delayed Draw Term Loan | Maximum | Forecast
Debt Instrument [Line Items]
Percentage of amount determining mandatory prepayment											50.00%
Initial Term Loan And Delayed Draw Term Loan | Minimum | Forecast
Debt Instrument [Line Items]
Percentage of amount determining mandatory prepayment											0.00%
Initial Term Loan And Delayed Draw Term Loan | Received Individually | Minimum | Forecast
Debt Instrument [Line Items]
Proceeds from disposition of assets used in prepayment of credit agreement in fiscal year											$ 3,000,000
Initial Term Loan And Delayed Draw Term Loan | Received In Aggregate | Forecast
Debt Instrument [Line Items]
Proceeds from disposition of assets used in prepayment of credit agreement in aggregate											$ 10,000,000
Prepayment of credit agreement in aggregate, period											18 months
Initial Term Loan And Delayed Draw Term Loan | Proceeds Received From The Issuance of Indebtedness | Forecast
Debt Instrument [Line Items]
Percentage of amount to net proceed, Determining mandatory prepayment											100.00%
ABR Borrowings
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate									0.50%
ABR Borrowings | Credit Suisse's Statutory Reserve Rate
Debt Instrument [Line Items]
Debt instrument, floor rate	0.75%						0.75%		0.75%
Term Loan Three And Delayed Draw Term Commitments
Debt Instrument [Line Items]
Long term debt, bearing fixed interest rate	5.25%						5.25%		5.25%
Initial Term Loan
Debt Instrument [Line Items]
Debt instrument interest rate	5.74%						5.74%		5.74%
Term Loan 1
Debt Instrument [Line Items]
Debt instrument interest rate				7.50%
Debt instrument, frequency of payments						quarterly
Debt instrument, periodic payment, recurring escalation period						2 years
Term Loan 2
Debt Instrument [Line Items]
Debt instrument, frequency of payments					quarterly
Debt instrument, face amount					$ 130,000,000
Debt instrument, interest rate stated percentage					5.00%
Discount rate, period					3 days
Discount rate					0.50%
Embedded derivative fair value					$ 51,300,000
Change in fair value of embedded derivative								$ 5,100,000		$ 5,400,000
Term Loan 2 | Payment in Kind (PIK) Note
Debt Instrument [Line Items]
Debt instrument, interest rate stated percentage					11.50%
Credit Agreement | Credit Suisse AG
Debt Instrument [Line Items]
Credit agreement, maximum amount				$ 685,000,000
Credit Agreement | Initial Term Loan And Term Loan Three | Credit Suisse AG
Debt Instrument [Line Items]
Debt instrument, face amount				480,000,000
Credit Agreement | Delayed Draw Term Loans | Credit Suisse AG
Debt Instrument [Line Items]
Credit agreement, maximum amount				$ 175,000,000
Initial Term Loan And The Delayed Draw Term Loans | ABR Borrowings
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate									1.00%
Eurodollar Borrowings
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				4.75%					4.50%
Eurodollar Borrowings | Basis Spread Determined Based On Credit Rating
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate									4.25%
Eurodollar Borrowings | Initial Term Loan And Delayed Draw Term Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0.75%
Term loan 3
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity, increase	$ 30,000,000						$ 30,000,000		$ 30,000,000
Term loan 4
Debt Instrument [Line Items]
Debt instrument, face amount												$ 295,000,000
Bridge Loan Agreement | Bridge Loan
Debt Instrument [Line Items]
Debt instrument interest rate		6.65%
Debt instrument, face amount		$ 250,000,000
Interest paid	4,200,000
Debt issuance fees		$ 3,500,000
Repayments of debt	$ 250,000,000.0
Bridge Loan Agreement | London Interbank Offered Rate (LIBOR) | Bridge Loan
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		6.50%
Senior Notes
Debt Instrument [Line Items]
Debt instrument interest rate	6.65%						6.65%		6.65%
Debt instrument, interest rate stated percentage	6.25%						6.25%		6.25%
Debt issuance fees	$ 6,800,000						$ 6,800,000		$ 6,800,000
Proceeds from the issuance of the Senior Notes									$ 300,000,000
Percentage of principal amount redeemed with net cash proceeds of certain equity offerings									40.00%
Redemption price percentage									106.25%
Senior Notes | Prior to October 1, 2024
Debt Instrument [Line Items]
Percentage of principal amount redeemed with net cash proceeds of certain equity offerings									100.00%
Senior Notes | Maximum | On or after October 1, 2024
Debt Instrument [Line Items]
Percentage of principal amount redeemed with net cash proceeds of certain equity offerings									103.13%
Senior Notes | Minimum | On or after October 1, 2024
Debt Instrument [Line Items]
Percentage of principal amount redeemed with net cash proceeds of certain equity offerings									100.00%
Term loan 5
Debt Instrument [Line Items]
Debt instrument, face amount	100,000,000						100,000,000		$ 100,000,000
Debt issuance fees	$ 1,000,000.0						1,000,000.0		$ 1,000,000.0
Third party professional fees							$ 100,000

XML

Long-Term Debt - Schedule of Maturities of Long-Term Debt (Details) $ in Thousands	Sep. 30, 2021 USD ($)
Debt Disclosure [Abstract]
Remainder of 2021	$ 1,623
2022	6,493
2023	6,493
2024	6,493
2025	6,493
Thereafter	918,461
Total	$ 946,056

XML

Due to Sellers - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Due to Sellers [Line Items]
Due to sellers current and non current	$ 24.9	$ 24.9	$ 41.1
Employment Agreements With Sellers
Due to Sellers [Line Items]
Due to sellers	16.4	16.4	34.5
Total bonus owed to sellers	8.5	8.5	$ 6.6
Total bonus charges to sellers	$ 2.5	$ 6.2

XML

Fair Value Measurements - Additional Information (Details) $ in Thousands		3 Months Ended		9 Months Ended
	Aug. 11, 2021 USD ($) tradingDay	Sep. 30, 2021 USD ($) shares	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) shares	Sep. 30, 2020 USD ($)	Jun. 03, 2021 shares	Dec. 31, 2020 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value, liability, recurring basis, level two debt		$ 944,000		$ 944,000			$ 474,000
Escrow shares issued (in shares) | shares		53,811,691		53,811,691
Business acquisition, equity interest issued value assigned	$ 30,000
Threshold consecutive trading days | tradingDay	20
Change in fair value of embedded derivative		$ 0	$ (5,138)	$ 0	$ (5,444)
Increase (decrease) in fair value of warrant liabilities		$ 14,650	0	$ (24,565)	0
Contingent Shares Issued in Connection with Acquisitions
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Escrow shares issued (in shares) | shares		2,720,966		2,720,966
Term Loan 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of embedded derivative			5,100		5,400
Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares) | shares		23,000,000.0		23,000,000.0		23,000,000.0
Increase (decrease) in fair value of warrant liabilities		$ 10,100		$ (2,400)
Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares) | shares		10,530,000		10,530,000		10,530,000
Increase (decrease) in fair value of warrant liabilities		$ 4,500		$ (22,200)
Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of preliminary consideration		20.00%		20.00%
Fair value adjustments		$ (3,940)	$ 0	$ (4,152)	$ 0
Contingent Consideration | Measurement Input, Risk Free Interest Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability measurement input		7.00%		7.00%

XML

Fair Value Measurements - Schedule Of Quantitative Information Regarding Level 3 Fair Value Measurements Embedded Derivative Liability (Details) - Embedded Derivative Liability - Level 3	Sep. 30, 2020	Jun. 01, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected date of event	Fourth Quarter 2020	Fourth Quarter 2020
Probability of change of control
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.80	0.90
Probability of issuance of debt
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.15	0.05
Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Embedded derivative liability, measurement input	0.38	0.39

XML

Fair Value Measurements - Schedule of Quantitative Information Regarding Level 3 Fair Value Measurements Warrant Liability (Details) - Warrant Liabilities - Level 3	Sep. 30, 2021 yr	Jun. 03, 2021 yr
Exercise price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	11.50	11.50
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	12.68	14.75
Term (years)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.7	5.0
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0.000000371
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0.00009	0.00008
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0
Public warrant price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	4.13	0

XML

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Carrying Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	$ 185,199	$ 5,172
Carrying Value | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	46,706	5,172
Carrying Value | Public Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	94,990
Carrying Value | Private Placement Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	43,503
Estimate of Fair Value Measurement | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	94,990	0
Estimate of Fair Value Measurement | Level 1 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0	0
Estimate of Fair Value Measurement | Level 1 | Public Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	94,990
Estimate of Fair Value Measurement | Level 1 | Private Placement Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0
Estimate of Fair Value Measurement | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0	0
Estimate of Fair Value Measurement | Level 2 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0	0
Estimate of Fair Value Measurement | Level 2 | Public Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0
Estimate of Fair Value Measurement | Level 2 | Private Placement Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0
Estimate of Fair Value Measurement | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	90,209	5,172
Estimate of Fair Value Measurement | Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	46,706	$ 5,172
Estimate of Fair Value Measurement | Level 3 | Public Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	0
Estimate of Fair Value Measurement | Level 3 | Private Placement Warrant Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Liabilities Fair Value Disclosure	$ 43,503

XML

Fair Value Measurements - Summary of Liabilities Measured At Fair Value Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 136,190	$ 75,800	$ 5,172	$ 23,429
Embedded derivative recognized under Term Loan 2			0	51,328
Contingent consideration recognized due to acquisitions	38,300	0	47,900	2,695
Warrants acquired in the Business Combination			163,058	0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3	0	(16,059)	0	(16,059)
Contingent consideration settled through equity			0	(1,958)
Contingent consideration payments	0	(3,000)	(2,214)	(3,000)
Ending Balance	185,199	61,879	185,199	61,879
Embedded Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value adjustments	0	5,138	0	5,444
Contingent Consideration
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value adjustments	(3,940)	0	(4,152)	0
Warrant Liabilities
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value adjustments	$ 14,649	$ 0	$ (24,565)	$ 0

XML

Variable Interest Entities - Summary of Aggregated VIE Assets and Liabilities and Performance (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Variable Interest Entity [Line Items]
Total Assets	$ 2,140,084		$ 2,140,084		$ 623,546
Total Liabilities	1,282,071		1,282,071		566,002
Total revenue	526,798	$ 263,133	1,200,096	$ 569,637
Operating expenses:
Selling, general and administrative expenses	75,926	27,391	157,348	70,234
Depreciation and amortization expense	16,955	5,379	30,746	12,741
Total operating expenses	536,433	256,520	1,222,188	566,549
Net loss	(9,635)	6,613	(22,092)	3,088
Variable Interest Entity, Primary Beneficiary | Physicians Groups
Variable Interest Entity [Line Items]
Total Assets	30,483		30,483		8,182
Total Liabilities	23,234		23,234		$ 12,371
Total revenue	12,321	79	14,621	79
Operating expenses:
Third-party medical costs	8,582	0	8,582	0
Direct patient expense	2,413	295	5,203	295
Selling, general and administrative expenses	7,277	1,125	12,540	1,324
Depreciation and amortization expense	353	0	860	0
Total operating expenses	18,625	1,420	27,185	1,619
Net loss	$ (6,304)	$ (1,341)	$ (12,564)	$ (1,540)

XML

Related Party Transactions - Additional Information (Detail)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 17, 2020 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) executive	Dec. 31, 2020 USD ($)	Aug. 24, 2018 USD ($)	May 25, 2018 USD ($)	Apr. 23, 2018 USD ($)
Related Party Transaction [Line Items]
Selling, general and administrative expenses from transactions with related party			$ 4,225,000	$ 3,289,000	$ 9,814,000	$ 8,428,000
Operating leases, monthly rent expense			6,900,000	3,100,000	15,900,000	8,200,000
Number of executives obtaining shares in repurchase of equity | executive								2
First Promissory Note
Related Party Transaction [Line Items]
Debt instrument, face amount											$ 100,000
Debt instrument, interest rate stated percentage											2.80%
Second Promissory Note
Related Party Transaction [Line Items]
Debt instrument, face amount										$ 50,000.00
ITC Holdings
Related Party Transaction [Line Items]
Operating leases, monthly rent expense			700,000	700,000	2,100,000	2,000,000.0
Payments for repurchase of equity								$ 400,000
Dental Excellence Partners, LLC
Related Party Transaction [Line Items]
Debt instrument, interest rate stated percentage												7.00%
Related party advance due amount												$ 4,500,000
Interest and fee income, loans and leases				0.0		200,000
Allowance for loan and lease losses, write-offs	$ 500,000
Advisory Services Agreement | In Tandem Capital Partners, LLC
Related Party Transaction [Line Items]
Expenses from transactions with related party		$ 300,000
Percentage of EBITDA for the prior calendar year		2.00%
Related party transaction, amounts of transaction			1,500,000	1,500,000	5,400,000	5,400,000
Selling, general and administrative expenses from transactions with related party				200,000		200,000
Administrative Service Agreement | Dental Excellence Partners, LLC
Related Party Transaction [Line Items]
Expenses from transactions with related party				700,000	1,200,000	1,600,000
Allowance for loan and lease losses, write-offs	400,000
Administrative Service Agreement | Dental Excellence Partners, LLC | Fee For Service and Other Revenues
Related Party Transaction [Line Items]
Revenue from related parties				100,000	100,000	400,000
Dental Service Agreement | Care Dental Group, LLC
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction				300,000	300,000	500,000
Related party transaction, fees per							$ 15
Humana Relationships | Humana
Related Party Transaction [Line Items]
Expenses from transactions with related party					0
Debt instrument, face amount									$ 60,000,000.0
Deferred rent credit									$ 13,500,000
Operating lease, expense					500,000
Humana Relationships | Humana | Minimum
Related Party Transaction [Line Items]
Debt instrument, interest rate stated percentage									8.00%
Humana Relationships | Humana | Maximum
Related Party Transaction [Line Items]
Debt instrument, interest rate stated percentage									10.00%
Humana Relationships | Humana | Thirdparty Medical Costs
Related Party Transaction [Line Items]
Expenses from transactions with related party				90,200,000	249,800,000	167,100,000
Revenue from related parties				131,900,000	335,900,000	239,700,000
General Contractor Agreements | Chief Executive Officer
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction			3,200,000	2,100,000	5,600,000	5,300,000
Other Service Provided | Chief Executive Officer
Related Party Transaction [Line Items]
Related party transaction, amounts of transaction			$ 400,000	$ 100,000	$ 900,000	$ 400,000
Other Service Provided | Dental Excellence Partners, LLC
Related Party Transaction [Line Items]
Allowance for loan and lease losses, write-offs	$ 100,000

XML

Equity-Based Compensation - Additional Information (Detail) $ in Millions			1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2021 USD ($) shares	Jun. 03, 2021 USD ($) d shares	Jun. 30, 2021 shares	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) shares	Sep. 30, 2020 USD ($)	Jun. 02, 2021 shares
Market Condition Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)		12,800,000				12,831,184,000
Common stock threshold consecutive trading days | d		20
Percentage of vesting awards during period		50.00%
Unrecognized compensation cost | $	$ 47.1			$ 47.1		$ 47.1
Weighted-average period over which unrecognized compensation cost is expected to be recognized						2 years 7 months 6 days
Grant date		Jun. 03, 2021
End date of performance period		Jun. 03, 2024
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense | $				9.0	$ 0.1	$ 12.1	$ 0.2
Weighted-average period over which unrecognized compensation cost is expected to be recognized						3 years 8 months 12 days
RSU granted (in shares)	2,249,972		2,590,472
Unrecognized compensation expenses | $	$ 65.2			$ 65.2		$ 65.2
Restricted Stock Units (RSUs) | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						1 year
Restricted Stock Units (RSUs) | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period						4 years
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting awards during period						25.00%
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting awards during period						25.00%
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting awards during period						25.00%
Restricted Stock Units (RSUs) | Share-Based Payment Arrangement, Tranche Four
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting awards during period						25.00%
2017 Profits Interest Units Plan | Profit Interest Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense | $		$ 1.0
2021 Stock Option and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)								52,000,000
2021 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)								4,700,000
Cumulatively increase of common stock reserved and available for issuance (in shares)								15,000,000
Percentage of cumulative increase of common stock capital shares reserved for future issuance over common stock issued and outstanding								1.00%

XML

Equity-Based Compensation- Schedule of Fair Value of Stock Options Granted Using Monte-Carlo Model (Detail)	Jun. 03, 2021 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing Cano share price as of valuation date	$ 18.00
Market Condition Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Closing Cano share price as of valuation date	$ 14.75
Risk-free interest rate minimum	1.68%
Risk-free interest rate maximum	2.00%
Expected volatility	45.00%
Expected dividend yield	0.00%
Expected cost of equity	9.00%

XML

Equity-Based Compensation - Summary of Activity of Unvested Market Condition Awards Granted (Detail) - Market Condition Awards - $ / shares		9 Months Ended
	Jun. 03, 2021	Sep. 30, 2021
Shares
Beginning Balance (in shares)		0
Granted (in shares)	12,800,000	12,831,184,000
Vested (in shares)		0
Forfeitures (in shares)		(97,486,000)
Ending Balance (in shares)		12,733,698,000
Weighted Average Grant Date Fair Value
Beginning Balance (in dollars per share)		$ 0
Granted (in dollars per share)		4.23
Vested (in dollars per share)		0
Forfeitures (in dollars per share)		4.23
Ending Balance (in dollars per share)		$ 4.23

XML

Equity-Based Compensation - Summary of Unvested Restricted Stock Units Activity (Detail) - Restricted Stock Units (RSUs)	9 Months Ended
	Sep. 30, 2021 $ / shares shares
Shares
Beginning balance (in shares) | shares	0
Granted (in shares) | shares	4,840,444,000
Vested (in shares) | shares	0
Forfeitures (in shares) | shares	(16,750,000)
Ending balance (in shares) | shares	4,823,694,000
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share) | $ / shares	$ 0
Granted (in dollars per share) | $ / shares	14.46
Vested (in dollars per share) | $ / shares	0
Forfeitures (in dollars per share) | $ / shares	14.75
Ending balance (in dollars per share) | $ / shares	$ 14.46

XML

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Nov. 01, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Loss Contingencies [Line Items]
Operating lease, rent expenses		$ 6.9	$ 3.1	$ 15.9	$ 8.2
Prime Vendor Agreement PVA
Loss Contingencies [Line Items]
Notice of termination, period	90 days
Purchase obligation	$ 0.8
New Agreement
Loss Contingencies [Line Items]
Purchase obligation	$ 0.6

XML

Commitments and Contingencies - Schedule of Minimum Future Payments (Details) $ in Thousands	Sep. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Remainder of 2021	$ 3,876
2022	13,987
2023	12,763
2024	11,125
2025	9,451
Thereafter	27,908
Total	$ 79,110

XML

Income Taxes - Summary of Income Tax Expense From Continuing Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Jurisdictional earnings:
U.S. losses	$ (41,206)	$ (11,760)	$ (46,053)	$ (25,456)
Foreign income (losses)	870	969	(1,112)	1,461
Total losses	(40,336)	(10,791)	(47,165)	(23,995)
Current:
U.S. Federal	0	0	0	0
U.S. State and local	0	(29)	0	(26)
Foreign	0	(251)	0	(222)
Total current tax expense	0	(280)	0	(248)
Deferred:
U.S. Federal	0	0	0	0
U.S. State and local	(221)	0	282	0
Foreign	(326)	(46)	480	(46)
Total deferred tax benefit (expense)	(547)	(46)	762	(46)
Total tax benefit (expense)	$ (547)	$ (326)	$ 762	$ (294)

XML

Income Taxes - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Jun. 03, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2021
Income Tax Disclosure [Line Items]
Effective tax rate		1.62%	(0.89%)
Unrecognized tax benefits				$ 0.0
Tax Receivable Agreement, percent of tax savings	85.00%
Other Liabilities
Income Tax Disclosure [Line Items]
Deferred tax liabilities				$ 0.7

XML

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss	$ (40,883)	$ (11,117)	$ (46,403)	$ (24,289)
Less: net loss attributable to non-controlling interests	(26,246)		(41,283)
Net loss attributable to Class A common stockholders	(14,637)		(5,120)
Dilutive effect of warrants on net loss to Class A common stockholders	0		(8,780)
Net loss attributable to Class A common stockholders - Diluted	$ (14,637)		$ (13,900)
Dilutive effect of warrants on net income to Class A common stockholders
Weighted average common stock outstanding - basic (in shares)	170,871,429		168,100,210
Net income per share - basic (in dollars per share)	$ (0.09)		$ (0.03)
Dilutive effect of warrants on weighted average common stock outstanding (in shares)	0		1,212,048
Weighted average common stock outstanding - diluted (in shares)	170,871,429		169,312,258
Net income (loss) per share - diluted (in dollars per share)	$ (0.09)		$ (0.08)

XML

Net Loss Per Share - Additional Information (Details) $ in Millions		3 Months Ended	9 Months Ended
	Aug. 11, 2021 USD ($) tradingDay	Sep. 30, 2021 shares	Sep. 30, 2021 shares
Business Acquisition [Line Items]
Escrow shares issued (in shares)		53,811,691	53,811,691
Threshold consecutive trading days | tradingDay	20
Business acquisition, equity interest issued value assigned | $	$ 30.0
Contingent Shares Issued in Connection with Acquisitions
Business Acquisition [Line Items]
Escrow shares issued (in shares)		2,720,966	2,720,966

XML

Net Loss Per Share - Summary of Diluted Net Loss Per Share (Details) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	53,811,691	53,811,691
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	4,823,694	4,823,694
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	12,733,698	12,733,698
Contingent Shares Issued in Connection with Acquisitions
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	2,720,966	2,720,966
Public Warrants | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	23,000,000	23,000,000
Private Placement Warrants | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Escrow shares issued (in shares)	10,533,333	10,533,333

XML

Segment Information - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021 reporting_segment
Segment Reporting [Abstract]
Number of reportable segments	1